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Abstract
The research presented in this thesis describes the production and applications o f polyclonal and 
monoclonal antibodies to warfarin, an anticoagulant used in the management of a variety o f 
thromboembolic disorders.
4'-nitrowarfarin was initially reduced in the presence of zinc and dilute acetic acid to 4'- 
aminowarfarin, which was characterised by a combination of infra-red spectral and nuclear 
magnetic resonance studies. 4'-aminowarfarin was then used for the production of a variety of 
drug-protein conjugates, incorporating different carrier molecules and coupling chemistries. 
They were subsequently characterised by a combination o f SDS-PAGE, UV-spectral studies 
and size-exclusion high performance liquid chromatography (HPLC) with UV (280 nm) and 
photodiode array (200-400 nm) detection. The drug-protein conjugates were then used for the 
production, purification and characterisation of both mouse monoclonal and rabbit polyclonal 
antibodies to warfarin.
Rabbit polyclonal antibodies were initially produced and used in the development of a 
competitive ELISA for warfarin and also for the development of a BIACORE-based inhibition 
immunoassay. A panel o f murine monoclonal antibodies to warfarin was also generated by 
somatic cell fusion procedures, using the spleens of mice, following in vivo immunisation with a 
variety of warfarin-protein conjugates. Positive clones were selected and cloned by limiting 
dilution. Antibody concentration determinations of purified antibody fractions and ‘spent’ 
hybridomas were made using a well-based ELISA technique and a biosensor assay. Affinity 
determinations of the selected monoclonal antibody preparations to warfarin and structurally 
related analogues were then determined using a well-based ELISA technique and also using 
several different assay formats using ‘real-time’ biomolecular interaction analysis.
The affinity-purified antibody preparations were then used in the development of a BIACORE- 
based inhibition immunoassay for warfarin in biological matrices. The stability of various 
immobilised ligands was initially determined and working concentration ranges were 
determined for each antibody preparation. A selected monoclonal antibody (i.e. 3-2-19) was 
then used for the determination of warfarin in plasma ultrafiltrate, which reflects the free active 
concentration of the drug in plasma. The samples assayed by BIACORE inhibition 
immunoassay were also analysed by HPLC for the purposes of validating the developed 
immunoassay technique. The technique was then used for the determination of the degree of 
protein-binding of warfarin in patient plasma samples, following determination of the total 
warfarin plasma concentration by HPLC.
Chapter 1 
Introduction
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1.1. History/Background:
The emergence of warfarin as a drug of therapeutic potential can be attributed to the fine work of 
Karl Paul Link and his team at the University of Wisconsin during the late 1930’s and early 
1940’s [Link, 1943-44, -45, -59], In the early 1920’s cattle were found to be bleeding to death 
on the plains of North Dakota and Alberta, Canada. Many perceived this to be due to a new type 
of haemorrhagic septicaemia. The pioneering investigators, two veterinarians, Schofield in 
Canada and Roderick in North Dakota, concluded that the disease was in fact due to improperly 
cured hay from Melilotus alba or theM  officinalis family.
Both Schofield and Roderick soon recognised that withdrawal of the spoiled hay, or transfusion 
of fresh blood from normal cattle could control the onset of the ‘disease’. In 1931, Roderick 
observed that the disease occurred in two phases: an initial prolongation of the prothrombin time 
(up to week 2) followed by spontaneous haemorrhage (weeks 3 to 5). Using Howell's prothrombin 
precipitation technique, Roderick demonstrated that solutions of ‘prothrombin’ from ‘affected’ 
cattle were unable to coagulate unlike those prepared from normal cattle and concluded that the 
delayed/complete removal of the clotting power of the blood was in fact due to a prothrombin 
deficiency.
In 1933 work began in the laboratory of K.P. Link to isolate the offending agent. The first step 
was the development of a reproducible and sensitive prothrombin assay to assess the 
anticoagulant potency of the test hay samples received. This resulted in the development of a 
bioassay using dilute plasma (12.5%) that facilitated the more sensitive detection of smaller 
changes in prothrombin activity for measuring the ‘potency’ of test hays (Campbell et al., 1948). 
Initial extraction, isolation and identification of the anticoagulant agent proved difficult. This led 
to the development of an elaborate extraction scheme whereby the anticoagulant was eventually 
crystallised by Campbell in 1939 (Campbell et al., 1948) and identified by Heubner as 3,3'- 
methylenebis-4-hydroxycoumarin or Dicoumarol. The biological synthesis of dicoumarol occurs 
during the spoilage of cured hay, whereby, coumarin is oxidised to 4-hydroxycoumarin which, 
when coupled with formaldehyde, leads to the production of dicoumarol (Figure 1.1).
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Figure 1.1: Structure o f Dicoumarol (3,3'-methylenebis-4-hydroxycoumarin)
Over 100 analogues of the parent 4-hydroxycoumarin compound, were synthesized and tested for 
anticoagulant potency using Campbell’s bioassay (Stahmann et al. 1944). The work of 
Stahmann concluded that the minimal structural requirements for anticoagulant activity were an 
intact 4-hydroxycoumarin residue with the 3-position substituted by a carbon residue or H-atom, 
whilst maximum anticoagulant activity requires 4-hydroxycoumarin with the 3-position 
containing a  keto group in a 1,5-spatial relationship with respect to the 4-hydroxycoumarin 
group. Warfarin (3-(a-acetonylbenzyl)-4-hydroxycoumarm) was subsequently synthesized by 
Dcawa in 1944 (Lkawa et al., 1944), with the name warfarin arising out of a  combination o f the 
letters from Wisconsin Area Research Foundation and coumarin.
Figure 1.2: Structure of Warfarin (3-(a-acetonylbenzyI)-4-hydroxycoumarin)
Dicoumarol was originally used as a rat poison. However, it’s activity was not sufficiently 
potent for adequate rodent control, primarily due to the large vitamin K intake by rodents from 
grains and cereals. Warfarin was subsequently used to a much greater effect and became the 
market leader in rodent control. The clinical potential o f the drug was not fully realised until the 
ingestion o f the drug in the form o f rat poison by an army inductee who was subsequently 
admitted to hospital, with what had previously been described as the symptoms of ‘sweet clover
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disease’. The incident acted as a catalyst and reignited interest in the coumarin anticoagulants 
which had been dismissed a decade previously (Link, 1943-44). Two clinicians Shapiro (1953) 
and Clatanoff (1954) observed from their studies on warfarin that it possessed greater potency 
and bioavailability (irrespective of the route o f administration) than any of the other oral 
anticoagulants tested, and pioneered it’s use in the clinical setting.
Today, warfarin is the most widely prescribed oral anticoagulant (Hirsh et al. 1995) for the 
treatment of a variety of clinical conditions including atrial fibrillation, acute myocardial 
infarction and has shown recent promise as a HIV-1 inhibitor (section 1.9.1.) The chemical 
structures of several structural analogues o f warfarin that are clinically widely used, are shown in 
Figure 1.3.
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Figure 1.3: Chemical structure o f Oral Anticoagulants
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1.2. Mechanism o f Action o f Warfarin:
One of the most important biological functions of vitamin K is the post-translational modification 
of precursor proteins to form clotting factors, which involves the y-carboxylation of glutamic acid 
residues (GLU) to y-carboxyglutamic acid (GLA) residues in the presence of vitamin K and 
molecular oxygen (section 1.2.3. and Figure 1.4). In conjunction with this carboxylation 
reaction, an epoxidation reaction occurs, converting the active form of vitamin K to vitamin K 
2,3-epoxide, which is in turn converted back to the quinone form by vitamin Kj epoxide reductase 
to complete the vitamin K cycle (Suttie, 1993). Consequently, any interference with the normal 
functioning of the vitamin K cycle will impair the production o f active clotting factors.
1.2.1. Vitamin K  cycle:
Dietary intake and microbiological synthesis in the gut meets the vitamin K requirement of 
mammals, and phylloquinone is the most active source to meet the vitamin K requirements in 
humans. O’Reilly (1976) outlined the major factors necessary to prevent vitamin K deficiency as:
(a) normal dietary intake of the vitamin (b) the presence of bile in the intestine (c) a normal 
absorptive surface in the liver and (d) a normal liver.
The direct link between vitamin K and blood coagulation was first established by Heinrik Dam 
whilst studying the dietary effects of chickens fed a ‘lipid-free’ diet. Dam (1929) discovered that 
the blood of chickens maintained on such a diet was devoid of clotting activity. However, when 
cereals were replaced back into the diet, the coagulation status of the chickens returned to normal. 
Vitamin K (phylloquinone, 2-methyl-3-phythyl-l,4-naphtoquinone) was identified as the agent 
necessary to cure the clotting defect in the chickens. The haemorrhagic condition was initially 
believed to be solely due to the depletion of the concentration of prothrombin (factor II). 
However, it was later discovered that the levels of factors VII, IX and X were also depleted and 
these proteins subsequently became known as the Vitamin K-dependent clotting factors (Suttie,
1993). A unique feature of the vitamin K-dependent proteins is the y-carboxyglutamyl residues 
(Gla) formed during post-translational modification of these proteins (section 1.2 .3. and Figure
1.4).
1.2.2. Isolation and Identification o f 'Abnorm al’ Prothrombins:
The possibility that two distinct forms of prothrombin may exist was first stated by Hemker et al. 
(1963) whilst studying patients undergoing oral anticoagulant therapy. The presence of a protein,
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which was antigenically similar to native prothrombin, but lacking its biological activity was first 
demonstrated by Ganrot and Nilehn (1968) and Josso et al. (1968). It was subsequently 
demonstrated that the two forms of prothrombin could be separated in the presence but not the 
absence of calcium ions (Stenflo, 1970). Stenflo and Ganrot (1972) then purified the ‘abnormal’ 
prothrombin to homogeneity using a combination of gel filtration and polyacrylamide gel 
electrophoresis, and found that the levels of the ‘abnormal’ prothrombin were elevated following 
dicoumarol treatment whilst normal prothrombin levels were found to be decreased. The amino 
acid and carbohydrate composition of the two forms of prothrombin were found to be 
indistinguishable, whilst the electrophoretic mobility of the abnormal prothrombin was found not 
to vary with the concentration of calcium ions in the buffer. The ‘abnormal’ form of the clotting 
factors formed during anticoagulation therapy subsequently became known as PIVKA’s (Proteins 
Induced by Vitamin K Antagonism).
The specific difference between the two forms of prothrombin was identified to be due to the 
presence of additional carboxyl molecules of glutamic acid residues in the prothrombin molecule 
(Nelsestuen et al., 1974; Stenflo et al., 1974). It is the y-carboxyglutamyl residues (Gla) situated 
in the amino terminal of vitamin K-dependent proteins, which confer the unique metal-binding 
properties of this class of calcium-binding proteins. Upon occupancy of these metal-binding 
sites, the vitamin K-dependent proteins undergo a conformational change that allows the proteins 
to interact with the phospholipid bilayers or cell membranes. The inability of abnormal 
prothrombins to bind to phospholipid bilayers results in these ‘acarboxy’ proteins exhibiting a 
slower activation of the coagulation cascade and the observed anticoagulation effect manifested 
as a prolonged prothrombin times.
1.2.3. Vitamin K-dependent carboxylase:
The enzyme responsible for the post-translational modification of the glutamic acid residues 
(GLU) on precursor clotting factors to y-carboxyglutamyl residues (GLA), necessary for the 
clotting ability of clotting factors is the vitamin K-dependent carboxylase (Berkner, 2000). The 
carboxylation reaction requires molecular oxygen, carbon dioxide and vitamin K as a cofactor. 
The hydroquinone form of vitamin K (vitamin KH2) is reduced to the epoxide form of the vitamin 
(vitamin K 2,3-epoxide) in conjunction with the carboxylation reaction. Vitamin K 2,3-epoxide is 
then recycled to the quinone form of the vitamin by a vitamin K-epoxide reductase. Elevated 
levels of the epoxide form of the vitamin can be found in the plasma of orally anticoagulated
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patients (Nakamura et al., 1994). The quinone form of the vitamin is subsequently reduced back 
to the hydroquinone form of the vitamin by a vitamin K reductase as shown in Figure 1.4. to 
complete the vitamin K cycle.
Oral anticoagulants exert their anticoagulant effect by inhibiting the cyclic inter-conversion of 
vitamin K, by inhibition of the epoxide- and vitamin K-reductases leading to a depletion of the 
hydroquinone (i.e. active) form of the vitamin. By inhibiting this regeneration of the epoxide form 
of the vitamin back to the hydroquinone form, partially carboxylated forms of the vitamin In­
dependent clotting factors of varying Gla content are secreted; and pools of these partially 
carboxylated forms of prothrombin have been isolated and studied (Malhortra et al., 1981; 
1991). A decrease in the number of Gla residues on the prothrombin molecule from 10 to 9 was 
found to result in a 30% decrease in coagulant activity, whilst a decrease to below 6 Gla residues 
reduces the coagulant activity by almost 95%.
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Vitamin K-dependent carboxylase y-carboxy glutamyl-jj residues 
\HOOC COOHCOOH
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Figure 1.4: Conversion o f  glutamic acid residues (Glu) on precursor proteins to
y -carboxyglutamic acid residues (Gla) necessary fo r the production o f  active 
clotting factors. The reaction is catalysed by a vitamin K-dependent 
carboxylase and in tandem with this reaction the hydroquinone form o f  vitamin 
K  is oxidised to a 2,3-epoxide form o f  the vitamin. The epoxide is then reduced 
to the quinone form by a vitamin K  epoxide reductase, which is then 
regenerated to the hydroquinone form by vitamin K  reductase. Oral 
anticoagulants inhibit the cyclic regeneration o f  vitamin K  producing only 
partially carboxylated clotting factors with little/no clotting ability.
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1.3. Pharmacokinetics o f  Warfarin
Warfarin exists as a racemic mixture of two optical isomers: (R)- and (S)- warfarin, whose 
potencies and pharmacokinetics have been extensively reviewed (Lewis & Trager, 1970; 
Hermans & Thijssen, 1993; King et al., 1995). Warfarin enantiomers exhibit stereoselectivity 
and regioselectivity in their metabolism by human cytochromes P450 (Kaminsky & Zhang, 
1997).
-Warfarin ^-W arfarin
Figure 1.5: Optical enantiomers o f  warfarin.
1.3.1. Absorption
Following oral administration warfarin is almost completely absorbed from the gastrointestinal 
tract (Hirsh et al., 1995), with peak plasma concentrations being reached 60-90 minutes 
following administration (King et al., 1995). No identifiable differences between the absorption 
profiles of the two enantiomers have been identified.
1.3.2. Distribution & Protein Binding
Following absorption the drug is highly protein bound (>99%), leaving only a small portion of 
free active drug circulating in the plasma (section 4.1.4.). The binding of warfarin and it’s 
analogues to human serum albumin have been extensively studied (Ferrer et al. 1998; Bertucci et 
al., 1999; Dockal et al., 1999). Human serum albumin is composed of three structurally similar 
globular domains, HSA I, HSA II and HSA III. Dockal et al. (1999) have recently probed the 
ligand-binding specificities of HSA much more selectively using three cloned recombinant 
domains of HSA. The affinity of HSA to warfarin was then studied using the technique of 
induced circular dichroism. The primary warfarin-binding site was found to be located on 
domain II with a secondaiy binding site was found on domain I. Bertucci et al. (1999)
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demonstrated that the (S)-enantiomer has a higher affinity for HSA using competitive 
displacement studies on a chiral stationary matrix to which HSA was anchored. This high degree 
of protein binding predisposes warfarin to a range of possible drug interactions, which can have a 
dramatic effect on the degree of anticoagulation achieved (section 1,8).
1.4. Warfarin metabolism:
The metabolism of warfarin in human shows great inter-individual variability (O’Reilly et 
al., 1963; Lewis & Trager, 1970; Lewis et al., 1973). The mean half-life of warfarin is 36-42 
hours and is independent of dose. Warfarin is essentially catalysed by a series of Cytochrome 
P450 enzymes to a series of hydroxylated metabolites (Kaminsky & Zhang, 1997), and a series of 
carbonyl reductases in the endoplasmic reticulum and cytosol reduce the carbonyl side chain to 
yield diastereomeric alcohols (Herman & Thijssen, 1989) (Figure 1.6).
The (S)- isomer has approximately 5 times the anticoagulant potency (Vanscoy and Coax , 1995) 
of the (R)- isomer. The hydroxywarfarins exhibit no anticoagulant potency, whilst the warfarin 
alcohols have a significantly reduced anticoagulant potency relative to the parent molecule (Lewis 
etal., 1973).
The plasma half-life and extent of protein binding of other oral anticoagulants are listed in Table
1.1 (Kelly & O’Malley, 1979; Palereti & Legnani, 1996).
Table 1.1 Extent of Plasma protein Binding and Plasma Half-Life:
Oral Anticoagulant Plasma Half-life (ti/2) (hrs) Protein Binding (%)
R-Warfarin 35-58 99
S-Warfarin 24-33 99
R-Acenocoumarol 8-10 99
S-Acenocoumarol 0.5-1.0 99
Phenprocoumon 72-120 99
Dicoumarol* 24-96 99
Ethylbiscoumate* 2-5 90
* Both dicoumarol and ethylbiscouinate have two couinarin ring structures (Figure 1.1. and
1.3) and a dose-dependent half-life which increases with increasing dose.
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Early studies involving warfarin metabolism identified the hydroxywarfarins, namely 6- and 7- 
hydroxywarfarin, and the warfarin diastereomeric alcohols, as the primary metabolites of 
warfarin (Lewis & Trager, 1970). Pohl etal. (1976) demonstrated the stereochemical aspects of 
warfarin metabolism using rat liver microsomes and found that the formation of 7- 
hydroxywarfarin was selective for the (R)- enantiomer, which was also metabolised more rapidly 
than the (S)- isomer.
Recent studies using human microsomes and recombinant P450’s have probed the regio- and 
stereoselectivity of warfarin much more extensively (Rettie et al. 1992; Zhang et al., 1995). 
Zhang et al. (1995) probed the (R)- warfarin metabolism using two isozymes namely 
CYP4501A1 and CYP4501A2, and found that (R)- warfarin 6-hydroxylation rates could be used 
as markers of hepatic P4501A2, whilst 6-hydroxylation/8-hydroxylation rates could be used as 
markers for P4501A1. These particular isozymes have been shown to be of particular 
importance because of their ability to bioactivate chemical carcinogens.
Rettie et al. (1992) demonstrated that a CYP4502C9 is responsible for ultimately terminating the 
anticoagulant activity of the more potent (S)- enantiomer, through the stereoselective metabolism 
of (S)- warfarin to 7-hydroxy and 6-hydroxywarfarin metabolites in the ratio of 3.5:1, 
respectively.
Two of the human cytochromes involved in the metabolism of warfarin exhibit polymorphisms,
i.e. CYP2C9 and CYP1A1. Mutations in CYP2C9 results in three allelic variants CYP2C9*1, 
CYP2C9*2 and CYP2C9*3. A case study by Steward et al. (1997) describes a patient showing 
extreme sensitivity to warfarin at low doses and further analysis showed that the patient was 
homozygous for CYP2C9*3. Patient plasma analysis showed that plasma (S-)/(R-) ratios were 
eight times that of the normal patient group. The authors concluded that expression of allelic 
variant of CYP2C9*3 resulted in the diminished clearance of (S-) warfarin and a subsequent 
increased therapeutic response. A similar study Takahashi et al. (1998) examined 86 patients on 
warfarin for genetic polymorphisms of CYP2C9 and it was found that patients who were 
heterozygous for the CYP2C9 mutation had reduced metabolism of (S-) warfarin but not the (R-) 
warfarin enantiomer. The authors postulated that genetic polymorphisms of CYP2C9 may 
possibly account for the wide range of variability in therapeutic patient dosing, as a result of the 
reduced in vivo metabolism of the more potent (S)-enantiomer.
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Figure 1.6. Main metabolic pathways o f  warfarin in humans
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1.5. Excretion
Elimination of warfarin is primarily related to changes in the degree of drug protein binding, 
which alters the plasma concentration of circulating free drug available for metabolism. The 
major metabolites of warfarin 6- and 7-hydroxywarfarin and the two diasteromeric warfarin 
alcohols are eliminated in the urine with less than 2 % of the administered dose excreted as 
warfarin, although the rate of elimination shows high inter-individual variability with plasma half 
lives ranging from 20-60 hours (Lewis and Trager, 1970; Palareti and Legnani, 1996).
1.6. Microbial Models o f  Mammalian metabolism
The metabolism of warfarin has been extensively studied in mammalian systems and 
consequently provides an excellent model for the study of microbial systems to monitor warfarin 
metabolism. Microbial models of drug metabolism may be defined as: ‘the use of micro­
organisms (bacteria, fimgi and yeasts) to facilitate the study of the metabolism of a variety of 
drugs in mammalian systems’ (Davis, 1988). The use of microbial models to study the 
metabolism of drugs was first proposed by Smith & Rosazza (1974) following a study of 
microbiological hydroxylations of a variety of aromatic substances. The majority of Phase I 
biotransformations (oxidations, dehydrogenations, reductions, hydrolyses) have been observed in 
microorganisms.
The use of such microbial systems offers considerable advantages over traditional in-vivo and in- 
vitro studies making them attractive options for a number of reasons including:
(a) Facile manipulation of experimental parameters to facilitate the production of a 
particular metabolite e.g. Increased aeration to increase the production of oxidative 
metabolites.
(b) Preparative-scale metabolite production: allows for the facile scale-up of bio­
transformation products thereby allowing structure elucidation. As reactions are enzyme- 
mediated they can be used for preferential product stereoselectivity as chemical reagents 
can frequently yield complex reaction mixture products.
(c) Single vs. multiple pathways: as outlined above experimental parameters can be tailored 
to produce a particular metabolite simplifying isolation and purification procedures.
(d) Reduced experimental costs: microbial biotransformations are comparatively
inexpensive.
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(e) Lessen animal demand: becoming of greater importance with the growing ethical and 
legal demands to reduce animal usage.
Davis and co-workers (1986, -87, -88) have extensively studied the microbial metabolism of 
warfarin. The bacterium Nocardia corallina (ATCC 19070) was shown to exhibit complete 
substrate and product stereoselectivity with racemic warfarin being reduced to (S)-warfarin-(S)- 
alcohol with no reduction of (R)-warfarin (Davis et al., 1982)(Figure 1.7). Arthrobacter species 
(ATCC 19140) exhibited stereoselectivity in the (S)-reduction of racemic warfarin to (R)-(S)- 
warfarin-(S)-alcohol (Davis and Rizzo, 1982).
Aspergillus niger has been shown to metabolise warfarin to a-diketone metabolites (Rizzo and 
Davis, 1988), whilst Cunnighamella bainieri was found to produce 4-hydroxywarfarin as the 
primary metabolite (Rizzo & Davis, 1986). Catharanthus roseus metabolised racemic warfarin 
to 6-hydroxywarfarin and diastereomeric warfarin alcohols (Hamada et al., 1993), with the 
fungus Beauveria bassiana (IMI 12939) producing 4-hydroxywarfarin, a-diketone and two ring 
cleaved warfarin metabolites, previously unreported (Griffiths et al., 1992). Cunninghamella 
elegans (ATCC 36112) was found to produce several of the phenolic metabolites of warfarin 
including 4-, 6-, 7- and 8-hydroxywarfarin whilst also suggesting production of a previously 
unreported phenolic metabolite, namely: 3-hydroxywarfarin (Wong & Davis, 1987). A list of 
some of the micro-organisms studied to date and the major metabolites produced are given in 
Table 1.2.
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Table 1.2: Metabolites of warfarin produced by microbial systems in vitro -.
Micro-organism Authors Metabolites produced
Cunnighamella
elegans
Wong & Davis (1991, 
1989)
6-, 7-, 8-, 4- and 3- 
hydroxywarfarins, diastereomeric 
alcohols, warfarin diketone and 
aliphatic hydroxywarfarins
Aspergillus niger Rizzo & Davis (1988) a-diketone metabolites
Nocardia corallina Davis & Rizzo (1982) (S)-warfarin-(S)-alcohol
Arthrobacter species Davis & Rizzo (1982) S-reduction of racemic warfarin to 
(R)-(S)-warfarin-S -alcohol
Beauveria bassiana Griffiths et al. (1992) 4-hydroxywarfarin, a-diketone 
and two ring cleaved warfarin 
metabolites
Catharanthus roseus Hamada et al. (1993) 6-Hydroxywarfarin and the 
warfarin alcohols
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Arthrobacter species 
Nocardia corallina
o^N >
9-(S)-warfarin-11 -(S)-a!cohol
Arthrobacter species
9-{R)-warfarm-l 1 -(S)-alcohol
Figure 1.7; Reduction o f  R, S-warfarin to S-warfarin-S-alcohol by Arthrobacter
species and Nocardia corallina and to R-warfarin-S-alcohol by 
Arthrobacter species.
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1.7. Warfarin Resistance:
Resistance to warfarin has been defined as: "the inability of Oral Anticoagulant Therapy (OAT) 
to bring the Prothrombin Time (PT) down to adequate levels of anticoagulation when 
administered at a dose near or equivalent to the normally recommended doses" (LeFrere et al., 
1987). Occurrences of warfarin resistance in the literature are somewhat rare, consisting 
primarily of case reports.
For the purposes of this review, it may be simpler to describe warfarin resistance as hereditary 
resistance (HR), or acquired resistance (AR), as outlined by the proposed classification system 
outlined below in Figure 1.8:
Proposed Warfarin Resistance Classification Scheme
Figure 1.8: Proposed Warfarin resistance classification scheme, outlining the major
classifications o f  warfarin resistance namely, acquired (AR) and hereditary 
(HR) resistance. HR is believed to be caused by an abnormal receptor with an 
increased affinity fo r vitamin K  and a reduced affinity fo r  the coumarins, whilst 
there are many mechanisms that can be used to describe the various modes o f  
acquired resistance.
1.7.1. Hereditary Resistance:
The cases of definitive resistance in the literature are rare, as only four definitive cases of 
hereditary resistance have been confirmed by similar studies of family members (O' Reilly 1964, - 
70; Alving et al., 1985; Warner et al., 1986). Hereditary resistance is believed to be caused by 
an abnormal receptor with an increased affinity for vitamin K and a reduced affinity for the
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coumarins. Cases of this nature were first described over 30 years ago with the inability of 
patient to attain the desired degree of anticoagulation even with greater than 20 times the normal 
therapeutic concentration (O' Reilly, 1964). The patient's twin brother's response to warfarin was 
also documented to be similar to that of the patient. Other family members were also tested and it 
was postulated then (O’ Reilly, 1964), that HR is an autosomal dominant characteristic. Warner 
et ah (1986) reported the case of a 12 year old black girl who required greater than 10 times the 
average daily dose to achieve adequate levels of anticoagulation, familial follow-up studies 
showed that the girls mother was also found to have a similar resistance to warfarin therapy. The 
resistance was not absolute and could be overcome with large doses of the drug, suggesting an 
altered affinity o f the enzyme or hepatic receptor for warfarin.
Other cases of warfarin resistance in the literature have been documented as HR (Keuh et ah, 
1982; Holt et ah, 1983; Diab et ah, 1994), although as no other family members were tested for 
this resistance, hereditary resistance cannot be confirmed; although such studies were not possible 
in all cases (Keuh et al., 1982).
1.7.2. Acquired Resistance:
Several cases of acquired resistance (AR) to warfarin have been reported in the literature (De 
Wolff and Cate, 1979; Lutomski et ah, 1987; MacLaren el al., 1997) and some of the 
mechanisms which have been implicated in cases of AR are shown in Figure 1.8.
Several cases of warfarin resistance associated with intra-venous lipid administration have also 
been documented (Lutomski et al., 1987; MacLaren et ah, 1997), and the use of heparin therapy 
has been recommended for those receiving lipid emulsions in such cases. The precise mechanism 
of this particular interaction is not fully understood and has been suggested to be due to enhanced 
binding of warfarin to albumin, or a result of enhanced clotting factor production.
The literature contains one report of warfarin resistance in a patient due to malabsorption 
(Talstad et ah, 1994). The case study reveals a patient who after two years of satisfactory 
anticoagulation therapy with warfarin experienced selective malabsorption of warfarin and it’s 
congeners. The dosage required after two years of warfarin therapy was 5 times the initial 
prescribed dosage. Non-compliance, concomitant drug intake or gastro-intestinal disease could 
not be used to explain the malabsorption. Enhanced clearance of warfarin has also been reported
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(Hallak el al., 1993) and found to be due to an intrinsically high oral clearance of the more active 
(S)- isomer. Familial studies were also carried out to rule out the possibility of HR, with one of 
the patient’s sisters demonstrating a similar metabolic profile.
Accidental ingestion of exogenous vitamin K from liquid oral supplements (O’ Reilly, 1971; Lee 
and Schwartz, 1981) or from leafy green vegetables particularly rich in vitamin K such as kale 
and broccoli (Walker, 1984) has also led to thrombotic events. Several instances where patients 
have demonstrated signs of acquired resistance to warfarin have also been reported (Lee el al., 
1981). However, many of these have been attributed to patients ingesting a diet rich in leafy 
green vegetables as part of a weight reducing diet, the net result being the increased exogenous 
intake of vitamin K undermining the previous adequate levels of anticoagulation.
Chu el al. (1996) recently described the first reported naturally occurring mutation in the 
propeptide sequence of Factor IX that directly affects the carboxylation by y-glutamyl 
carboxylase. A patient whose PT was in the desired therapeutic range was admitted to hospital 
with bleeding complications. It was subsequently found that the patients Factor IX activity was 
<1% on warfarin therapy, but returned to normal levels when warfarin therapy was terminated. A 
mutation predicting a substitution of an Ala- residue to a Thr-residue at position 10 in the pro­
peptide region of Factor IX was found. Ala-residues at position 10 in vitamin K-dependent 
proteins are highly conserved and, therefore, likely to be important in the binding of the 
carboxylase for y-carboxylation. This in turn results in a reduced affinity of the carboxylase for 
the Factor IX precursor and demonstrates a previously unreported mechanism of warfarin 
‘sensitivity’.
In an attempt to aid the physician in the diagnosis of patients with an abnormal response to 
warfarin, Bentley et al. (1986) produced a dosage-algorithm from a study of well-controlled 
patients. The study provides the physician with two algorithms that can help the physician 
identify the causes of the abnormal warfarin response and dose accordingly.
1.8. Drug Interactions:
Warfarin is currently the most widely prescribed oral anticoagulant in the United States and 
potential interactions with a variety of other drugs have been examined with several excellent 
reviews published to date (Serlin and Breckenridge, 1983; Buckley and Dawson, 1992; Freedman
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and Olatidoye, 1994; Wells et al, 1994; Chan, 1995; Harder and Thurmann, 1996). 
Concomitant drug therapy with warfarin can have a profound impact on the level of anticoagulant 
effect achieved, potentiating the anticoagulant effect through several mechanisms such as protein 
binding displacement leads to a hypothrombinaemic effect, which can lead to serious bleeding 
complications. The coumarin anticoagulants possess three distinguishing characteristics that 
render them susceptible to potentiating/inhibiting drug interactions:
(a) A narrow therapeutic range
(b) Highly plasma/protein bound
(c) Metabolised by cytochrome P450.
The interactions with warfarin can be broadly described as occurring by either pharmacodynamic 
or pharmacokinetic mechanisms (Serlin & Breckenridge, 1983; Harder and Thurmann, 1996) 
aswell as some interactions best characterised as idiopathic in nature (Freedman and Olatidoye,
1994). The pharmacokinetic interactions result in alterations in the circulating drug 
concentration by means of a change in the degree of plasma protein binding, increased 
metabolism, reduced absorption or increased plasma excretion. Pharmacodynamic interactions 
generally speaking have no effect on the circulating concentration of drug, but they can have a 
synergistic action resulting in increased anticoagulation through various mechanisms: for 
example, with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).
The interaction of cholestyramine with warfarin has been reported to reduce the oral 
bioavailability of warfarin with a reduction in the prothrombin time (PT) of approximately 25%. 
Cholestyramine binds warfarin in the intestinal tract which interrupts the enterohepatic 
recirculation of warfarin, by decreasing reabsorption it will increase its elimination rate and 
increased excretion of unchanged warfarin into the stool (O’ Reilly, 1987). The effect of plasma 
protein binding displacement by several classes of drugs has also been documented (Buckley and 
Dawson, 1992; Harder and Thurmann, 1996). O’Reilly (1987) has suggested that the effects of 
plasma protein displacement of warfarin from its protein binding sites are overstated, as the 
resultant increase in free plasma warfarin concentration following protein displacement causes a 
transient increase in the degree of anticoagulation. The drug however, is then redistributed 
throughout the body and the rate of metabolism increases until the plasma concentration returns 
to pre-steady state levels (Koch-Weser and Sellers, 1971).
The majority of pharmacokinetic interactions with warfarin are caused by a change in the 
metabolism of warfarin either by an increase in enzyme induction (e.g. with rifampicin) which
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leads to an increase in the rate of metabolism of warfarin, decreasing it’s plasma half-life, thereby 
reducing the anticoagulant effect; or else enzyme inhibition (e.g. cimetidine) whereby the plasma 
half-life is extended, augmenting the anticoagulant effect.
The stereoselective nature of warfarin metabolism can also result in the preferential metabolism 
of a particular isomer. For example, sulfinpyrazole causes inhibition of the catalytic activity of 
P4502C9, the isozyme which is primarily responsible for the metabolism of the more potent (S)- 
isomer to it’s inactive metabolites, namely (S)-6- and (S)-7-hydroxywarfarin in the ratio’s of 
3.5:1, respectively (He et al., 1995). The effect of sulfinpyrazole is biphasic, which means that 
an initial potentiation is followed by inhibition of the anticoagulant effect (Wells et al., 1994). 
He et al. (1995) concluded from their in vitro studies using human liver microsomes, which 
showed a reduced inhibitory effect in vitro rather than in vivo, that the drug interaction may be 
due to a circulating sulphide metabolite of sulfinpyrazole, rather than sulfinpyrazole itself, and 
suggested that the cause of many other drug-drug interaction may be as a result of the effects of a 
circulating metabolite rather than the parent drug.
Warfarin drug interactions with the NSAlDs (Non-Steroidal Anti-Inflammatory Drugs) have also 
been extensively reviewed (Pullar and Capell, 1983; Chan, 1995) and Chan has described the 
mechanisms and significance of the as occurring by means of three possible mechanisms:
1. Direct Hypoprothrombinémie effect of aspirin, which inhibits the clotting factor synthesis of 
factors VII, IX and X.
2. Pharmacokinetic mechanisms: Displacement of warfarin from plasma albumin by NSAIDs 
and inhibition of metabolism of (S-)-warfarin by phenylbutazone.
3. Pharmacodynamic interactions through a direct effect on platelet function thereby prolonging 
clotting time.
Chan (1995) suggests that the combined use of NSAIDs and warfarin be generally discouraged 
because of the increased risk of warfarin-associated bleeding episodes. It is suggested that if 
NSAIDs are required by patients already receiving warfarin therapy, that they should be 
introduced slowly over the first week or two of therapy, and the PT monitored closely. Similarly, 
the PT should be monitored when the administration of the NSAIDs is stopped because of the 
possibility of potential loss of anticoagulant control (Hirsh et al., 1995).
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The major pharmacodynamic interactions that may occur with warfarin include interactions :
• Drugs affecting availability of Vitamin K: antibiotics that affect the cyclic inter­
conversion of the vitamin K cycle such as the cephalosporins also augment the 
anticoagulant effect by producing vitamin K deficiency from ‘bowel sterilization’ 
(O’Reilly, 1976; Bechtold et a /.,1984).
• Drugs affccting haemostasis: NSAIDs such as aspirin, as noted previously, augment the 
anticoagulant effect through their inhibitory effect on platelets.
• Certain pathological disease states: Hepatic dysfunction impairs the normal synthesis of 
clotting factors, and liver disease alone results in a prolongation of the prothrombin time. 
Hypermetabolic states, such as hyperthyroidism, augment the anticoagulant effect of 
warfarin through two possible mechanisms - increased catabolism of clotting factors or 
that D-thyroxine increases the affinity of warfarin for it’s receptor site in the liver and 
thus decreases the rate of clotting factor synthesis (Demirkan et al., 2000). The 
decreased response of oral anticoagulants in hypothyroid states is suggested to be due to 
the reduced catabolism of clotting factors.
Freedman and Olatidoye (1994) have described those interactions with warfarin whose 
mechanism is not fully understood as being idiopathic in nature. The use of dietary vitamin E 
supplements is currently increasing because of the growing evidence that they may be useful in 
preventing atherosclerosis and coronary heart disease (Rimm et al., 1993), and consequently the 
number of patients taking these supplements is increasing. The levels of the four vitamin In­
dependent clotting factors were found to be depleted in a patient ingesting vitamin E supplements 
and on warfarin therapy (Corrigan et al., 1981). The patient had multiple haemorrhagic 
complications, and the authors postulated a link between the vitamin E supplement and vitamin 
K. However, a study by Kim & White (1996) using high dose vitamin E supplements with a 
small patient group whose PT were stable on warfarin therapy concluded that the likelihood of an 
interaction between warfarin and vitamin E was minimal and that the supplements could be used 
safely.
1.9. Uses & Applications:
Warfarin is primarily used in the treatment of a variety of thromboembolic disorders, including 
atrial fibrillation, deep vein thrombosis and threatened stroke. The intensity of the anticoagulant 
treatment as measured by the INR is adjusted according to the severity of the thromboembolic
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condition. Guidelines as to the correct levels of anticoagulation have been recommended based 
on the results of several well-designed clinical trials (Hirsh et al., 1995; Sebastien and Tresch, 
2000)(Table 1.4). A brief description of several alternative applications of warfarin arc 
described below.
1.9.1. HIV-1 inhibitor:
The urgent requirement for suitable therapeutic agents to arrest the development of the AIDS 
epidemic has led to the identification of a wide variety of potential agents. The variety of 
therapeutic agents developed to date, have primarily been peptidomimetic HIV-1 inhibitors whose 
poor oral bioavailability and rapid excretion has limited their therapeutic potential. A point 
mutation in the HTV-1 genome was shown to result in non-infectious virions, illustrating the 
therapeutic potential of HlV-protease inhibitors as targets for AIDS therapy (Kohl et al., 1988).
Warfarin has shown promising results as a potent HTV inhibitor in vitro (Bourinbaiar et al., 1993 
(a, b); Tummino et al., 1994; Thaisrivongs et al., 1994 -96). Tummino et al. (1994) studied 13 
analogues of warfarin and found that 9 of the analogues studied show significant inhibitory 
activity of HTV-1 protease. Results demonstrated that substitution of the benzopyran-2-one ring 
at the 6-, 7- and 8-positions greatly modulates the inhibitory activity, with 7-, 8-dimethylwarfarin 
being the most potent inhibitor (Ki= 1.9(xM). The inhibitory activity was shown not to be greatly 
affected by substitution of the phenyl substituent of the 3-oxo-butyl group.
Bourinbaiar et al. (1993(a)) evaluated the effects o f several coumarin compounds on HIV 
infectivity and replication. In separate experiments conducted, the presence of the coumarin- 
based compounds at the time of inoculation using free HTV virus showed reduced levels of 
infectivity. Similar experiments where MOLT-4 lymphocytes were co-cultured in the presence of 
HIV-1 infected ACH-2 lymphocytes in the presence of coumarin compounds also demonstrated 
reduced levels of HTV-1 infectivity. These results suggest that the coumarin molccules tested had 
inhibitory effect on both the incidence of the cell-free and cell-cell mediated HTV-infection, 
respectively. The effects of 7-hydroxy-, 4-hydroxycoumarin and warfarin were then tested on 
chronically infected ACH-2 lymphocytes, and all of the compounds tested exhibited an antiviral 
effect. The incorporation of 3H-leucine was determined to assess whether the inhibitory effects of 
the coumarins, was due to growth suppression of the cells. The growth pattern of the cells 
showed a reduction in the RT activity, suggesting the anti-viral effect of coumarins is unrelated to 
the suppression of cell proliferation. The cellular viability of the drug-treated cells was also
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comparable to that of control cells. The results suggest that the HIV-1 specificity of the 
coumarins is greater than that of RT-selective nucleoside inhibitors such as AZT which are 
ineffective in inhibiting the cell-cell transmission of HIV-1. The coumarins have the additional 
advantage of being able to inhibit viral production without being cytostatic, (Bourinbaiar el al., 
1993(b)) a property of few anti-viral drugs.
Studies by Thaisrivongs et al. (1994, -96) using a fluorescent-based screening assay of over 5000 
compounds revealed phenprocoumon (substitution of 3-oxobutyl group of warfarin with ethyl 
substituent) as a potent HTV-1 protease inhibitor and demonstrated that it had improved 
inhibitory activity (Ki=l(xM) compared to warfarin. The crystal structure of 
phenprocoumon/HTV-1 protease complex was studied at 2.5 A0 resolution and revealed that the 
two oxygen atoms of the lactone moiety were positioned within hydrogen bonding distance of the 
two amides of the enzyme. This relationship between the hydrogen bonding and the enzyme 
formed the basis for the design of more potent non-peptidomimetic HIV protease inhibitors (U- 
96988, Ki=38nM) which entered phase I clinical trials. Subsequent studies identified a family of 
sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones, one of which was shown to be 
effective against a panel o f AZT-resistant HTV-1 clinical isolates in PBMC (Thaisrivongs el al., 
1996). Clinical trials of Tipranavir a potent orally bioavailable HTV-1 protease analogue of the 
5,6-dihydro-4-hydroxy-2-pyrones sulfonamide class (Ki= 8pM) is currently underway 
(Thaisrivongs and Strohbach, 1999).
1.9.2. Antimetastatic properties:
Warfarin has also demonstrated potential as an anti-metastatic agent in several clinical trials and 
animal models conducted (Zacharski et al. 1981, Amirkhosravi & Francis 1995). Warfarin has 
shown particularity promising results in the treatment of SCCL (Small Cell Carcinoma Lung) a 
tumour cell type that is characterised by a coagulation associated pathway (Zacharski et al., 
1984). Zacharski et al. (1981) found that the median survival rates of warfarin-treated patients 
was increased to 50 weeks compared to 24 weeks for the control group. The study also found 
that the warfarin-treated group showed a significant time to increased progression of disease. An 
independent study by Chahinian et al. (1989) to evaluate the combined effects of warfarin and 
chemotherapy in SCCL showed that the complete and partial response rates were similarly 
significantly elevated by approximately 7% overall in the warfarin-treated group.
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Warfarin has also been used in the treatment of a variety of other illnesses including IgA 
nephropathy, which occurs as a general defect in the clearance of immune complexes, and IgA 
complexes which are poorly solubilised by the complement system deposit in the kidneys (Nolin 
and Courteau, 1999). Intraglomerular coagulation has been associated with the glomerular injury 
in IgA nephritis, as the mesangial cells swell and multiply within the glomerulus causing 
thrombosis. The use of a combined triple therapy of dipyridamole (an anti-platelet agent), 
cyclophosphamide and warfarin was found to be particularly effective in preventing the 
progression of the disease (Woo etal., 1996).
1.10. Warfarin: Contraindications:
1.10.1 Pregnancy:
Oral anticoagulants are used during pregnancy to prevent venous thromboembolism in high-risk 
patients (Ginsberg and Hirsh, 1995). Warfarin can cross the placental barrier and may cause 
damage to the foetus in utero, and have been associated with a condition known as Foetal 
Warfarin Syndrome (FWS). There is also an increased risk of foetal mortality and stillbirth with 
the use of warfarin during pregnancy. The use of warfarin during the first 6 weeks of pregnancy 
may be safe (Ginsberg and Hirsh, 1995) however the risk of warfarin embryopathy is increased if 
taken during weeks 6-12 of the first trimester (Hall et al., 1980). In a study of 418 pregnancies 
in which oral anticoagulants were used (Hall et al., 1980) one sixth resulted in abnormal livebom 
infants and one sixth in abortion or stillbirth with the remaining two thirds of births apparently 
normal. The majority of embryopathies with warfarin therapy were noted to occur when warfarin 
is taken during the first trimester of pregnancy, and nasal hypoplasia is the most common 
occurrence which results in a flattened upturned appearance of the nose, whilst in severe cases the 
nose appears depressed into the face (Hall et al., 1980). Hall et al., (1980) found that in all cases 
of embryopathy warfarin was administered between weeks 6 and 9 of gestation. The authors also 
concluded that there does not seem to be a critical time period for CNS associated abnormalities, 
however the majority occur during the second and third trimester. The CNS abnormalities were 
found to be due more debilitating than those of embryopathy, with a significant incidence of 
mental retardation (30%). Other CNS abnormalities associated with warfarin administration 
during pregnancy include Dandy-Walker syndrome (Kaplan, 1985) and blindness (Hall et al., 
1980). A study by Gartner et al. (1993) on the use of various coumarin derivatives and the 
associated teratogenic risk during pregnancy found that eye anomalies appear to occur only with 
warfarin therapy and the incidence of CNS-malformations was greater with phenprocoumon 
therapy. A recent study by Chan et al. (2000) of women with mechanical prosthetic valves
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requiring oral anticoagulant therapy during pregnancy found that the incidence of foetal 
embryopathy is higher in women maintained on warfarin therapy throughout the full pregnancy. 
In a second group of women, where warfarin was substituted with heparin therapy between weeks 
six and twelve there was an increased risk of thromboembolic complications.
1.10.2. Overdose/Reversal o f  effect:
Bleeding is the most common complication of warfarin therapy and the risk of patient 
haemorrhage increases with increasing intensity of oral anticoagulant treatment. Excessive 
anticoagulation with warfarin can be controlled with discontinuation o f drug treatment, 
replacement with fresh frozen plasma or tissue factor concentrates, or with administration of 
vitamin K1 (Baglin, 1998). There are very few guidelines as to the adequate dose level of 
vitamin K required to achieve the desired degree of anticoagulation, although recommendations as 
to possible doses have been made (Vanscoy and Coax, 1995; Taylor el al., 1999). When the 
anticoagulant effect of warfarin needs to be reduced, decreasing the administered dose should be 
the first consideration. If  more immediate effects are required, vitamin K can be administered 
orally or slowly intra-venously, although the administration of vitamin K intra-venously has been 
associated with anaphlyaxis. In a recent study of patients whose PT’s were outside the 
therapeutic range (over-anticoagulated) Brigden el al. (1998) found that alcoholism and liver 
disease were more prevalent in the over-anticoagulated group compared to the control group and 
that non-compliance and drug-interactions were also identified in 20% of reported cases. 
Reduction of the anticoagulant dose of the over-anticoagulated patients has been reported to be as 
safe and effective as vitamin K treatment in many cases (Glover and Morrill, 1995; Brigden et 
al., 1998).
There have also been several reported cases of attempted overdosage using warfarin and its 
congeners (Swigar el al., 1990; Kriz-Kozak and Lammle, 1999, Figure 4.23). Kruse and Carlson 
(1992) report the case of attempted suicide with brofadicoum overdosage in a 25-year old male. 
Brofadicoum a structural analogue o f warfarin, was initially developed to overcome the increased 
prevalence of rodents resistant to warfarin ingestion, and has a toxic potency 200 times that of 
warfarin and a half-life almost 60 times longer. The patient was initially treated with fresh 
plasma and oral vitamin K and released. However, the patient subsequently returned some 15 
weeks later following further ingestion of brofadicoum and died from a brain haemorrhage.
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1.10.3. Necrosis:
Warfarin-induced skin necrosis is a rare complication associated with warfarin or other coumarin 
derivatives with a prevalence of 0.01-1.0% (Sallah et al., 1998; Chan et al., 2000). It usually 
occurs within the first 10 days of therapy, although there have been cases of reported late-onset 
necrosis (Essex et al., 1998). Warfarin-induced skin necrosis is often associated with initial high 
loading doses of the drug. The precise mechanism of the induced necrosis is still unclear, 
although it is believed to result from a transient imbalance in the anticoagulant-procoagulant 
system, leading to decrease in the anticoagulant protein C during warfarin therapy. 
Approximately one-third of patients who have skin necrosis have been found to be protein C 
deficient. Protein C is a vitamin K-dependent protein that in conjunction with protein S, 
inactivates activated factors V and VIII, down-regulating coagulation. The plasma half-life of 
protein C is approximately 6-8 hours, so following warfarin ingestion a hypercoaguable state 
may exist as a result of the rapid fall in protein C activity, relative to the procoagulant factors II 
and X which have considerably longer half-lives. Protein C-deficient persons show a more 
dramatic fall in protein C concentrations making them even more predisposed to thromboembolic 
episodes (Zimbelman et al., 2000). Occasionally the necrosis can be severe enough to warrant 
amputation of the affected areas or even result in mortality (Jillella and Lutcher, 1996). Miura 
et al. (1996) found that it generally occurs in obese women over 50 years of age who have been 
treated for thrombophlebitis or pulmonary embolism and seems more prevalent in areas where 
there is an increased subcutaneous fat content. The recommended alternative is to resume 
warfarin therapy with an initial low loading dose of the drug, as the use of heparin has been 
associated with osteoporosis (Hirsh et al., 1995)
1.10.4. Fracture risk
Warfarin has also been associated with an increased incidence of fracture risk (Booth and Myer, 
2000). The putative effect of vitamin K on bone is thought to be mediated by its role as a 
cofactor for the carboxylation of certain glutamic acid residues to y-carboxyglutamic acid 
residues (Gla) in vitamin K-dependent proteins. Several vitamin K-dependent proteins have been 
identified in the skeleton such as osteocalcin and matrix Gla protein (MGP). Caraballo et al. 
(1999) reported an increased incidence of fracture in those patients undergoing oral anticoagulant 
therapy. The incidence of fracture risk was also shown to be positively correlated with the 
intensity of anticoagulant treatment, suggesting an adverse effect of warfarin on the axial skeleton
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in humans, although the authors concluded that the incidence of risk o f fracture does not imply an 
overall increase in the likelihood of osteoporosis.
1.11. Monitoring Anticoagulant Therapy:
The anticoagulant effect o f warfarin can be measured using a variety of indices, the most 
commonly used method being the Prothrombin test (PT time).
1.11.1. Prothrombin Time (PT)
The PT is sensitive to changes in the concentrations o f factors II, VII and X. During the first few 
days of warfarin therapy; the PT primarily reflects the decrease in plasma concentration of factor 
VII which has the shortest half-life, and, subsequently the depression of levels of factors II and X. 
The time taken for all of the coagulation factors to reach new steady-state levels varies from 2-7 
days, depending on the half-life of the various clotting factors. I f  an immediate anticoagulant 
effect is required heparin is usually overlapped with warfarin therapy for the first 4-5 days of 
treatment.
Table 1.3: Half-life of Vitamin-K dependent clotting factors.
Clotting Factor Half-Life (hours)
Factor II (Prothrombin) 72-96
Factor VII 4-6
Factor IX 20
Factor X 48-70
The PT is performed by mixing citrated plasma with calcium and a tissue thromboplastin reagent 
that contains the tissue extract and phospholipid necessary to activate the coagulation cascade. 
There can be considerable variation in the degree of ‘responsiveness’ of the commercially 
available thromboplastins depending on the tissue (lung, brain or placenta) and species (rabbit vs. 
human) of origin. The degree of ‘responsiveness’ of a particular thromboplastin reflects its 
ability to activate Factor X by Factor VII as the level of each decreases (Hirsh, 1995). 
Consequently there could be considerable variation in the PT’s reported by different laboratories 
depending on the thromboplastin reagent used making inter-laboratory comparison of PT’s very 
difficult indeed.
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In an attempt to try and standardise the varying responsiveness of the various thromboplastins 
used the INR (International Normalised Ratio) system was introduced by the World Health 
Organization in 1977. A batch of human brain thromboplastin was designated as the first 
standard reference batch of thromboplastin against which all other preparations could be 
referenced (Poller, 1987). The following algorithm was developed to allow for proper 
standardisation when reporting PT’s.
Patient Plasma PT1 1 1\ — Control Plasma PT  
m R =  P T R ISI
PTR: Prothrombin Time ratio = Ratio of Prothrombin time of patient plasma to that of
control plasma.
ISI: International Sensitivity Index
The ISI, International Sensitivity Index, measures the responsiveness of various thromboplastins 
relative to international reference standards, The lower the ISI the more responsive the 
thromboplastin used.
Despite the potential benefits and concensus on the use of the INR system several problems also 
exist with its use (Hirsh et al., 1995). The first problem is that of the use of insensitive 
thromboplastins (ISI>2.5) resulting in erroneous INR’s as the calculated PTR is raised to the 
power of the ISI (Vanscoy and Coax, 1995). Therefore, the use of thromboplastins with ISPs 
close to 1.0 is suggested. Similarly, manufacturers assigning an incorrect ISI to a specific batch 
of thromboplastin can have an erroneous effect on the recorded PT.
Furie et al. (1984) suggested that measurement of the native prothrombin antigen is more 
predictive of bleeding and thromboembolic complications in patients treated with warfarin. Furie 
et al. (1990) found in a randomised trial, using the traditional PT and the prothrombin antigen 
concentration assay, that there was a significant decrease in the number of complications with the 
native prothrombin antigen group than the PT measured anticoagulated group. Overall there was 
an 85% decrease in the complication rate with the prothrombin antigen-measured group, 
suggesting possible clinical benefit for its measurement. Despite the reduced incidence of 
bleeding episodes associated with the prothrombin antigen assays determined by Furie et al.
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(1990), the PT remains the most commonly employed technique clinically, primarily as a result of 
the rapidity of analysis that is feasible.
The intensity of anticoagulation required will also vary considerably depending on the 
thromboembolic condition, and recommended INR ranges have been made by the American 
College of Chest Physicians (ACCP) and are outlined below in Table 1.4 (Beckey et al., 1999). 
The current trend towards less intense anticoagulation aims to reduce both the frequency and 
risks of bleeding episodes and the need for frequent monitoring. The key, however, is the balance 
between effect and side-effect (Lodwick, 1999).
Table 1.4. Recommended International Normalised Ratios (INRs) for various
thromboembolic conditions
Indication Recommended INR
Deep Vein Thrombosis (DVT) 2.0-3.0
Mechanical heart valves 2.5-3.5
Prevention of recurrent MI after initial MI 3.0-4.5
Prevention of systemic embolism in atrial 2.0-3.0
fibrillation
MI=Myocardial infarction
The frequency of bleeding episodes associated with warfarin therapy is related to the degree of 
anticoagulant therapy. Gitter et al. (1995) found that the incidence of bleeding episodes was 
greatest during the first month of therapy (1.6%), and decreased to approximately 1/3 o f that rate 
during the first 3 months. The study also found that a malignant condition was most strongly 
associated with bleeding episodes.
Determining the optimal dose of warfarin for any patient is a highly individualised matter as there 
is great inter-patient variability in the PT response to warfarin (Lutomski et al., 1995). Dosing is 
generally begun with an initial loading dose of warfarin (5-10 mg) and the INR is monitored 
carefully during the first weeks of therapy until the desired INR range has been reached. Sim and 
Chang (1995) developed an elaborate computer software program incorporating warfarin 
pharmacokinetics and pharmacodynamics in an attempt to improve the accuracy in evaluating 
steady-state dosages during initialisation of warfarin therapy required. The study showed that
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current physician-determined-doses required a greater number of INR measurements and the 
statistical frequency of patient underdosing was greater compared to the computer-modelled 
dosage values. The study suggested possible merits for the use of computer modelling with 
respect to predicting steady-state dosage requirements in the clinical setting coupled with proper 
clinical evaluation. Oates et al. (1998) recently described a method for initiating warfarin 
therapy in elderly out-patients using a decision tree and dosage algorithm which included factors 
such as alcohol intake, concomitant medication, age, sex, weight and liver failure. The dosage 
scheme developed which involved predicting the maintenance dose following 2 weeks of 2mg 
warfarin requiring for only weekly INR determinations to be made. Only the sex of the patient 
had a significant enough effect to be included in the dosage prediction algorithm.
The influence of patient age as a discriminant in warfarin dosage requirements has also been 
examined and studies have shown that a significant correlation exists between the two. Gurwitz 
et al. (1992) found that for each decade past 50 years of age mean warfarin requirements 
decreased by approximately lmg. This increased sensitivity to warfarin in the elderly has also 
been postulated to be due to decreased clearance of warfarin with age (Mungall, 1992). Warfarin 
‘sensitivity’ has also been described in the elderly where the increased effect of warfarin has been 
suggested to be due to an increased affinity for warfarin rather than vitamin K (Shepherd et al., 
1977; Vanscoy and MacAuley, 1991)
Gender differences have also been associated with increased sensitivity to warfarin. A study by 
Hara et al. (1994) examined gender differences in the anticoagulant effect of warfarin in rats. 
The study found in male and female rats both fed warfarin from 2 weeks of age that the PT was 
prolonged to the same degree at 4 weeks but that the effect was reduced with ageing and at 14 
weeks no anticoagulant effect was observed in the female rats. Ovariectomized rats showed a 
similar prolongation of the coagulation time comparable to the male rats which was subsequently 
reduced by the addition of 17-p-cstradiol. Male rats treated with 17-f3-cstradiol also showed a 
prolongation of prothrombin time and it was concluded that the gender difference observed in the 
anticoagulant effect of warfarin in rats may be due to the estradiol levels in plasma as the plasma 
levels of warfarin remained unchanged.
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1.12. W arfarin-The ‘ReboundPhenom ena’:
The expression ‘rebound-phenomena’ is used to describe a hypercoagulable state that exists 
following withdrawal of warfarin treatment. Cessation of warfarin therapy commonly results in 
the low-grade activation of the coagulation system, although the degree of activation is transient 
in most cases. However, higher levels of activation have been observed for certain individuals 
predisposing them to an increased incidence of thrombotic complications (Palareti and Legnani, 
1996).
The first reported effects of recurrent thromboembolism in patients following cessation of oral 
anticoagulation treatment upon warfarin withdrawal was reported by Cosgriff & Stuart (1953). 
It was suggested that a state of ‘hypercoagulability of the blood’ existed in these patients and 
coined the term ‘rebound phenomenon’ to describe the condition. The development of newer 
more sensitive techniques capable of detecting markers of blood hypercoagulability has allowed 
for the detection of lower levels of different markers of hypercoagulability (e.g. activated factor 
VII, prothrombin fragments).
Two hypothesis have been used to explain the nature of the increased levels of blood coagulation 
and thrombin generation following withdrawal of oral anticoagulant therapy (Palareti and 
Legnani, 1996). The first explanation is that increased levels of blood coagulation have been 
observed in patients with venous or arterial thrombotic disease, independent of the occurrence of 
the thrombotic episodes (Bauer et al., 1985; Merlini et al., 1994). The reduced prothrombin 
levels during warfarin therapy balance the levels of increased coagulation, and when 
anticoagulant therapy is withdrawn the activation of coagulation is no longer ‘counterbalanced’ 
by the oral anticoagulant effect. This ‘catching up’ effect of the procoagulant factors was first 
described by Wright (1960) and later by Hirsh (1982).
The second explanation describes how an actual ‘rebound phenomena’ may actually occur 
following cessation of warfarin therapy. The levels of Factor VU (triggers blood activation and 
has a role in thrombotic events) and Factor IX showed recovery times of circa. 2 days (Schofield 
et al., 1987), whilst the activated form of factor Vila were shown to reach significantly higher 
levels when anticoagulant therapy is stopped compared to pretreatment levels. Conversely, the 
return to normal levels of the anticoagulant proteins C and S was slower creating an imbalance 
between pro- and anticoagulant factors which may lead to activation of blood coagulation 
(Palareti and Legnani, 1996). It has been shown that the degree of hypercoagulability is more
3 3
marked when discontinuation of warfarin is immediate rather than gradual. When anticoagulants 
are phased out gradually, the differences between the procoagulant and anticoagulant proteins are 
less marked reducing the likelihood of blood activation and the possibility of the ‘rebound 
phenomenon’.
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1.13 Aim s o f  thesis:
Current methodologies for the detection of warfarin require extensive sample pre-treatment and 
derivatisation for the measurement of the unbound fraction of warfarin in plasma and are 
unsuitable for the routine analysis. The aim of this thesis was to develop a panel of antibodies to 
warfarin, which it was envisaged would be used in the development of a rapid, sensitive 
BIACORE inhibition immunoassay suitable for the analysis of warfarin in biological fluids.
Chapter 3 describes the derivatisation of 4'-nitrowarfarin to 4'-aminowarfarin which following 
characterisation, was used in the production of drug-protein conjugates. The drug-protein 
conjugates were then used for the production of polyclonal antibodies to warfarin in rabbits. The 
affinity-purified polyclonal antibodies were then used in the development of a competitive ELISA 
for warfarin.
Chapter 4 describes the development and validation of a BIACORE-based inhibition 
immunoassay for the detection of the free fraction of warfarin in plasma ultrafiltrate. Several 
assay formats were investigated and the use of directly immobilised drug surfaces were shown to 
possess the optimal stability and ligand binding characteristics for the routine analysis of 
biological samples. The assay system developed was subsequently validated against an existing 
validated HPLC technique for the analysis of warfarin, and showed excellent correlation with 
approximately 10-fold lower limits of detection. The validated assay was then used for the 
determination of the unbound fraction of warfarin in patient samples and used to calculate the 
degree of plasma protein-binding.
Chapter 5 describes the production and characterisation of a panel of monoclonal antibodies to 
warfarin following somatic cell fusion procedures. Detailed affinity analysis of selected 
monoclonal antibodies was then carried out using a well-based ELISA technique and also by 
BIACORE analysis. Both techniques produced equivalent thermodynamic data and the relative 
merits of each procedure are discussed.
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Chapter 2 
Materials & Methods
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2.1. Equipment
Table 2.1 Equipment model used and suppliers.
Class Model Source
BIACORE™ BIACORE™ 1000, BIACORE™ 
3000
BIACORE AB
Centrifuges Heraeus Christ Labofuge 6000 Heraeus Instruments Inc.
Biofuge A Microcentrifuge Heraeus Instruments Inc.
Sorvall refrigerated centrifuge Du Pont Instruments
CO2 Tissue culture EG 115 IR Heraeus Instruments Inc./Jouan
incubator
HPLC Apparatus System Beckman Gold Beckman Gold
Varian Star 9030 pump, 9012 UV J.V.A. Analytical Ltd.
detector, Fluorescence detector, AI-
200 autosampler
Microscope Nikon Diaphot inverted microscope Micron Optical Co. Ltd.
pH meter 3015 pH meter Jenway Ltd.
NMR Spectrometer 400MHz AC400 NMR spectrometer Brucker Ltd.
IR Spectrophotometer Nicolet The Nicolet Instrument Corp.
Protein Electrophoresis Atto dual minislab system AE-6450 Atto Corp.
Apparatus
Rocker Platform Stuart Platform Shaker STR6 Lennox
HPLC column C18 Supleco Discovery™ Supelco
Biosep SEC-4000 Phenomenex
Spectrophotometers U.V.-160A
Spectrophotometer
Shimadzu Corp.
Titertek Multiscan plate reader Medical Supply Company
Sonicator & Waterbath RM6 Lauda waterbath A.G.B. Scientific Ltd.
Laminar Flow Unit Holten 2448K laminar air flow unit Holten Laminar A/S
Blood Tube Rotator SB1 Blood tube rotator Medical Supply Company
Evaporation Unit Pierce Evaporation Unit Pierce
Millipore Filtration Millipore Filtration Dcvice A.G.B. Scientific Ltd.
Apparatus
Ultrafiltration Cell Stirred Cell 8400 Amicon Inc.
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Full Addresses:
AGB: Dublin Industrial Estate, Dublin 11, Ireland.
Amicon Inc.: Beverly, Massachusetts 01915, U.S.A.
Atto Corp.: 2-3 Hongo 7-Chrome, Bunkyo-Kui, Tokyo 113, Japan.
BIACORE AB: St. Albans, Hertfordshire AL13AW, England.
Brucker Ltd.: Banner Lane, Coventry CV4 9GH, England.
Du Pont Instruments: Instrument Products Division, Newtown, Connecticut 06470, U.S.A. 
Heraeus Instruments Inc.: 111-a Corporate Boulevard, South Plainfield, New Jersey 
07080, U.S.A.
Holten Laminar A/S: Gydevang 17, DK 3450 Allerod, Denmark.
Jenway Ltd.: Gransmore Green, Felsted Dunmow, Essex, CM6 3LB, England.
Jouan: Zone Industrialle de Brais, Saint Nazaire, France.
J.V.A. Analytical Ltd.: Long Mile Rd., Dublin 12, Ireland.
Lennox: P.O Box 212A, John F. Kennedy Dr., Naas Rd., Dublin 12, Ireland.
Medical Supply Company: Damastown, Mulhuddart, Dublin 15, Ireland.
Nicolet Instrument Corp.: 5225-1 Verona Rd., Madison, WI 53711, U.S.A.
Nikon Corporation: 2-3 Marunouchi 3-chome, Chiyoda-ku, Tokyo, Japan.
Pharmacia Biosensor: St. Albans, Hertfordshire ALI 3AW, England.
Phenomenex: Melville House, Queens Avenue, Hurdsfield Ind.Est., Macclesfield, Cheshire 
SK10 2BN, England.
Pierce: 3747 North Meridian Road, PO box 117, Rockford, IL 61105, U.S.A.
Shimadzu Corp.: 1 Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto 604, Japan.
Supelco: Supelco Park, Bellefonte, PA 16823-0048, U.S.A.
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2.2.1. Consumable items
Table 2.2 Consumables used and suppliers
Class Item Source
Hardware CM5 Chips Pharmacia Biosensor
TLC plates Riedel de Haen
HPLC vials J.V.A. Analytical Ltd.
0.2 fun filters A.G.B. Scientific Ltd.
Eppendorf tubes, sterile universal 
containers and gilson tips
Sarstedt Ltd.
Nunc Maxisorp plates Nunc
Tissue Culture plastic-ware Coming Costar
Nanosep™ Ultrafiltration
membranes
Amicon Inc.
Full Addresses:
Amicon Inc.: Beverley, Massachusetts 01915, U.S.A.
Corning Costar: High Wycombe, Buckinghamshire HP 13 6EQ, England. 
Nunc: P.O. Box 280-Kamstrup DK, Roskilde, Denmark.
Riedel de Haen: Wunstorfer Straße, D-3106, Seelze 1, Hanover, Germany. 
Sarstedt Ltd.: Sinnottstown Lane, Drinagh, Co. Wexford.
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2.2.2. Reagents and Chemicals
All chemicals were reagent grade and were purchased through Sigma Chemical Co. (Poole, 
Dorset, England) except as noted below.
Table 2.3 Reagents & Chemicals used and suppliers:
Class Chemical Supplier
Chemicals Acencoumarin (Sintrom®) Ciba-Geigy
Deuterated dimethyl sulphoxide (DMSO) Aldrich Chemical Co.
Biochemistry Alkaline phosphatase4abelled antibodies Southern Biotechnology 
Ltd.
Phosphate buffered Saline tablets Oxoid Ltd.
Tissue culture Briclone N.C.T.C.C.
Dulbecco's modification of Eagles medium Gibco BRL
Fetal calf serum Gibco BRL
HEPES Gibco BRL
Hybridoma SFM™ Gibco BRL
L-glutamine Gibco BRL
Non-essential amino acids Gibco BRL
Phosphate-buffered saline tablets Oxoid
Sodium pyruvate Gibco BRL
Aldrich Chemical Co.: Old Brickyard, New Rd., Gillingham, Dorset SP8 4JL, England. 
Ciba-Geigy: CH-4002 Basle, Swizerland.
Gibco BRL: Trident House, Renfrew Rd., Paisley PA4 9RF, Scotland.
N.C.T.C.C,: National Cell and Tissue Culture Centre, Glasnevin, Dublin 9, Ireland.
Oxoid: Basingstoke, Hampshire, England.
Southern Biotechnology: 160A Oxmoor Boulevard, Birmingham, Alabama 35209, U.S.A.
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2.3. Standard solutions:
Phosphate Buffered Saline (PBS-1):
One tablet was dissolved per 100 mis of distilled water according to the manufacturer’s 
instructions. When dissolved, the tablets prepare Dulbecco’s A PBS which contains 10 mM 
phosphate buffer and 0.14 M NaCl, pH 7.2-7.4 (referred to in text as PBS-1).
Phosphate Buffered Saline 2 (PBS-2):
PBS-1 was prepared as described above, with 0.3 M NaCl added (referred to in text as PBS- 
2).
Wash Buffer:
PBS-1 containing 0.05% Tween-20 (v/v).
Diluent Buffer:
PBS-1 containing 0.05% (v/v) Tween-20 and 5% (v/v) FCS.
Hepes Buffered Saline (HBS):
Hepes buffered saline (BIACORE running buffer) containing 50 mM NaCl, 10 mM HEPES, 
3.4 mM EDTA and 0.05% (v/v) Tween-20 was prepared by dissolving 8.76 g of NaCl, 2.56 
g of HEPES, 1.27 g of E.D.T.A. and 500 fil of Tween 20 in 800ml of distilled water. The 
pH of the solution was then adjusted to pH 7.4 by the addition of 2M NaOH. The final 
volume was then made up to 1,000 ml in a volumetric flask. The solution was filtered 
through 0.2 fun filter and degassed prior to use.
SDS-PAGE (Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis) 
solutions:
Protein Electrophoresis 
Polyacrylamide Gel Electrophoresis (PAGE)
Polyacrylamide gel electrophoresis (PAGE) was carried out using the discontinuous system, 
in the presence of sodium dodecyl sulphate (SDS), as described by Laemmli (1970). 8% 
(w/v) resolving and 4% (w/v) stacking gels were normally used and prepared from the 
following stock solutions as outlined in Table 2.4.
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Stock Solutions:
(A) 30% (w/v) acrylamide containing 0.8% (w/v) bis-acrylamide.
(B) 1.5 M Tris-HCl, pH 8.8, containing 0.4% (w/v) SDS.
(C) 0.5 M Tris-HCl, pH 6.8, containing 0.4% (w/v) SDS.
(D) 10% (w/v) ammonium persulphate.
Solution Resolving Gel Stacking Gel
Acrylamide (A) 3.3. ml 0.83 ml
Distilled Water 4.17 ml 2.9 ml
Resolving Gel 
Buffer (B)
2.5 ml
Stacking Gel 
Buffer (C)
— - — 1.25 ml
Ammonium 
Persulphate (D)
100 pi 25 nl
TEMED 10 pi 5 Hi
Table 2.4. The quantities o f stock solutions required for the preparation o f 
resolving and stacking gel used for polyacrylamide gel electrophoresis.
Samples were dissolved in solubilisation buffer (0.06 M Tris-HCl, pH 6.8, 2% (w/v) SDS, 
25% (v/v) glycerol, 0.014 M 2-mercaptoethanol, 0.1% (w/v) bromophenol blue) and boiled 
for 8 mins before loading onto the gel. The gel was electrophoresed in electrode buffer, pH
8.3, containing Tris (0.025 M), glycine (0.192 M) and 0.1% (w/v) SDS, at 15 mA (stacking) 
and 25 mA (resolving) using an ATTO vertical mini electrophoresis system until the blue 
dye reached the bottom of the gel.
Staining o f gels with Coomassie Brilliant Blue:
Gels were stained with Coomassie staining solution for visualisation of protein bands. Gels 
were stained for 1 hour in 0.2% (w/v) Coomassie Brilliant Blue in methanol:acctic 
acid:distilled water (3:1:6). Gels were destained overnight in methanol:acetic acid:distilled 
water (3:1:6).
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Coomassie Blue Stain Solution
Coomassie Blue R-250 1.250 g
Methanol 227 ml
dH20  227 ml
Glacial acetic acid 46 ml
The components were dissolved, mixed thoroughly, filtered through Whatman paper 
grade number 1, and stored at room temperature (R.T.) in a dark bottle.
Destain Solution
Methanol 150 ml
Glacial acetic acid 50 ml
dH20  300 ml
The above components were mixed, thoroughly, and stored at R.T.
Electrophoresis Buffer
Tris.HCl 03.00 g
Glycine 14.40 g
SDS 01.00 g
The components were dissolved in 1L of dH20 , and stored at R.T.
Sample Buffer
1M Tris.HCl (pH 6.8) 0.60 ml
50% (v/v) Glycerol 5.00 ml
10% (w/v) SDS 2.00 ml
2-ME (2-Mercaptoethanol) 0.50 ml
1% (w/v) Bromophenol blue 0.90 ml
The components were thoroughly mixed together, and stored at -20°C.
Acrylamide Stock Solution (A)
Acrylamide 29.20 g
Bisacrylamide 00.80 g
The components were dissolved in 100ml dH20, and stored in the dark at 4°C.
4X Resolving Gel Buffer (B)
2M Tris-HCl (pH 8.8) 75.0 ml
10% (w/v) SDS 04.0 ml
dH20 21.0 ml
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The components were thoroughly mixed together, and stored at 4°C.
4X Stacking gel Buffer (C)
1M Tris.Cl (pH 6.8) 50.0 ml
10% (w/v) SDS 04.0 ml
dH20  46.0 ml
The components were thoroughly mixed together, and stored at 4°C.
Ammonium Persulphate Solution (D)
Ammonium persulphate 0.10 g
dH20  1.00 ml
The components were mixed thoroughly and stored at R.T.
Electrophoresis buffer
Tris 03.10 g
Glycine 14.40 g
Methanol 200.0 ml
The components were dissolved in 1,000 ml of dH20 , and stored at R.T.
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2.4. Chemical derivatisation and purification of 4'- 
aminowarfarin:
2.4.1. Production o f  4'-anunowarfarin (3-(a-acetonyl-p-aminobenzyl)-4- 
hydroxycoumarin:
2.00 g of acenocoumarin (4,-nitrowarfarin) were added to a flask containing 3.00 g of zinc 
granules and 50 ml of 30% (v/v) acetic acid solution. The reaction was allowed to proceed 
at room temperature with constant stirring and followed by TLC (Thin Layer 
Chromatography) as described in section 2.4.2. Allowing the chemical reduction of the 
nitro- group proceed for too long, also resulted in the partial reduction of the ketone groups 
on the parent acenocoumarin molecule. Consequently, the reaction was stopped before 
reaching completion. Filtering the reaction mixture through Whatman filter paper (grade 
number 1) quenched the reaction mixture. This served two purposes, firstly to remove the 
reaction catalyst and unwanted zinc granules, and secondly, to remove the nitro- containing 
starting material, acenocoumarin, which is only partially soluble, compared to 4'- 
aminowarfarin in dilute acid solutions. The filtered acidic reaction mixture was then quickly 
back-extracted into ethyl acetate. The ethyl acetate extract was then dried for 20 minutes 
over anhydrous magnesium sulphate in a round-bottomed flask with constant stirring. The 
resulting solution was then filtered and vacuum dried under rotary evaporation.
2.4.2. TLC Analysis o f  4'-aminowarfarin.
TLC analysis of the reaction mixture was performed by removing a portion of the reaction 
mixture with the aid of a glass Pasteur pipette into an eppendorf tube. This solution was then 
extracted into ethyl acetate after vortexing for 2 minutes on a vortex apparatus. The ethyl 
acetate extract was then spotted onto a TLC plate and placed in a tank containing a solution 
of methanol:chlorofiom (2:98, v/v) as mobile phase. The TLC plate was developed and 
viewed under a UV lamp. When the reaction had proceeded sufficiently far enough, the 
reaction was quenched as per section 2.4.1.
2.4.3. Silica column chromatography o f  4'-aminowarfarin\
The mobile phase (mcthanol:chloroform, 2:98)(v/v) was mixed with silica grade 40 to form a 
slurry, which was then added to a 20 cm glass column. The mobile phase was then recycled 
through the column several times with the aid of a peristaltic pump, to ensure adequate 
packing of the column, and allowed to elute until it just covered the top of the silica column. 
The partially purified reaction mixture, containing the putative reaction product (i.e. 4'-
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aminowarfarin) and trace impurities of the starting material 4'-nitrowarfarin, was 
resuspended in the minimum volume of column mobile phase, and carefully applied to the 
top of the packed silica column bed. The reaction mixture was then drawn evenly onto the 
silica column, and the glass bulb reservoir refilled with column mobile phase and 
reconnected to the peristaltic pump. 5 ml fractions of the column eluant were collected in 
test-tubes and analysed for character and purity by TLC analysis under UV light (section 
2.4.2). The fractions corresponding to the 4'-aminowarfarin sample were then pooled and 
rotary evaporated under vacuum.
2.4.4. Analysis o f  4 '-aminowarfarin by Infra-Red spectroscopy:
20 mg of 4'-aminowarfarin were mixed with potassium bromide (KBr), and the mixture was 
crushed using a mortar and pestle to produce a very fine powdered suspension. The 
powdered suspension was then compressed using a disc press. The resulting disc was then 
placed in the slot of Nicolet® spectrometer that had been previously blanked with a 
potassium bromide disc. The spectra were analysed and peak identification was made by 
comparison to reference spectra.
2.4.5. Analysis o f  4 '-aminowarfarin by Nuclear Magnetic Resonance spectroscopy: 
20 mg of 4'-aminowarfarin were dissolved in deuterated dimethyl sulfoxide (DMSO). This 
solution was then filtered through glass wool into a NMR tube. This sample was then 
analysed using a 400MHz Brucker® NMR spectrometer. The resulting proton NMR spectra 
were then integrated using dedicated Brucker® software that allowed for proton integration 
and identification.
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2.5. Production of drug-protein conjugates:
4'-aminowarfarin-protein conjugates were produced and characterised as described in section
2.5.1.-2.6.3. for use as immunogens and subsequent screening procedures, in the production 
of monoclonal and polyclonal antibodies to warfarin.
2.5.1. Diazotisation o f  primary amine:
The acidified nitrite solution provides the source for the nitrosonium ion (I) which 
electrophilically replaces the hydrogen in the primary amino group to form the N-nitroso
derivative (II). This has a tautomeric structure, the hydroxydiazo form (III) yielding the
diazonium ion (IV) under acidic conditions.
An outline o f  the reaction mechanism involved in the diazotisation o f  the primary 
amine to  allow for subsequent coupling is given below:
ArNH2 + 2H+ + 2HC1 ->  A rN sN 'C P  + NaCl + H 20
Reaction scheme:
2N 02 + 2tT -> 2HN02 «
0=N-0-N=0 «
-IT
ArNH2 + "NO ->
ArNH-N-0 <=>
ArN=N-OH + H+ <=>
Acidic conditions
2.5.2. Drug conjugate preparation:
The drug-protein conjugates were produced according to the method of Satoh et al. (1982). 
A 0.014 mM solution of sodium nitrite was prepared by dissolving 9.7 mg in 10 ml of water. 
350 mg of 4'-aminowarfarin were then dissolved in 50mls of a solution containing 0.1 M
O-NO-N-O + H 20
0=N+ + 0-N=0 (I)
Nitrosonium ion
ArNH-N-0 (II)
N -N itrosoderi vati ve
ArN=N-OH (III)
Hydroxydiazoform
ArN^N" + H20  (IV)
Diazonium ion
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HC1 and 7 mM potassium bromide. The sodium nitrite solution was added dropwise to the 
solution containing 4'-aminowarfarin, and maintained with continuous stirring on an ice-bath 
for 1 hour. This solution was then added dropwise to a 5% (w/v) solution o f BSA (Bovine 
Serum Albumin), the pH was maintained between 9.0-9.5 with the simultaneous addition of 
0.1 M NaOH. This solution was then stirred overnight at 4°C. The resulting dark brown 
solution was then dialysed against several changes of PBS-1, and lyophilised prior to further 
studies.
For the production of KLH (Keyhole Limpet Haemocyanin) conjugates, the protein solution 
was made up in PBS-1 containing 0.9 M NaCl, to allow for solubilisation of KLH. 100 mg 
of 4'-aminowarfarin were activated as per section 2.5.1. and added to 40 mg of KLH, and the 
reaction followed as described above. The resulting drug-protein solution was dialysed 
against several changes of PBS-1 with 1.0 MNaCl added. The resulting dark brown solution 
was lyophilised for further studies.
2.5.3. Production o f  conjugates utilising D ST crosslinkers:
Sulfo-DST (DisulfoSuccinimidyl tartrate) is a water-insoluble, homo-bifunctional N- 
Hydroxysuccinimide ester. Primary amines are principal targets for NHS esters. Accessible 
a-amine groups present on the N-termini o f peptides and proteins react with NHS-esters.
20 mg of BSA were dissolved in 2 ml of PBS-1 and 90 mg of 4'-aminowarfarin in a 1% (v/v) 
DMSO solution were added to the protein solution. The crosslinker that was prepared just 
prior to use in PBS-1 to a final concentration of 5 mM, was then added to the protein and 
drug mixture. The reaction mixture was incubated on ice for 2 hours. The reaction was then 
quenched for 15 minutes by the addition of a 1 M Tris-HCl buffer, pH 7.5, and incubated for 
a further 15 minutes.
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2.6. Characterisation of drug-protein conjugates:
All drug-protein conjugates were characterised by a combination of SDS-PAGE, UV and 
HPLC-photodiode array (PDA) scans.
2.6.1. HPLC-PDA and H PLC-U V analysis o f  drug-protein conjugates and  
affinity-purified antibody:
The Beckman system Gold™ HPLC system was attached to a PDA or UV detector. Samples 
were separated using a Biosep SEC-4000 (Phenomenex) column with a particle diameter of 
10(xm. The mobile phase consisted o f PBS-1, which had been previously filtered and 
degassed. The flow rate was set to 1.0 ml/min. HPLC-PDA scans were produced and 
recorded from 200-400 nm. From the resulting spectra and plot overlays of the PDA-scans 
obtained for the drug-protein conjugates and protein solutions, a peak at approximately 
310nm (A ^  warfarin =308 nm) can be seen that corresponds to the drug portion of the 
conjugate. Size exclusion chromatography of drug-protein conjugates, affinity-purified 
antibody fractions and standards of known molecular weight was also carried out using the 
experimental conditions described above, except that UV detection at 280 nm was used 
instead of PDA detection. From the constructed calibration curve of log (molecular weight) 
versus time, it was possible to estimate the molecular weight of the drug-protein conjugates 
and purified antibody fractions.
2.6.2. SDS-PAGE analysis o f  drug-protein conjugates:
SDS-PAGE gels were run according to the conditions described in section 2.3. Drug-protein 
conjugates and ‘control’-protein (i.e. protein solutions which underwent the same chemical 
procedure except the drug was omitted from the coupling step) were prepared in 
solubilisation buffer and placed in adjacent wells in the gel using a Hamilton syringe. 
Proteins used in all characterisation procedures were subjected to the same experimental 
procedures as those for the proteins used in the coupling reactions.
2.6.3. Ultraviolet spectroscopy:
The lyophilised drug-protein conjugates were prepared in PBS-1, and their UV spectra 
analysed from 200-400 nm. UV spectra of similar concentrations of ‘control’ protein were 
also prepared and recorded. The UV spectrum of the 4'-aminowarfarin drug molecule was 
also recorded over a similar wavelength range. Direct comparison of the three spectra gave 
putative confirmation of the conjugation of 4'-aminowarfarin to the protein molecules, to 
form the conjugates of interest.
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2.7. Production of immunoaffinity matrices:
Immunoaffinity matrices were prepared by the chemical coupling of 4'-azowarfarin-BSA to 
sepharose-4B and Triazine 4XL. The immunoaffinity matrices were then used for the 
affinity-purification of polyclonal antibodies to warfarin from ammonium sulphate 
precipitated rabbit immunoglobulin fractions.
2.7.1. Preparation o f  4 '-azowarfarin-BSA sepharose column:
4'-azowarfarin-BSA was coupled to CNBr-Sepharose 4B according to the manufacturer’s 
instructions. 6 g of CNBr-Sepharose 4B was weighed out and swollen in 100 mM HC1 for 1 
hour, giving approximately 20 ml of wet gel. The gel was then sucked dry on a Buchner 
funnel with a filter of pore size 0.2 |xm, and washed twice with 250 ml of PBS-1. 200 mg of 
4'-azowarfarin-BSA was then dissolved in coupling buffer (0.1 M NaHC03, pH 8.3, with 0.5 
MNaCl).
The coupling solution was then added dropwise to the gel, under gentle rotation, and the 
mixture rotated overnight at 4°C. The reaction mixture/ gel was then washed successively 
with 200 ml each of, 0.1 M sodium bicarbonate pH 8.5, PBS-1, and PBS-1 containing 1.0 M 
NaCl. The excess active amine groups were then blocked, by mixing the gel with 40 ml of
1.0 M ethanolamine for 2 hours under gentle rotation. The gel was then washed with 0.1 M 
acetate buffer, pH 4.0, containing 0.5 MNaCl and with coupling buffer, and stored in PBS-1 
with azide (0.02%, v/v) at 4°C.
2.7.2. Preparation o f  a 4 '-azowarfarin-BSA Triazine column:
Triazine activated agarose 4XL is a unique activated adsorbent for highly efficient 
immobilisation of proteins and other ligands. Coupling occurs primarily through surface 
lysine and histidine residues on the ligand to yield neutral linkages that exhibit good stability 
across the pH range.
Using a Buchner funnel, the gel was allowed to drain through a 0.2 fun filter, the storage 
preservative discarded, and the gel washed with at least 20 volumes of distilled water and 
allowed to drain under gravity. The Triazine 4XL gel was then washed with at least 10 
volumes of coupling buffer (50 mM acetate buffer, pH 5.0 containing 0.5 M NaCl) and 
allowed to drain under gravity, and placed into a universal container suitable for mixing. A 
10 mg/ml solution o f 4'-azowarfarin-BSA was then made up in 50 mM acetate buffer, pH 
5.0, sodium chloride was then added to bring final concentration to 0.5 M NaCl. The gel 
was then added to an equal volume of protein solution with gentle mixing at 4°C for 2 hours.
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The gel was then washed with 10 volumes of coupling buffer, and the gel resuspended in 2 
M imidazole, pH 5.0, and mixed for 2hrs at room temperature to block residual active 
groups. The gel was then washed with 5 volumes of ultrapure (UP) water and 5 volumes of 
20% (v/v) ethanol, coupling buffer, PBS-1 containing 1.0 M NaCl and stored in PBS-1 with 
azide (0.02%, v/v) until required.
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2.8. Animal experiments:
2.8.1. Licensing
All procedures involving the use of animals were approved and licensed by the Department 
of Health, and every precaution was taken to ensure the minimum distress to the animals.
2.8.2.1. Immunisation protocol fo r  mice fo r  the production o f  monoclonal 
antibodies to warfarin.
Balb/C mice of age 5-10 weeks old were used for the production of monoclonal antibodies to 
warfarin, using the immunisation schedule described below:
Day 1: A 2 mg/ml solution of 4'-azowarfarin-thyroglobulin/Keyhole Limpet
Haemocyanin (KLH) or 4'-aminowarfarin-DST-thyroglobulin
(DiSuccinimidyl Tartrate) was prepared in PBS-1 and mixed with an equal 
volume of Freund's Complete Adjuvant (FCA). This solution was then 
vortexed to form an emulsion, and 300 (al of the emulsion used to immunise 
mice by intraperitoneal (i.p.) injection.
Day 21: Mice were re-immunised intraperitoneally with a similar dose of the
immunogen above in Freund's Incomplete Adjuvant (FICA).
Day 28: Mice were bled from the tail vein, and the specific antibody titre determined.
Post-Day 28: Mice were boosted intraperitoneally with a similar mix o f conjugate and
FICA as per day 21.
Post-Day 28: The above immunisation and blood sampling sequence was continued until a
satisfactory antibody titre was recorded. Oncc the antibody titre was 
sufficiently high, the mouse was immunised intravenously (i.v.)(250 |xl))(3- 
4 days prior to sacrifice) with the respective conjugate in PBS-1.
The mouse was then sacrificed by cervical dislocation, the spleen removed 
and used for subsequent monoclonal antibody fusion procedures.
2.8.2.2. Immunisation protocol fo r  the production o f  rabbit polyclonal antibodies 
to warfarin:
New Zealand White Rabbits > six months old were used for the production of polyclonal 
antiserum to warfarin, using the immunisation schedule described below:
Day 1: A 2 mg/ml solution of 4'-azowarfarin-thyroglobulin/Keyhole Limpet
Haemocyanin (KLH) was prepared in PBS-1 and mixed with an equal
5 2
volume of Freund's Complete Adjuvant (FCA). The rabbit was then 
immunized at various sites by intradermal injection with an emulsion (1 ml) 
consisting of a 1 mg/ml solution of the immunogen (4'-azowarfarin- 
thyroglobulin/Keyhole Limpet Haemocyanin (KLH)) mixed 1:1 with 
Freund's Complete Adjuvant (FCA).
Day 21: A lml-blood sample from the ear vein (primary bleed) was removed, and the
specific antibody titre determined.
Day 31: The rabbit was re-immunised as before using Freund's incomplete adjuvant.
Day 41: A 1 ml blood sample was obtained as before (secondary bleed), and the
specific antibody titre determined (section 2.11.1).
Antiserum recovery'.
The above cycle of blood sampling/titration and re-immunisation was carried out at 10-day 
intervals until the antibody titre was seen to plateau. At this stage the animal was sacrificed, 
and the blood recovered by cardiac puncture.
2.8.3. Preparation o f  rabbit serum:
The harvested rabbit serum was allowed to clot at room temperature for 2 hours and 
refrigerated overnight at 4°C. The serum was then centrifuged at 4,000 r.p.m. for 30 
minutes. The supernatant was removed and stored at -20°C until required.
2.8.4. Monoclonal antibody production by ascitic growth:
Ascitic fluid (also called ascites) is an intra-peritoneal fluid extracted from mice that have 
developed a peritoneal tumour. For antibody production, the tumour is induced by injecting 
hybridoma cells into the peritoneal cavity of mice of the same genetic background as the
hybridoma.
Balb/C mice of the same genetic background as the hybridomas were given an intra- 
peritoneal injection o f 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane). This solution 
acts as an immuno-adjuvostimulant /irritant to the mice, which respond by secreting nutrients 
and recruiting monocytes and lymphoid cells into the peritoneum, thus creating a rich 
environment for hybridoma growth. 7-10 days later, 2-3 xlO7 hybridoma cells were injected 
intra-peritoneally. Tumour growth was evident after 1-2 weeks and the mice were sacrificed. 
The ascitic fluid was drained under sterile conditions by insertion of a needle into the 
peritoneal cavity. The harvested cells were then cultured as described in section 2.10.4.
5 3
2.9. Antibody purification:
2.9.1. Purification o f  polyclonal rabbit serum:
2.9.1.1. Ammonium sulphate precipitation:
The ammonium sulphate precipitation of rabbit serum was carried out according to the 
method of Hudson & Hay (1980). 10ml of rabbit serum were diluted 1:2 with PBS-1 and the 
required volume of saturated ammonium sulphate was added to bring the final concentration 
to 45% (v/v). This mixture was then stirred at room temperature for 30 minutes, and the 
resulting precipitate centrifuged at 3,000 r.p.m. for 20 minutes. The precipitate was then 
resuspended in a volume of PBS-1, equal to that of the original volume of serum. Saturated 
ammonium sulphate was then added to bring the final concentration to 40% (v/v) and the 
mixture centrifuged at 3,000 r.p.m. for 20 minutes. The pelleted precipitate was then 
resuspended, in a volume equal to one-third of the original volume of serum. The 
resuspended precipitate was then dialysed overnight against PBS-2 with 0.02% (w/v) sodium 
azide at 4°C.
2.9.1.2. A ffinity purification o f  polyclonal anti-warfarin antibodies:
A 10 ml 4'-azowarfarin-BSA sepharose-4B column was equilibrated with running buffer 
(PBS-2 containing Tween 0.05% (v/v)). The dialysed ammonium sulphate rabbit 
immunoglobulin fraction was applied to the immunoaffinity column, collected and passed 
through the column twice more to ensure saturation of the column. The column was then 
washed with two column volumes of wash buffer. 0.1 M glycine-HCl (pH 2.5) was then 
added to the column and fractions collected in 1ml eppendorf tubes containing 150 fxl 1.0 M 
Tris-HCl, pH 8.5. The Tris-HCl buffer immediately neutralized the acidic immunoglobulin 
fractions eluted from the column, thus preserving the immunological activity o f the eluted 
antibody fractions. The absorbance of each fraction was measured, at 280 nm, and the 
fractions containing immunoglobulin were pooled and dialyzed against PBS-2 at 4°C.
2.9.2. Monoclonal antibody purification:
2.9.2.1. Concentration o f  tissue culture supernatant:
200 ml of spent supernatant from the relevant hybridoma cell line was collected over a 
period of time as described in section 2.10.4. Sodium azide was added to a final
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concentration of 0.02% (w/v) to the supernatants, which were then stored at 4°C until 
required.
The supernatant was concentrated 10-fold to a final volume of 20 ml, using a stirred 
ultrafiltration cell with a 76 mm diaflo ultrafilter membrane, with a molecular weight cut-off 
of 100,000 daltons, and the concentrate stored at 4°C until required.
2.9.2.2. Protein G/A affinity purification o f  murine and goat anti-mouse
immunoglobulin:
lml of a suspension of immobilised protein G (immobilised on Sepharose 4B) (stored in 
PBS-1 containing 20% (v/v) ethanol) was equilibrated in a column with 20ml of PBS-1. 10 
ml of concentrated hybridoma supernatant, or, 2 ml o f goat serum containing anti-mouse 
immunoglobulin was passed through the column, the eluate collected and passed through the 
column a second time. 25 ml of wash buffer was passed through the column and, 
subsequently, the retained protein was eluted with 0.1 M glycine-HCl buffer (pH 2.5). 850 
pi fractions of eluate were collected in eppendorf tubes containing 150 pi o f Tris-HCl (pH
8.5). The absorbance of each fraction was measured, at 280 nm. Those fractions containing 
significant protein were pooled, dialysed against PBS-2 and stored at -20°C until required 
for further use.
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2.10. Mammalian Cell Culture:
All mammalian cell cultures were cultured aseptically and grown in a humidified 5% C 02 
atmosphere, at 37°C.
2.10.1. Preparation o f  mammalian cell culture media:
All cell lines were grown in DMEM (Dulbecco's modification of Eagle's medium) 
supplemented with 10% (v/v) foetal calf serum (FCS), 2 mM L-glutamine, and 25 jxg/ml 
gentamycin (referred to as DMEM).
For somatic cell fusion procedures, three additional media preparations were prepared. 
DMEM lacking foetal calf serum was prepared for use during somatic cell fusion 
procedures. Additionally, HAT (Hypoxanthine, Aminopterin and Thymidine) medium was 
prepared, which consisted of DMEM supplemented with 1 mM sodium pyruvate, non- 
essential amino acids (NEAA; 1%, v/v), 100 (jM  hypoxanthine, 400 nM aminopterin, and 16 
(iM thymidine (referred to as HAT medium). This particular culture medium allowed for the 
selective growth of hybridoma cells post-fusion in the presence of Sp2/0 cells, which are 
unable to proliferate in HAT medium because they lack the requisite enzyme systems 
(section 5.1.1.). DMEM supplemented with 1 mM sodium pyruvate, non-essential amino 
acids (1%, v/v), 100 ^M hypoxanthine and 16 fiM thymidine was also prepared (referred to 
as HT medium).
2.10.2. Recovery o f  frozen cells:
Cells were recovered from liquid nitrogen by rapidly thawing at 37°C, and transferring to a 
sterile universal containing DMEM. The cells were then centrifuged at 2,000 r.p.m. for 10 
minutes, resuspended in fresh culture medium, transferred to a tissue culture flask and 
incubated at 37°C in a humidified 5% CO2 incubator. Prior to incubation, a 100 (xl sample of 
the resuspended pellet was tested for cell viability using Trypan blue (section 2.10.3.). Only 
cells with > 90% viability on recovery from frozen stocks were further cultured.
2.10.3. Cell counts and Viability testing:
All cell counts were made using an improved Neubauer Counting Chamber. Viable cell 
counts were obtained by mixing 100 (xl of cell suspension with 20 (xl of a commercial 
isotonic Trypan blue solution (Sigma, 0.25% (w/v)). The viable cell count was carried out 
within 5 min. of the addition of Trypan blue. A sample of this mixture was then used to 
perform the cell and viability count. Viable cells excluded the dye and remained white,
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while dead cells were stained blue. Cells were visualised under phase contrast on an 
inverted microscope at 40 X magnification. All cells were pelleted by centrifugation, and all 
centrifugations were at 2,000 r.p.m. for 5 minutes unless otherwise stated.
2.10.4. Growth o f  suspension cell lines:
The Sp2/0 (ATCC CRL 1581) cell line was cultured in DMEM. The cells were subcultured, 
using a split ratio of 1:4, at approximately 70% confluency. For subculturing, the cells were 
flushed off the surface of the flask using a Pasteur pipette, collected and centrifuged at 2,000 
r.p.m. The pellet was then resuspended in 4 ml of fresh culture medium. 1 ml of the 
resuspended pellet was then transferred to T-75 flasks containing 14 ml of fresh DMEM.
2.10.5. Storage o f  cell lines:
Cells were harvested from the surface of a confluent T-75 flask by flushing the surface of the 
flask with a Pasteur pipette, and pelleted by centrifugation at 2,000 r.p.m. Pellets were 
resuspended in 4 ml of a 10% (v/v) solution of DMSO (Dimethyl sulphoxide) in FCS, and 
aliquoted into 4 cryovials. A freezing-tray was used to gradually cool the cells, over a 2.5 hr. 
period, in the vapour-phase of liquid nitrogen. They were then immersed in the liquid-phase 
for long-term storage.
2.10.6. Mycoplasma screening:
Cell lines were screened for mycoplasma contamination in conjunction with the National 
Cell and Tissue Culture Centre, Dublin City University.
2.10.6.1. Cell culture o f  N R K  cells:
Adherent NRK (normal rat kidney) cells were cultured in DMEM. When cells had reached 
70% confluency, the medium was poured off, and the flask rinsed three times with 10ml of 
sterile PBS. 3ml of trypsinising solution (Gibco 0.025% (v/v) and 0.02% EDTA (v/v)) was 
added to the flask, which was replaced back in the incubator until all of the cells had 
detached. 5 ml o f fresh DMEM was then added to this cell suspension, which was then 
centrifuged at 2,000 r.p.m. and the pellet resuspended in the required volume of fresh 
DMEM.
2.10.6.2. Screening fo r  mycoplasma contamination:
NRK cells were cultured for at least 3 passages prior to mycoplasma screening in antibiotic- 
free medium. Hoechst stain was used for visualisation of the mycoplasma. Mouse myeloma 
cell lines used for somatic cell fusion procedures, and various hybridoma cell lines were
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grown in antibiotic-free media for 2 weeks prior to screening for mycoplasma, to ensure any 
intracellular antibiotic was removed. Cells were then seeded at a low density and allowed to 
proliferate for 3 days to 70% confluence, the conditioned medium was then removed and 
stored for subsequent screening at -20°C.
NRK (Normal Rat Kidney) cells were prepared to a final cell density of 2 x 103 cells/ml in a 
modified version of DMEM containing 5% FCS (v/v) and 1% L-glutamine (v/v), and 1 ml of 
cell suspension was then added onto sterile coverslips in petri-dishes. The cells were then 
incubated at 37°C overnight. The following day, 0.5 ml of conditioned medium was 
removed from the test samples and added to the NRK cells growing on the coverslips. The 
petri-dishes were then incubated for a further 3-4 days at 37°C.
The medium from each petri-dish was then removed and the coverslips were washed twice 
with sterile PBS, and once with PBS/Camoy's fixative (cold). 2 ml of Camoy's fixative 
(glacial acetic acid: methanol, 1:3, v/v) was then added to each coverslip and allowed to fix 
for 10 minutes. The samples were then allowed to air-dry overnight.
2ml of the DNA-intercalating dye Hoechst 33258 (working stock 50 ng/ml) was then added 
to each sample. The samples were then allowed to stain for 10 minutes in low-light. After 
10 minutes, the stain was very carefully removed and each coverslip washed with 3 x 2 ml of 
sterile distilled water. The washed coverslips were then mounted onto slides, and with the 
aid of a drop of mounting medium observed under the microscope using the 100 X objective 
lens using a fluorescent microscope. Uncontaminated cells show strong fluorescence in the 
nuclei only, whereas mycoplasma contaminated cells are detected by cytoplasmic staining of 
the mycoplasmic DNA.
2.10.7. Hybridoma production and isolation:
2.10.7.1. Somatic cell fusion:
Sp2/0 cells were grown for at least two weeks, prior to fusion. Cells were not grown above 
50% confluency, and were subcultured at a split ratio of 1:2 the day before fusion. On the 
day of fusion, the medium was poured off the Sp2/0 cells, and fresh DMEM lacking FCS 
was added. Cells were resuspended and counted. The cells were stored on ice until required.
Splenocytes, from an immunised mouse were harvested, resuspended in DMEM lacking 
FCS, and counted. The splenocytes and Sp2/0 cells were mixed to give a cell ratio of 10
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splenocytes per Sp2/0 cell. This cell mixture was pelleted by centrifugation at 1,250 r.p.m. 
and washed 4 times with 5 ml of DMEM lacking FCS.
All of the supernatant, from the final wash, was removed, except for 50-100 pi (simply 
pouring of the supernatant sufficed). The cells were resuspended by tapping the outside of 
the centrifuge tube with a finger until all of the cell pellet could be observed to be in 
solution. The cell suspension was placed in an ice-water bath, and 1.5 ml o f 50% (v/v) PEG 
(polyethylene glycol, molecular weight 1540 Da) which had been previously cooled to 4°C 
was added to the cell suspension, over a 1 minute period, with constant mixing. Mixing was 
maintained for another 1.5 minutes. The centrifuge tube was removed from the ice-water 
bath, and enclosed in the palm of the hand. 20 ml of pre-warmed (37°C) DMEM lacking 
FCS was then added at a constant rate with the aid of a Gilson pipette over a 5 minute 
interval with continual, slow, swirling of the centrifuge tube. The resulting suspension was 
placed at 37°C in a water bath for 15-20 minutes. The suspension was centrifuged, at 1,000 
r.p.m. for 10 minutes, and the cells resuspended at a cell density of 1.2xl06 cells/ml, in HAT 
medium supplemented with 5% (v/v) Briclone. The suspension was plated, in 96 well plates, 
at 0.1 ml per well, and incubated for 7 days. On day 7, 50 pi of fresh HAT medium 
supplemented with 5% (v/v) Briclone was added to each well. On day 8, 50 pi of spent 
medium was removed and fresh medium was added. Wells were then fed as required.
2.10.7.2. Screening fo r  specific monoclonal antibody production:
70 pi of ‘spent’ hybridoma supernatant was removed from the masterplate wells, and 
replaced with fresh DMEM supplemented with 5% (v/v) Briclone. The 'spent' hybridoma 
medium was then screened for specific anti-warfarin antibody production by conventional 
ELISA as described in section 2.11.1. Positive wells from the initial screening were then 
transferred to 48-well plates, and subsequently to 6-well plates for cloning.
2.10.7.3. Cloning o f  anti-warfarin specific hybridomas:
Cells from wells, which tested positive in the ELISA, were expanded in HAT medium, from 
96-well plates, to 48-well plates and finally to 6-well plates. Cells were cloned, by limiting 
dilution, when they had reached 50% confluency. Briefly, cells were resuspended, and 
diluted to 100 cells/ml in HT supplemented with 5% (v/v) Briclone. The cell suspension was 
plated, then, at 100 pl/well in 96-well plates. After 7 days, 50 pi of fresh HT containing 5% 
(v/v) Briclone was added, and on day 8 half the medium was changed. Wells were fed as 
required. Screening for positive wells proceeded, using an ELISA as per section 2.11.5, 
using neat medium from the well, as the test sample. Selected hybridoma supernatants were
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then screened at this stage using a variety of drug-protein conjugates employing different 
coupling chemistries and in a competitive assay format as described in section 2,11.5. Only 
cells that demonstrated inhibition in the competitive assay format were expanded further. 
Positive wells were expanded, as already described, and recloned twice at 10 cells/well, and 
once at 1 cell/well. The second time, cells were cloned in DMEM containing 10% (v/v) 
FCS, NEAA (1%, v/v), and 1 mM sodium pyruvate rather than in HT medium. Positive 
wells at this stage were considered, to be monoclonal.
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2.11. Solid phase immunoassays:
2.11.1. E L IS  As fo r  titration o f  antibody levels in serum samples/hybridoma 
supernatants:
100 pi of a solution of 50 pg/ml 4'-azowarfarin-BSA prepared in PBS-1, was added to all of 
the wells of a Nunc maxisorp plate, and incubated at room temperature overnight. Wells 
were washed with 5 x 200 (¿1 of wash buffer, and 100 pi of a 5% (v/v) solution of FCS in 
PBS-1 was added to each well, and incubated for 90 minutes at 37°C. This was to 'block' 
any remaining adsorption sites on the plastic surface.
Wells were then washed out with 5 x 200 pi of wash buffer. 100 pi of test sample (i.e. the 
appropriate dilution of rabbit/mouse serum sample or hybridoma supernatant) was added to 
the wells of the plate. Samples were diluted in PBS-1 containing 0.05% (v/v) Tween-20 and 
5% (v/v) FCS, and for the determination of antibody titres in mouse and rabbit serum, serial 
doubling dilutions were started at a dilution of 1/200. Hybridoma supernatants were 
normally screened neat for specific antibody. Samples were incubated for 90 minutes at 
37°C.
Wells were washed with 5 x 200 pi of wash buffer, 100 pi o f secondary antibody (alkaline 
phosphatase conjugated to a goat anti-mouse antibody or a goat anti-rabbit antibody), diluted 
as required in diluent buffer, was added to each well and incubated for 90 minutes at 37°C. 
Wells were washed with 5 x 200 pi of wash buffer, and 100 pi of substrate was added per 
well. The substrate used was para-nitrophenyl phosphate (pNPP) provided in tablet form, 
and dissolved in the required volume of dH20  immediately before use, according to the 
manufacturers instructions. Substrate was left to develop in the dark at room temperature, or 
overnight at 4°C. Absorbance readings were read at 405 nm using a Titertek plate reader.
2.11.2. Isotyping o f  monoclonal antibodies:
ELISA plates were coated and blocked as described in section 2.11.1. 100 pi of culture 
supernatant from positive hybridomas, following cloning by limiting dilution, was then 
added to each well of the coated plate. Alkaline-phosphatase labeled goat anti-mouse 
immunoglobulin subtypes were then added to the wells and the ELISA developed as 
described in section 2.11.1. Wells giving positive results defined the monoclonal antibody 
isotype.
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2.11.3. Determination o f  antibody working dilution:
ELISA plates were coated and blocked as described in section 2.11.1. Serial dilutions of 
purified monoclonal and affinity-purified rabbit polyclonal antibody were then prepared in 
diluent buffer, starting dilutions at 1/1000. Ten serial dilutions were then prepared by 
doubling dilution in diluent buffer. 100 (xl of test sample was then added to the wells of the 
plate in triplicate, and incubated at 37°C for 90 minutes.
Wells were then washed with 5 x 200 j.tl of wash buffer, and 100(il of the appropriate 
secondary antibody (i.e. alkaline phosphatase conjugated to a goat anti-rabbit or anti-mouse 
isotype specific antibody) prepared in diluent buffer was added to each well, and the plate 
incubated at 37°C for 90 minutes. Wells were then washed with 5 x 200 |jl of wash buffer 
and 100 (4,1 o f substrate (pNPP) was added per well. The plate was developed at room 
temperature in the dark or overnight at 4°C. Absorbance was measured using a Titcrtek plate 
reader at 405 nm. The optimal dilution of purified antibody (i.e. rabbit polyclonal/mouse 
monoclonal) was determined in this manner as the dilution taken from the mid-point of the 
linear portion of the sigmoidal curve obtained.
2.11.4. Determination o f  optimal conjugate loading density:
4'-azowarfarin-BS A was prepared in PBS-1 at various concentrations, namely 100, 50, 25, 
10, and 5 (xg/ml. A 100 ^g/ml solution of BSA control was also prepared in PBS-1 as a 
control. 100fxl of the respective conjugate concentration was used to coat two rows of a 
Nunc Maxisorp immunoplates overnight at room temperature. The ELISA was developed 
as per section 2.11.3. The optimal conjugate loading density was defined as that coating 
density that gave the widest linear working range over the greatest range of antibody 
dilutions used.
2.11.5. Competitive ELISA
Nunc Maxisorp plates were coated and blocked as described in section 2.11.1. Serial 
dilutions of warfarin ranging in concentration from 0.03-5,000 ng/ml were prepared in 
diluent buffer lacking FCS (5%, v/v). 50 (al of each drug concentration was then added to 
the wells of a coated microtitre plate, and 50 fj.1 of purified antibody at 2 x working dilution 
was added to the wells of the plate. The plate was then developed as described in section
2.11.1. Absorbance values were then measured at 405 nm using a Titertek plate reader. 
Absorbance values at each antigen concentration were then divided by the absorbance 
measured in the presence of zero antigen to give normalised absorbance readings (see
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Appendix 1A). A plot of the normalised absorbance reading versus antigen concentration 
(ng/ml) was used to construct the calibration curve.
2.11.6. Affinity analysis using E L ISA :
The method of Friguet et al. (1985) was employed (section 5.2.6.1). Briefly, the day before 
the ELISA analysis, a series of antibody-antigen mixtures were prepared in eppendorf tubes 
and placed on a rocking platform at room temperature overnight, and allowed to reach 
equilibrium. These solutions each contained a constant but unknown concentration of 
antibody. This concentration was nominally referred to as "1". The antibody:antigen 
solutions each contained a constant concentration of antibody, and varying but known 
concentrations of antigen ([A]). Additionally, serial doubling dilutions of antibody were 
prepared from that antibody dilution given the nominal antibody concentration o f " 1". These 
dilutions were used to construct a standard curve of nominal antibody concentration versus 
absorbance at 405 nm. The following morning, the nominal concentration of free antibody 
in each solution was determined by ELISA, as per section 2.11.1. Absorbance readings at 
405nm values were related to nominal concentration values, by reference to the constructed 
standard curve of nominal antibody concentration versus absorbance at 405 nm.
The fraction of total antibody, bound by antigen (v), was calculated for each antigen 
concentration. The slope of a plot of 1/v versus 1/[A] (Klotz plot) defined the dissociation 
constant for the interaction.
2.11.7. Determination o f  mouse immunoglobulin concentrations by affinity- 
capture ELISA
Goat anti-mouse immunoglobulin which had been previously affinity-purified according to 
section 2.9.2.2. was diluted to a final concentration of 10 jJ-g/ml in PBS-1, and 100 jjI added 
to the wells of an ELISA plate and allowed to coat overnight at room temperature. The plate 
was then blocked as described in section 2.11.1. Dilutions of mouse IgG of known 
concentration ranging from 3.90-1000 ng/ml were prepared in diluent buffer. Dilutions of 
affinity-purified antibody and hybridoma supernatant ranging from 1/2000 to 1/16,000 and 
1/1,000 to 1/4,000, respectively, were also prepared in diluent buffer. 100 |al of the solutions 
containing mouse IgG of known concentration, and the dilutions of both hybridoma 
supernatant and affinity-purified antibody were added to the wells of the ELISA plate in 
triplicate. The ELISA was developed as described in section 2.11.1 using a goat anti-mouse 
alkaline phosphatase-labelled secondary antibody. A calibration curve o f absorbance at 405 
nm versus mouse IgG concentration allowed for the determination of the mouse IgG 
concentration in the affinity-purified and hybridoma supernatants.
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2.12. BIACORE Studies:
2.12.1. Preconcentration studies:
The BIACORE™ with CM5 chips, was used for all ‘real-time’ analyses. For a detailed 
description of the theory and practice of this instrument, the reader is referred to Jonnson et 
al. (1991). For preconcentration studies, 4'-azowarfarin-BSA was dissolved at a 
concentration of 50 pg/ml in 10 mM sodium acetate buffer, at a range of pH values between 
3.8-5.5. These were passed, sequentially, over an underivatised chip surface, and that pH 
giving the greatest mass (measured in terms of response units (RU)) pre-concentrated at the 
surface of the chip, was used for subsequent warfarin-BSA immobilisation procedures.
2.12.2.1. Immobilisation o f  drug-protein conjugates:
The chip surface was activated, by passing 35 pi of a solution containing 0.05 M NHS and 
0.2 M EDC in ultra-pure (UP) H20 , over the chip surface at a flow rate of 5 pl/min. 35 pi of 
a solution of 4'-azowarfarin-BSA in 10 mM acetate buffer, pH 4.8, was passed over the 
surface at a flow rate of 5 pl/min. Unreacted NHS groups were ‘capped’ (section 4.2.2.), by 
passing 35 pi of a 1 M ethanolamine (pH 8.5) solution over the surface at a flow rate of 5 
pl/min.
2.12.2.2. Direct immobilisation o f  drug onto chip surface:
Direct immobilisation of drug directly onto the chip surface, was performed manually 
outside the BIACORE instrument. The chip was first allowed to equilibrate to room 
temperature. 40 pi of HBS buffer (section 2.4.) was added to the sensor chip well and left 
for 5minutes, this served to prime the chip surface. This solution was then removed using 
lint-free adsorbent paper, taking great care to ensure that paper did not touch the dextran 
matrix. Equal volumes of 0.4 M EDC and 0.1 M NHS were then mixed, and 40 pi of the 
resulting solution, containing 0.05 M NHS and 0.2 M EDC in UPH20 , was added to the chip 
well and left for 15 minutes. The EDC/NHS was then removed using adsorbent paper. 4'- 
aminowarfarin, at a concentration of 50 pg/ml in 10m M sodium acetate buffer, pH 5.5, was 
then added to the chip well and allowed to react for 20 minutes. The chip was then blocked 
by adding 40 pi o f a 1.0 M ethanolamine (pH 8.5) solution to the chip well and left for 20 
minutes. The chip was then extensively washed with distilled water and dried under 
nitrogen. The chip could then be stored in HBS or in a desiccator for later use.
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2.12.3. Regeneration studies:
To assess the stability o f the immobilised drug-protein conjugates or directly immobilised 
drug surfaces, a known concentration of antibody was passed over the chip surface and the 
surface regenerated with mild acid/base solution (10-25 mM HC1 was usually sufficient to 
dissociate the complex). This cycle of binding and regeneration was usually completed for 
greater than 100 cycles, and the binding signal measured to assess the stability and suitability 
of the immobilised surface for assay purposes.
2.12.4. Non-specific binding studies:
Purified monoclonal and polyclonal antibody solutions, and hybridoma supernatants at the 
requisite dilution were passed over an immobilised BSA surface and the dextran matrix 
itself. Non-specific binding to either dextran or immobilised BSA surface was 'titered' out 
by the addition of either molecule to the antibody solution.
2.12.5. Universal standard curve:
4'-aminowarfarin was immobilised on a sensor chip as described in section 2.12.2.2. Serial 
dilutions of antibody supernatant and purified antibody were passed over the surface under 
conditions of mass transfer limitation (MTL) at 10 fil/min for 4 minutes (section 5.1.11.2 and
5.2.4.2.) The rate of antibody binding (dR/dT) was calculated from the slope of the binding 
curve and plotted against the logarithm of the reciprocal of the antibody dilution factor used. 
From the curve and algorithm, the concentration of antibody [nM] in both solutions was 
calculated.
2.12.6. Competitive/Inhibition assays:
Warfarin was prepared at a series of concentrations ranging from 0.03-5,000 ng/ml by serial 
dilution, using Hepes Buffered Saline (HBS) as diluent. Antibody was then mixed with the 
various antigen concentrations using the BIACORE autosampler. The antibody:antigen 
mixture was allowed to equilibrate for a specified time interval (normally 5-10 minutes). 
The equilibrium mixtures were then passed sequentially, in random order, over the chip 
surface at 10 fxl/min for 4 minutes, and the chip surface regenerated between cycles by 
pulses of the appropriate regeneration solution for each antibody type (section 4.2.3.1.). The 
amount of bound antibody following injection of the antibody:antigen mix was measured in 
terms of response units (R). The respective responses (R), were then divided by the response 
measured for the antibody:antigen mixture containing zero antigen (Ro), to give normalised 
binding responses (R/Ro)(Appendix 1A). A plot of antigen concentration ng/ml versus
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normalised binding responses (R/Ro) could then be used to construct the calibration plot 
using BIAevaluation 3.1 software.
2.12.7. Solution affinity analysis using BIAcore:
4'-azowarfarin-BSA (13,000 RU) was immobilised using the conventional EDC/NHS 
coupling chemistry. Serial dilutions of Protein G-purified anti-warfarin monoclonal 
antibodies of known concentration were passed over the immobilised surface, and a 
calibration curve was constructed of mass bound measured in terms of response units, versus 
antibody concentration (nM). A known concentration o f antibody was then incubated with 
varying concentrations of warfarin (nM), and allowed to reach equilibrium overnight. The 
equilibrium samples were then sequentially passed over the immobilised surface and the 
binding response calculated. The response values measured were used to calculate the 
amount of'free antibody' in the equilibrium mixtures, from the constructed calibration curve. 
A graph was then constructed of drug concentration (nM) versus 'free antibody 
concentration' (nM), and using the solution phase interaction models in BIAevaluation 3.1 
software, the overall affinity constant could be determined.
2.12.8. Steady state affinity analysis using BIAcore
4'-azowarfarin-BSA (-1200 RU) and BSA (~1500 RU) were immobilised on separate flow 
cell surfaces of a sensor chip. Serial dilutions of purified monoclonal antibodies to warfarin 
of known concentration, were then sequentially passed over the chip surfaces using 'on-line' 
reference curve subtraction. A graph was then constructed of the equilibrium binding 
response (Req) measured versus antibody concentration (nM). Using the steady-state 
interaction model in BIAevaluation 3.1 software, the affinity constant could then be 
calculated for the interaction.
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2.13 HPLC studies:
2.13.1. Preparation o f  plasma ultrafiltrate:
50 ml of blank plasma obtained from Sigma, was placed in an Amicon concentration device 
containing a 1 kDa molecular weight cut-off membrane. The plasma ultrafiltrate was 
collected under positive pressure and stored at -20°C until required for further analysis.
2.13.2. Extraction o f  warfarin from  plasma samples:
1.0 ml of patient plasma was placed in blood tubes and 50 pi of internal standard, p- 
chlorowarfarin, was added to a final concentration of 500 ng/ml. 1.0 ml of 1.0 M sulphuric 
acid was then added to the plasma samples, which were then placed on a blood-tube rotator 
for 30 minutes. 5 mis of ethyl acetate were then added to the plasma acid extracts, and 
placed back on the blood tube rotator for a further 60 minutes. The samples were then 
centrifuged at 3,500 r.p.m., and 4.5mls of the organic layer removed and placed in 
evaporating tubes under nitrogen at 35°C. The samples were then reconstituted in 200 fxl of 
mobile phase as described in section 2.13.4. prior to injection onto the HPLC system. Drug 
concentrations were measured using the HPLC method described in section 2.13.4.
2.13.3. Preparation o f  patient plasma ultrafiltrate:
Patient samples were placed in Nanosep™ ultrafiltration devices that contain a 1 kDa 
molecular weight membrane cut-off filter. The samples were centrifuged at 8,000 r.p.m. on 
a microccntrifugc for 30 minutes. Following ultracentrifugation, the plasma ultrafiltrate was 
collected and analysed by HPLC and BIACORE immunoassay as described in section
2.13.4. and 2.12.6., respectively.
2.13.4. H PLC detection o f  warfarin in plasma ultrafiltrate and plasma:
Mobile phase for HPLC analysis of warfarin in plasma ultrafiltrate and plasma, was prepared 
by mixing 570 ml of acetonitrile, with 426 ml of water and 4 ml of glacial acetic acid 
together in a volumetric flask. The mobile phase was then filtered through a 0.2 |a.m filter, 
and placed in a sonicator for 20 minutes. HPLC measurements were performed using a 
Varian Star HPLC system comprising 9012-pump, 9050-UV detector, AI-200 autosampler 
and Varian Star software version 5.1. The chromatographic separation was achieved on a 
Supelco Discovery™ C-18 column, of dimensions 150 x 4.6 mm, and a particle diameter of 
5 pm, using a flow rate of 1.0 ml/min. UV detection of the column effluent was recorded at 
308 nm (the absorbance maxima of warfarin in the particular mobile phase).
6 7
2.13.5. Fluorescent post-column H PLC  detection o f  warfarin in patient
plasma samples:
Mobile phase was prepared as described 2.13.4. Plasma samples for analysis were prepared 
as described in section 2.13.2. A post-column reaction coil was then used to mix the column 
effluent, with the post-column reagent, 12% (v/v) triethanolamine at a  flow rate of 0.3 
ml/min. Fluorescent detection was performed at excitation and emission wavelengths, of 
310 and 370 nm, respectively.
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Chapter 3
Production and Applications of Polyclonal 
Antibodies to Warfarin
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3.1. Introduction:
The mammalian immune system has evolved a diverse range of powerful mechanisms to 
identify foreign cells, viruses and macromolecules and eliminate them from the body. The 
mechanisms by which the body’s immune system performs this ‘natural surveillance’ can be 
broadly divided into two categories: non-adaptive and adaptive immunity.
Non-adaptive immunity is a cell-mediated non-specific response to foreign cells and includes 
such internal systems as phagocytosis by macrophages and cell lysis by natural killer (NK) 
cells. The body has also developed external barriers such as skin and mucous membranes 
that prove effective against environmental agents. Similarly, chemical influences such as pH 
and secreted fatty acids also provide effective barriers against invading micro-organisms.
The adaptive immune response can be further divided into the humoral and cell-mediated 
immune response. In contrast to non-adaptive immunity, the effectiveness o f the adaptive 
immune response improves with re-exposure to the foreign molecule, and the agent to which 
the acquired immune response is induced is commonly referred to as the immunogen. 
Immunogenicity can be defined as the ability of a foreign molecule to elicit an immune 
response, whilst the term antigenicity refers to the ability of a particular molecule to be 
bound by antibody, and the antibody-bound molecule is consequently referred to as the 
antigen. There are three main types of lymphocytes that mediate the acquired immune 
response: B-cells, cytotoxic T cells (Tc) and helper T-cells (TH). T-cells recognise antigen 
only when it is associated with a membrane component of the major histocompatability 
complex (MHC), resulting in the differentiation of T-cells into memory and effector cells. 
Th cells recognise antigen in conjunction with MHC II proteins and are responsible for the 
release of cytokines that play a crucial role in the amplification of the immune response. TH 
cells are made up of two distinct populations namely: ThI and Th2 that differ in terms of 
their cytokine secretion characteristics. TH1 cells are primarily responsible for the activation 
of cytotoxic T-cells (IL-2, IFN-y), whilst TH2 cells are responsible for the activation of B- 
cells (IL-4, IL-5). Tc cells bind to MHC I molecules peptide-bound molecules generating 
cytotoxic T-lymphocytes that are responsible for the destruction of the target cell by 
apoptosis, or causing the release of cytotoxic substances (e.g. perforins) which cause 
membrane permeability leading to target-cell death. The humoral immune system is 
mediated by B-cells in conjunction with T-helper cells, and it is the complex interactions 
between these three particular cell types that mediates the humoral and cellular immune 
system.
7 0
The lymphatic system describes the organs that are responsible for lymphocyte maturation, 
differentiation and proliferation. The lymphoid organs can be further divided into primary 
and secondary lymphoid organs that are responsible for the maturation and proliferation of T 
and B-lymphocytes and the proliferation of antigen-driven differentiation, respectively. The 
primary lymphoid organs are the thymus gland and the bone marrow, which are responsible 
for the antigen-independent differentiation of progenitor cells from the bone marrow into T 
lymphocytes, and the development of antibody-producing B-cells, respectively. The 
majority of T-cell maturation takes place during foetal development, which involves the 
maturation into various classes of T-cells capable of binding to various epitopes or antigenic 
determinants via a specific cell-surface receptor on the T-cell (T-cell receptor, TCR).
The secondary lymphoid organs comprise the spleen, lymph nodes and a variety of other 
secondary systems including the mucosa-associated lymphoid tissues (MALT) and tonsils. 
It is in these particular organs where antigen-driven differentiation takes place.
3.1.2. The Humoral Im m une response:
To elicit an immune response the particular antigen must possess three particular 
characteristics, namely: a high molecular weight, a degree o f ‘foreignness’ to the host, and a 
degree of chemical complexity. With regard to molecular weight it is usually only 
macromolecules with a molecular weight of greater than 6 kDa that are capable of invoking 
an immune response. Small molecular weight compounds such as drug molecules are 
incapable of stimulating an immune response themselves, however, following conjugation to 
larger molecular weight carriers; the small molecular weight haptens can become 
immunogenic. The antigen must also possess a degree of chemical complexity, as large 
macromolecules with repeating units are seldom immunogenic. Finally, the immune system 
must also recognise the antigen as foreign (i.e. ‘non-self) and be able to respond 
immunologically.
The first exposure of an individual to an immunogen is generally referred to as the primary 
immune response. It is the culmination of a series of events following this primaiy immune 
response that ‘primes’ the immune system for subsequent exposure to the particular antigen. 
Following exposure to antigen, which may have been as a direct result of an immunisation 
procedure or a result of injury, macrophages and other cells of the reticuloendothelial system 
(RES) engulf the foreign antigen and as all of these cells process antigen in the same non­
specific fashion they are collectively termed -  antigen presenting cells (APC). The use of 
adjuvants (e.g. Freund’s Complete Adjuvant), altering the form of the antigen and using 
various immunisation sites are effective ways of increasing the immunogenicity of a
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particular antigen. Generally speaking particulate insoluble antigens are the best 
immunogens. Adjuvants function in two ways: they firstly protect the antigen by trapping it 
in a local deposit, and secondly, they attract macrophages and increase the local rate of 
phagocytosis.
Following phagocytosis, the antigen is presented on the surface o f the antigen-presenting 
cells (APC) in conjunction with MHC (Major Histocompatability Complex) Class II. TH 
cells then bind with the MHC class II-antigen complex via their T cell receptors, which 
resemble antibody molecules in many respects. The T-cell receptor is a heterodimer 
comprised of a -  and p-chains that are comprised of variable and constant regions, which 
form the binding site. The binding of the TH cell to the APC triggers a series of events 
resulting in T-cell proliferation and differentiation and the release of interleukin-1 (IL-1). 
The activated TH cells are responsible for the release of IL-2 that plays a key role in B-cell 
proliferation. In a similar fashion, antigens are also processed by B-cells, although the 
uptake is specific for each particular antigen. The antibody-antigen complex is internalised 
and the antigen processed and expressed on the surface with class II protein which provides a 
source of complex for binding to the TH cells that are specific for the antigen-protein 
complex (Figure 3.1).
For the generation o f a strong immune response the interaction between B and T-cells is of 
crucial importance in regulating antibody production, and leading to B-cell production and 
the production of antigen-specific antibody. The processing of antigen by B-cells followed 
by T-cell recognition of the displayed fragment, leads to B-cell stimulation by TH cells. The 
failure to form such complexes is why haptens (e.g. small molecules such as drug 
compounds) are unable to invoke the necessary binding between the T-cell receptors and 
class II determinants, and why the use of carrier molecules (e.g. thyroglobulin) must be 
employed. The binding of the TH to B-cells, causes the B-cells to synthesise a receptor for 
interleukin-4 (IL-4) which is synthesised by activated TH cells, and in turn leads to the 
production of IL-5 by B-cells which results in differentiation of B-cells into memory and 
plasma cells. Plasma cells are responsible for the secretion of large amounts of specific 
antibody and are terminally differentiated with a lifespan of approximately 3-4 days. B 
memory cells do not secrete antibody but remain in the body for long periods with their 
specific antibody cell-surface receptor primed for future exposure to the antigen.
The process of B-cell differentiation is accompanied by somatic mutation of the amino acid 
sequences of the variable heavy and light chains, producing antibodies with differing 
affinities for the antigen in the germinal centres of the spleen and lymph nodes which contain 
follicular dendritic cells that retain the antigen on their surface for presentation to B-cells.
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The higher affinity B-cells are preferentially selected for proliferation as their cell-surface 
antibody is capable of binding the antigen more efficiently, in a process known as affinity 
maturation. B-cells with low-affinity towards the particular antigen are selected against by 
apoptosis, ensuring the proliferation of only the higher affinity variants. Class-switching 
also occurs during the differentiation process, whereby the B-cells expressing the IgM/D cell 
surface antibody may switch to synthesis of IgG, IgA or IgE molecules. Consequently, upon 
re-exposure to the antigen the immune response evokes a much more potent response 
involving the memory B-cells that are o f higher affinity and predominantly o f the IgG class.
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Figure 3.1: The interaction between an antigen presenting T-cell and B-cell
leading to T- and B-cell activation in a primary response. Antigen 
is initially phagocytosed by antigen presenting cells (APC) and 
presented on the surface as MHC class 11-antigen complex. TH cells 
bind to this complex through their T-cell receptor, triggering T-cell 
proliferation and differentiation. For the generation o f  a strong 
humoral immune requires the interaction o fT H cells and B-cells. B 
cells can also bind and process antigen, and recognition o f  the 
displayed fragment by Th cells leads to the B-cell stimulation, 
proliferation and differentiation into memory and plasma cells 
capable ofproducing large quantities o f  antibody following affinity 
maturation in the germinal centers.
Memory cell Plasma cell
Activated TH cell expressing 
IL-2 rcceptois
Release o f cytokines IL-2, 
IL-4, IL-5
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3.1.3. Antibody Structure:
Antibodies are glycoproteins of the immunoglobulin supergene family (Steward, 1985), 
which share a variety of key structural and functional features. Analysis of the structure of 
antibodies began in earnest in 1959, following the discovery by Porter that immunoglobulins 
could be separated into various parts following digestion with papain, namely into two Fab 
portions and one Fc portion (Figure 3.2). Edelman then discovered that digestion with 
mercaptoethanol further reduced the y-globulin into four chains: two identical sets of 
molecules, designated heavy («53 kDa) and light («22 kDa) chains because of their differing 
molecular weights.
One light chain associates with the amino terminal of one heavy chain to form an antigen- 
binding domain (Fab). Interchain disulphide bonds hold the heavy and light chains together 
with various intrachain bonds in various antibody chains. Five main classes of antibody 
(isotypes) have been resolved that differ in the structure of their heavy chains (Table 3.1). 
The basic four-chain model holds for all antibody isotypes with specific heavy chains for 
each class, y for IgG, fj. for IgM, 8 for IgD, a  for IgA and e for IgE. The light chains have 
also been serologically divided into k and X chains, although these are similar in each 
isotype class. Each antibody isotype has been further divided into sub-classes (e.g. IgG,, 
IgG2a, etc.). It is the variation in the heavy chain sequences that accounts for the variation in 
effector function elicited by the various proteins at differing stages during the immune 
response. The intrachain disulphide bonds within the antibody molecule are responsible for 
the formation of loops within the chains, resulting in the formation of globular domains of 
approximately 100 amino acid residues in length. The structure of the domains of each 
antibody chain has been designated by a letter signifying their position on the antibody 
molecule. The VH and VL exhibit the greatest degree of variability in amino acid sequence, 
whilst the constant regions (i.e. CL, ChI, Ch2 etc.) are much more constant in terms of amino 
acid sequence (Figure 3.2).
The hinge region is a short amino acid sequence situated between the ChI and Ch2 regions 
of the immunoglobulin heavy chains (with the exception of IgM and IgE) and is composed 
primarily of proline and cysteine residues. The hinge region permits flexibility of between 
60-180° of the two Fab arms of the antibody molecule, allowing the Fab arms to open and 
close to accommodate antigen binding.
The variable region of an antibody is responsible for the antigen recognition, specificity and 
affinity and is comprised o f approximately 110 amino acid residues. Variability within the V 
region is a highly organised process within specific regions of the variable region, known as
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the hypervariable regions, forming a region complementary in structure to the antigen 
epitope and these are so called the complementarity-determining regions (CDRs). The CDR 
region can be further sub-divided into three different regions (i.e. CDR1, CDR2 and CDR3) 
of about 10 amino acid residues in length between which lies more conserved sequences 
known as the framework residues. When the heavy and light chains are formed the variable 
(V) region is formed, the CDR sequences are exposed, forming a cleft that serves as the 
antigen-binding pocket. It is the precise amino acid sequence, shape and positioning of this 
cleft or pocket as result of the combination of the six CDR sequences which form 
hypervariable loops that confers the particular antibody specificity.
Table 3.1: Functions and Structural Features o f  Antibody Isotypes
Characteristic IgG IgM IgD IgA IgE
Molecular
Weight
150 kDa 950 kDa 175 kDa 165 kDa 
(monomeric) 
390 kDa 
(secretory)
190 kDa
Heavy chain Y M- S a s
Valency 2 5/10 2 4 2
Concentration in 
serum
8-16 mg/ml 0.5-2 mg/ml 40 (xg/ml 1-4 mg/ml 0.4 ng/ml
Function Secondary
response
Primary
response
Poorly 
understood, 
it is a surface 
component of 
many B-cells
Major Ig 
component of 
external 
secretions 
(e.g. saliva, 
sweat, tears)
Protection 
against 
parasites and 
involved in 
allergic 
reactions
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Figure 3.2: The immunoglobulin molecule. The antibody is composed o f two identical
light (25 kDa) and heavy (50 kDa) chains. The heavy (H) chains are 
composed o f  five domains namely: one variable (V), three constant (Cnl, 
CH2, Ch3), and one hinge region. The variable region is comprised o f  a 
single variable and constant domain. The hinge region provides the 
flexibility to allow fo r the individual antibody-binding sites to bind antigen. 
Interchain disulphide bridges connect the heavy and light chains; there are 
also intrachain disulphide bonds that form loops within the chain. The CDR 
regions confer the specificity to the particular antibody-binding site, and 
exhibit high amino acid sequence variability.
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3.1.4. Antibody Affinity:
The net interaction between an individual antibody’s antigen binding site and the 
corresponding epitope dictates the affinity of the interaction between the two molecules. 
Antibody affinity is thermodynamically described in terms of the equilibrium constant, KA, 
by the following expression: 
where,
ka
[Ag] + [Ab] <-> [Ag:Ab] (1)
kd
K a = \ A g A b \ _  ( 2 )
\A g\\A b\
The term avidity is used to describe the overall affinity arising from the multivalent binding 
of the antigen-binding sites of an antibody to a multivalent antigen. As a result of the 
multivalent binding of an antibody to an antigen, such multivalent antibody-antigen 
interactions often exhibit extreme stability and reduced dissociation rates as a result of the 
multimeric interactions (e.g. IgM), although the individual dissociation rates would resemble 
the univalent interaction.
The affinity of the interaction between an antibody and antigen is the net result of the 
intermolecular forces between the two molecules, and four types of such intermolecular 
forces have been identified. They include hydrogen bonding, ionic interactions, Van der 
Waals forces and hydrophobic interactions. Hydrogen bonding involves the interaction of a 
H-atom covalently linked to an electronegative atom with the unshared electron pair of 
another electronegative atom. Ionic interactions are the result of the attraction between 
oppositely charged groups and consequently can be disrupted by changes in salt 
concentration or pH. Hydrophobic interactions involve the association of non-polar 
(hydrophobic) residues in aqueous environments. Van der Waals forces are the result of 
interactions between electron clouds of neighbouring molecules as two polar groups come in 
close contact. This results in the induction o f oscillating dipoles between the two molecules 
resulting in a net attractive force. The strength of these particular forces is only effective 
over short distances, which can usually be disrupted by high ionic strength or extremes of 
pH.
The structure of antibody-antigen crystal complexes has also allowed for greater 
understanding of the formation of immune complexes. Crystal structures have revealed that 
following antibody-antigen binding that structural changes in the antibody upon complex 
formation include side chain rotations, movements o f CDR loops and displacement o f Vh
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relative to VL (Davies el a l, 1996). Crystal studies o f a germline Fab fragment with its 
hapten were compared by Wedemayer et al. (1997) with the corresponding affinity-matured 
antibody fragment, which has a greater than 30,000 times greater affinity for antigen. The 
crystal studies of the antibody:antigen complexes revealed that the germ-line antibody 
combining site underwent significant structural changes following binding of hapten, whilst 
the hapten bound to the affinity-matured antibody by a ‘lock and key’ type mechanism. The 
gross structural changes observed were also accompanied by significant re-organization of 
the combining site residues. These results demonstrate that the germline antibody is 
pluripotential with respect to the possible number of recombinations it can assume in 
response to antibody binding, and that these mutations become fixed during the affinity 
maturation process to a particular high-affinity conformation that stimulates the immune 
response. It can therefore be seen that such flexibility within the germline can greatly 
expand the structural diversity of the primary immune repertoire.
3.1.5. The Genetic Basis o f  Antibody Diversity:
The variable region of the heavy and light chain of an antibody encodes for antibody 
diversity. It is the heterogeneity that exists within this sequence that is responsible for the 
generation of an effective immune response. Since the range of antigens is so diverse in both 
size and structure, the repertoire of antibodies must be correspondingly diverse, and four 
distinct processes encoding for this diversity have been identified (Tonegawa, 1983).
It has been shown that the genetic information encoding for the immunoglobulin polypeptide 
chain is contained in various gene segments in the chromosomes of a germ-line cell. During 
the development of the lymphocyte, these particular gene segments are recombined to give 
rise to a new functional gene (i.e. combinatorial diversity). Variable light chain genes are 
encoded by the V and J regions, whilst heavy chain gene sequences are composed of gene 
segments from the V, D and J loci. Following B-cell maturation, the various VDJ sequences 
on the heavy chain, and VJ sequences on the light chain recombine to form a complete 
functional gene. During the recombination process, to bring a D region adjacent to a V 
region, a process known as ‘looping out’ occurs, whereby the intervening gene segments are 
deleted by recombinase enzymes. Consequently, the number of different possible 
permutations in terms of sequence arrangement for each particular chain, is the product of 
the number of V, D and J sequences particular to each sequence.
The recombination of the various VJ and VDJ sequences also gives rise to what is known as 
junctional site diversity as a result of the imprecise joining ends of the various sequences 
which can lead to changes in amino acid sequences at junction sites altering the binding site
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specificity. Junctional insertional diversity is the result of the insertion of small sets of 
nucleotides between the V-J and D-J sequences. Somatic mutations are also introduced at a 
high frequency in the amino terminal, which in turn creates additional diversity with regard 
to antibody specificity (Benjanimi et al., 1996).
The process of class or isotype switching occurs in mature B-cells as a result of antigenic 
stimulation. Constant H regions are found downstream of the variable region genes, in the 
sequence p, 5, y, s and a. Each constant region has at it’s 5' end a repeating base sequence 
called the switch region, which allows for any o f the VDJ sequences to recombine with the 
CH regions (except for the 5 gene which has no switch region). The influence of antigen and 
T-cell derived cytokines regulates this unique mechanism, allowing antibodies with a unique 
specificity to associate with a variety of effector functions as a result of their constant region 
sequence.
DJ joining Constant 
Region
VDJ joining Constant
Region
Germ Line DNA
200 Variable Genes 12 D regions 6 J Regions
Constant
Region
Mature B-cell DNA
Functional Gene
Figure 3.3: Two separate processes are involved in the recombination o f  a heavy chain
gene. Heavy chain gene segments are composed V (variable), D (diversity) and J  (joining) 
segments. The constant regions encode fo r  the antibody isotype. The first recombination 
step brings the D and J  segments together, looping out the intervening DNA by recombinase 
enzymes, which introduce further variability at the point o f  cleavage. The second step brings 
the V region gene alongside the DJ sequence, thereby fixing the specificity o f  the antibody, 
and giving rise to a functional B-cell variable heavy chain gene.
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3.1.6. Purification o f  Immunoglobulins:
Immunoglobulins are relatively robust molecules capable of maintaining biological activity 
following exposure to extremes o f pH for short periods of time, and storage for relatively 
long periods at -20°C. The purification of antibodies from serum, cell culture supernatants 
or cell lysates is often a necessity as the crude antibody preparations can often result in 
difficulties with particular assay systems. The degree of purity of antibody required for the 
particular purpose usually dictates the type of purification system employed. A variety of 
techniques have been developed for the isolation of immunoglobulin fractions from various 
matrices (Harlow & Lane, 1988), and the majority of these techniques exploit their differing 
solubilities in various solvent systems and their high isoelectric points (Steward, 1985).
The use o f ammonium sulphate is commonly employed as an initial clean-up step for the 
isolation of relatively pure immunoglobulin fractions (Hudson & Hay, 1980). As the salt 
concentration increases, hydrophobic interactions between molecules increase, eventually 
leading to the precipitation of immunoglobulins at particular salt concentrations. The use of 
chromatographic separation systems such as DEAE anion-exchangc columns, which exploits 
the basic nature of antibodies has also been described for the purification of crude antibody 
preparations (Carty & O’ Kennedy, 1988). The partitioning and purification of antibodies in 
aqueous two-phase systems (e.g. aqueous solutions of PEG/salt) has also been demonstrated 
to be a powerful, economical system for the large-scale purification of immunoglobulins 
(Andrews et al., 1996).
Protein A and G may also be used for the isolation of IgG. Protein G is a 30 kDa bacterial 
cell wall protein isolated from the group G streptococci, and binds to immunoglobulin 
molecules primarily through their Fc regions. Protein G binds with a higher affinity to 
particular immunoglobulin molecules such as mouse IgGi that do not bind particularly well 
to Protein A. Protein A is a 42 kDa cell wall component of several strains of Staphylococcal 
aureus and binds specifically to the Fc region of immunoglobulin molecules. The protein 
consists o f four high affinity binding sites (KA = 108 M '1), and is able to maintain activity 
after repeated exposure to extremes of pH rendering it suitable for routine purification 
procedures (Hermanson et al., 1992). Protein A and G can be easily coupled to sepharose to 
produce solid supports with high immunoglobulin capacity, exhibiting low degrees of non­
specific binding. Following application of the crude antibody preparation to such column 
supports and subsequent washing to remove non-specifically bound protein, the bound 
antibody can be eluted by exposure to high/low pH solutions.
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Affinity-purification techniques involve the covalent coupling o f the antigen of interest (e.g. 
4'-aminowarfarin) to a solid support (e.g. Sepharose-4B), and offer a convenient means of 
obtaining antigen-specific antibody preparations of high purity, as not only extraneous non­
specific protein is eluted but also non-specific immunoglobulin. The bound antibody can 
then be eluted using a combination of low pH and high salt buffers (e.g. Glycine-HCl 
buffer).
3.1.7. Immunoassays:
Immunoassays are the fastest growing analytical technique for the detection and 
quantification of a wide range of molecules (e.g. steroids, tissue markers), and have been 
extensively reviewed elsewhere (Wild, 1994; Price and Newman 1997).
One of the most commonly employed techniques for measuring antibody-hapten 
interactions, is the use of Enzyme-Linked ImmunoSorbent Assay (ELISA), which is now 
more commonly employed than radioimmunoassay techniques, primarily as a result of the 
hazardous nature and disposal of radioimmunoassay reagents. A schematic of the principle 
of the technique is shown in Figure 3.4., which is a modification o f the immunoassay 
principle originally described by Yalow and Berson (1959). Such competitive ELISA assay 
formats describe the competition between free and immobilised forms of antigen for binding 
to a limiting quantity of antigen-specific antibody. Direct immobilisation of small 
molecular weight haptens to ELISA plates is often difficult and the use o f hapten-protein 
conjugates is most commonly employed, which bind directly to the wells of y-irradiated 96- 
well immunoplate, primarily through hydrophobic interactions. The use of conjugates 
employing different carrier molecules and coupling chemistries to those used for initial 
immunisation purposes is thus necessary to ensure specificity of the bound antibody towards 
the hapten only, and not the carrier molecule or a combined drug-protein epitope (Danilova 
etal., 1994; Fasciglione etal., 1996).
A wide variety of ELISA formats are possible (Price and Newman, 1997), however, the 
competitive ELISA format is described in the context of the assay format utilised for the 
detection and development of a competitive immunoassay for warfarin. The hapten of 
interest that is covalently coupled to a protein (e.g. 4'-azowarfarin-BSA), is added to the 
wells of a 96-well immunoplate, and binds to the immunoplate predominantly through 
hydrophobic interactions. Loosely bound protein is then removed by washing with a 
solution containing detergent (e.g. wash buffer section 2.3.). A blocking agent (e.g. 5% FCS 
in PBS-1) is then added to the wells to ‘block’ any remaining available adsorption sites on 
the surface of the plate. The use of such blocking agents is necessary to ensure that no non­
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specific binding of either primary or secondary-labelled antibody to the wells of the plate 
occurs. A solution containing a limiting constant amount of antibody and varying known 
concentrations of antigen are then applied to the wells of the immunoplate, and incubated for 
a specified time interval. Competition then occurs between free antigen in solution and that 
immobilised to the immunoplate for binding to the antigen-specific antibody. The contents 
of the well are then removed and the plate washed to remove any non-specific antibody. The 
presence of antigen-specific antibody (i.e. affinity-purified rabbit anti-warfarin antibodies) in 
the wells o f the immunoplate can then be determined using a species-specific secondary 
enzyme-labelled antibody for the primary antibody (e.g. alkaline phosphatase-labelled goat 
anti-rabbit immunoglobulin). Following washing of the plate wells, a substrate solution is 
added to the wells and converted to a coloured product in the presence of enzyme. The 
intensity o f the colour solution formed is then measured spectrophotometrically at the 
appropriate wavelength. In such assay formats as the concentration of free antigen (i.e. 
warfarin) in solution increases, less antibody is available to bind to the solid-phase 
immobilised antigen (i.e. 4'-azowarfarin BSA). Consequently, an inverse relationship exists 
between the intensity of the coloured solution formed and the concentration o f free antigen 
in solution. In this way, the concentration of warfarin in unknown solutions can be 
detennined by reference to a suitable standard curve. The sensitivity of such competitive 
ELISA formats can be optimised using the appropriate dilution of antibody preparation and 
immobilised conjugate. However, the ultimate sensitivity of all immunoassay procedures is 
primarily a factor of the intrinsic affinity of the antibody preparation for the particular 
antigen.
8 3
Figure 3.4:
•  4'-azowarfarin-BSA 
® Blocking solution
\  Affinity-purified rabbit anti-warfarin antibodies 
A  Alkaline phosphatase labelled goat anti-rabbit IgG
D
+ Blocking solution
+ Affinity-purified 
rabbit anti-warfarin 
antibodies
B
+ AP-labelled 
goat anti­
rabbit IgG
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Schematic o f  the principle o f  direct ELISA, as used fo r the measurement oj 
antibody titres in purified samples. 4'-azowarfarin-BSA is used to ‘coat’ the 
wells o f  a 96-well immunoplate, and sticks to the y-irradiated plate primarily by 
hydrophobic interactions (A). The wells o f  the immunoplate are then blocked 
with a suitable blocking solution (e.g. 5% (v/v) F.C.S. solution in PBS-l) to 
block any remaining absorption sites on the plate (B). The antibody-containing 
samples are then added to the wells o f  the immunoplate, and, following a 
suitable incubation step, washed (i.e. wash buffer section 2.3.) to remove non­
specific protein(C). A species-specific secondary enzyme-labelled antibody is 
then added to the wells o f  the immunoplate and incubated fo r a suitable period 
o f  time (D). The wells are washed extensively again, and a substrate added to 
the wells o f  the plate, which in the presence o f  enzyme (i.e. secondary antibody) 
forms a coloured product whose absorbance can then be measured 
spectrophotometrically at the appropriate wavelength fo r  the substrate (E).
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Results and Discussion:
3.2 Conjugate Synthesis and Characterisation
3.2.1. Synthesis and Characterisation o f  4 ’-aminowarfarin
4'-aminowarfarin was synthesised by a modification of the method of Satoh et al. (1982) as 
outlined in section 2.4.1. This method involved the hydrogenation of acenocoumarin (4'- 
nitrowarfarin) in the presence of Raney nickel. This technique was initially modified to 
include the use of a palladium on carbon catalyst in the presence of hydrogen, due to the 
potentially explosive nature o f the Raney nickel and hydrogen mixture. The reaction 
mixture was periodically analysed by TLC as described in section 2.4.2. to assess the extent 
of product formation. This particular reaction yielded 4'-aminowarfarin in relatively pure 
quantities, but took several days to reach completion. The slow rate of reaction was 
attributed to the reduced catalytic activity of the palladium catalyst compared to the use of 
Raney nickel as described by Satoh et al. (1982). Attempts were thus made to simplify the 
reaction procedure for the safe and relatively facile generation o f relatively larger quantities 
of 4'-aminowarfarin for the production of drug-protein conjugates.
The initial proposed technique involved the reduction of the nitro group o f acenocoumarin in 
the presence of tin and dilute hydrochloric acid (1 M). However, the reducing conditions for 
this particular technique were considered too harsh for the reduction of 4'-nitrowarfarin, as 
the procedure not only resulted in the reduction of the nitro group, but also what was 
believed to be the reduction of the ketone moieties on the parent compound yielding several 
reaction products as analysed by TLC (Figure 3.5). The use o f zinc granules in the presence 
of dilute acetic acid (10%, v/v) proved to be the safest and simplest means of routinely 
producing the putative 4'-aminowarfarin product. However, the technique also suffered from 
some of the difficulties described for the reduction reaction in the presence of tin, namely, 
over reduction of the parent compound. It was then decided to proceed with the reduction 
procedure described, but to stop the reaction before reaching completion which may have 
resulted in the reduction of the ketone moiety groups on the parent acenocoumarin molecule 
(i.e. ketone group of 4-hydroxycoumarin ring and the ketone group attached to the aliphatic 
carbon). This resulted in a reaction mixture containing both the unreacted 4'-nitrowarfarin 
and also 4'-aminowarfarin. The separation of these two particular compounds was achieved 
by a combination of filtration and column chromatography. The initial filtration step 
removed the zinc granules from the reaction mixture, whilst it also allowed for the straight­
forward separation of 4'-nitrowarfarin, which is only partially soluble in dilute acid, from the 
amine-containing 4'-aminowarfarin which is readily soluble in dilute acid solutions. The
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reaction was monitored throughout by TLC analysis. However, visual inspection of the 
reaction mixture also afforded some knowledge of the extent o f the reaction, which turned 
from a creamy white colour to a deeper orange colour as the reaction proceeded, due to the 
formation of the soluble 4'-aminowarfarm product. The dilute acid solution was then quickly 
back-extracted into ethyl acetate to protect the reaction product from further reduction. The 
relatively pure reaction mixture was then dried over anhydrous magnesium sulphate to 
remove any water remaining in the ethyl acetate fraction and evaporated to dryness on a 
rotary evaporator. The sample was then purified to homogeneity by column chromatography 
as described in section 2.4.3. The collected fractions containing 4'-aminowarfarin that were 
assayed by TLC (Figure 3.5) were pooled and evaporated to dryness on a rotary evaporator.
Figure 3.5: Thin Layer Chromatography o f  starting material 4'-nitrowarfarin (a,Rf =
0.67), and 4'-aminowarfarin (b, R f=  0.33) mixture viewed under a UVlamp 
following chromatography through a silica gel column. A mobile phase 
containing methanol and chloroform (2:98, v/v) was used to separate the 
reaction product from starting material. The presence o f a single spot 
confirms the purity o f  the reaction mixture.
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3.2.2.1. Characterisation o f  4'-aminowarfarin by Infra R ed (IR) spectral studies: 
The purity and character of the putative 4'-aminowarfarin compound was confirmed by a 
combination of infra-red (IR) and NMR (Nuclear Magnetic Resonance) studies as described 
in sections 2.4.4. and 2.4.5., respectively. The infra-red spectrum of a compound is 
essentially the superposition of absorption bands of specific functional groups, and IR 
studies may thus be qualitatively used for the confirmation of specific functional groups in a 
molecule. The chemical reduction of 4'-nitrowarfarin to 4'-aminowarfarin, involves the 
reduction of the nitro- group on position-4 of the phenyl substituent to the corresponding 
amine. The IR spectrum of both starting material and product are included in Figure 3.6. and 
Figure 3.7 for comparison. Analysis of the IR spectrum of 4'-nitrowarfarin shows two strong 
bands at 1350 and 1530 cm'1 corresponding to the symmetric and asymmetric stretches of the 
nitro-group, respectively. These bands are absent in the IR spectrum of 4'-aminowarfarin 
confirming the reduction of the functional groups. The stretch at -1700 cm 1 corresponding 
to the carbonyl group evident in both infra-red spectra, is indicative of the presence of a 
carbonyl group in both molecules. An additional stretch is also evident at approximately 
3400 cm"1 corresponding to the presence of a hydroxyl group in both starting material and 
reaction product. The IR spectrum of 4'-aminowarfarin shows a shoulder peak at 3300 cm'1 
on the hydroxyl group confirming the presence of an amine group in the reaction product 
which is further confirmed by the presence of an amide stretch at -1650 cm'1.
3.2.2.1. Characterisation o f  4'-aminowarfarin by Nuclear Magnetic Resonance 
(NMR) studies:
Nuclear magnetic resonance (NMR) permits the identification of atomic configurations of 
molecules from the absorption of energy of spinning nuclei in a strong magnetic field when 
irradiated by a second weaker field perpendicular to it. Absorption occurs when the nuclei 
undergo transition from one alignment to another one and such transitions depend on a 
number of factors including: the field strength, electronic configuration about the molecule, 
the type of molecule and intermolecular interactions. Consequently, NMR can be used to 
identify the presence of specific functional groups, and also their location in a particular 
molecule resulting in the delineation of atoms within a molecule. An important parameter of 
nuclear magnetic resonance is what is known as chemical shift. In different chemical 
environments, the same atom can be shielded from the applied field depending on the 
distribution of the surrounding electrons. It is the particular shifted resonance frequencies 
that characterize neighbouring molecules within an atom. Using chemical shift values, it can 
be seen that the presence of an amine and a nitro group on the phenyl ring will result in 
differing chemical shifts for the protons attached to this particular ring. The proton NMR
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spectra of the starting material 4'-nitrowarfarin and product 4'-aminowarfarin are shown in 
Figures 3.8. and Figures 3.9, respectively. The aromatic protons in the starting material 4'- 
nitrowarfarin (acenocoumarin) are situated between 7.2 p.p.m and 8.2 p.p.m. The protons at 
8.0-8.2 p.p.m. have been assigned as the protons adjacent to the nitro-group at the para- 
position on the phenyl susbstituent. Nitro groups have a deshielding effect, and result in 
pulling the aromatic protons downfield, and this could be used to describe the presence of 
the aromatic protons at 8.1-8.2 p.p.m. using the assigned J-values (i.e 7.27 +0.95 = 8.22).
Close examination of the aromatic portion of 4'-aminowarfarin reveals the absence of these 
two particular protons, and the presence of an additional peak at approximately 6.6. p.p.m. 
Amine groups have a shielding effect and result in the pulling the protons upfield, and this 
can be used to explain the positioning of the aromatic protons at these lower p.p.m. values 
(i.e. 7.27 -  0.75 = 6.5 p.p.m.). The proton NMR for the remainder of the molecule is 
essentially unchanged, as the remainder of the protons are unchanged as a result of this 
particular chemical reduction.
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Figure 3.6: IR spectrum for 4'-nitrowarfarin, prepared as described in section 2.2.4. The
two strong bands at ~1530 c m a n d  1350 cm'1 corresponds to the N 0 2 
asymmetric and symmetric stretches, respectively. The band at 3400 cm’1 
corresponds to the presence o f  a hydroxyl group on the molecule, whilst the 
band at ~1700 cm'1 corresponds to the carbonyl group o f  the molecule.
Figure 3.7: IR spectrum for 4 ’-aminowarfarin prepared as described in section 2.2.4. The
strong band at ~1650 cm'1 corresponds to the N-H stretch, which is also evident 
in the shoulder peak (—3300 cm'1) on the hydroxyl band at 3400 cm'1. The band 
at ~1700 cm'1 corresponds to the carbonyl group o f  the molecule.
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Figure 3.8: NMR spectra o f  4'-nitrowarfarin, which shows the aromatic protons o f  the
molecule ranging from 8.2 - 7.2 p. p.m. which were shifted downfield as a result 
o f  the electron deshielding effect o f  the nitro group at the para-position on the 
phenyl substituent.
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Figure 3.9: NMR spectra o f  4'-aminowarfarin, which shows the aromatic protons o f  the
molecule ranging from 6.8 - 7.9 p. p.m. which were shifted downfield as a result 
o f  the electron withdrawing effect o f  the amine group at the para-position on 
the phenyl substituent,
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3.2.2. Production and Characterisation o f  warfarin-protein conjugates:
Various 4'-azowarfarin-protein conjugates were generated for the production and affinity- 
purification of polyclonal rabbit antibodies to warfarin, as warfarin (308 Da) is too small to 
elicit an immune response itself and so required conjugation to a carrier protein molecules in 
order to make it immunogenic. There are a variety of coupling chemistries available for 
coupling proteins to small molecules such as warfarin (Hermanson, 1996). The choice of 
coupling chemistry employed is generally selected as a result of the chemical residues 
available for coupling and whether or not spacer molecules need be employed to distance the 
molecule from the carrier protein.
The conjugation procedure for the coupling of 4'-aminowarfarin to various proteins (i.e. 
thyroglobulin, keyhole limpet haemocyanin (KLH), bovine serum albumin (BSA) and 
ovalbumin) was carried out according to the molar ratios described by Satoh et al. (1982) in 
section 2.5.2. Briefly, 4'-aminowarfarin was activated in an acidified sodium nitrite solution 
according to the reaction scheme outlined in section 2.5.1. to yield highly reactive diazonium 
ions. The activated diazonium ions then react with free amino groups on proteins to yield 
diazonium-coupled drug-protein conjugates. Drug-protein conjugates containing diazonium 
bonds yield highly coloured complexes that are also extremely stable due to the presence of 
the double bond chemistry. The conjugates produced were dialysed against several changes 
of PBS-1 to ensure complete removal of unconjugated 4'-aminowarfarin from the reaction 
mixture. In all cases the use of diazonium coupling resulted in the presence of dark-brown 
coloured solutions, which turned to a pale-tan colour following lyophilisation.
+ NaN02
Figure 3.10: Reaction scheme fo r the production o f  diazo-coupled drug-protein (e.g. 4'-
azowarfarin-protein) conjugates as described in section 2.5.
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4'-aminowarfarin was also coupled to BSA and thyroglobulin using the homo-bifunctional 
N-hydroxysuccinimide ester, sulfo-disuccinimidyl tartrate (DST) as described in section
2.5.3. The drug-protein conjugates produced yielded a pure white powder upon 
lyophilisation. Sulfo-DST incorporates a four-atom spacer between the drug molecule and 
the carrier protein, and these particular conjugates were used primarily in the production and 
screening of monoclonal antibodies to warfarin (section 2.10.7.).
The conjugates were initially analysed by UV-spectroscopy from 200-400 nm, this allowed 
for the putative confirmation of the coupling procedure by direct comparison of the UV 
spectra for the drug-protein conjugates versus those for the unconjugated protein and drug 
molecules. The ‘control’ BSA sample (section 2.6.2.) shows a peak at approximately 280 
nm corresponding to the protein peak. Comparison of the ‘control’ spectra (Figure 3.11. (a)) 
with that of the conjugate molecule (Figure 3.11 -(b)), shows a second peak at approximately 
310 nm which gives putative confirmation of the covalent coupling of 4'-aminowarfarin to 
the protein molecule, as a similar peak maxima is evident for the drug molecule itself (Figure 
3.11. (c)).
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Figure 3.11: UV spectra were measured fo r  each drug-protein conjugate as described in
section 2.6.3. Direct comparison o f  the UV spectra obtained fo r  ‘control’ BSA (A)(section 
2.6.2.) with those obtained for 4'-aminowarfarin-DST-BSA (B) and 4'-aminowarfarin shows 
a shoulder peak at approximately 310 nm fo r  the drug-protein conjugate. A similar peak is 
evident at 310 nm for the drug itself which is indicative o f  the coupling o f  4'-aminowarfarin 
to BSA using the DST crosslinker
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The drug-protein conjugates were then characterised using HPLC with photo-diode array 
(PDA) detection as described in section 2.6.1. Size exclusion chromatography allows for the 
separation of proteins on the basis o f molecular size following passage through the size 
exclusion column, and has been described for the separation of protein mixtures and 
conjugate preparations (Carty & O’ Kennedy, 1988). The use of photo-diode array detection 
allows the column effluent to be monitored across discrete wavelength bands. In this case all 
the spectra were analysed from 200-400 nm. The conjugates were analysed using a 
Beckman Gold software system. Following elution from the column, the drug-protein 
conjugates could be visualised ‘on-screen’ in terms of a contour map, and showed two 
particular absorption maxima at approximately 280 and 310 nm corresponding to the protein 
and drug portion of the molecule, respectively. The data from these particular 
chromatograms was transferred into Sigmaplot® software and 3-D contour plots were 
constructed for the conjugates analysed. The contour plots for ‘control’ BSA and 4'- 
azowarfarin-BSA are shown in Figures 3.15 and 3.16, respectively. Examination of the 
contour plot for BSA shows a peak maxima at 280 nm, whilst the conjugate reveals two 
peaks at approximately 280 nm and a shoulder peak at 310 nm on the main protein peak 
demonstrating the covalent coupling o f 4'-aminowarfarin to BSA.
The conjugates were also analysed by SDS-PAGE as described in section 2.3. and the gel 
following electrophoresis is shown in Figure 3.14. The gel picture shows ‘control’ BSA and 
4'-azowarfarin-BSA run in two adjacent wells, and demonstrates that the coupling procedure 
had no deleterious effect on the protein as one discrete band is seen for both protein samples. 
The conjugates were also analysed by HPLC with UV-detection at 280 nm as described in 
section 2.6.1. The void volume,Vo, of the size exclusion column was initially determined by 
passing Blue dextran through the column. The retention time of each sample was 
determined, Ve, and divided by the time taken for the sample to elute in the column void 
volume (i.e. Ve/Vo). The results are shown in Table 3.2. A calibration curve was then 
constructed of Ve/Vo versus the log of the molecular weight of the protein standards of 
known molecular weight, and from the constructed calibration plot shown in Figure 3.12. it 
was possible to estimate the molecular weight of the drug-protein conjugates. The molecular 
weight of 41 -azowarfarin-BSA was estimated to be approximately 85 kDa, which implies a 
high drug-protein ratio of approximately 60:1. The plot overlay (Figure 3.13) of the 
chromatograms for BSA and warfarin-BSA shows the conjugate eluting a fraction earlier 
from the column confirming the increased molecular weight. Estimation of the drug-protein 
coupling ratio was not possible using UV spectrometry due to the presence of the diazo 
bond, which would have distorted any possible measurements due to the coloured intensity 
of the sample and completely different molar extinction coefficients.
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The 4'-aminowarfarin-DST-BSA protein conjugates produced were believed to have 
undergone a significant degree of protein-protein cross-linking as assessed from the retention 
time of the conjugate which was similar to that of thyroglobulin despite using a greater than 
100-fold molar excess of antigen over protein in the conjugate preparation. SDS-PAGE 
studies also confirmed the high degree of cross-linking as assessed by the minimal migration 
of the protein sample following gel electrophoresis.
Table 3.2: Molecular Weight standards Calibration Curve:
Sample Mol. Wt. 
(Da)
Log Mol. 
Wt.
Retention 
Time, 
Tr (mins)
V e/Vo
Blue Dextran 2,000,000 6.301 5.75 1
Bovine Serum Albumin 66,000 4.819 8.55 1.487
Ovalbumin 45,000 4.653 9.03 1.571
Peroxidase 44,000 4.643 9.154 1.5924
Carbonic Anhydrase 29,000 4.4.62 9.568 1.664
Cytochrome C 12, 400 4.093 10.469 1.821
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Figure 3.12: Size exclusion chromatography o f a set o f  protein standards o f known
molecular weight were passed down a Phenomenex 3000 SEC column using 
PBS-I as mobile phase at a flow-rate o f  1.0 ml/min with UVdetection at 280 
nm. The retention time, Tr, o f  each sample was recorded, and divided by the 
time taken for a sample to elute in the column void volume, Vo (Tr= Ve as 
flow rate =1.0 ml/min). This value, Ve/Vo, was then plotted against the log 
o f  the molecular weight o f  the respective protein sample to construct the 
calibration plot. From the regression line, it was then possible to estimate 
the size o f  the 4'-azowarfarin-BSA and thyroglobulin conjugates. The 4'- 
azowarfarin-BSA conjugate was estimated to be approximately 85 kDa in 
size, implying a drug-protein coupling ratio o f  approximately 60:1, 
respectively.
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Figure3.13: Plot overlay o f  ‘control’ BSA and 4'-azowarfarin-BSA following
chromatography on a Phenomenex SEC 3000 column using PBS-1 
al a flow rate o f  1.0 ml/min as mobile phase with IJV detection at 
280 nm. The conjugate shows a slightly shorter retention time o f  
~8.3 minutes compared to ‘control ’ BSA which showed a retention 
time o f  approximately 8.62 minutes as a result o f  the increased 
molecular weight following the conjugation procedure.
Figure 3.14: SDS-PAGE analysis o f  4'-azowarfarin-BSA (lane A) and ‘control ’ BSA (lane
B) as described in section 2.3. The drug-protein conjugate and ‘control' 
protein showed that the conjugate had migrated slightly less than the 
‘control’ BSA, as a result o f  the increased molecular weight.
9 7
Figure3.15: 3-D Contour plot fo r  ‘Control’ BSA following Size Exclusion 
Chromatography with photo-diode array (PDA) detection as described in 
section 2.6.1. A large peak can be seen at 280 nm corresponding to the 
protein molecule.
Figure 3.16: 3-D Contour plot fo r  4-azowarfarin-BSA following Size Exclusion
Chromatography with photo-diode array (PDA) detection as described in 
section 2.6.1. A large peak can be seen at 280 nm corresponding to the 
protein molecule, with an additional shoulder peak with a maxima at 310 nm 
confirming the covalent coupling o f  4'-aminowarfarin to BSA.
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3.2.3. Production and Affinity-Purification o f  anti-warfarin antibodies:
For the production of polyclonal anti-warfarin antibodies, rabbits were immunised 
intradermally with the characterised conjugates as described in section 2.8.3. The rabbits 
were initially immunised at various sites and the specific serum titre monitored as described 
in section 2.11.1. The titres following immunisation are shown in Figure 3.17. When the 
antibody titre has reached a sufficiently high titre the rabbit was sacrificed and the blood 
harvested by cardiac puncture.
The serum was then prepared as described in section 2.8.3. The rabbit serum was then 
partially purified using ammonium sulphate precipitation as described in section 2.9.1.1. to 
yield an immunoglobulin fraction of relatively high purity. This fraction was then dialysed 
extensively against PBS-2 and affinity-purified as described in section 2.9.1.2. Two 
immunoaffinity matrices were initially constructed for the purification of the rabbit serum 
employing the use of cyanogcn-bromide sepharose-4B and Triazine agarose 4XL, as 
described in section 2.7.1. and 2.7.2., respectively. From immunoaffinity procedures carried 
out, the cyanogen-bromide activated sepharose column proved more effective in terms of 
affinity-purification, and this was considered to be due to a higher coupling ratio of ligand 
(i.e. 4'-azowarfarin-BSA) to the column as measured from the extracts following the 
coupling procedure. The levels of specific immunoglobulin were also slightly lower for the 
Triazine column than the sepharose immobilised ligand, despite the comparable total protein 
content. It was postulated that the use o f triazole (2 M, pH 5.0, as per manufacturer’s 
instructions) as a blocking agent to cap the excess active amine groups may have resulted in 
the generation of a very hydrophobic matrix given the molecular structure of triazole. The 
increased hydropbobicity in the column may have therefore resulted in increased non­
specific binding to the column and overall reduced efficiency in terms of an affinity matrix. 
The bound antibodies were eluted from the column using 0.1 M glycine-HCl (pH 2.5) and 
collected in 1 ml eppendorf tubes containing 150 jal of 1 M Tris-HCl (pH 8.5), which 
neutralised the eluted acidic antibody fractions, thereby retaining the immunological activity 
of the eluted fractions. The affinity-purified fractions were then dialysed against several 
changes of PBS-2 at 4°C. The titre of the affinity-purified antibody following affinity- 
purification was determined as described in section 2.11.1 and showed a specific antibody 
titre of greater than 1/1,000,000 (Figure 3.18).
The purity of the affinity-purified fraction was determined by size exclusion chromatography 
as described in section 2.6.1. using a Phenomenex 3000 SEC column and PBS-1 as mobile 
phase at a flow rate of 0.5 ml/min with UV detection at 280 nm. The resulting 
chromatogram is shown in Figure 3.19, indicating the purity of the fraction whose molecular 
weight was made by reference to a calibration plot of known molecular weight standards.
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Figure 3.17: Final rabbit serum titre as determined by direct ELISA as described in
section 2.11.1. The final titre recorded was in excess o f  1/500,000. The results shown are 
the mean o f  triplicate results ±  standard deviation.
1/Dilution Faotor o f Antibody Sample
Figure 3.18: Titre o f  affinity-purified antibody following affinity purification on a 4'-
azowarfarin-BSA sepaharose-4B column as described in section 2.9.1.2. The dialysed 
fraction o f  ammonium sulphate-precipitated immunoglobulin was passed through the column 
several times. The bound anti-warfarin antibodies eluted with 0.1 M  glycine-HCl (pH 2.5), 
and collected in eppendorf tubes containing 150 fd o f 1 M  Tris-HCl (pH 8.0). The fractions 
collected were then assayed spectrophotometrically at 280 nm and those fractions 
containing protein dialysed against several changes o f  PBS-2 at 4°C overnight. The 
dialysed fraction was then assayed fo r  specific antibody (section 2.11.1.) and showed a 
specific antibody titre o f  greater than 1/1,000,000, as shown above. The results shown are 
the mean o f  triplicate results ±  standard deviation.
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Figure 3.19: Size exclusion chromatography o f affinity-purified polyclonal rabbit anti­
warfarin antibodies carried out as described in section 2.6.1. using a 
Phenomenex 3000 SEC column with PBS-1 as mobile phase at a flow rate o f  
0.5 ml/min with UV detection at 280 nm. The single peak on the 
chromatogram whose retention time corresponds to approximately 155 kDa 
by reference to a standard curve o f  proteins o f  known molecular weight 
shows the identity and purity o f  the immunoglobulin fraction
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3.2.4. Cross-Reactivity Studies:
Cross-reactivity may be defined as a measure of the antibody response to structurally related 
molecules, as a result o f shared epitopes. Given the unique specificity o f antibodies, one of 
the first steps in immunoassay design is the assessment of reactivity towards structurally 
related molecules that share such common epitopes (Wild, 1994). Assessment of the cross­
reactivity of polyclonal antisera is limited to the analysis o f binding specificity towards 
structurally related antigens (e.g. metabolites and structural analogues), and can be assessed 
by setting up serial dilutions of the competing antigen in parallel with the similar dilutions of 
the specific antigen as described in section 2.11.5, The cross-reactivity is often conveniently 
defined as the point where the reduction in signal recorded in the presence o f a particular 
analyte concentration (Ax) gives a 50% reduction in the signal in the presence o f zero analyte 
(Ao) (i.e. Ax/Ao=50%). This concentration value can then be expressed as a percentage of 
the analyte giving the same decrease in signal.
Therefore,
% Cross-Reactivity = Concentration o f analyte giving 50% decrease in signal -  Zi x 100% 
Concentration of cross-reactant giving 50% decrease in signal Z2
Concentration of analyte/cross-reactant (ng/ml)
Figure 3.20: The potential cross-reactivity o f  a particular antibody preparation towards
a structurally related compound can be conveniently described as a 
percentage o f  the reactivity towards the specific analyte by expressing the 
concentrations o f each reagent that gives 50% inhibition as shown in 
equation above.
For the production o f drug-protein conjugates the point of attachment o f the drug to the 
carrier protein is of critical importance, as it will dictate the specific epitopes available for 
antibody-binding, and thus the specificity of the polyclonal antisera produced. The nitro- 
group on the parent molecule was chosen as the point of attachment for two particular 
reasons. Firstly, it provided a convenient means o f conjugation. Secondly, as the major
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human metabolites of warfarin involve hydroxylations o f the 4-hydroxycoumarin ring 
structure and carbon side chain of the molecule (Figure 1.6), it was believed that conjugation 
via the phenyl substituent would confer a greater degree o f specificity to the polyclonal 
antibodies produced against warfarin. The cross-reactivity towards the metabolites of 
warfarin available was determined and the ELISA developed as described in section 2.11.5.
The results from the cross-reactivity study are shown in Table 3.3 and Figure 3.21. The 
cross reactivity of the affinity-purified polyclonal antibodies demonstrates an almost 
identical cross-reactivity (« 98%) towards acenocoumarin, as expected given that the two 
compounds are essentially identical except for the presence o f the nitro group. Given that 
this particular region does not confer any antibody specificity being the point of conjugation 
(Figure 3.10), this would explain the similar affinity of the polyclonal antibody preparation 
to acenocoumarin. The affinity-purified antibodies showed cross-reactivity of approximately 
28 and 3% towards 6- and 7-hydroxywarfarin, respectively. Cross-reactivity studies were 
also carried out using 4-hydroxycoumarin (which comprises half of the molecule), coumarin, 
7-hydroxycoumarin, and 7-hydroxycoumarin-4-acetic acid. Cross-reactivity towards these 
particular compounds in each case was negligible and typically o f the order of <0.1%.
Table 3.3: Cross-Reactivity o f  Affinity-Purified Rabbit Anti-Warfarin Polyclonal Antibodies 
with Structurally Related Analogues:
Compound % Cross Reactivity
Warfarin 100
Acenocoumarin 98
6-Hydroxywarfarin 28
7-Hydroxywarfarin 3
7-Hydroxycoumarin <0.1
4-Hydroxycoumarin <0.1
Coumarin <0.1
7-Hydroxycoumarin-4-acetic acid <0.1
The 3-dimensional geometrical structures of warfarin and it’s major human metabolites 
analysed, namely 6- and 7-hydroxywarfarin were constructed using Hyperchem® molecular 
modelling software package. This particular package utilises molecular mechanics and a 
combination o f algorithms to generate the geometrical shape of molecules based on the sum 
of the potential energies within the molecule, which is defined as the force field (Allinger et 
al. 1989). Using the software package the geometry of the molecule is systematically
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adjusted to give the lowest potential energy state for a particular molecule. The constructed 
geometrical structures for (R)-7-hydroxywarfarin, (R)-warfarin, and (R)-6- hydroxywarfarin 
and are shown in Figure 3.22(a)-(c). It should be noted however, that the structural 
configurations displayed are the optimised configurations using the software package and are 
by no means an absolute configuration. Significant bond rotation can occur within a 
molecule, particularly at single bond residues which provide greater molecular flexibility to 
the molecule, implying that warfarin would be free to rotate about any of these particular 
bonds. From the models it can be seen that the 4-hydroxycoumarin residue and the carbonyl 
side chain appear to lie along the same plane, orthogonal to the phenyl substituent (i.e. the 
point of conjugation). It can be postulated therefore that the majority o f the antibody- 
binding site is directed against the 4-hydroxycoumarin ring structure and carbonyl side- 
chain. Consequently, substitutions (e.g. hydroxylations to the coumarin ring) could lead to 
differing specificities of antibody binding pocket for the antigen, as the ‘complementarity’ of 
the binding domain is disturbed. In this context, the hydroxylation at position-7 of the 4- 
hydroxycoumarin ring could be expected in the context of a polyclonal antibody population, 
to have a more marked effect on the antibody affinity given the suggested epitope region, 
than a hydroxylation at position 6 of the 4-hydroxycoumarin residue, which would concur 
with the experimental observations noted. The fact that the degree of cross-reactivity 
towards the coumarin and it’s hydroxylated metabolites is negligible implies that the 
antibodies require both the coumarin ring structure and the presence o f the carbonyl side 
chain for antibody recognition. Unfortunately, as no other hydroxywarfarin metabolites were 
available for study, this hypothesis was unable to be substantiated. However, based on these 
stated assumptions, hydroxylations at position 8 and reduction of the carbonyl side chain to 
yield the warfarin alcohols would be expected to bring about corresponding changes in the 
affinity o f the antibodies towards these metabolites.
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Figure 3.21: Cross-reactivity studies o f  polyclonal antibodies. Cross-reactivity studies
were carried out on the affinity-purified warfarin polyclonal antibodies as 
described in the text and section 2.11.5. to structurally related molecules o f  
warfarin. The antibodies demonstrated little or no reactivity towards 
coumarin-based molecules suggesting that the presence o f  the carbonyl 
group and possibly the phenyl ring are also required fo r  antibody 
recognition. The purified antibodies showed differing degrees o f  affinity 
towards both 6- and 7-hydroxywarfarin which could be explained by the 
substitution at position 7 o f  the 4-hydroxycoumarin ring structure which 
based on the optimised geometrical configurations o f  these molecules 
(Figure 3.22(a)-(c)) could play a more crucial role in terms o f  antibody 
recognition.
1 0 5
Figure 3.22. (a). 7-Hydroxy-R-Warfarin.
Figure 3.22.(b). R-Warfarin.
Figure 3.22.(c). 6-Hydroxy-R-Warfarin.
Figure3.22: The 3-dimensional geometrical structures o f  (R)-warfarin and 6- and 7-
hydroxy-(R)-warfarin were constructed using Hyperchem ® software which determines the 
geometrical configuration o f  molecules using force-field algorithms that are continually 
systematically adjusted to give the optimal geometry o f  the particular molecule. From the 
constructed models the 4-hydroxycoumarin ring structure and the carbonyl substituent 
appear to lie in the same plane orthogonal to the phenyl ring substituent used as the point o f  
conjugation, and provide the majority o f  the antibody-recognition site. Blue, red and black 
balls and lines correspond to carbon, oxygen and hydrogen molecules, respectively.
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3.2.5. Development o f  a competitive ELISA fo r  Warfarin:
A competitive enzyme-linked immunosorbent assay (ELISA) was developed for the 
detection of warfarin in solution using the characterised drug-protein conjugates and the 
affinity-purified rabbit polyclonal anti-warfarin antibodies.
3.2.5.1. Determination o f optimal conjugate coating density and antibody working dilution:
In competitive ELISA the highest degree of sensitivity in terms o f detection limits, is 
achieved with the concentration of primary antibody approaching zero. The limits of 
detection in competitive ELISA are therefore a function of the intrinsic antibody affinity (or 
range of affinities as is the case with a polyclonal antibody preparation), and the equilibrium 
between both the free and immobilised forms of the antigen. Consequently, utilising too 
high a conjugate loading density (i.e. solid-phase form of immobilised antigen) will shift the 
binding equilibrium in favour of binding to the ELISA plate and cause reduced sensitivity to 
free antigen in solution (i.e. the desired detectable analyte). Similarly, utilising too high a 
concentration of antibody preparation, means that there will be greater free antibody in 
solution and the assay system will only be suitable for the detection of high concentrations of 
free analyte in solution (i.e. where antibody concentration approaches zero). It is essential 
therefore to optimise both the concentration of the solid-phase antigen and the optimal 
concentration of antibody (i.e. the working dilution of antibody) to be used for competitive 
ELISA techniques.
The optimal dilution of conjugate loading density was determined as described in section
2.11.4. Briefly, a range of conjugate loading densities ranging from 5 to 100 (xg/ml of 4'- 
azowarfarin-BSA were prepared in PBS-1 and applied to the plate and antibody dilution 
curves constructed using serial doubling dilutions of affinity-purified antibody. The optimal 
conjugate loading density was defined as that conjugate coating density (^ig/ml) that gave the 
widest linear detection range over the range of antibody dilutions used. A conjugate loading 
density of 50 fxg/ml was found to be the optimal loading density for 4'-azowarfarin-BSA 
conjugates as shown in Figure 3.23. Similar determinations for the optimal conjugate 
loading densities for the various other drug-protein conjugates were made, as the 
concentration used for each conjugate preparation is a direct function of each particular drug- 
protein coupling ratio.
The optimal dilution of antibody to be used in competitive ELISA experiments was 
determined by setting up a standard curve of serial doubling dilutions of affinity-purified 
antibody as described in section 2.11.1. using the optimal conjugate loading density for the
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particular immobilised solid-phase antigen. From Figure 3.18 it can be seen that using an 
antibody dilution taken from the asymptotes of the sigmoidal curve would be insensitive to 
small changes in antibody concentration. The working dilution of antibody for such 
competitive assay purposes is taken from the linear portion of the sigmoidal antibody 
dilution curve, where there is the greatest change in absorbance for a similar change in 
antibody dilution. For the affinity-purified antibody preparation used the working dilution of 
antibody was determined to be 1/25,000 (Figure 3.18).
3.2.5.2. Competitive ELISA for  the detection o f warfarin:
A series of warfarin concentrations ranging from 12.5-3125 ng/ml were prepared as 
described in section 2.11.5. 50 (xl of each of these antigen concentrations was then applied 
to the wells of a coated ELISA plate (see section 2.11.1.). Affinity-purified rabbit anti­
warfarin antibodies was then prepared at twice the working dilution of antibody, and 50 |xl of 
this antibody preparation added to the wells of the ELISA plate so that the final antibody 
concentration on the plate was equal to that of the working dilution of antibody determined 
in section 3.5.1. The various warfarin concentrations were added to the wells of the ELISA 
plate in random order using a random number generator, to ensure there was no bias in any 
measurements conducted, as a result of thermodynamic effects within the plate. The mean 
normalised absorbance value was then determined at each antigen concentration (sec 
Appendix 1A). The use of the mean normalised absorbance values (A/Ao) allowed for direct 
comparison between ELISA intra-assay results.
Four-parameter equations o f the form above were fitted to the data sets of mean normalised 
absorbance versus warfarin concentration obtained for immunoassays curves using 
BIAevaluation 3.1 software. The constructed calibration curves also allowed for the 
determination of unknown values using the dedicated software package. In this way it was
R  =  Rh i - R in  -  Rlo
Where RHi
R lo  
Cone
Response at infinite concentration 
Response at zero concentration 
Analyte Concentration (ng/ml) 
Fitting constant 
Fitting constant
Ai
A2
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possible to calculate the degree of precision of analytical measurements at different 
concentrations points relative to the fitted four-parameter equation. The inter-assay variation 
was calculated by performing the assay over three separate days, and a separate calibration 
curve constructed for each normalised absorbance (A/Ao) value versus the respective 
warfarin concentration for each assay. The mean back-calculated concentration at each 
antigen concentration was then used to calculate the inter-assay mean, standard deviation and 
coefficient of variation for the intra-assay curve. The inter-assay and intra-assay results are 
shown in Table 3.4 and Table 3.5, respectively.
The percentage accuracy values obtained for both the ELISA inter- and intra-assay variation 
were typically of the order of less than 7% which is well within the recommended guidelines 
for immunoassay calibration plots demonstrating the accuracy and reproducibility of the 
method (Findlay et al., 2000). The low percentage coefficient of variation obtained also 
underlines the precision of the ELISA technique.
Table 3.4: Inter-Assay variation fo r  the determination o f  Warfarin by competitive ELISA
(n=3).
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back- 
Calculated Warfarin 
Concentration 
(ng/ml)
% C.V. % Accuracy
1562.5 1447.48 1.59 7.39
781.25 817.38 2.01 4.62
390.63 418.36 3.48 7.10
195.31 205.95 6.09 5.44
97.85 87.07 4.22 11.14
48.84 50.15 4.37 2.6
24.42 25.87 5.83 5.94
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Figure 3.23: Determination o f  optimal conjugate loading density. Wells o f  an
immunoplate were coated with varying concentrations o f  conjugate ranging 
from 5-100 jug/ml. Serial doubling dilutions o f  affinity purified antibody 
were then added to the wells o f  the plate as described in section 2.11.4. The 
conjugate loading density that gave the widest linear detection range over 
the antibody dilution series used, and 50 /ug/ml was chosen as the optimal 
conjugate loading density. The results shown are the average o f  duplicate 
results.
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Table 3.5: Intra-Assay variation fo r  the determination o f  warfarin using affinity-purified 
rabbit anti-warfarin antibodies (n=6) \
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back- 
Calculated Warfarin 
Concentration 
(ng/ml)
% C.V. % Accuracy
1562.5 1429.85 6.63 8.54
781.25 836.92 4.84 7.12
390.63 422.15 1.76 8.02
195.31 195.85 6.99 0.28
97.85 89.26 4.02 8.64
48.84 49.95 5.39 2.28
24.42 22.72 4.85 6.96
Warfarin Concentration (ng/ml)
Figure 3.24: Intra-Assay Variation fo r  competitive ELISA fo r  warfarin using affinity-
purified rabbit anti-warfarin antibodies. A 4-parameter equation was fitted  
to the data set using BIA evaluation 3.1 software. The inter-assay mean and 
coefficient o f  variation were calculated and are tabulated in Table 3.5. 
Each point on the curve is the mean o f  six replicate measurements.
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3.3. Conclusions:
This particular chapter describes the chemical synthesis of the compound 4'-aminowarfarin 
following the reduction of acenocoumarin in the presence of dilute acid and the catalyst zinc. 
The modified reaction scheme provided a convenient, safe and reproducible means of 
routinely producing 4'-aminowarfarin without the need for an elaborate and potentially 
hazardous experimental setup as required for the hydrogenation reactions. Purification and 
subsequent characterisation of the reaction product provided unambiguous confirmation of 
the structure of the reaction product.
4'-aminowarfarin was then used for the production o f a variety of drug-protein conjugates, 
which were subsequently characterised by a combination o f size exclusion chromatography 
with UV and PDA detection, and SDS-PAGE analysis. The drug-protein coupling ratio for 
the diazo-coupled protein conjugates was particularly high (i.e. 60:1 for 4'-azowarfarin- 
BSA), and could be used to explain the extremely high antigen-specific titres (i.e. greater 
than 1/1,000,000) obtained, highlighting the immunogenicity of the conjugates produced.
The use of the immunoaffinity purification matrices provided a relatively simple means of 
obtaining an antibody preparation of high purity, free from extraneous protein and 
immunoglobulin. The use of such immunoglobulin preparations simplifies future 
experimental work where high protein concentrations in the antibody preparations used, can 
give rise to spurious errors associated with the non-specific binding of extraneous protein to 
wells of the immunoplate or chip surface in the context of BIACORE experiments (see 
Figure 4.12).
The purified antibodies were then used in the development of a competitive ELISA for the 
detection of warfarin in solution. The inter- and intra-assay variation for the competitive 
ELISA were typically of the order of 5-10%, and demonstrated the accuracy (intra-assay) 
and reproducibility (inter-assay) of the technique. These values are also well within the 
current recommended guidelines for immunoassay calibrations, that suggest that tolerance 
limits of 20% be applied to immunoassay curves with respect to assay precision (Findlay et 
al,, 2000). The cross-reactivity studies carried out demonstrated that the majority of the 
antibodies to the warfarin conjugate shared a common epitope between the 4- 
hydroxcoumarin ring structure and the carbonyl substituent as postulated from the 3- 
dimensional molecular structures constructed. The use of such modelling techniques provide 
intuitive information as to the probable geometrical configuration of small molecules such as 
drugs, which are not always evident from 2-dimensional configurations. Such tools should 
therefore be consulted before the synthesis of drug-protein conjugates, so that a clearer
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picture of the possible epitopes can be identified, which can be subsequently utilised to 
confer molecular specificity, or alternatively, for the production of broad-spectrum 
specificity antibodies for a particular class of drugs through careful selection of the point of 
conjugation.
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Chapter 4
Development and Validation of a BIACORE- 
based inhibition immunoassay for the 
detection of warfarin in biological matrices
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4.1 Introduction:
The development of biosensor devices has grown enormously over the past two decades. 
Biosensors can be broadly described as sensing devices incorporating a biological sensing 
element coupled to a variety of transducing mechanisms (e.g. electrochemical, optical- 
electronic), which together relate the concentration of analyte to a measurable electronic 
signal (Rogers, 2000). The development of biosensors has been extensively reviewed 
elsewhere (Griffiths & Hall, 1993; Pancrazio et ah, 1999; Rogers, 2000). The current trend 
in biosensor technology is towards miniaturised, chip-based, microarrays capable of multi­
analyte detection (Ekins, 1998; de Wildt et ah, 2000). The mode of operation and 
applications of several commercial SPR biosensors is reviewed with a particular emphasis on 
their applications as tools for the biopharmaceutical industry.
4.1.1. SPR Biosensors:
Surface plasmon resonance biosensors have become important tools in the 
biopharmaceutical industry, primarily because o f their ability to generate a wealth of 
qualitative and quantitative information simultaneously. Qualitative information generated 
by molecular screening of small molecules can identify potential drug candidates (Markgren 
et ah, 2000), whilst ‘ligand-fishing’ experiments can identify possible interacting pairs of 
molecules and target agents (Catimel et al., 2000). SPR systems can also be used as a means 
of monitoring purification procedures (Lackmann et ah 1996), and have been successfully 
used for the purification of the ligand for HEK (Human EPH-like Kinase). SPR instruments 
offer a unique means of monitoring immune complex formation and studying reaction 
kinetics and determining equilibrium constants, and also allow for the determination of 
active analyte concentrations (Karlsson et ah, 1993). Thermodynamic constants can also be 
generated by measuring reaction rates at different temperatures (Roos et al., 1998), as well as 
studying reaction stoichiometry by careful experimental design (Morton & Myszka, 1998). 
There are a number of SPR-based devices currently commercially available including: the 
BIAcore range of instruments (BIAcore AB), the BIOS-1 system (Windsor Scientific 
Limited), the IAsys instrument (Affinity Sensors), and the Texas Instruments SPR device 
(TI-SPR). A brief explanation of the mode of operation of each is described below.
4.1.1.1. Surface Plasmon Resonance:
For convenience the principle of SPR is described in the context of the BIACORE range of 
instruments that utilises the optical phenomenon of surface plasmon resonance to monitor 
biomolecular interactions in ‘real-time’. When light is incident on two media of different 
refractive index (e.g. glass and water), a portion of the light coming from the medium of
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higher refractive index is refracted and the remainder of the light is reflected (Figure 4.1). 
When the angle of incident light is greater than the critical angle of incidence, the light is 
totally internally reflected and no light is refracted across the interface between the two 
surfaces of different refractive index. Under conditions of total internal reflection (TIR), an 
electric vector component of the incident light known as the evanescent wave, propagates 
into the medium of lower refractive index a distance of approximately one wavelength. The 
evanescent wave decays exponentially with the distance travelled from the interface into the 
lower dense medium. In BIAcore the interface between the glass and water layer is coated 
with a thin layer of metal (e.g. gold, silver). The energy carried by the evanescent wave can 
be ‘coupled’ or transferred to electrons within the metal layer, causing the electrons to 
oscillate or resonate, resulting in the generation of a surface plasmon wave. This ‘coupling’ 
or ‘resonance’ effect occurs when there is a match between the energy of the surface 
electrons and the energy of the incident light photons. The coupling of energy between the 
surface electrons and the evanescent wave can be observed by measuring the amount of light 
reflected by the metal surface. All the light is reflected at most wavelengths, except for the 
surface plasmon resonance (SPR) angle where most of the light is absorbed, which can be 
observed by a dip in the intensity of the reflected light measured. The angle at which SPR 
occurs is dependent on a variety of factors including: the properties of the metal film (e.g. 
thickness, uniformity, composition), the wavelength of incident light and the refractive index 
of the medium either side of the metal film. As the wavelength o f light and the properties of 
the metal film are constant, SPR can be used to probe the refractive index o f the aqueous 
layer adjacent to the gold layer. Consequently, any interaction resulting in a mass effect will 
result in a refractive index change at the chip surface will be reflected by a corollary effect 
on the measured SPR angle. The displacement of the SPR angle as result of biological 
interactions occurring at the chip surface is measured in ‘real-time’ and interpolated as a 
sensorgram.
At the heart of the SPR measurement with the majority o f commercial instruments (e.g. 
BIACORE and IAsys) is the sensor chip itself (Figure 4.2). There are currently a variety of 
chip surfaces available commercially available both from BIACORE and from IAsys which 
can be tailored for the intended general application (Rich & Myszka, 2000). The majority of 
applications on both instruments utilise a carboxymethylated (CM) dextran surface, which 
essentially forms a hydrogel at the sensor surface creating a hydrophilic environment with 
low non-specific binding, as well as providing a convenient means for immobilising various
116
Incom ing white Glass rw a c to r  Array
Reflected Light
light
A A A AA A A A ] Chip surface withgold film
Buffer Flow Flow  cell
Figure 4.1 Schematic o f the basis ofSPR measurements with the BIACORE instrument:
(A) In the example illustrated, antibody (Y) immobilised at the gold sensor chip surface
using conventional coupling chemistries (e.g. EDC/NHS). Plane polarised light is 
emitted from a high efficiency light emitting diode and is focused onto the gold chip 
surface in the shape o f  a wedge shaped beam by means o f  a glass prism under 
conditions o f  total internal reflection. The reflected light is then measured by a two- 
dimensional photo-diode array. Under conditions o f  total internal reflection at a 
metal-coated interface an electromagnetic portion o f  the light known as the 
evanescent wave penetrates into the medium o f  lower refractive index. The angle at 
which this occurs is known as the resonant angle (i.e. SPR angle = angle a), and a 
sharp shadow or dip occurs in the reflected light at this particular angle (i.e. angle 
a), designated by the dark bold line in the reflected light. The angle at which SPR 
occurs is dependent on a number o f  factors including the refractive index o f  the 
layer adjacent to the metal film. SPR can thus be used to probe and monitor the 
interactions occurring at the chip-surface in ‘real-time ’.
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(B) Antigen (O) is then injected over the antibody-immobilised chip surface. Binding o f  
antigen to immobilised antibody causes an increase in the mass bound at the sensor 
chip surface and a subsequent change in the refractive index at the sensor chip 
surface, causing a shift (6 )  in the resonant angle o f  the reflected light (i.e. from  
angle a to angle b). The shift in the resonant angle is proportional to the change in 
the mass o f  analyte bound at the sensor chip surface.
(C) A plot o f  the change in the resonant angle (0) measured in ‘real-time’ following 
antibody: antigen binding versus time, is interpolated by the instrument software to 
generate the characteristic SPR response curve. The change in the SPR angle is 
converted to arbitrary response units by the instrument software. The response 
signal measured is proportional to the concentration o f  bound analyte. A change o f  
approximately 1 kRU corresponds to a mass change in surface protein concentration 
o f  approximately 1 ng/mm2.
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Figure 4.2: Photographs o f  miniature TI-SPR device (a), CM5 dextran chip (b)
and CMS probe(c). CM-dextran provides a convenient means o f  
attaching proteins and other molecules to the sensor surfaces for  
SPR analysis. The hydrophilic nature o f  the carboxymethyl dextran 
(CM) also provides an environment amenable to most biological 
reactions. The CM5 probe is utilised in connection with the BIAprobe 
device which is a manually operated device, which is operated in a 
pipette style configuration, and is ideally suitedfor the monitoring 
relatively crude matrices such as bacterial culture supernatants and 
blood (Quinn et al., 1997). The gold sensing layer on the Tl-SPR 
device can be overlaid with disposable SPR chip.
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molecules. Direct immobilisation of proteins directly onto gold surfaces can result in 
significant denaturation o f the immobilised protein. Carboxymethylation o f the dextran 
layer also places a net negative charge on the dextran, which is fully charged above pH 7. 
This allows positively charged proteins (i.e. below their pi) to become electrostatically 
attracted to the bound dextran layer effectively ‘pre-concentrating’ the protein to the chip for 
subsequent protein immobilisation procedures.
4.1.1.2.Resonant Mirror Based devices:
An example of this type of technology is the commercial IAsys instrument, in which the 
polarised laser light is also totally reflected of the underside of the IAsys sensor surface. 
This particular instrument utilises a dielectric layer o f high refractive index (e.g. titania) 
instead of the gold sensing layer in BIACORE (Cush et al., 1993). The high refractive index 
layer is separated from the glass prism by means of a layer of low refractive index. A 
schematic of the system is illustrated in Figure 4.3. At certain incident angles there is a 
phase matching between the incident beam and resonant modes of the high index layer. At 
the point of resonance, light couples along the high index waveguide layer and propagates 
along the sensing layer before being coupled back into the prism. During resonance a phase 
shift occurs between the reflected electric (TE) and magnetic (TM) modes causing a phase 
shift (of the order o f 2n) in the measured response which is observed as constructive 
interference and can be measured in ‘real-time’. The angle at which resonance occurs is 
dependent upon the refractive index o f the sensing layer. The IAsys instrument also utilises 
a cuvette-based design as opposed to a flow cell configuration, which is continually stirred to 
reduce mass transport effects and has a much larger surface area than the BIACORE chip.
Figure 4.3: Surface plasmon resonant based mirror device (IAsys). Incident light after
passing through a prism undergoes total internal reflection at the boundary with the low 
refractive index layer and generates an evanescent layer at the sensing layer. The incident 
angle at which resonance occurs is dependent on the refractive index at the surface o f  the 
sensing layer. Binding interactions at the sensing surface causes a shift in the angle o f  
reflected light, which are related to the mass change at the sensor chip surface.
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4.1.1.3.Input-Output Coupling devices:
The BIOS-1 instrument is an example of this type of system and it is comprised o f a 
waveguiding film of high refractive index (e.g. Si0 2 /Ti0 2 ) on a glass support with a sub­
micron diffraction grating that allows the diffracted light to propagate into the waveguide. 
Under conditions o f TIR the waveguiding film can trap light, and the angle at which this 
occurs is again dependent on the refractive index of the surface layer in contact with the 
metal film. Consequently, the angle at which the light is coupled into the detector also 
changes according to the refractive index change at the sensor chip surface. The BIOS-1 
system incorporates a laser whose angle of incidence is continually varied, and the angle at 
which surface plasmon resonance occurs is measured by an integrated optical scanner 
containing photodiodes at each end of the waveguide.
4.1.1.4.Miniature TI-SPR device:
Released by Texas Instruments in 1996, this fully integrated miniature SPR sensor contains a 
light emitting diode (LED), polarizer, thermistor (to allow for correction due to temperature 
fluctuations) and two 128 silicon photo diode arrays housed in an epoxy resin moulding 
which was designed in the form of the Kretschmann geometry prism (Figure 4.4(a)). 
Mirrored surfaces are thermally evaporated onto the internal surfaces of the device except for 
the SPR sensing portion of the device. The wedge shaped beam reflects off the SPR sensing 
layer and is reflected onto the PDA array by means of a mirror. The SPR minimum can then 
be measured in ‘real-time’ following dedicated signal processing (Kukanskis el ah, 1999). 
The system offers the capability for ‘remote-sensing’ and is available in a hand-held pipctte- 
style format called the Spreeta™ device. A schematic of the device in illustrated in Figure 
4.4(b) with the attached flowcell.
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Figure 4.4(a): Cross-section o f  miniature TI-SPR instrument. Mass changes are related to 
changes in the resonant angle and position o f  the reflectance minima, which 
can be detected using a dedicated software package in ‘real-time ’.
Figure 4.4(b): Schematic o f  TI-SPR device fitted  with flow cell. The control box interfaces 
with the device and allows the device to be installed onto a PC which 
together with dedicated software (SPR-MIN1 MS-Windows software) to 
allow control o f  data acquisition, processing and display as a virtual control 
panel as seen on the laptop.
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4.1.2. Applications o f SPR technology:
Surface plasmon resonance detection allows for the label-free ‘real-time’ detection of 
interacting analytes. Labelling procedures can have a marked effect on the specificity and 
binding activity o f antibodies (Hoyer-Hansen et al., 2000). The advantages of ‘label-free’ 
detection renders the system suitable as a screening device for unmodified ligands, 
particularly when screening for potential drug candidates and in ‘ligand-fishing’ experiments 
with relatively crude complex mixtures of proteins (Lackmann et al., 1996). SPR biosensing 
systems have also been reported for the detection of blood group antigens in whole blood 
using immobilised antibodies (Quinn et al., 1997). The potential applications of SPR 
technology are continually increasing with the development o f miniaturised and more 
portable formats (Kukanskis et al., 1999) making SPR instruments an increasingly more 
important device in modem biophysical analytical laboratories. Some of the more recent 
applications o f SPR technology are described below:
4.1.2.1. Target Characterisation & Small Molecule Detection:
The use of SPR-based instruments is gaining increasing momentum in the area of 
biopharmaceutical discovery and the characterisation of biomolecules. Biosensors can be 
used to generate kinetic information regarding receptor-1 igand interactions, and to assess the 
binding activity of different molecules, which is in turn related to their function. The 
growing number of potential therapeutic targets emerging from the field of functional 
genomics allied to economic and scientific advances has increased the need for enhanced 
drug-screening methodologies capable of high throughput. The lack o f labelling, small 
sample consumption (50-100 |xl) and high sample throughput (>500 per day) renders SPR- 
based biosensors extremely useful in high-throughput screening (HTS) for small molecular 
weight analytes in lead drug discovery. By providing kinetic binding data unattainable using 
more traditional equilibrium-based assays, useful information regarding complex 
information can be generated, allowing for the preferential selection of particular higher 
affinity ‘binders’.
Developments in SPR technology, particularly with the latest BIACORE 3000 instrument 
with reduced flow cell size and on-line reference curve subtraction has greatly increased the 
feasibility of direct detection of small molecular weight analytes (Morton & Myszka, 1998). 
Markgren et al. (1998, 2000) utilised direct detection of small molecular weight analytes as a 
means of screening and ranking a panel of HIV-1 inhibitors. By immobilising HIV-1 
proteinase directly onto the sensor chip, the authors were able to identify and rank potential 
inhibitors based on their association and dissociation rates. Kampranis et al. (1999) studied 
the binding interaction between wild-type and mutant DNA gyrases and a number of anti­
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bacterial agents, including coumarin and cyclothialidine drugs. SPR analysis of the drug- 
protein interactions allowed the identification of the particular residues that were responsible 
for binding to the DNA gyrase.
4.1.2.2. Pharmacological Applications:
A great deal of time and money is spent in the pharmacological industry identifying new 
possible drug target molecules. For example, the average costs of developing a small 
molecule drug has been estimated to be approximately $500 million dollars with a lead-time 
to market of approximately 12-15 years; biopharmaceuticals costs are somewhat less ($200 
million) with a development time of between 5-7 years (Hensley & Myszka, 2000). 
Following their identification, such targets must then be characterised in terms of their 
individual absorption, distribution, metabolism and excretion profiles (ADME). Such 
studies are generally speaking only carried out on a small number of potential drug 
molecules; the use of SPR biosensors can greatly facilitate such studies of larger numbers of 
molecules. The binding of a drug to serum proteins such as albumin and a-acid 
glycoprotein can greatly impact on the pharmacokinetic profile of such compounds, as a high 
degree of protein binding reduces the free drug concentration in the plasma pool and the 
desired therapeutic effect. Similarly circulating drug-protein complexes (e.g. warfarin-HSA) 
also serves to extend the duration of action of the drug following metabolism of the free-drug 
fraction (Wandell & Wilcox-Thole, 1983). The affinity of individual drug compounds to 
plasma proteins is therefore an important parameter of the compounds potential therapeutic 
usefulness, efficacy and potential side effects. Traditional methods for determining drug- 
protein binding which will be discussed in greater detail later include ultracentrifugation, 
equilibrium dialysis (Ferrer et al., 1998) and chromatographic methods (Shibukawa et a l,
1990). The ability to determine as much as possible with respect to a drugs ADME profile 
as early as possible in the discovery process is becoming increasingly important with the 
larger number of potential drug candidates being identified. Frostell-Karlsson et al. (2000) 
investigated the interactions of a panel of 19 drug compounds with immobilised human 
serum albumin (HSA). The intensity of the binding response determined following injection 
of the drug compound over the HSA-immobilised surface was used as a means of 
determining the potential degree of HSA binding. The degree of drug-protein binding 
measured using biosensor techniques, correlated well with traditional techniques and 
comparable association constants were obtained.
Two new chips constructs released by BIACORE have made it possible to construct stable 
membrane surfaces within the flow cell. Evans & MaeKensie (1999) have recently reviewed 
the different methods available for constructing lipid bilayers on chip surfaces. The
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generation of such membrane surfaces offers several advantages over the conventional 
dextran-coated surfaces for studying membrane-bound proteins in that: the proteins are 
specifically orientated, and also that multivalent interactions can occur as a result of 
membrane fluidity which more closely resembles the in vivo environment.
An understanding of the intestinal absorption profile of new drug candidates is o f importance 
when screening, particularly in being able to differentiate between drugs that demonstrate 
low, medium or high absorption. As the majority of drugs are administered orally, the 
fraction of drug absorbed from the intestine is of considerable significance. In vivo studies of 
drug absorption have been difficult to perform and the requirement for suitable in vitro 
models is growing. Several other recent techniques based on liposome-partitioning (Balon et 
al., 1999) and liposome-chromatography (Liu et al., 1995) has also been described to 
simulate drug absorption profiles from the intestine. Danelian et al. (2000) investigated the 
direct interaction of a panel of 27 drugs with a liposome-immobilised surface. The 
interaction between the immobilised liposomes and the various groups was monitored using 
a direct binding assay by SPR. The simulated absorption data produced correlated with 
previously reported oral absorption data, and allowed for the classification of the compounds 
absorbed by the transcellular route into low, medium and high membrane permeability based 
on the measured responses.
4.1.2.3. Proteomics
Recent interest has focused on more intensive proteomic studies, with technologies capable 
of screening up to 10, 000 compounds per day. Screening therefore is no longer the problem, 
instead it is the need to find new targets to fuel the expanding screening processes. Recent 
attention has thus been focused on identifying new ligand-receptor pairs and the 
characterisation of protein-protein interactions, making SPR systems the logical candidates 
for ‘orphan’ ligand screening procedures (Williams, 2000). ‘Ligand-fishing’ is the process 
by which ‘orphan receptors’ are screened against multitudes of compounds, cells and tissue 
extracts to identify putative targets. Traditional ligand-fishing techniques have relied on the 
use of immunoprécipitation, which suffers from a general lack of sensitivity. SPR 
biosensors can be seen thus to serve two purposes in the area of proteomic analysis: to be 
able to confirm detection and quantify direct binding of ligand from cell lysates and 
conditioned media. Secondly, they can also function as micropurification devices capable of 
recovery of sufficient quantities of analyte for subsequent analysis and characterisation 
(Williams & Adonna, 2000). Such ligand fishing procedures have been successfully applied 
and validated in micro-preparative scale by Catimel et al. (2000) for the recovery of 
sufficient quantities of bound ligand for subsequent characterisation using reverse-phase
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HPLC and SDS-PAGE analysis. The concentration of bound ligand following elution from 
SPR instruments is also usually o f sufficiently large quantity to allow for detection by mass 
spectrometry (MS). Sonsken et al. (1998) described an elaborate elution procedure for 
combined BIACORE-Maldi-MS analysis that allows for elution of bound analytes in as little 
as 4(xl of eluant. This tandem format offers the benefits of sensitive affinity-capture, and 
subsequent fingerprint MS characterisation of the eluted analytes. Mass spectrometry offers 
several advantages such as specificity, sensitivity and rapidity over the majority of protein 
identification techniques which rely on proteolytic digestion of separated proteins and 
subsequent analysis of proteins by PAGE. The quantities o f protein recoverable from most 
SPR biosensors are ideal for mass spectral analysis; whereby sequence information can be 
obtained at the femto (10 15) and attomolar (1018) concentration range in seconds. Nelson et 
al. (1997(a)) performed MS analysis of analytes bound directly to the sensor chip surface, 
and also coupled MS with the use of the SPR probe instrument whose relatively large surface 
area allows for greater quantities of analytes to be recovered, and also given the exposed 
nature of the sensor surface collection and elution of analytes is also simplified (Nelson et 
al., 1997(b)).
4.1.3. SPR Biosensors as a tool in Protein Engineering:
With the recent advances in genetic engineering the need for quick, precise analytical 
instrumentation capable of selecting antibodies of the desired specificity from the millions of 
specificities available becomes a prerequisite (Malmborg & Borrebaeck, 1995). SPR 
biosensors thus represent a unique, simple and rapid approach for analysing recombinant 
antibodies and phage displayed libraries from the screening and selection procedures right 
through to determination of kinetic constants and antibody specificity epitope mapping 
experiments. Given the relatively large number of candidates screened during panning 
procedures, ELISA is the most common format of analysis. However, as ELISA is an 
equilibrium process antibodies with high off rates may thus be lost, alternatively BIACORE- 
based selection procedures allow for the visualisation of the entire binding pattern. Marks et 
al. (1992) demonstrated that it is also possible to directly screen bacterial supernatants 
without any further purification procedures required. Selection procedures based on elution 
and re-screening of eluted phage could be used to increase specific phage titres and have 
demonstrated a 10-57% increase in specific phage titres (Malmborg et al., 1996). The fact 
that biosensor-based technologies arc also capable of measuring active antibody 
concentrations, which may be lower than the ‘nominal’ concentration as measured 
spectrophotometrically, is also of significance when determining association constants which 
consequently will be lower than the true value. Epitope mapping performed on biosensors 
offers the possibility of studying the stoichiometry and kinetic analysis of the binding of
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several antibodies to the same antigen (Huber el al., 1999), and is of importance when 
selecting antibodies to particular structural features of the antigen which may be related to its 
function. Biosensors are also useful as a means of monitoring complex fermentation 
mixtures and procedures on-line. They have been successfully used for the systematic 
change of overexpression conditions in E.coli bacterial supernatants and periplasm extracts, 
for the optimal generation conditions of an anti-angiogenesis antibody used for tumour 
targeting applications (Viti el al., 1999) by monitoring the levels of antibody expression in 
‘real-time’.
The recent advances in protein engineering has facilitated the development and synthesis of 
novel enzymes with improved stability and catalytic performance, through the dissection of 
the role of individual amino-acids in catalysis and the use o f site-directed mutant enzymes 
(Wilkinson el al., 1984). Combinatorial mutagenesis has facilitated the task of producing 
such new products, and the role of biosensors will play a crucial role in the selection and 
characterisation of the desired catalytic activities from such libraries. Recent interest on 
enzyme engineering has focused on improving the catalytic properties and substrate 
specificities of existing enzymes. Biosensor selection procedures, based on catalysis and the 
physical selection of phage-enzymes which convert reaction substrate to product, have been 
successfully applied in a number of instances (Dcmartis et a l ,  1999). Antibodies to the 
reaction product can then be used for the physical selection of phage-enzyme complexes 
having catalysed the reaction, which can then be selectively eluted and removed.
4.1.4. Drug-Protein Binding:
The degree of drug-protein binding can have a marked influence on the pharmacokinetic or 
pharmacodynamic profile o f a drug, and ultimately the therapeutic efficacy of the 
administered drug. It is the ‘non-protein’ bound or essentially free drug fraction of the 
administered drug in plasma that dictates it’s pharmacokinetic profile. The degree of drug- 
protein binding will thus determine its volume of distribution, plasma half-life and, 
eventually, the elimination o f the drug from the body. Various disease states (e.g. uremia, 
malignancy), concomitant drug therapy, genetic and age-related factors have all been shown 
to influence the degree of drug-protein binding. Clinical conditions such as uremia, 
hypoalbuminemia and hepatic insufficiency have been related with reduced protein binding, 
whilst increased levels of drug-protein binding have been associated with acute myocardial 
infarction, renal transplant and malignancy (Wandell & Wilcox-Thole, 1983).
Plasma proteins such as albumin and a-acid glycoprotein bind reversibly to drugs primarily 
through hydrophobic and hydrophilic interactions, although Van der Waal’s and hydrogen
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bonding have also been implicated. The binding equilibrium between drugs and proteins can 
be described by the following expression:
ka
[D] + [P] <-» [DP]
kd
Ka = [DPI / [D] [P]
Where [D] = Plasma molar concentration of drug
[P] = Plasma molar concentration of protein
[DP] = Plasma molar concentration of drug-protein complex
Ka = association constant for drug-protein complcx.
ka = association rate constant
ka = dissociation rate constant
Modification of the structure of albumin as is the case following the binding of aspirin to 
albumin results in acetylation of the albumin forming acetylalbumin, which can also alter the 
affinity of the interaction between particular drugs and proteins. The plasma binding of 
warfarin and it’s analogues to human serum albumin (HSA) has been extensively studied 
(Chignell, 1970; Sellers & Koch-Weser, 1975; Bertucci et ah, 1999; Dockal et ah, 1999; 
Forstell-Karlsson, 2000). HSA is composed of three structurally similar globular domains 
IA, IB, IIA, IIB, IIIA and IIIB and is normally present in plasma at a concentration between 
39 and 55mg/ml (Wandell & Wilcox-Thole, 1983). Dockal et al. (1999) recently dissected 
the binding of warfarin to HSA using various recombinant domains of human serum albumin 
in an attempt to elucidate the essential elements required for the formation of the warfarin 
binding site on HSA. Affinity constant determinations by fluorescence titration revealed that 
the warfarin binding site was located primarily on subdomain IIA, with a secondary binding 
site on domain I, and structural contributions on domain IIB. Bertucci et al. (1999) probed 
the binding of warfarin enantiomers to site I on HSA using a chiral stationary matrix to 
which HSA was anchored. Displacement studies demonstrated significant differences in the 
binding of the enantiomers to site I on HSA. Competitive binding displacement studies 
demonstrated that (S)-warfarin was a direct competitor for (R)-warfarin, confirming that the
(S)-enantiomer has a higher affinity for HSA.
Warfarin is primarily bound to plasma albumin and any decrease in plasma albumin levels 
(e.g. hypoalbuminemia) as a result of reduced synthesis, excessive renal failure or increased 
catabolism will thus be reflected in an increased free drug concentration. Given the intended 
pharmacological effect o f warfarin (i.e. prolongation of the prothrombin time (PT)) and its
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narrow therapeutic window, any change in the equilibrium which results in an increased 
plasma free drug concentration can thus result in fatal consequences. A vast amount of 
literature has described potential inhibitory and potentiating factors in the overall metabolism 
of warfarin because of its narrow clinical window and widespread clinical use. Greater 
emphasis is now being placed on proper patient education with respect to potential 
interactions with foodstuffs (Wells et al., 1994), and concomitant drug therapies (Chan, 
1995; Harder & Thurmann, 1996). Any decrease in the plasma free drug concentration can 
result in reduced anti-coagulation and an increased incidence of thrombotic events, or 
alternatively, an increased free drug concentration can result in an increased likelihood of 
haemorrhagic complications as a result of increased anti-coagulation.
4.1.4.1 Methods fo r measuring free drug concentrations:
Many methods have been used to study drug-protein interactions, although many tend to lead 
to a particular bias with respect to the measured concentration of either free or protein-bound 
drug (Wandell & Wilcox-Thole, 1983). Equilibrium dialysis was traditionally the method of 
choice employed to assess the degree of drug-protein binding, and is based on the principle 
that an unbound drug will equilibrate across a semi-permeable membrane between protein 
and buffer containing solution by placing the drug-protein solution in buffer solution and 
allowing the solution to dialyse until equilibrium is attained. At equilibrium, the 
concentration of drug in the buffer solution is considered representative of the unbound drug 
fraction in the protein solution. For pharmacokinetic studies such a procedure is obviously 
limiting with respect to time constraints (i.e. the time taken to reach equilibrium is usually of 
the order of hours), the sample volumes required and the dilutional effects observed.
Ultrafiltration procedures, for the separation of free drug from the protein-bound portion, 
offer a relatively simple and rapid procedure that can be performed at physiological 
temperatures, without the dilutional effects observed with equilibrium dialysis. The 
procedure simply utilises a fine low molecular weight membrane (l-3kDa) to separate free 
drug from protein-bound drug following centrifugation. A detailed discussion describing the 
use of the two techniques with regard to free-drug concentration determinations is described 
elsewhere (Bowers et al., 1984).
High performance frontal chromatography (HPFA) has also been used to assess the degree of 
binding of warfarin and other drugs to HSA (Shibukawa et al., 1990). Using this 
chromatographic technique a sample o f the drug-protein mixture at equilibrium is injected 
onto the HPLC column. The particular type of HPLC column utilised is comprised of a 
specially designed stationary phase that excludes large macromolecules such as albumin, but
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retains smaller molecules such as warfarin on the hydrophobic ligands in the pores 
(Pinkerton et al., 1989). When a sufficient volume of the drug-protein mixture is injected 
onto the column, a zone appears at the top of the column where the concentration of drug in 
the mobile phase reaches steady-state and the drug-protein binding in solution is reproduced 
in the column. The net result is that the drug is eluted as a trapezoidal peak with a plateau, 
which corresponds to the free drug concentration in plasma. The appearance of such a 
plateau is essential in HPFA. Several precautions should be taken when performing HPFA 
to ensure that the equilibrium of the drug-protein complex is not disrupted by careful 
selection of mobile phase conditions. The use of ion-pair reagents and buffers of different 
ionic strength to the equilibrium mixture should also be avoided when possible.
Parikh et al. (2000) described a method for the determination of the degree of drug-protein 
binding between potential drug candidates and serum proteins based on the quenching of the 
intrinsic tryptophan fluorescence of serum albumin and a-acid glycoprotein as measured by 
spectrofluorimetry. The dissociation constants measured for the complex compared well 
with those obtained using more traditional techniques such as equilibrium dialysis. The 
technique also has the added benefit that it does not involve membrane separations, lengthy 
dialysis procedures or chromatographic techniques for quantitation.
The use of ultracentrifugation that separates the fractions of plasma into concentration 
gradients based on their relative size, molecular weight and shape can also be employed to 
separate free drug from protein-bound drug. However, the technique is not widely used due 
to the time-consuming and expensive nature of the process. Cross-linked dextran gels that 
separate on the principle of size exclusion have also been used to separate free drug from 
protein-bound drug; however, the time-consuming and tedious nature are limiting factors for 
the routine use of this particular technique.
4.1.5. Analysis o f  warfarin:
There are currently a wide range of sensitive analytical methods available for the quantitative 
determination of warfarin and it’s metabolites in human and animal biological samples, 
utilising various modes o f detection ranging from chromatography to phosphorescence-based 
measurements (Table 4.1). The majority of techniques described in the literature require 
extensive sample pre-treatment (i.e. protein precipitation, liquid-liquid/ solid phase 
extraction, evaporation and reconstitution) to determine the plasma concentration levels of 
warfarin.
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Early techniques described for the detection of warfarin in plasma were primarily based on 
thin-layer chromatography (TLC) of radiolabelled ligands followed by scintillation counting. 
Thin layer chromatography allows for the separation of organic molecules on a solid silica 
support by the capillary action of an organic solvent along the silica support. Separation of 
the migrating molecules can thus be achieved by selective change of the polarity of the 
organic solvent phase. Lewis and Trager (1970) described such a technique for the 
determination of warfarin and it’s metabolites in biological fluids, identification o f the 
resolved compounds was achieved by a combination of atomic spectroscopy and 
fluorescence analysis.
The development of high-performance liquid chromatography (HPLC) greatly advanced the 
study of a wide range of drug molecules, allowing for accurate determination o f their 
pharmacokinetic profiles without the use of radiolabelled ligands. Chromatographic 
separation in HPLC, like TLC is the net result of specific interactions between sample 
molecules with both the stationary phase and the mobile phase. The variety of solid phase 
supports currently available (e.g. C2/8/12/18 and cat-/anion exchange columns) allows for 
greater variability in the types of interactions which is reflected in the degree of separation 
achieved. HPLC analysis of warfarin is predominantly carried out by reverse-phase HPLC, 
which employs the use of a suitable polar mobile phase and a non-polar stationary phase, 
typically employing hydrophobic C l 8 or C8 carbon chains. A list of many of the published 
chromatographic techniques and the detection methods employed is shown in Table 4.1.
A number of investigators have employed the use of derivatisation schemes to enhance the 
detectability of warfarin by ultraviolet and fluorescence detection methods and to allow for 
resolution of warfarin enantiomers (Banfield & Rowland, 1984). Post-column reaction 
techniques are carried out following the separation of the components on the analytical 
column, by mixing the column effluent with the desired derivatising reagent by means of a 
post-column reaction coil. The majority of post-column reaction techniques have employed 
the use of a suitable basic solution to utilise the native fluorescence of warfarin at high pH 
values (Steyn et al., 1986). Recent advances in column chromatography have allowed for 
the development of various columns incorporating P-cyclodextrin molecules capable of 
enatiomeric resolution o f the warfarin enantiomers (Ring & Bostick, 2000).
The pharmacokinetic profile of warfarin in man has been extensively reviewed (King et al., 
1995). Cai et al. (1994) studied the pharmacokinetic profile of 12 stroke patients on warfarin 
therapy by solid phase extraction of warfarin from plasma, and precolumn derivatisation to 
form diastereoiosmeric esters, followed by post-column reaction with fluorescent detection.
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The authors reported the mean plasma concentration o f (S)-warfarin to be 0.47+0.17 pg/ml, 
with that of the (R)-enantiomer to be equal to 0.69±0.18 pg/ml. Studies of the free drug 
fraction found the average protein-binding of (S)-warfarin to be equal to 99.6710.33%, 
studies of the (R)-enantiomer demonstrated a slightly less plasma protein-bound 
concentration of 99.44+0.33%. For determination of free enantiomer concentrations, 
enhanced sensitivity was achieved by adjustment of the photomultiplier tube (PMT). The 
limit of detection for the free drug assay was found to be 8.05 ng/ml for the (S)-isomer and 
6.21 ng/ml for the (R)-isomer. The limits of detection routinely attainable by the many 
published chromatographic publications arc often unable to accurately determine the levels 
of free plasma concentrations of warfarin in patient samples, which in the majority of cases 
are at least an order of magnitude outside the desired quantification limits. The current trend 
in anticoagulant therapy is towards lower intensity treatment (Lodwick, 1999). 
Consequently, there is a need to develop newer more sensitive analytical techniques capable 
of detecting lower concentrations of warfarin in biological fluids, for the accurate 
determination of the physiologically free fraction of warfarin in plasma.
‘Warfarin-like’ anticoagulants have been routinely used as rodenticides, where repeated 
ingestion of the rodenticide results in death by haemorrhage. The determination of such 
residues is often important in cases of accidental ingestion by non-target animals. The 
anticoagulant residues are normally not present in the stomachs of poisoned animals. The 
liver is usually the most useful material for diagnostic analysis, where the residues are 
normally present in the livers of the affected animals at concentrations ranging below 1 fxg/g 
(Jones, 1996). Langseth & Nymoen (1991) developed a HPLC method for the determination 
of brofadicoum, bromadiolone, coumateryl, difenacoum and warfarin in a variety of animal 
liver tissues. The procedure described involved the initial homogenisation of the liver 
samples, followed by liquid-liquid extraction and subsequent solid-phase extraction of the 
residues. The residues were detected using UV (ultraviolet) or fluorescence detection, with 
reported limits of detection for the rodenticides being 0.005 pg/g, with the exception of 
warfarin which had a limit of detection 0.08 pg/g. Jones (1996) described a similar method 
for the detection of the same rodenticides in animal liver tissues using gel-permeation 
chromatography (GPC) as a clean-up procedure followed by post-column reaction with 
fluorescent detection. The reported limit of detection for warfarin was 0.010 pg/g and 0.002 
pg/g for each of the other rodenticides.
Capitâl-Vallvey et al. (1999) recently described a phosphorescence-based assay for the 
detection o f warfarin in plasma and water samples using solid-phase room-temperature
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transmitted phosphorescence. Phosphorescence spectrometry involves a change in electron 
spin and consequently phosphorescence lifetimes are usually much longer than fluorescent 
lifetimes (i.e. of the order 10^-10 seconds). The technique described involves initially 
spotting the samples onto Whatman filter paper together with sodium hydroxide and iodide. 
The filters are then dried and the transmitted phosphorescence measured at 467nm using two 
quartz plates to reduce the quenching effect o f oxygen. Interference produced by human 
serum was eliminated by the addition o f sodium thiosulphatc. A linear range of detection of 
warfarin between 300 and 4,000ng/ml was reported, with a lower limit of detection of 80 
ng/ml.
Bush and Träger (1983) described a gas chromatographic-mass spectrometry (GC-MS) for 
the determination of warfarin and it’s metabolites from microsomal incubations. The 
procedure developed involved two different extraction schemes that allowed for the selective 
separation of warfarin from its metabolites. Following the extraction procedure the 
compounds are reconstituted in BSTFA (N, O-bis- (Trimethylsilyl)-trifluoracetamide) that 
silylates the alcohol groups of warfarin alcohols, which serves to stabilise them prior to GC- 
MS analysis. The cited limit of detection for the GC-MS technique is of the order of 2 ng/ml 
with a reported lower limit of quantitation of 20 ng/ml.
Gareil et al. (1993) developed a capillary electrophoresis (CE) technique for the 
determination of warfarin enantiomers utilising a ß-cyclodextrin column as a chiral selector, 
with reported lower and upper limits of detection of 200 ng/ml and 20 ng/ml, respectively. 
Computer-modelling studies by Armstrong et al. (1986) have shown that the coumarin 
moiety of warfarin penetrates into the hydrophobic cyclodcxtrin cavity with the phenyl 
substituent remaining outside the larger mouth of the cone.
Hutt et al. (1994) reported the development o f an amperometric biosensor for warfarin 
utilising a platinum carbon felt to which the bacterium Nocardia corallina was chemically 
linked utilising carbodiimide chemistry. The electron mediator ferrocene was also coupled 
to the carbon electrode to improve electron transduction. Nocardia corallina was shown to 
stereospecifically reduce (S)-warfarin to the corresponding (S,S)-warfarin alcohol (see 
Figure 1.7). The biosensor was capable of detecting warfarin in the linear range 1.5-150 
(xg/ml.
Cook et al. (1979) developed a stereoselective radioimmunoassay (RIA) for the enantiomers 
of warfarin in rat-dosed subjects. 4'-carboxyethyl analogues of (R)- and (S)-warfarin were 
produced and analysed by an elaborate reaction scheme that involved the resolution of the d-
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10-camphorsulfonate diastereoisomers for the production of optically pure radioligands. The 
synthesised 4'-carboxyethyl enantiomer analogues were subsequently coupled to bovine 
serum albumin (BSA) for the production o f enantiomeric conjugates. The rabbit sera 
generated following injection of each enantiomeric conjugate produced enantiomeric 
antibodies with cross-reactivity to the opposite enantiomer o f the order o f 0.3-3.0%. The 
analytical procedure was based on a displacement radioimmunoassay (RIA) incorporating 
the use of tritium- labelled warfarin.
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Table 4.1 Techniques and  detection limits fo r  warfarin analysis:
Detection Method Limits of Detection/ 
Quantitation (ng/ml)
Reference:
Thin Layer Chromatography (Primarily Qualitative detection Breckenridge & Onne (1973)
(TLC) limits not reported)
Radioimmunoassay (RIA) L.O.D pg range Cook eta l. (1979)
Phosphorescence 300-4,000 ng/ml Capitän-Vallvey et al. (1999)
Capillary Electrophoresis (CE) 200-20,000 ng/ml Garcil et al. (1993)
HPLC- Total:
Fluorescence- L.O. D. »  0.2 ng/ml Lee et al. (1981)
1-100 ng/ml (free) Steyn et al. (1986)
500-10,000 ng/ml (total) Steyn et al. (1986)
6.0-450 ng/ml King et al. (1995)
Ultraviolet- 40-800 ng/ml Fasco et al. (1977)
100-5,000 ng/ml De Vries et al. (1982)
100-1000 ng/ml Chan & Woo (1988)
HPLC-Enantiomeric:
Fluorescence-
12.5-2500 ng/ml Naidong & Lee (1993)
100-6,000 ng/ml Banfield & Rowland (1984)
Ultraviolet- L.O. D. *  20 ng/ml De Vries & Schmitz-Kummer 
(1993)
12.5-2500 ng/ml Ring & Bostick (2000)
Surface Plasmon Resonance 
based Immunoassay
Fitzpatrick & O’ Kennedy
Monoclonal: 0.5-500 ng/ml
Polyclonal: 10-2000 ng/ml
Amperometric biosensor 1,500 ng/ml-150 ng/ml Hutteta l. (1994)
Gas-chromatography Mass L.O. D. «2 ng/ml Bush et al. (1983)
Spectrometry (GC-MS) L.O. D. «10 ng/ml De Vries et al. (1985) 
Kunze e ta l. (1996)
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4.1.6. M easures o f  Analytical Performance:
When developing a new analytical assay procedure, various parameters of analytical 
significance must be considered, and these parameters for the validation of bioanalytical 
techniques by chromatographic techniques are particularly well defined and substantially 
reviewed (Karnes et al., 1991; Braggio et al., 1996; Hubert et al., 1999). Until 1990 there 
were no real validation criteria outlined for the validation of immunoassays (Shah et al.,
1991), despite the increasing use of immunoassay procedures in the clinical setting (Gaines 
Das, 1999; George et al., 2000). Findlay et al. (2000) recently addressed particular issues of 
bioanalytical validation peculiar to immunoassays, in an attempt to standardise the validation 
parameters for immunoassay procedures which the authors believed were not adequately 
described by the existing literature recommendations (Shah et al., 1991). Bruno (1998) 
addressed the growing need for validation of immunoassays performed on BIACORE 
instruments, and described the relevant validation parameters according to current ICH 
guidelines (International Congress of Harmonisation).
Several differences exist between chromatographic and immunoassay assay procedures. 
Firstly and most importantly, chromatographic techniques rely on the measurement of a 
specific physicochemical property of the analyte in question whose measured response is 
usually directly proportional to the concentration of the analyte, and thus best described by a 
linear calibration model. Immunoassays rely on the antibody-antigen interaction for the 
specific analyte measurement, and the constructed calibration plot is inherently sigmoidal in 
shape and best fitted with a four-parameter logistical fit. The working range of 
immunoassays is as a result slightly limited when compared to chromatographic procedures. 
Also, depending on the source of the antibody preparation (i.e. polyclonal or monoclonal), 
there can be significant variation in reagent variability, although the development of 
monoclonal and recombinant techniques has obviated the majority of these difficulties. 
Despite these limitations, the use of immunoassays offers several advantages compared to 
chromatographic techniques when compared on an individual assay and capital cost 
investment. The sample throughput of immunoassays is significantly better than 
chromatographic techniques, which can also involve extensive sample pre-treatment and 
derivatisation steps. Generally speaking the inherent physicochemical properties of a 
molecule dictates the detection limits attainable chromatographically, and the lack of suitable 
chromophoric or electrochemically active functional groups can be limiting factors in the 
detailed analysis of the pharmacokinetics of a particular drug molecule. Given the recent 
advances in genetic engineering, the possibility of producing antibodies and fragments 
thereof with enhanced affinities (KD«10'15M) (Boder et al., 2000), has advanced the 
possibility of determining even lower analyte concentrations in complex matrices without the
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need for extensive sample pre-treatment. Similarly, with the use of such antibody libraries 
and the unique specificity of the antibodies, common biosensor detection formats can be 
used for the analysis of a wide range of analytes, without the need for developing individual 
chromatographic assay separation techniques.
Findlay et al. (2000) commented that many of the existing recommendations with respect to 
the measured degrees of assay precision were too stringent given the inherently less sensitive 
nature of immunoassays compared to chromatographic assays. The authors suggested that 
the previous minimum acceptable limits of accuracy be increased from the previous 
published acceptable limits of 15% (20% at the lower limit of quantitation (LLOQ)) to 20% 
(25% at the LLOQ). Wong et al. (1997) recently described the validation of an 
immunoassay for the simultaneous detection of the concentrations of a humanised mouse 
antibody in mouse serum, and also for the presence of murine antibodies to the humanised 
antibody in the mouse serum. The main parameters addressed by the authors for the 
validation of the biosensor assay included: precision, accuracy, linearity, stability of the 
immobilised ligand, specificity and sensitivity. The stability of the immobilised ligand is an 
additional parameter that requires validation in the development of biosensor assays, unlike 
ELISAs. This must be determined prior to sample analysis through monitoring the binding 
capacity of the immobilised ligand by a series of consecutive binding-regeneration cycles. 
Depending on the nature of the immobilised ligand, the binding capacity may be drastically 
reduced by repeated regeneration exposure to mild acidic and basic pulses and/or the 
combined use of organic solvents (e.g. particularly for immobilised antibody molecules). 
Wong et al. (1997) suggested the use of independent positive controls to monitor the ligand 
surface-binding capacity, and to continue with the use of the immobilised surface when the 
binding capacity for the positive controls remains within 20% of the original measured 
binding response value.
4.L6.1. BIACORE as an analytical detection device fo r  the measurement o f  low molecular 
weight analytes:
Immunoassays are generally the method of choice for the detection of larger macromolecules 
and biomarkers. However, with recent developments in biosensor and antibody technology 
that has allowed for the standardisation of reagents, the use of immunoassays is continually 
growing for the measurement of smaller molecular weight molecules such as warfarin. 
Competitive immunoassays are generally the preferred assay format for such analytes, where 
the detection of analytes is based on competition between free and immobilised forms of the 
antigen (Figure 4.5). In equilibrium well-based ELISA systems, the measured response (i.e. 
absorbance) is inversely proportional to the concentration of competing analyte in solution.
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The response measured using BIACORE and other SPR-based biosensors is the net result of 
analyte binding (i.e. mass effects at the chip surface). BIACORE utilises a flow cell as 
opposed to other SPR-based biosensors that incorporate a well-based system, which allows 
for the detection of analytes in solution as they pass over the derivatised sensor chip surface. 
For the detection of small molecular weight analytes, the most commonly employed assay 
format is the inhibition-based assay whereby an equilibrium drug-antibody mixture is passed 
over the derivatised chip surface. The measured binding response is thus inversely 
proportional to the analyte concentration as the greater free analyte in the antibody: drug 
mixture will ‘inhibit’ the binding of antibody to the chip surface (Figure 4.5).
The potential use of SPR-based biosensor assays in the food industry was demonstrated by 
Crooks et al. (1998) who developed and validated an assay for the detection of the 
antibiotics sulfamethazine and sulfadiazine in pig bile samples (n= 2081), which have been 
shown to be good determinants of the extent of sulfonamide accumulation in the kidney. 
The biosensor assay results reported the number of false positives for sulfamethazine and 
sulfadiazine, to be 0.14% and 0.34%, respectively, whilst simultaneous ELISA 
measurements reported the number of false positives for sulfamethazine and sulfadiazine, to 
be 1.54% and 1.44%, respectively. The biosensor assay also identified a number of false 
negatives missed by the ELISA procedure (frequency of false negatives by ELISA for 
sulfamethazine of 0.14% and for sulfadiazine of 0.24%, respectively).
Deckert & Legay (1999) developed a BIACORE assay for the determination of an 
immunoreccptor assay for the chimeric human/mouse antibody Simulect directed against 
interleukin-2 (IL-2). The inter- and intraday coefficients of variation for the assay were 1.6 
and 1.7% respectively, with the overall accuracy for the assay was 98.5%±1.0.
The development of a biosensor-based immunoassay for the detection of warfarin in 
biological matrices is described with an investigation into the stability (i.e. binding capacity) 
of various immobilised ligands. Monoclonal and polyclonal antibodies were used to develop 
the inhibition-based SPR immunoassay, and a schematic of the interaction occurring at the 
sensor surface is shown in Figure 4.5. The ability o f the assay to measure free warfarin 
concentrations in plasma ultrafiltrate was assessed, and the results obtained were correlated 
with HPLC analysis. Analytical issues regarding the accuracy, precision and robustness of 
the various immunoassays are also addressed. The developed immunoassay was 
subsequently used to measure the free-fiaction of warfarin in patient plasma ultrafiltrate and 
used to determine the degree of plasma protein-binding of warfarin by comparison with the 
total plasma concentration as determined by HPLC techniques.
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Figure 4.5. Schematic o f  the antibody-.antigen interaction occurring at the sensor chip
surface. Equilibrated mixtures o f  antibody and antigen are injected over a 
functionalised sensor chip surface (e.g. 4'-azowarfarin-BSA, 4'- 
aminowatfarin). The amount o f  antibody available to bind to the chip 
surface will be ‘inhibited’ by the free warfarin concentration in solution (i.e. 
the greater the free analyte concentration in solution, the less free antibody 
available fo r  binding to the chip surface).
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4.2 Results & Discussion:
4.2.1. Preconcentration o f  4'-aminowarfarin-protein conjugates:
For the successful immobilisation of drug-protein conjugates at the sensor chip surface it is 
essential to maximise the interaction between the carboxymethylated dextran (CM-dextran) 
surface and the target drug-protein molecule, in this instance 4'-azowarfarin-BSA. At pH 
values greater than 7, the CM-dextran surface has a net negative charge, and proteins at pH 
values below their isoelectric point (pi) (i.e. will have a net positive charge) will be 
electrostatically attracted to the chip surface. Low ionic strength buffers (e.g. 10 mM acetate 
buffer) are employed for protein immobilisation procedures as they favour such electrostatic 
attractions between the dextran layer and the protein of interest. This ‘preconcentration’ step 
is an effective way of maximising the potential interaction between the hapten-protein 
conjugate and the CM-dextran layer for subsequent immobilisation, and increasing the 
potential yield of immobilised ligand.
A solution of 50 fig/ml 4'-azowarfarin-BSA was prepared in 10 mM acetate buffer and 
transferred into eppendorf tubes. The pH of each warfarin-BSA solution was adjusted to the 
desired pH value by the dropwise addition of a 10% (v/v) solution o f acetic acid. Each 
protein was passed sequentially over an underivatised sensor chip surface at 10 jxl/min for a 
period of 3 minutes as described in section 2.12.1. The differing degree of preconcentration 
can be measured by the response prior to the end of the injection for each protein solution at 
the various pH values. Following injection, the flow of running buffer over the chip surface 
is usually sufficient to dissociate the electrostatic attraction between the protein and CM- 
dextran surface (Figure 4.6). The degree of preconcentration illustrates a significant increase 
at pH values below 5. From these preconcentration experiments, it was possible to 
determine that the optimal pH for 4'-azowarfarin-BSA immobilisation procedures, was pH 
4.8 in 10 mM acetate buffer.
4.2.2. Im m obilisation o f  H apten-protein  conjugates:
Ligand immobilisation in BIACORE analysis involves the sequence of surface activation, 
ligand preconcentration/immobilisation and surface deactivation. Activation o f the sensor 
chip surface usually results in the modification of up to 40% of the carboxyl groups in the 
hydrogel, and reducing the activation contact period is the simplest method for regulating the 
yield of immobilised ligand. There are a wide variety of immobilisation chemistries 
available for coupling proteins and drug molecules to the CM-dextran chip, depending on the 
residues available for coupling. The most commonly employed strategy is the use o f EDC 
(N-ethyl-N'-(dimethylaminopropyl)carbodiimide) and NHS (N-hydroxysuccinimide)
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chemistry. Using the water-soluble carbodiimide EDC, surface carboxyl groups can be 
transformed into active ester functional groups in the presence of NHS. The surface NHS 
esters then are available to react with suitable amine groups on the protein. The reaction 
works best between pH 6 and 9, whilst the efficiency of the reaction decreases rapidly below 
pH 4.5. Hapten-protein conjugates are often characterised by low isoelectric points, which 
can make adequate levels of surface immobilisation difficult using conventional EDC/NHS 
chemistry. In many such instances, the pH chosen for immobilisation procedures is often a 
compromise between the effective preconcentration pH and a pH level at which EDC/NHS 
chemistry works well (i.e. the pH chosen for immobilisation procedures may not always be 
the pH at which the most effective preconcentration occurred). Deactivation or ‘capping’ of 
unreacted NHS-esters was achieved by treatment with 1 M ethanolamine hydrochloride (pH 
8.5), which also served to remove non-covalently bound protein by reducing the electrostatic 
attraction between the protein and CM-dextran surface.
For immobilisation of 4'-azowarfarin-BSA the procedure was carried out as described in 
section 2.12.2.1. Immobilisation of the drug 4'-aminowarfarin directly onto the chip surface 
was carried out as described in section 2.12.2.2., direct immobilisation of drug was 
performed external to the BIACORE instrument due to the relatively high concentration of 
DMSO (5-10%) in the coupling buffer. Following surface deactivation, the chip surface was 
pulsed with two 30 second pulses of 30 mM HC1, which ensured complete removal of non- 
covalently bound protein. A typical immobilisation strategy for the coupling of 4'- 
azowarfarin-BSA to the sensor chip surface is demonstrated in Figure 4.7. Routinely, it was 
possible to attain surface immobilisation of greater than 10,000 response units (RU) of 4'- 
azowarfarin-BSA. Immobilisation of 4'-aminowarfarin directly to the chip surface resulted 
in approximately «200 RU bound to the chip surface. Given the molecular weight ratio of 
4'-aminowarfarin to 4'-azowarfarin-BSA (i.e. 318 Da to 84 kDa), this represents a 
significantly large increase in epitope concentration at the sensor chip surface, and is 
reflected in the 20-fold dilution of antibody required with such surfaces compared to 
conjugate surfaces. Immobilisation of high concentrations of analyte is essential for 
performing experiments under conditions of mass-transport limitation (MTL) (sections
5.1.11.2 and 5.2.4.2).
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Figure 4.6: Preconcentration o f  4'-azowarfarin-BSA onto a CM-dextran chip surface.
Solutions o f  50 fig/ml o f  4'-azowarfarin-BSA in 10 mM acetate buffer at 
various pH  increments were passed over an unactivated CM-dextran surface 
at 10 fjl/min fo r  a period o f  3 minutes. The low ionic strength o f  the buffer 
used favours the electrostatic attraction between the negatively charged 
dextran layer and the positively charged protein (i.e. below isoelectric 
point). The degree o f  ‘preconcentration ’ was measured from the response 
prior to the end o f  each sample injection The ionic strength o f  running 
buffer (150 mM NaCl) was sufficient to dissociate the electrostatically 
attracted conjugate from the chip surface. The optimal pH  for 
immobilisation o f  4'-azowarfarin-BSA onto a CM-dextran chip surface was 
calculated to be p H  4.8, and all subsequent immobilisation procedures o f  4'- 
azowarfarin-BSA were thus prepared in 10 mM  acetate buffer (pH 4.8).
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Figure 4.7: Immobilisation o f  4'-azowarfarin-BSA onto a CM-dextran chip surface:
(1) HBS running buffer is initially passed over the chip surface and a 
baseline measurement recorded.
(2) Following mixing a solution containing 0.05 M N H S  and 0.2 M E D C  is 
passed over the chip surface to activate the chip, the large increase in SPR 
signal is due primarily to a bulk refractive index change.
(3) A small increase in baseline is recorded following activation o f  the chip 
surface (-200RU).
(4) A solution containing 50 ng/ml o f  4 '-azowarfarin-BSA in 10 mM  acetate 
buffer (pH 4.8) is passed over the chip surface fo r a period o f  10 minutes.
(5) The amount o f  bound ligand adsorbed is recorded whilst most o f  the non- 
covalently bound protein has been eluted.
(6) Deactivation o f  surface NHS-esters with 1M ethanolamine hydrochloride 
(pH 8.5), which also serves to elute non-covalently bound conjugate.
(7) Two regeneration pulses with 30 mM  HCl serves to remove any 
remaining non-covalently bound conjugate.
(8) 12,500RU o f  4'-azowatfarin-BSA remain bound following the 
immobilisation procedure.
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4.2.3. Development o f an inhibition immunoassay fo r  warfarin:
To establish effective working range concentration parameters for the detection o f warfarin 
and suitable regeneration conditions for dissociation of the antibody-antigen complex 
following the binding of antibody to the derivatised chip surface, a model assay system was 
developed in running buffer (Hepes Buffered Saline, HBS). The analytical validation 
parameters as outlined by Wong et al. (1997) were initially used to assess the overall 
performance characteristics of the immunoassay, these included: accuracy, precision and the 
stability of the immobilised ligand. The use of directly immobilised 4'-aminowarfarin drug 
surfaces and 4'-azowarfarin-BSA conjugates were compared to ascertain which provided the 
optimal ligand binding characteristics and stability. The use of monoclonal and polyclonal 
antibodies to warfarin was also evaluated to determine which gave the more sensitive and 
reproducible assay performance.
4.2.3.I. Regeneration conditions:
An important characteristic of a biosensor assay unlike ELISAs that must be determined 
prior to sample analysis, is the binding capacity of the immobilised ligand. Ideally, it is 
preferable to be able to perform multiple measurements (>50) on a single derivatised chip 
surface to allow for routine sample analysis. Wong et al. (1997) suggested that the ligand 
binding capacity be maintained within 20% of positive control values, and be routinely 
checked throughout the course of the assay to monitor the ligand-binding capacity.
The binding-capacity of both directly immobilised drug surfaces and conjugate immobilised 
drug surfaces were determined by a series of binding and surface regeneration sequences to 
assess at which point the binding capacity deviated outside the desired performance range 
(<20%). Regeneration cycles of both monoclonal and polyclonal antibodies to warfarin were 
also compared on the two types of immobilised surfaces.
Affinity-purified polyclonal (4'-azowarfarin-BSA-sepharose-4B) and monoclonal (Protein- 
A/G) antibody samples were serially diluted in HBS running buffer as described in section
2.12.3. Antibody solutions (nominally a 1/100 dilution of each antibody preparation) were 
then repeatedly injected and the surface regenerated. Two 30 second pulses of 30 mM HC1 
was sufficient to dissociate the bound monoclonal antibody from the chip surface, whilst the 
bound polyclonal antibodies could be dissociated using mild acid (15-20 mM HC1) and base 
(lOmM NaOH) pulses. Surface regeneration studies conducted demonstrated that the sensor 
chip surfaces to which the drug 4'-aminowarfarin was directly coupled were essentially ‘in­
exhaustible’ with respect to antibody-binding capacity, and demonstrated no decrease in 
antibody-binding capacity over the course of greater than 140 cycles (Figure 4.8). Such
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surfaces were in fact used for in excess of 1,000 cycles. The coefficient of variation of 
antibody binding over the course of 140 cycles was 0.82%. The binding capacity of 4'- 
azowarfarin-BSA surfaces was also assessed using both the monoclonal and polyclonal 
antibodies to warfarin. The conjugate surfaces displayed an initially relatively high decrease 
in binding capacity that began to plateau out after approximately 20 cycles (Figure 4.9). 
Consequently, studies performed with such conjugate immobilised surfaces were exposed to 
at least 25 regeneration cycles prior to sample analysis. The regeneration conditions needed 
to dissociate the polyclonal antibody :antigen complexes were not quite as harsh as those 
required for surface regeneration using the monoclonal antibodies, and an acid/base was 
usually sufficient to dissociate the complex. Also interesting to note is the slightly more 
variable binding response attained with the polyclonal antibodies compared to their 
monoclonal counterparts (Figure 4.10). The bound polyclonal antibodies showed a small 
slow dissociation rate from the immobilised surfaces that can be observed from the binding 
curve after the sample injection end in Figure 4.12. The monoclonal antibodies bound to the 
4'-aminowarfarin immobilised chip surface demonstrated essentially no dissociation from the 
chip surfaces, which can be observed from the overlaid interaction curves at various antigen 
concentrations (Figure 4.13).
These results imply that the use of directly immobilised drug molecules should be employed 
whenever target molecules with suitable reactive groups (e.g. the amine moiety on 4'- 
aminowarfarin) are available for direct coupling to the chip surface. Firstly, such surfaces in 
this instance provided excellent stability of the immobilised ligand (although, the stability of 
the immobilised ligand molecule may vary with exposure to various pH extremes), and 
secondly extremely low coefficients of variation were observed over the course o f binding 
studies (<1%). However, as the results demonstrate the use of drug-protein conjugates is 
applicable in many instances, provided the regeneration conditions maintain the binding 
capacity of the immobilised ligands. The use o f drug-protein conjugates can be a limiting 
factor, particularly when trying to dissociate high affinity antibody: antigen interactions 
(Keating, 1998). The small molecular weight o f the target analyte (308 Da) is somewhat 
restrictive in the type of immunoassay format available for the direct detection o f analyte. 
Extremely high concentrations of IgG would need to be immobilised at the chip surface to 
attain any reasonable response for the direct detection of warfarin, which in turn would be 
reflected by a correspondingly large increase in the concentrations of analyte detectable. 
Direct chemical coupling of antibodies to the chip surface suffers from particular drawbacks; 
namely the regeneration conditions required too often result in significantly reduced surface 
binding capacity as a result of antibody dénaturation. Secondly, direct immobilisation of 
antibodies does not afford any specific orientation of the antibody molecules for subsequent
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binding to antigen. The most reproducible assay condition for such assay formats has been 
to employ the use of suitable affinity-capture surfaces, typically those incorporating Protein 
A/G. Protein A-coated surfaces specifically bind (KD ~ 10'9 M) and orientates the antibody 
molecules through their Fc regions, and have been shown to be capable of reproducibly 
being used for greater than 120 binding-regeneration cycles (Quinn et al., 1999). The use of 
such affinity-capture systems is encouraged when the quantity o f antibody utilised is not a 
limiting factor, and the target analyte is large enough for direct detection formats. Another 
notable feature of the use of directly immobilised drug surfaces is the substantially reduced 
quantity (i.e. 10-fold) of antibody required for assay purposes, a direct result o f the increased 
surface epitope concentration, which again can be an important parameter given the high 
cost of many commercial antibody preparations. The use of guanidine hydrochloride was 
also routinely employed to dissociate bound antibody from the chip surface, typically at the 
end of analysis procedures prior to undocking the sensor chip for further analysis. Agents 
such as guanidine hydrochloride and guanidine thiocyanate are extremely effective 
regeneration solutions for dissociating high affinity antibody: antigen interactions and have 
been successfully used with directly immobilised drug surfaces (Nieba et al., 1996).
4.2.3.2. Assessment o f  Non-Specific Binding:
The degree of non-specific binding of the monoclonal and polyclonal antibodies to both the 
dextran layer and the immobilised BSA portion of the drug-protein conjugate, was assessed 
by passing antibody at the requisite dilution (i.e. 1/100 dilution) over a blank CM-dextran 
and BSA-immobilised sensor chip surfaces as described in section 2.12.4. Figure 4.11 
demonstrates the simultaneous injection of a 2 nM injection o f monoclonal antibody over an 
immobilised 4'-aminowarfarin-BSA and BSA surface, respectively. The response following 
injection over the derivatised BSA surface is essentially negligible (~0.6RU) compared to 
the response measured over the 4'-azowarfarin-BSA surface (~243RU). Similarly, the 
binding responses measured when affinity-purified polyclonal antibody (~ 780RU) was 
passed over both BSA (-0.6RU) and blank dextran (~4.3RU) surfaces was also negligible. 
The low degree o f non-specific binding observed for both the polyclonal and monoclonal 
antibodies can be attributed primarily to the immunoaffinity purification procedures 
employed that removed the majority of extraneous proteins (i.e. non-specific protein), 
resulting in highly purified immunoglobulin fractions (Figures 5.8 and 5.9). Recent 
advances in instrument hardware particularly with the BIACORE 3000 instrument, which 
has the capability for ‘on-line’ reference curve subtraction has overcome many of the 
difficulties associated with matrix effects and non-specific interactions. The use of ‘on-line’ 
reference curve subtraction can be used in situations where complete removal of the non­
specific interaction cannot be achieved, or due to drifting baseline measurements, which can
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be observed in particular with the affinity-capture assay formats previously described, 
allowing for visualisation of the specific biomolecular interaction only.
Regeneration Cycle Number
Figure 4.8: 140 consecutive regeneration cycles o f a 4-minute binding o f monoclonal
antibody (3-2-19) to the directly immobilised 4'-aminowarfarin drug 
surface. The surface was regenerated with two 30-second pulses o f 30 mM  
HCl. The binding response demonstrated a coefficient o f  variation o f 0.82% 
over the course o f  140 cycles and no decrease in the measured binding 
response over the course o f  the regeneration study (i.e. cycle 1= 446.2, 
cycle 140 = 446.4). Directly immobilised drug surfaces were essentially 
‘inexhaustible’ with respect to antibody binding capacity and can be used 
for greater than 1,000 cycles.
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Figure 4.9: 75 consecutive regeneration cycles o f  a 4-minute binding o f  monoclonal
antibody (3-2-19) to an immobilised 4'-azowarfarin-BSA surface. Surface 
regeneration was achieved with two 30-second pulses o f  30 mM HCl. The 
binding response demonstrated a coefficient o f  variation o f  3.82% over the 
course o f  75 cycles. It can be observed from the plot that after 
approximately 20 regeneration cycles, the binding response began to 
plateau. Consequently, any assays performed using such conjugate surfaces 
were exposed to at least 20 regeneration cycles prior to sample analysis. 
After the first 20 regeneration cycles (i.e. from cycles 21-75), the coefficient 
o f  variation fo r  the measured binding response decreased to 1.88%, with a 
decrease in the antibody binding capacity o f  the immobilised surface by 
approximately 7.2% over this regeneration cycle range.
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Figure 4.10: Binding regeneration studies carried out using polyclonal antibodies on 4'-
azowarfarin-BSA immobilised CM-dextran surfaces. Mild acid (15-20 mM  
HCl) and base (10 mMNaOH) pulses were sufficient to dissociate the bound 
polyclonal antibody from the conjugate surface. The ligand binding 
capacity was shown to decrease by approximately 16 % over the course o f  
the regeneration cycle (n=86), and demonstrated a %C.V. o f  4.8%  over the 
course o f  the binding study.
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Figure 4.11: Simultaneous injection o f  2 nM  monoclonal antibody (3-2-19) sample over
immobilised 4'-azowarfarin-BSA (----- )  and BSA (— ) surfaces. The
negligible degree o f  non-specific binding to BSA immobilised surface 
(0.6RU) compared to the response recorded on the immobilised 4'- 
azowarfarin-BSA (246RU), can be attributed primarily to the particular 
immunoaffinity purification procedures employed.
Time (seconds)
Figure 4.12: Injection o f  a 1/100 dilution o f  affinity-purified (i.e. 4'-azowarfarin-BSA-
Sepharose 4B) polyclonal antibodies over an immobilised 4'-azowarfarin- 
BSA surface at 10 pl/min fo r  4minutes, resulted in approximately 780RU o f  
bound antibody. The amount o f  antibody binding which can be observed 
after the initial bulk refractive index change non-specifically to the dextran 
layer (4.3RU) or the immobilised BSA surfaces (0.8RU) was negligible.
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4.2.33. Determination o f  Working Range o f  Model Inhibition Assay Range in PBS:
Having established the binding capacity and the degree of non-specific binding associated 
with the binding interactions, the working range of the biosensor assay for each antibody 
type was then evaluated. The validation criteria described by Wong et al. (1997) in the 
development and validation of a biosensor-based immunoassay with regard to sensitivity, 
ligand-binding capacity, accuracy, and precision were assessed for the detection of warfarin 
for each antibody type (i.e. mono-/polyclonal) on the different immobilised (i.e. drug/drug- 
protein) surfaces. Two monoclonal antibodies (i.e. 3-2-19 and 2-5-16) to warfarin were also 
evaluated in terms of sensitivity. A brief description o f the main definitions and terminology 
used in reference to bioanalytical methods is included in Appendix 1A.
For the determination o f the working range of the inhibition immunoassay, dilutions of 
warfarin were firstly prepared in HBS buffer as described in section 2.12.6. to determine the 
working range of the biosensor assay for each antibody preparation. Dilutions of warfarin 
were prepared in HBS buffer ranging from 0.24 to 500 ng/ml for the monoclonal antibody 
inhibition assays, and from 1.22 to 5,000 ng/ml for the polyclonal antibody inhibition assays. 
The affinity-purified anti-warfarin antibody preparations were mixed with the corresponding 
dilution of warfarin using the autosampler, and allowed to equilibrate for a period of 5 
minutes. The samples were then passed in random order, over the derivatised chip surface 
and regenerated using the appropriate predetermined regenerant for each antibody type (i.e. 
monoclonal/polyclonal). A typical antibody binding response curve is illustrated in Figure 
4.13. The response measured following the binding of unliganded antibody from the 
equilibrated antibody: antigen mixtures could be thus determined. The binding response at 
each antigen concentration (R ag)  was subsequently divided by the antibody binding response 
determined in the presence of zero antigen concentration (R o), to give normalised binding 
responses, which allowed for direct inter-assay comparison. Calibration curves for both the 
polyclonal and the two monoclonal antibodies were constructed as described in section
2.12.6. Examples of the calibration plots constructed for the various antibody preparations 
are illustrated in Figures 4.14.- 4.15. The intra- (precision) and inter-assay (reproducibility) 
variability was determined for each antibody preparation (Table 4.2.- 4.4). In this context, 
based on the degrees of precision, reproducibility, sensitivity and accuracy recorded, a direct 
comparison could be made with respect to each immobilisation format and particular 
antibody preparation. From the inter- and intra-assay studies, it was concluded that the 
monoclonal antibody preparation 3-2-19 on a directly immobilised 4'-aminowarfarin drug 
surface performed with the highest degrees of accuracy, reproducibility and precision, and 
was thus selected for the development of the biosensor assay for the determination of 
warfarin concentrations in plasma ultrafiltrate samples.
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Figure 4.13: Overlaid interaction curves for various equilibrated antibody: warfarin
concentrations in plasma ultrafiltrate. The measured binding response was 
used to calculate the normalised binding response values, which were 
subsequently used to construct the calibration curves. The bound antibody 
showed essentially no dissociation from the sensor chip. The sensor chip 
could be easily regenerated using two 30 second pulses o f  30 mM HCl.
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The intra-assay variation (precision/repeatability) for the SPR-immunoassay was calculated 
by calculating the coefficient of variation between samples assayed during a single assay 
run. The inter-assay variation (reproducibility) for each antibody preparation was calculated 
by performing the assay on three separate days and calculating the precision, or coefficient 
of variation between batches.
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Figure 4.14: Intra-Assay curve fo r  warfarin in HBS using the monoclonal 2-5-16 on a 4'-
aminowarfarin chip surface. The residual plot (precision profile) 
demonstrates the excellent correlation o f  the data set to the four-parameter 
model f i t  ( t f  = 2.85 x  I O'5). The heteroscedastic nature o f  the precision 
profile illustrates the randomness o f  the associated error (i.e. no systematic 
bias). The calibration plot was constructed using BIAevaluation 3.1 
software package. The results shown are the average o f  triplicate results.
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The intra- and inter-assay coefficients of variation are tabulated below for immunoassays 
studies performed using monoclonal 2-5-16 on a directly immobilised 4'-aminowarfarin chip 
surface. On the basis of results obtained from binding assays performed using the various 
antibody preparations on different immobilised surfaces, the antibody preparation and 
immobilised ligand, were selected for development of an inhibition immunoassay with 
respect to sensitivity and reproducibility of the antibody preparation and the 
stability/binding- capacity of the immobilised ligand.
Table 4.2: Intra-Assay Variation (Precision) fo r  monoclonal antibody 2-5-16 on a
directly immobilised 4'-aminowarfarin chip surface (n=3):
Actual Warfarin 
Concentration 
(ng/ml)
Back-Calculated
Warfarin
Concentration
(ng/ml)
% Accuracy % Coefficient o f  
Variation
500 501.26 0.25 3.15
250 249.12 0.35 3.97
125 126.13 0.90 2.32
62.5 60.67 2.93 2.04
31.25 32.02 2.47 1.13
15.625 15.95 2.05 1.14
7.81 7.52 3.68 0.17
3.91 3.87 0.86 0.58
1.95 1.84 5.85 0.43
0.98 1.19 21.92 0.61
0.49 0.53 7.59 1.11
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Table 4.3: Inter-Assay Variation (Reproducibility) for monoclonal antibody 2-5-16 on
a directly immobilised 4'-aminowarfarin chip surface (n=3):
Actual Warfarin 
Concentration 
(ng/rnl)
Back-Calculated
Warfarin
Concentration
(ng/ml)
% Accuracy % Coefficient o f  
Variation
500 551.364 10.27 2.91
250 261.78 4.71 3.40
125 118.87 4.91 4.31
62.5 60.86 2.62 9.46
31.25 31.65 1.28 8.46
15.625 15.78 0.97 6.77
7.81 7.75 0.84 5.09
3.91 4.06 3.94 3.65
1.95 1.79 8.10 0.78
0.98 0.94 4.14 0.83
0.49 0.48 0.02 0.44
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Table 4.4: Intra-Assay Variation (Precision) fo r affinity-purified polyclonal antibodies
on a 4'-azowarfarin-BSA chip surface (n=4):
Actual
Concentration
(ng/ml)
Back-Calculated
Concentration
(ng/ml)
% Accuracy % Coefficient o f 
Variation
5000 4824.90 3.50 6.76
2500 2687.46 7.50 4.82
1250 1316.87 5.35 4.76
625 618.66 1.01 2.47
312.5 285.21 8.73 1.81
156.25 141.46 9.47 0.98
78.13 78.75 0.80 0.89
39.06 43.83 12.21 0.73
19.53 22.64 15.94 0.80
9.77 10.15 3.93 0.39
4.88 4.13 15.36 0.55
Warfarin Concentration (ng/ml)
Figure 4.15: Intra-Assay calibration curve fo r  affinity-purified polyclonal antibodies on a
4 '-azowarfarin-BSA chip surface. The results shown are the average o f 4 
replicates. The calibration curve was plotted using BIAevaluation 3.1 
software package.
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4.2.3.4. Assessment o f matrix composition on the antibody : antigen binding interaction: 
The composition of human plasma is relatively homogeneous, and the approximate 
contributions o f various plasma constituents to plasma osmolality are given in Table 4.5. 
(Zilva & Pannell, 1979). The major contributor to the ionic strength (> 90%) of human 
plasma is sodium and it’s associated anions, whose ionic concentration is normally in the 
reference range from 0.133-0.145 M, with relatively lower contributions from other ions in 
solutions. Certain pathological conditions such as uraemia and hyperglycaemia can disrupt 
the normal plasma osmolarity.
Table 4.5: Approximate Contributions o f  plasma constituents to plasma osmolarity:
Constituent Concentration mmol/1
Sodium 133-145
Potassium 3.5
Calcium 2.5
Magnesium 1
*Taken from Zilva & Pannell (1979)
To assess the potential effect of varying salt concentrations on the measured antibody 
response, a titration of salt concentration versus measured antibody response was constructed 
as described in section 2.12.9. Briefly, a fixed dilution o f antibody (i.e. 1/100) was mixed 
with varying concentrations of sodium chloride spanning greater than twice the expected 
physiological ionic reference range for sodium (i.e. 0.120-0.155 M NaCl). A 20 pi sample 
of the respective salt concentration was allowed to equilibrate with 80 fil of antibody 
solution prepared in HBS buffer for 5 minutes with mixing on the BIACORE autosampler. 
The equilibrated samples were subsequently randomly injected in duplicate at a flow rate of 
10 (xl/min for 4 minutes over a directly immobilised 4'-aminowarfarin drug surface. The 
bound antibody was eluted and the remaining samples injected. The binding response 
measured at each salt concentration was measured and the results are illustrated in Figure 
4.16. Over the range of concentrations for sodium chloride tested, there was no statistically 
significant difference in the antibody binding response measured under the experimental salt 
concentrations investigated as tested by ANOVA (Analysis of Variance) analysis (F-value = 
0.506, Fcrit oo5, 7, s = 3.50). A plasma dilution step (i.e. 1 part in 5) was employed, as this 
particular dilution factor was found to be optimal in serving to minimise differences in the 
measured binding responses, occurring as a result o f the altered salt composition. Injection o f 
plasma ultrafiltrate over the immobilised 4'-aminowarfarin drug surface demonstrated no 
non-specific binding as expected, given the essentially pure nature o f the ultrafiltrate 
fraction.
1 5 7
1000
0.12 0.13 0.14 0.15 0.16
NaCl Concentration (M)
Figure 4.16: Antibody (80 ¡A) was mixed with various concentrations o f  salt solution o f  
known concentration and injected in random fashion over a 4'- 
aminowarfarin sensor chip surface at 10 ¡jl/min fo r  4 minutes and the 
binding response recorded. The antibody binding signal measured over the 
salt concentration range tested (0.12-0.155 M  NaCl), spans the 
physiological range o f  plasma salt concentration normally observed (i.e. 
Reference range 0.133-0.145 M  NaCl, (Zilva & Parnell, 1979)). ANOVA 
analysis performed on the measured binding response, demonstrated that 
the differences in binding signal recorded are insignificant over the salt 
concentration range examined, under the described test conditions. Results 
shown are the average o f  duplicate measurements ±  standard deviation. 
The coefficient o f  variation o f  the measured binding responses over the 
physiological reference range (0.130-0.145 M) was 0.38%.
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4.2.3.5. Determination o f  Working Range o f  Assay in Plasma Ultrafiltrate:
Plasma ultrafiltrate was prepared by ultrafiltration of blank human plasma through an 
Amicon separation device containing a 1 kDa molecular weight cut-off membrane under 
positive pressure as described in section 2.13.1. Dilutions of warfarin of known 
concentration were prepared in the concentration range 0.48-500 ng/ml in the ultrafiltrate of 
blank plasma. Dilutions of antibody solution (i.e. nominally 1/100) were then mixed with 20 
(xl of warfarin-spiked plasma ultrafiltrate of known concentration, and allowed to attain 
equilibrium for five minutes on the BIACORE autosampler. The equilibrium mixtures were 
then serially passed over the derivatised drug surface in random sequence, to ensure there 
was no bias in the recorded measurements. The normalised responses were then used to 
construct a calibration curve of the normalised response versus warfarin concentration 
(ng/ml) and a four-parameter logistic fit modelled to the data set using BIAevaluation™ 3.1 
software. The working range of the bioassay was calculated to be from 0.48-250 ng/ml 
(Figure 4.17). The intra-assay degrees of precision and accuracy are tabulated in Table 4.6. 
The coefficients of variation for the assay were typically of the order of 2-3%, except as 
expected towards the asymptotes of the spline curves where the degree o f precision 
decreased to 13.54% at the lower limit of quantitation. The coefficients of variation for the 
complete curve including the lower limit of quantitation (LLOQ)(i.e. 0.48 ng/ml) are all well 
within the current recommended validation guidelines for immunoassay procedures (Findlay 
et al., 2000).
4.2.3.6. Validation o f  the Analytical Biosensor Assay fo r  warfarin in Plasma Ultrafiltrate: 
For the validation of the immunosensor assay developed for warfarin, the assay was carried 
out over three separate days at 12 different analyte concentrations spanning the working 
range of the calibration curve from 0-500 ng/ml, with each analyte concentration value 
determined in duplicate. The inter-assay degrees of precision and accuracy are tabulated in 
Table 4.7 (Figure 4.18). Additionally, 8 independent standards of known concentration were 
also prepared in plasma ultrafiltrate for each calibration curve. From the calibration curves 
that were constructed for each assay procedure, the concentration of the independent 
standards could be determined by back-calculation from the constructed spline plot using the 
BIAevaluation™ 3.1 software. The reproducibility of the assay as measured by the inter­
assay variation, demonstrates that the assay is robust and reliably reproducible as observed 
from the degree of inter-assay variation which is typically of the order of 2-6%. At the 
asymptotes as noted previously, the coefficient of variation is approximately ~12%.
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4.2.3.7. HPLC Analysis o f  Warfarin plasma ultrafiltrate samples:
HPLC analysis of the warfarin-spiked plasma ultrafiltrate samples and independent standards 
was carried out as described in section 2.13.4. The samples were analysed by HPLC with a 
slight modification of the method of King et al. (1995), using a mobile phase flow rate of 1 
ml/min with ultraviolet detection at 308 nm (the absorption maxima for warfarin in the 
particular mobile phase). The post-run analysis of the chromatograms was conducted using 
Varian Star software (version 5.1). The retention time of warfarin on the column under the 
specified conditions was approximately 5.7 minutes (Figure 4.19). The peak heights of the 
injected warfarin standards were calculated using the dedicated software package, and a plot 
of the peak height versus warfarin concentration (ng/ml) constructed (Figure 4.20). Linear 
calibration models were fitted to the data sets, and from the regression lines it was possible 
to calculate the concentration of the independent standards from each of the calibration 
curves. The limit of detection using the current HPLC technique described was 5 ng/ml 
(section 2.13.4). Several attempts to reduce the limit of detection by the use of post-column 
reaction were made, by altering the flow rate and the basic post-column reagents used (e.g. 
triethanolamine and triethylamine). Although there are reports in the literature citing lower 
limits of detection below 1 ng/ml (Steyn et al., 1986), the lowest limits of warfarin 
detectable using the post-column detection procedure described (section 2.13.5) were of the 
order of approximately 5 ng/ml when the photomultiplier tube was at the highest sensitivity 
setting. These results are in agreement with those reported by other authors employing post- 
column reaction with fluorescent detection (Cai et al., 1994; King et al., 1995). 
Consequently, many of the independent standards (i.e. below 5 ng/ml) that were quantifiable 
by the SPR-based immunoassay were below the limit of detection of the HPLC technique.
4.2.3.8: Comparison o f  the independent analytical techniques:
To assess whether or not there was any statistical difference between the two analytical 
techniques, ANOVA analysis of the back-calculated concentration of the independent 
standards (n=8) run in conjunction with each assay (n=3) procedure was performed. The 
back-calculated concentrations using the two analytical techniques are tabulated in table 4.8, 
and the % accuracy determined for each sample using the appropriate calibration plot. 
ANOVA analysis demonstrated that over the concentration range assayed, that there was no 
significant difference between the values determined using the two different analytical 
techniques. An X-Y correlation plot of the back-calculated values for each analytical 
technique demonstrated excellent correlation (R2= 0.990).
The use of ultrafiltration has been reported by a number of authors for the determination of 
the free-drug fraction of various drugs (Menguy et al., 1998; Jortani et al., 1999) and is
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gaining increasing use primarily because of it’s simplicity of use and the speed of sample 
preparation (~20 minutes). The BIACORE inhibition immunoassay developed illustrates the 
potential of utilising SPR as a comparable analytical technique to HPLC for the quantitation 
low-molecular weight analytes. The results presented demonstrate the sensitivity attainable 
with the presented immunoassay format (<0.5 ng/ml), which has limits of detection at least 
an order of magnitude lower and in many cases two, lower than those reported for the 
detection of warfarin using HPLC with UV detection (Table 4.1, L.O.D. 5-50 ng/ml). The 
majority of fluorescence-based techniques utilise elaborate derivatisation and post-column 
schemes to exploit the native fluorescence of warfarin at basic pH values (Steyn et al., 1986; 
Cai et al., 1994), and the reported limits of detection of such techniques are comparable to 
the biosensor assay developed.
The biosensor assay developed for the analysis of warfarin is by no means exclusive, but 
instead should be considered as the development of a generic sensing platform for the 
development of low molecular weight analytes (unlike the majority of chromatographic 
assays which must be tailored to suit individual molecules). The validated assay format can 
be suitably modified for the detection of indeed any particular molecule by simply altering 
the immobilised ligand and the particular antibody. With the variety of coupling chemistries 
and chip surfaces available, almost any particular ligand can now be conveniently 
immobilised. The surfacc regeneration conditions can also be routinely modified depending 
on the chemical stability of the immobilised ligand. For example, for molecules that are 
labile or unstable at high/low pH values, the use o f organic solvents could be employed or 
alternatively, the use of agents such as guanidine hydrochloride could also be used to remove 
the immobilised high affinity antibodies from the chip surface.
The current assay format described was developed for the detection of warfarin in biological 
samples, namely plasma ultrafiltrate. Warfarin as a drug of therapeutic utility can be 
considered somewhat unique in terms of it’s pharmacokinetic profile, given that it is almost 
exclusively plasma protein-bound, and the fact that it is extremely potent physiologically 
despite its extremely low free drug concentration in the plasma pool. The intensity of 
warfarin treatment (1-2 mg/daily) is also considerably less than that administered for the 
majority of drug therapies, which are usually administered at considerably higher dosage 
levels (e.g. 10-250 mg). It is evident, therefore, that the assay developed for a drug with 
such a low circulatory plasma concentration, could easily be extrapolated as a tool for the 
analysis of the pharmacokinetic profile of particular drug candidates for which current 
methodologies are inadequate (e.g. many of the penicillin compounds: 
ampicillin/amoxicillin). Indeed, allied with the use of ultrafiltration for drugs that are not
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plasma protein-bound, patient plasma samples could be routinely analysed in the order of 10- 
15 minutes, which is considerably less than many of the existing chromatographic techniques 
that require in many cases extensive sample pre-treatment.
The concentration of warfarin determined in the plasma ultrafiltrate samples using the 
inhibition immunoassay was comparable to the concentrations obtained by existing HPLC 
methodologies. The lower limit of detection (i.e. an order of magnitude lower than that of 
the HPLC technique) of the immunoassay format made direct comparisons between 
standards at the lower end of the calibration range impossible. As Table 4.8 illustrates 
excellent correlation (R2= 0.990) was achieved between the independent assay results over 
the concentration range sampled. Similarly, the accuracy o f the independent measurements 
which was assessed by direct comparison with constructed calibration curves for each assay 
technique revealed that the accuracy of the inhibition immunoassay was in all cases 
comparable and many instances better than that recorded for the HPLC assay procedure.
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Table 4.6: Intra-Assay variation fo r  warfarin in plasma ultrafiltrate (n=2):
Actual
Concentration
(ng/ml)
Back-Calculated
Concentration
(ng/ml)
% Accuracy % Coefficient o f  
Variation
250 208.46 16.61 2.20
125 127.23 1.78 0.27
62.5 66.47 6.35 4.40
31.25 32.01 2.43 0.87
15.625 15.86 1.50 1.31
7.81 7.13 8.71 1.41
3.91 4.50 15.08 2.77
1.95 2.21 13.33 10.18
0.49 0.40 17.45 13.54
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Figure 4.17. Calibration plot o f  normalised response versus plasma warfarin ultrafiltrate
concentration constructed using BIAevaluation ™ software. The use o f  
BIAevaluation ™ software allowed for the determination o f  the concentration 
o f  warfarin in the independent standards run in conjunction with the 
calibration curve from the determined normalised response values. Results 
shown are the average o f  duplicate results. The low Chi2 value (rf) obtained 
(j? = 3.14x1 O'7)  illustrates the ‘goodness o f  the f i t ’ using the logistic four 
parameter equation fit.
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Table 4.7: Inter-Assay variation fo r  warfarin in plasma ultrafiltrate (n=3):
Actual
Concentration
(ng/ml)
Back-Calculated
Concentration
(ng/ml)
% Accuracy % Coefficient o f 
Variation
125 129.89 3.91 2.17
62.5 69.64 11.42 4.54
31.25 31.09 0.50 2.77
15.625 15.68 0.35 2.96
7.81 7.50 3.94 5.61
3.91 4.20 7.41 6.76
1.95 2.10 7.53 4.98
0.98 0.90 7.53 12.38
Warfarin Concentration (ng/ml)
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0.012
1 «. o8  - 0 . 012 -■
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Figure 4.18: Inter-assay (Reproducibility) variation fo r  warfarin in plasma ultrafiltrate
(n=3). The mean normalised response value at each antigen concentration 
from three independent assays was used to calculate the calibration curve 
and to determine the intra-assay variation. Results shown are the mean o f  
triplicate results.
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Figure 4.19: Plot overlay o f  three different warfarin concentrations in plasma
ultrafiltrate separated using a C-18 HPLC column with a mobile phase flow  
rate o f  1.0 ml/min and UV detection a t 308 nm. The peak area counts fo r  
each chromatogram were calculated using Varian Star 5.1 software (version 
5.1) and used to construct a calibration plot o f  peak area versus warfarin 
concentration in plasma ultrafiltrate (Figure 4.20) as described in section
2.13.4.
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Figure 4.20:
y = 40.565x + 79.891
Warfarin Concentration (ng/ml)
Standard curve fo r  warfarin (*) (0-500 ng/ml) in plasma ultrafiltrate as 
determined by HPLC. The peak area determined at each warfarin 
concentration was plotted against the respective warfarin concentration 
(ng/ml). From the linear calibration plot constructed, the concentration o f  
warfarin (ng/ml) in the independently prepared set o f  standards (* ) was 
back-calculated using the equation fo r  the regression f i t  line.
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Figure 4.21: The back-calculated warfarin concentration (ng/ml) fo r  an independent set
o f  standards were determinedfrom the calibration curves constructed on the 
day the samples were analysed by the two independent analytical techniques 
(HPLC and BIACORE). The back-calculated concentration values were 
then plotted against each other cmd a correlation coefficient o f  R2 =0.990 
was determined between the two data sets. ANOVA analysis o f  the data sets 
demonstrated no significant difference between the two analytical 
techniques fo r  the determination o f  warfarin in plasma ultrafiltrate samples.
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4.2.3.9. Determination o f the degree ofplasma protein binding:
The degree of protein binding of warfarin has been described by a number of techniques as 
described previously (Cai et al., 1994; Ferrer et al., 1998). The degree of plasma protein 
binding of warfarin was assessed in patient samples (n=20), by calculating the free drug 
concentration of warfarin human plasma and comparing this value with the total 
concentration of warfarin in human plasma measured by HPLC with UV-detection.
4.2.3.9.I. Determination o f the total plasma concentration o f warfarin samples:
Extraction of warfarin from plasma samples was carried out as described in section 2.13.2. 
Determination of the total plasma concentration of warfarin in human plasma was carried out 
as described in section 2.13.4. using a modification of the method of King et al. (1995). 
Briefly, 50 p.1 of internal standard /7-chlorowarfarin was added to 1.0 ml of human plasma. 
1 0 ml of 1 M sulphuric acid was then added to the plasma samples, which precipitated the 
protein fraction, releasing the drug from the bound drug-protein complex. The samples were 
then placed with constant rotation on a carousel for 30 minutes. 5 ml o f ethyl acetate was 
then added to each plasma sample, and the patient samples were placed on the rotary 
carousel at 30 r.p.m. for a further 60 minutes. 4.5 ml of the organic layer was then removed 
to a clean test-tube and evaporated to dryness under nitrogen. The patient plasma samples 
were reconstituted in mobile phase prior to sample injection onto the HPLC column. 
Quantitation of the plasma warfarin concentration of the patient samples was made by 
reference to a calibration curve of peak height ratio (p-chloro-warfarin: Internal standard) 
versus warfarin concentration. The total plasma concentrations demonstrated considerable 
variance in the patient plasma pool analysed, and the mean patient plasma concentration was 
determined to be 1,015±383.59 ng/ml. Two of the patient samples analysed for plasma 
warfarin concentrations (patient identification: 11328, 11387) demonstrated a plasma 
warfarin concentration of zero in the samples analysed and it was suggested that this might 
have been due to poor patient compliance. Unfortunately, no patient records were available 
with respect to the dosing regimen of each patient and this could explain for the wide inter­
patient variability in the plasma concentrations recorded (Table 4.9).
The HPLC method described was also routinely used in the analysis of patient plasma 
samples following suspected ingestion of warfarin and particular suspected cases of 
Munchausen's syndrome. HPLC analysis of such samples was performed to confirm the 
presence of such residues in the patient plasma and so to rule out other possible 
haematological complications. An example of such a typical patient chromatogram is 
illustrated in Figure 4.23. The peak height ratio of warfarin to internal standard was used to
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construct the linear calibration curve (Figure 4.22) from which the total plasma warfarin 
concentrations were calculated.
4.2.3.9.2. Determination o f the free warfarin concentration in the plasma ultrafiltrate o f 
warfarin patient samples:
Patient plasma samples (500 pi) were placed in Nanosep™ devices and centrifuged at 6,500 
r.p.m. for 30 minutes using an ultracentrifuge device. The plasma ultrafiltrate was then 
analysed by BIACORE immunoassay as described in section 2.12.6. The patient plasma 
ultrafiltrate was also analysed by HPLC as described in section 2.13.4. The concentration of 
warfarin in the patient plasma ultrafiltrate samples was calculated from constructed 
calibration plots. The degree of patient plasma protein binding was calculated by comparing 
the concentration of warfarin in the plasma ultrafiltrate samples to the total plasma 
concentration. The mean free drug concentration of warfarin was calculated to be 
99.72+0.24%. This value is in accordance with that described by Cai et al. (1994) who 
found the mean plasma concentrations of (R)- and (S)-warfarin to be 99.4±0.33% and 
99.67+0.33%, respectively. The samples analysed by immunoassay were also analysed by 
the HPLC technique described in scction 2.13.4. However, the concentrations of warfarin in 
the plasma ultrafiltrate were below the limit of quantitation for the existing method. The 
percentage degree o f protein-binding for warfarin in patient plasma calculated 
(99.7210.24%) is in agreement with that previously reported elsewhere employing the use of 
radiolabelled ligands (99.0310.20%) (Mungall et al., 1984). However, Mungall et al. (1984) 
described several discrepancies between the results obtained using both ultrafiltration and 
equilibrium dialysis and found that the observed discrepancies were due to radiochemical 
impurities in the radiolabelled ligand. The inhibition immunoassay system described 
employing the use of ultrafiltration offers a simple, accurate and rapid means of assaying 
free warfarin concentrations in plasma ultrafiltrate.
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Figure 4.22: Standard curve o f warfarin concentration versus peak-height ratio o f
warfarin: p-chlorowarfarin as determined by HPLC. The constructed 
standard curve was used to calculate the concentration o f  warfarin in 
patient samples. The plasma concentrations o f  the patient samples are 
demonstrated in Table 4.9. The free fraction o f  warfarin as determined by 
BIACORE immunoassay was then used to calculate the degree o f  plasma- 
protein binding in the patient samples assayed.
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Figure 4.23: Patient plasma chromatograms o f  ‘suspected’ warfarin ingestion. The
patient was admitted with extensive bleeding episodes and a prothrombin 
time o f  greater than 100 seconds (normal reference range 12-16 seconds).
‘Suspected' warfarin ingestion was confirmed by HPLC analysis, the patient 
was administered vitamin K  intra-venously and subsequently discharged. 
The actual plasma concentration o f  warfarin determined in the above 
sample by reference to a calibration curve o f  peak height ratio 
(warfarin internal standard (p-chloro-warfarin) versus warfarin
concentration (ng/ml) was calculated to be approximately 38.5 fig/ml, 
almost 30 times the average patient plasma concentration.
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Table 4.8 Concentration o f  back-calculated standards determined using HPLC and 
BIACORE immunoassay.
Actual
Concentration
(ng/ml)
BIACORE
back-calculated
concentration
(ng/ml)
% Accuracy o f  
BIACORE  
Immunoassay
HPLC assay 
back-calculated 
concentration 
(ng/ml)
% Accuracy o f  
HPLC assay
187.5 184.47 1.61 183.93 1.90
112.5 112.46 0.03 108.55 3.51
100 96.99 3.00 102.35 2.35
93.75 108.42 15.65 95.12 1.46
56.25 59.42 5.63 57.10 1.51
50 53.90 7.8 47.35 5.3
46.88 53.37 13.85 48.90 4.31
28.13 25.47 9.45 30.55 3.86
25 23.91 4.34 27.98 11.92
23.44 21.70 7.41 30.43 29.82
14.06 11.64 17.22 16.09 14.44
12.5 11.94 4.52 11.04 11.68
11.72 10.98 6.33 12.87 9.81
7.03 7.22 2.75 7.22 2.63
6.25 5.85 6.39 6.28 0.48
5.86 5.99 2.27 6.16 5.66
3.52 3.85 9.52 <L.O.D. N/A
3.13 3.35 7.05 <L.O.D. N/A
2.93 3.24 10.45 <L.O.D. N/A
1.47 1.71 16.58 <L.O.D. N/A
The limit of detection of the HPLC assay was determined to be approximately 5 ng/ml.
The degree of accuracy of the developed inhibition immunoassay was comparable to the 
HPLC technique over the concentration assayed and excellent correlation was achieved 
between the two data sets (R2 = 0.990).
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Table 4.9: Measurement o f  degree ofplasma protein binding in patient samples (n=20).
Patient
Identification
Number
Total Plasma 
Warfarin 
concentration 
(ng/ml) as 
determined by 
HPLC
Free Warfarin Drug 
concentration in 
plasma (ng/ml) as 
determined by 
HI A ('ORE 
immunoassay
% Protein-Bound 
Drug in plasma 
samples
11328 642.22 BLQ NQ
11346 2022.22 2.08 99.89
11350 757.22 BLQ NQ
11313 625.55 0.46 99.93
11377 973.89 1.56 99.84
11323 983.33 5.05 99.49
11321 792.22 4.42 99.44
11327 1150.56 2.85 99.75
11458 1398.89 4.49 99.68
11378 474.44 0.23 99.95
11436 882.22 2.36 99.73
11390 857.22 BLQ NQ
11320 1679.44 2.28 99.86
11333 930.00 1.03 99.88
11366 1217.78 BLQ NQ
11331 900.00 2.58 99.71
11328 0.00 0 NA
11387 0.00 0 NA
11315 802.78 7.24 99.10
11326 1185.00 0.45 99.96
NA = Not Applicable
NQ = Not Quantifiable
BLQ = Below Limit o f  Quantitation
The mean plasma concentration o f the patient plasma samples assayed was found to be 
1,0151383.59 ng/ml, whilst the average degree of plasma protein binding for the samples for 
which the degree o f drug-protein binding was estimable was calculated to be equal to 
99.7210.24%.
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4.2.3.10. Urine analysis o f  samples:
The inhibition immunoassay was also used for the detection o f warfarin in urine as described 
in section 2.12.6. The ionic composition of urine can illustrate considerable variation 
depending on the individual liquid volume intake. To compensate for the potential wide 
inter-individual variability in the salt composition of urine, the antibody sample was 
prepared in HBS of twice the normal ionic strength (i.e. 2 x [HBS]). Similarly, a dilution 
step (i.e. 1 in 5 urine dilution) was also employed to reduce the potential effect on the 
measured binding response due to the altered salt composition. The coefficients o f variation 
for the inhibition immunoassay over the assayed concentration range (%C.V. range 2-11% 
(Table 4.10)), were well within the recommended validation guidelines for immunoassay 
procedures (Findlay el al., 2000). The working range of the assay for the detection of 
warfarin in urine using the affinity-purified polyclonal antibodies to warfarin was from 10- 
5,000 ng/ml (Figure 4.24).
The polyclonal antibodies demonstrated a much broader dynamic range than their 
monoclonal counterparts, a reflection of the widely differing antibody affinities from the 
purified serum fraction. The polyclonal antibodies also showed increased cross-reactivity to 
warfarin and metabolites, and this could be exploited in the current immunoassay format, 
which as shown can be used for the detection of warfarin and it’s metabolites in urine 
samples. Proper patient compliance is extremely important in the management of warfarin 
anticoagulation, as dosage adjustments are made based on the pharmacological end-point of 
warfarin therapy (i.e. Prothrombin time measurements). Consequently, any dosage 
adjustments made on the basis of improper patient compliance can have extremely serious 
consequences upon return o f the patient to the recommended dosage regime. The current 
system could therefore be used an immunoassay screening technique to guarantee adequate 
patient compliance prior to dosage adjustment. A similar strategy could also therefore be 
used in cases of suspected warfarin ingestion similar to those outlined in section 4.2.3.9.1. A 
similar approach to monitoring patient compliance has been described by George et al. 
(2000) for monitoring methadone compliance in patient urinary samples by immunoassay. 
Such screening procedures could be used for rapidly determining substance abuse to a wide 
range of residues, by employing broad spectrum antibodies (poly-/monoclonal) capable of 
detecting particular classes of drugs of abuse (e.g. amphetamines). By immobilising 
different residues of abuse on the various flow cells (i.e. flow cell 1-4) in the BIACORE 
3000 instrument, a single injection o f patient sample (urine/plasma or saliva) could be 
rapidly used to identify the presence of such residues of abuse in the order of minutes. Such 
rapid screening techniques are essential to allow for rapid identification of the offending 
agent so that a suitable antidote may be administered.
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Table 4.10: Intra-Assay variation fo r  warfarin in urine samples (n=5):
Actual Warfarin 
Concentration 
(ng/ml)
Back-Calculated
Warfarin
Concentration
(ng/ml)
% Accuracy % Coefficient o f 
Variation
5000 4448.42 11.03 9.53
2500 2674.02 6.96 6.57
1250 1239.53 0.83 7.55
625 658.67 5.39 11.25
312.5 330.63 5.80 6.52
156.25 135.48 13.29 5.33
78.12 75.98 2.74 2.16
19.53 16.27 16.67 2.43
9.77 10.09 3.28 3.19
Warfarin Concentration (ng/ml)
Figure 4.24: Calibration curve fo r the detection o f  warfarin in urine using affinity-
purified polyclonal antibodies. The results shown are the average o f  (n=5) 
replicates. The spline curve was constructed using BIAevaluation ™, which 
allowed fo r  the determination o f  the relative accuracy o f  the data set from  
the fitted 4-parameter logistic fit.
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4.2.4. Conclusions:
This chapter has described the development and validation of an inhibition-based 
immunoassay for the detection of warfarin in biological samples. The use o f directly 
immobilised drug surfaces and the use of drug-protein conjugates were initially compared in 
terms of ligand-binding capacity. It was demonstrated in this instance, that the directly 
immobilised drug surface offered considerably better binding reproducibility (% C.V. = 
0.82%) over the binding-regeneration cycles studied (i.e. >140 cycles), which is primarily 
related to the exceptional stability of the immobilised drug molecule (4'-aminowarfarin) on 
the dextran surface. Whilst the immobilised 4'-azowarfarin-BSA was not comparable to the 
directly immobilised drug surface, the use of hapten-protein conjugates do offer an 
alternative when suitable reactive groups are not available for direct immobilisation of the 
drug. However, the use of hapten-protein conjugates can prove difficult particularly when 
trying to dissociate high affinity antibody:antigen interactions, where the use of adequately 
harsh regeneration solutions to regenerate the sensor surface, too often results in denaturation 
of the immobilised ligand. Similarly, immobilisation of sufficiently high yields of conjugate 
for routine sample analysis can sometimes prove difficult using EDC/NHS chemistry, as 
many hapten-protein conjugates are characterised by very acidic isoelectric points.
The validation of the inhibition assay with conventional chromatographic techniques 
demonstrated excellent correlation between the back-calculated concentrations for the 
independent standards using the two different analytical techniques described (R2 = 0.990). 
The limits of detection attainable with the developed inhibition immunoassay were more 
than an order of magnitude below those attainable using HPLC with UV detection (i.e. 
L.O.D. inhibition immunoassay = < 0.3 ng/ml, HPLC with UV-detection » 6ng/ml). The 
assay performance as measured by the conventional measures of analytical performance, 
namely precision, accuracy, reproducibility and robustness demonstrated that the assay 
performed comparably in every respect to the conventional chromatographic techniques.
The developed and validated inhibition immunoassay system was then used for the detection 
of warfarin in patient plasma ultrafiltrates. The free fraction o f a drug determines the 
pharmacokinetic profile o f many drugs is in the body, and so is the fraction of the most 
considerable significance pharmacologically. The use of ultrafiltration is the most 
convenient method of preparing such plasma ultrafiltrates because of the non-dilutional 
effects observed (Bowers et al., 1984). The matrix contribution to the measured binding 
response could be overcome by the suitable buffering and use of an appropriate dilution of 
sample. The mean free-drug concentration in the patient plasma samples assayed 
demonstrated that the degree of protein binding was approximately 99.72 ± 0.24%. This
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value correlates well with other values cited in the literature which found plasma protein- 
bound fractions of the order of ~ 99.5% (Mungall et al., 1984; Cai et al., 1994).
SPR systems have traditionally been used to monitor bio-molecular interactions in ‘real­
time’. The use of the present system could be regarded as the development and validation of 
a generic quantitative SPR inhibition immunoassay for the detection of a wide range of 
analytes in various matrices, as relatively facile manipulation of the experimental parameters 
(i.e. immobilised ligand, regeneration parameters and choice of antibody) can be achieved to 
tailor the assay for the detection of different analytes. The development o f the majority of 
chromatographic assays requires individual manipulation of mobile phases, extraction 
schemes and detection techniques for the detection of particular drug molecules. In many 
circumstances the limits of detection with such techniques are a factor of the 
physicochemical properties of the individual molecule, which can be limiting when 
particular suitable chromophoric or electroactive groups are not available. Alternatively, 
recent advances in genetic engineering with the development of phage-displayed libraries 
and various in-vitro affinity maturation techniques, has realised the potential of generating 
antibodies of extremely high affinities (Kn ~ 10"15M, Boder et al., 2000) to almost any 
molecule. Allied with the sensitivity of current SPR devices, the ability to accurately 
quantitate sub-picogram quantities of analytes for detailed pharmacokinetic/environmental 
studies is now a reality.
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Chapter 5
Production, Characterisation and 
Applications o f Monoclonal Antibodies to
Warfarin
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5.1. Monoclonal Antibodies:
Monoclonal antibodies were first produced over 25 years ago, following the fusion of a 
myeloma cell with that of an immune lymphoblast expressing a specific gene (Kohler and 
Milstein, 1975). The resulting fusion product a hybridoma (hybrid-myeloma) exhibits the 
immortality of the myeloma and the antibody producing properties of the splenocyte, thereby 
producing a virtually limitless supply of antibody of predetermined specificity and affinity.
Prior to the production of monoclonal antibodies by Kohler and Milstein, the lack of 
availability of antibodies of predefined specificity and affinity hampered the development 
and standardisation of many new emerging techniques such as ELISA and flow cytometry 
whose potential as diagnostic tools were being recognised. Indeed, Kohler & Milstein 
themselves may not fully have recognised the magnitude of their work for which they 
received the Nobel prize by concluding that:
“Such cultures could be valuable for medical and industrial use”.
Monoclonal antibodies have today, become an important tool: in basic research, in clinical 
laboratories as therapeutic agents, as components of diagnostic kits, in affinity 
chromatography and as carriers in drug-targeted therapy (de Geus & Hendriks en, 1998).
5.1.1. Production o f  M onoclonal Antibodies fo llow ing in vivo im m unisation:
For the production of monoclonal antibodies an animal (e.g. rat, mouse) is initially 
immunised with the antigen of interest. The serum response of the animal is closely 
monitored for antibody production to the antigen of interest, and when a sufficiently high 
serum titre has been achieved the animal is sacrificed and the splencocytes may be harvested 
for cell fusion procedures. A variety of myeloma cell lines are available as suitable fusion 
partners the most commonly employed being X63-Ag8.653 and Sp2/0-Agl4 cell lines, 
which were produced from a myeloma cell line developed following the injection of mineral 
oil into the peritoneal cavity of mice. The technique pioneered by Kohler and Milstein, 
employed the use of the HAT selection system described by Littlefield (1964). Myeloma 
cell lines lacking the enzyme hypoxanthine guanine phosphoribyl transferase (HGPRT) are 
unable to proliferate in the presence of HAT (Hypoxanthine, Aminopterin and Thymidine) 
medium. Aminopterin blocks the de novo biosynthesis of purines and pyrimidines required 
for DNA synthesis, and the HGPRT' cells lines are incapable of using the salvage pathways 
for DNA synthesis as they do not possess the requisite enzyme systems (Figure 5.1).
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M ain
biosynthetic
pathways
HGPRT
Thymidine 
„ kinase
Thymidine
Figure 5.1: Principle o f  the HAT system.
Aminopterin blocks the main biosynthetic pathways fo r  nucleic acid synthesis. Cells can use 
the salvage pathways fo r  nucleic acid synthesis by incorporating thymidine and 
hypoxanthine. Cells lacking either o f  the enzymes HGPRT or thymidine kinase (e.g. Sp2/0- 
Agl4) are incapable o f  nucleic acid synthesis and die o ff in HAT culture medium.
Splenocytes carry the functional enzyme (HGPRT*), but are incapable of proliferation in 
culture and naturally die off. In this context, HAT medium may be considered to be ‘semi- 
selective’. Following the fusion procedure, a variety of cell fusion products exist, however 
only splenocyte-myeloma fusion products (i.e. hybridomas) which carry the functional 
enzyme (HGPRT*), are capable of proliferation in the HAT medium. A variety of agents 
(‘fiisogens’) have been used for cell fusion procedures, the most commonly used agent is 
polyethylene glycol, a polywax which promotes cell fusion and transfer o f nuclei (Hurrell, 
1985). The above technique although most commonly applied for the production of rat and 
mouse monoclonal can also be used for other species including human hybridomas. Tonsils 
and other lymphoid tissues can be used as a source for B lymphocytes, instead of the spleen. 
Due to the lack of human non-secreting myeloma cell lines, murine meyloma cell line are 
used as fusion partners and tend to produce unstable hybridomas which rapidly lose the 
ability to produce immunoglobulin, although some success has been had using human CLL 
as a fusion partner (Hurrell, 1985). A schematic o f the procedure is illustrated in Figure 5.2
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Figure 5.2 : Principle o f  Monoclonal Antibody Production
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5.1.2. Production o f M onoclonal Antibodies fo llow ing in vitro im m unisation:
Monoclonal antibodies can also be produced by ‘in vitro’ stimulation of an antibody 
response (Borrebaeck et ah, 1983). B-lymphocytes are harvested from the spleens of naive 
(i.e. non-immunised) animals and incubated for a period o f typically 5-9 days, with the 
antigen o f interest, prior to somatic cell fusion procedures. The technique offers the 
advantages of reduced immunisation schedules and quantity of antigen required, but suffers 
from the disadvantage that the majority of antibodies raised to the antigen o f interest are the 
result of a primary immune response (predominantly IgM in nature with reduced quantities 
of IgG), and the antibodies are consequently of lower affinity, typically in the micromolar 
range. Wallen & Borrebaeck (1991) demonstrated a statistically significant correlation 
between the antigen concentration employed and the affinities of monoclonal antibodies 
generated. The use of a primary in vivo immunisation followed by a secondary in vitro 
stimulation (IVB, in vitro boost) has also been shown to produce greater quantities of IgG 
antibodies of increased affinity (De Boer et al., 1989). To date, little success is reported in 
the literature with respect to in vitro forms of immunisation, particularly for monoclonal 
antibody production to small haptens. Bonwick et al. (1996) generated monoclonal 
antibodies to the pesticides flucofuron and sulcofuron, following in vitro immunisation. 
However, although the antibodies demonstrated specificity with respect to binding to drug- 
conjugates on ELISA plates, concentrations o f free pesticide up to 1 mg/ml were unable to 
prevent binding to solid phase antigen. It was suggested that the effects o f multi-specific, 
low affinity interactions (i.e. IgM) would be favoured and, therefore, negate the effect of free 
pesticide (Borrebaeck, 1989). Conventional in vivo immunisations are still required to 
produce antibodies of sufficiently high affinity, particularly to small molecular weight 
molecules. The use of IVI may provide a useful source of mRNA for recombinant work.
5.1.3. Production o f M onoclonal antibodies to sm all haptens:
Coupling of haptens to carrier proteins is generally required for an anti-hapten antibody 
response. Fasciglione et al. (1996) identified three critical factors for the production of 
specific immunoconjugates. These include: the hapten conjugation method employed, the 
choice of carrier molecule and the amount of neodeterminants introduced. The conjugation 
method should increase the specific antibody response to the hapten. Fasciglione et al. 
(1996) found that the choice of carrier protein specifically modulates the serum titre and 
affinity o f clones generated. It was also demonstrated that hydrophobic haptens can modify 
the tertiary structure of carrier proteins and become hidden in the core of protein, thereby 
limiting the interaction with the immune response and serum response generated. The use of 
specific hydrophilic carriers such as poly-L-lysine and sepharose was thus suggested for 
small hydrophobic haptens (Fasciglione et ah, 1996).
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The chemical link employed between small molecular weight analytes and carrier proteins is 
responsible for the changes in the structure of small haptens, and ultimately their antigenicity 
and immunogenicity. The use of a different coupling chemistry via different amino acid 
residues is recommended for the selection of antibodies to small haptens to maximise the 
selection o f positive clones specific for the hapten, and not a combined protein-hapten 
epitope (Danilova, 1994).
The importance of the appropriate immunoassay format employed for determining the 
specificity and affinity of antibodies must also be addressed. Delcros et al. (1995) found that 
the affinity of a particular monoclonal antibody, SPM8-2, appeared to depend on the whether 
the polyamine was free in solution and the type of conjugate immobilised. The discrepancy 
between relative affinities in solution and bound to the solid phase, was attributed to the 
different mode of linkages employed in the production of conjugates (EDC versus 
glutaraldehyde). Coupling using EDC chemistry resulted in a different polyamine structure 
(i.e. transforms a diamine to a monamine), and, as a result, the affinities for solid phase 
bound EDC-coupled antigen and antigen in solution were completely different. These 
examples serve to highlight the importance of an understanding of how the different 
coupling chemistries employed, and chemical nature of the hapten can directly impinge on 
the primary structure of proteins and small molecules and their subsequent interaction with 
antibodies.
5.1.4. C loning Techniques:
Kohler and Milstein used a plaque assay technique to screen for antibody-producing clones. 
Today most hybridoma supernatants are screened using conventional ELISA or biosensor- 
based techniques (de Wildt et al., 2000). Following screening, ‘positive’ (i.e. hybrids 
sccreting specific antibody of interest) clones are propagated, and the hybridomas are then 
cloned to isolate the individual cells secreting the specific antibody of interest. The most 
commonly used method for cloning is that of limiting dilution, which involves repeated 
dilution and selection of ‘positive’ clones following screening (Harlow & Lane, 1988). After 
several rounds of cloning the hybridoma can be considered to be statistically ‘monoclonal’ in 
nature (Lietske & Unsicker, 1985). Difficulties associated with the limiting dilution method 
of cloning have been reviewed in detail elsewhere (Underwood & Bean, 1988). There are a 
number of traditional techniques available for cloning (Davis et a l  1982; Bell et al., 1983), 
and one of the more sophisticated current technologies involves the transfer of single cells by 
means of a Peltier controlled pipette (Wewetzer & Seilheimer, 1995). The transfer of cells 
into wells of a microtitre plate is microscopically visualised and in this manner, the accurate 
transfer of individual hybridoma cells is assured. The transfer of individual cells greatly
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reduces the time required for cloning procedures compared to the cloning by the traditional 
limiting dilution method.
5.2.5. Propagation Techniques f o r  M onoclonal antibody production:
Monoclonal antibodies can be propagated by either in vivo or in vitro techniques. The 
underlying principle and developments that have taken place with respect to these two forms 
of antibody production are outlined below:
5.1.5.1 In-vivo antibody production:
Hybridoma growth as ascites fluid was initially the primary technique employed when 
monoclonal antibodies were required in larger quantities, because there were very few 
efficient and cost effective in vitro techniques available at the time. The peritoneal cavity of 
syngeneic mice is initially ‘primed’ with either Freund's Incomplete Adjuvant (FICA) or 
pristane (2,6,10,14-tetramethypentadecane), which serve as immunostimulants attracting 
monocytes, lymphoid cells and other nutrients into the peritoneal cavity, thereby creating a 
suitable environment for hybridoma growth. Approximately 7-10 days later, hybridoma 
cells (typically ~106 cells) can be injected into the peritoneal cavity. The peritoneal cavity of 
mice provides a continuous supply of oxygen, permanent inactivation of metabolites and 
active phagocytosis of dead cells and cell debris, where the cells can multiply to high cell 
densities secreting antibody into the ascitic fluid (Marx, 1998). The age, sex and strain of 
the mice can affect the yield of antibody recorded. Higher concentrations of antibody have 
been recorded in male mice which have been shown to have a longer period of secretion and 
greater volume of ascites, whilst mice between 43-75 days of age have also been shown to 
produce higher antibody concentrations (Brodeur et a l, 1984). The ascites fluid containing 
the hybridoma cells and antibodies can then be collected aseptically by 'tapping' the 
peritoneal cavity (i.e. draining the ascites fluid from the periteonal cavity by means of a 
needle and syringe), and the hybridoma cells cultured in vitro or passaged to another animal 
if required.
The advantages of using an in-vivo form of antibody production is that cell densities up to 
1010 cells/ml with antibody yields in the mg/ml range can be routinely produced, without the 
need for elaborate techniques or equipment in a mycoplasma free environment (Hendriksen 
& de Leeuw, 1998). There are several disadvantages associated with the procedure, 
including contamination with biochemically identical immunoglobulins of the host. 
However, the use of SCID mice allows the production of antibodies free of endogenous Ig 
(Pistillo et al., 1992). There are fisks associated with product contamination by viruses
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Ipathogenic to humans, which becomes increasingly important if the antibodies are required 
for therapeutic or prophylactic purposes. The potential for genetic alteration of hybridoma 
cells grown in vivo has also been reported, and conformational changes have also been 
observed in DNA from cells passaged in mice and correlated with cell-associated pristane 
(Garrett et al, 1987). Human hybridoma cells grown as ascites in nude mice have also 
exhibited gross morphological change and alteration in DNA content compared to cells 
grown in vitro (Truitt el a l, 1984). The growing public, ethical and legal pressures to replace 
in-vivo forms of animal experimentation with comparable in-vitro techniques, has led to the 
development of numerous in-vitro technologies for monoclonal antibody production 
(Falkenberg, 1998(a); Lipski et al., 1998).
5.1.5.2. In-vitro antibody production:
The primary objective in the development of suitable in-vitro technologies was to simulate 
an environment, similar to that of the peritoneal cavity of mice capable of producing large 
quantities of antibody in a concentrated form similar to ascitic fluid. In-vitro production 
systems can be categorised according to the principle of the culture system employed (Marx, 
1998):
• Static and agitated suspension culture systems
• Membrane-based and matrix-based suspension systems
• High-cell density bioreactors
The quantity and purity of the MAb required, generally speaking will dictate the type of 
production method employed (Peterson, 1998).
Cells grown in vitro culture have two basic needs: a constant supply of gaseous and water- 
soluble nutrients, and to be able to remove toxic metabolites from (e.g. gaseous C 02 and 
soluble lactic acid and ammonium ions) the culture medium. The principle behind the 
various means of in vitro cell culture are described below:
Static and Agitated suspension culture systems:
For the small-scale production of antibody sufficient to meet those of most academic 
research laboratories, tissue culture flasks provide adequate levels of antibody production. 
Hybridomas typically yield from 5-50 fj.g/ml of antibody depending on the individual 
hybridoma growth characteristics. Transfer of gaseous nutrients is achieved by diffusion, 
whilst withdrawal and replacement of media is required to replace water-soluble nutrients 
and remove waste metabolites. Consequently antibody concentrations achieved using static 
culture systems are lower, in the 1-100 (ig/ml range. The osmolality of the growth medium 
has also been reported to have a direct correlation on the rate of antibody production of
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certain hybridoma cell lines (Oh et a l,  1993). Oyaas et al. (1994) found that when particular 
hybridoma cell lines were placed in media made hyperosmotic through the addition of NaCl 
or sucrose, the rate of antibody production approximately doubled compared to cell lines 
maintained at physiological osmolality. The use of osmotic stress decreased the maximal 
cell densities attainable, which to some degree negated the positive effects on the overall rate 
of antibody production. However, when an osmoprotective compound such as glycine 
betaine was added to the NaCl or sucrose-stresscd cultures, the overall concentration of 
antibody recorded was more than double that of control cells. These results suggest that the 
use o f osmotic stress and osmoprotective compounds (e.g. glycine betaine, sarcosine and 
proline) may have potential future benefits for in vitro systems to enhance specific rates of 
antibody production.
One of the more recent commercial additions to this type of culture technology is the use of 
gas permeable membranes, such as the commercially available i-MAB™ gas permeable bag. 
The system is comprised of a gas permeable bag that allows for greater exchange of gaseous 
molecules. The cells do not achieve significantly higher numbers but appear to produce 
more antibody yield per cell in tests carried out to date (Lipski et al., 1998). The system also 
offers the advantage that once initiated it is a completely enclosed system thereby reducing 
the possibility of contamination, whilst the system can be maintained for up to 3 weeks.
Agitated culture systems such as those employing roller bottle flasks achieve higher levels of 
antibody production through greater levels of oxygenation as a result of culture agitation and 
removal of CO2 from the culture medium. The cells multiply at a greater rate and use up 
media faster, achieving higher antibody concentrations.
Membrane based and matrix-based suspension systems:
Early devices of this nature constructed included Milsteins' ‘oscillating bubble chamber’ 
(Pannell & Milstein, 1992) which employed a piece of dialysis tubing placed at a diagonal in 
a roller bottle flask. During rolling the bubble moves back and forth, thus mixing and 
keeping the cells in culture. The ‘Berlin tumbling chamber’ (Jaspert et al., 1995) and the 
‘Bochum glass mouse’ employed similar dialysis type constructions and provided the 
solutions for some of the more recent commercial constructions (e.g. miniPERM®, 
CELLine®) (Trebak et al., 1999; Falkenberg, 1998(a)).
Devices belonging to this category typically employ two chambers, one housing the cells and 
products (i.e. antibodies), and another containing the medium reservoir (Nagel et al., 1999).
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In such systems, the cells are contained in a chamber separated from the medium reservoir 
by means of a dialysis membrane. Efficient exchange of nutrients and excretion of toxic 
metabolites is achieved by means of diffusion of medium through the dialysis membrane. 
The low oxygen content of aqueous media and the high oxygen consumption rate of 
hybridoma cells in vitro limited the growth of cells. Falkenberg (1998) overcame this 
difficulty by employing the use of a semi-permeable silicone rubber seal on the culture unit 
with agitation that allows for sufficient transfer of oxygen into the culture system to meet the 
high oxygen requirement within the culture system. CELLine 1000™ membrane systems are 
capable of producing antibody concentrations from 0.7-2.5 mg/ml, during periods of culture 
up to 40 days (Trebak etal., 1999).
High-cell density bioreactors:
Hollow fibre vessels are the most advanced technology for the production of antibodies, 
which is reflected in their cost and operation requirements. Hollow fibre bioreactors are 
comprised of two main units: the cell culture reservoir, and the hollow fibre bioreactor 
(Figure 5.3). The hollow fibre bioreactor unit is composed of a unit containing a bundle of 
semi-permeable fibres with a molecular weight cut off (MWCO) o f 10-50 kDa. Cells are 
inoculated into the hollow fibre core and bathed in culture medium passing through the 
hollow fibres. The molecular weight cut-off of the membranes permits the transfer of small 
molecular weight molecules (e.g. nutrients and toxic metabolites), but excludes the 
movement of cells and antibodies, which grow to high cell density in the bioreactor unit, 
capable of producing antibody in the mg/ml range. Culture medium is pumped back to the 
cell culture reservoir after passage through the hollow fibres. An evaluation of hollow fibre 
systems compared to other in vitro methods of antibody production by Gorter et al. (1993) 
revealed that the amounts of bispecific antibody produced by the hollow fibre bioreactor, 
were equal to that from ascitic fluid from 200 mice, or 38L of tissue culture supernatant.
One of the major difficulties with hollow fibre systems is achieving adequate levels of 
oxygen aeration to meet the high cellular requirement in the bioreactor core. Oxygen 
saturated media is pumped through the hollow fibre under high flow rates to meet the oxygen 
requirements within the bioreactor. Several attempts have been made to overcome these 
difficulties by incorporating oxygen carriers such as stabilised haemoglobin and 
perfluorocarbons into the culture medium, in an attempt to overcome this limiting factor with 
the use of hollow fibre systems. A recent study investigated the advantages of incorporating 
various oxygen carriers originally designed as blood substitutes into the cell culture medium 
as a means of increasing the dissolved oxygen content, and consequently, the antibody
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production capacity o f hollow fibre bioreactors. Levels of antibody production were 
increased from 20-104% depending on the particular hybridoma line and oxygen carrier 
chosen. Of the carriers evaluated, Erythrogen™-l, a chemically stabilised form of 
haemoglobin proved to be the most efficacious additive, more than doubling the 
concentration of antibody achieved compared to control cells at a final concentration of 0.1% 
(w/v) (Shi e ta l., 1998).
One disadvantage o f all the in vitro systems described, is that to date none o f the devices are 
capable o f active elimination of dead cells and cell debris, which can be a limiting factor 
with respect to cell growth and maximal antibody concentrations attainable.
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Table 5.1: Summary o f  various forms o f  antibody production
Method Advantages Disadvantages
Ilt-ViVO: Ascites Cost (£/mg antibody) 
Antibody concentrations 
mg/ml range 
Ease of production 
‘Mycoplasma-free ’ 
environment
Concern (legal/ethical) with 
the use of live animals 
Variability in yield from 
animal to animal 
Separate facility required 
Possibility of contamination 
with murine viruses
In-Vitro:
Tissue Culture Flasks Technically easy 
Consistent yield 
Relatively cost effective
Large volumes of media for 
processing
Time-consuming with respect 
to feeding and passaging 
hybridoma cell lines
Gas Permeable Bags 
(e.g. i-MAB™)
Technically easy 
Consistent yield 
Cost effective in terms of 
media consumption and labour 
required
Culture periods up to 30 days 
Reduced operator handling 
Enclosed system
Large volumes of media for 
processing
Membrane based 
systems (e.g. 
miniPERM, 
CELLine).
Higher antibody 
concentrations attainable in 
relatively small volumes 
Culture periods up to 40 days
Increased medium 
consumption depending on 
cell concentrations achieved
Hollow fibre 
Cartridges
Antibody concentrations of 
mg/ml range achieved in 
small volume
Culture periods up to 30 days 
Media may contain high 
concentration of FCS without 
contamination of product
Large volumes of media 
expended
Initial investment high 
Possibility of mechanical 
faults associated with high 
flow rates/pressures (e.g. 
leakages within system)
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5.1,6. C him eric/H um anised Antibodies:
The development of MAbs has had a considerable impact on the area of clinical diagnostics, 
but the expected success in the area of human therapy to date has not been fully realised 
(Clark, 2000). Three problems were initially encountered with the use o f monoclonal 
antibodies in human therapy: they did not always trigger the requisite effector function, they 
had a short life span in vivo, as the antibodies often elicited a HAMA (Human Anti-Mouse 
Antibody) response. The HAMA elicited results in the increased clearance o f the antibody 
from the circulation thereby negating the therapeutic potential; and has been reported to 
cause severe allergic reactions (Jaffers et al., 1986). To try and circumvent this particular 
response, chimeric antibodies were constructed where the mouse variable regions were 
joined to human constant regions (Boulianne et a t, 1984). Chimerisation solved some of 
the initial problems associated with murine Mabs: as it allowed for increased half-life in the 
circulatory system through interaction with the Brambell receptor (FcRn), which protects the 
IgG from catabolism thereby recycling it back to the serum pool (Ghetie & Ward, 2000); and 
the ability to recruit effector cells such as complement and cytotoxic cells (Glennie and 
Johnson, 2000). V-region humanisation has also been carried out to try and humanise the 
antibodies even further by changing some of the amino acid sequences thought to be non- 
critical to antigen binding to more ‘human-like’ sequences whilst retaining the murine CDR 
sequences necessary for antigen binding (Riechmann et a l,  1988).
Two new strategies that have evolved for the production of ‘fully human antibodies’ involve 
the use of recombinant antibody technology through the expression of naive variable regions 
expressed on the surface of bacteriophage and the use of transgenic mice. Recombinant 
methods of human antibody production generally speaking require successive rounds of 
panning and mutagenesis to produce antibodies of sub-nanomolar affinities comparable to 
conventional MAbs (Vaughan et a l,  1998).
Transgenic mice (Xenomouse™) have also been constructed whereby the micc 
immunoglobulin genes have been replaced with human Ig genes on YAC (Yeast Artificial 
Chromosomes) transgenes, which carry the majority of the human variable repertoire as well 
as the possibility o f undergoing class-switching from IgM to IgG and efficient affinity 
maturation. Xenomouse™ strains of mice recognise human antigens as foreign, and are 
capable of producing antibodies with sub-nanomolar affinities (Mendez et al., 1997). 
Human antibodies from mice can be differentiated from their human cell counterpart by the 
glycosylation pattern, which contains the Galal-3Gal residue. Human serum antibody titres 
of up to lOOpg/ml against Galal-3Gal residue have been recorded, and it has been argued
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(Borrebaeck, 2000), that the in vivo administered transgenic antibody would not survive long 
in human circulation following complexation with anti-Galal-3Gal antibodies. However, 
antibodies from transgenic mice have shown promising results in a number of clinical trials 
to date, with plasma half-lifes similar to normal Ig and no detectable anti-human antibody 
responses recorded (Green, 1999). Xenomouse antibodies are also adaptable to production 
directly from hybridomas, transgenic plants or recombinant cell lines.
5.1.7. Recom binant Antibodies:
The development of phage display technology has realised the possibility o f producing 
‘tailor-made’ antibodies of high affinity to any particular antigen (Hoogenboom & Chames,
2000). The connection between genotype (antibody V regions) and phenotype (binding 
specificity) allows for selection and enrichment of specific phage with the desired 
specificity. The principle involves cloning DNA into phage genome as a fusion to one of 
phage coat proteins. Following expression the antibody fragments are presented on the 
surface of the phage with the encoding DNA residing inside the phage. The phage display 
library can then be panned by selection of phage with specific binding affinity towards a 
particular immobilised target ligand. The affinity o f the antibodies created has been reported 
to be proportional to the size of the antibody library (Sblattero & Bradbury, 2000).
The antibody libraries may be constructed from naïve or immunised donors, and also from 
synthetic libraries. Immunised donors will already be enriched for specific immunoglobulin, 
some of which will have undergone affinity maturation. Naïve libraries from which high 
affinity antibodies may be selected are particularly useful for selection of human antibodies 
(Hoogenboom et a i,  1998).
The affinity of the selected antibodies is very often not sufficiently high enough and may 
require in vitro affinity maturation to produce antibodies of suitable affinity (Hemminki et 
al., 1998), This can be achieved in a variety of ways from the use of mutator strains, the use 
of error prone PCR (Harayama, 1998), chain or oligonucleotide directed mutagenesis 
shuffling (Jirholt et al., 1998). The introduction of diversity into the V genes allows for the 
creation of a ‘mature’ secondary library from which higher affinity variants may be selected. 
BIACORE-based selection procedures allows for the selection of particular variants with 
respect to specific affinity and kinetic rate constants (Dueñas et a l, 1996). ScFvs with 
femtomolar association constants, the highest yet reported for monovalent ligands have been 
produced using a similar approach of ‘molecular breeding’ involving repeated cycles of 
affinity mutagenesis (Boder et al., 2000). The potential applications of such higher affinity
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variants with association constants 1000 fold greater than possible by in vivo maturation, is 
particularly interesting for developing areas such as immunotherapy and tumour targeting.
5.1.8. A lternative Expression systems fo r  antibody production:
A variety of expression systems are available for the production of antibodies and antibody 
fragments, including the use of bacteria, yeast, plants, insect cells and mammalian cells. 
Each has it’s own advantages and limitations with respect to ease of production, and the 
glycosylation pattern of antibodies recorded, two potentially relatively low cost antibody 
expressions systems are described.
5.1.8.1. ‘Plantibodies
Hiatt et al. (1989) was the first to report genetically engineered tobacco plants capable of 
synthesising correctly folded immunoglobulin heavy and light chains. A variety of 
‘plantibodies’ have since been constructed, three of which are currently in use as 
immunotherapeutic products for the treatment of caries and cancer (Larrick et al., 1998). 
Plantibodies offer several advantages as potential protein sources compared to other 
mammalian and bacterial systems: including the production of antibodies on an agricultural 
low-cost scale, and potential increased safety as plants do not serve as human pathogen hosts 
(e.g. HIV, prions). Ma et al. (1995) produced secretory IgA (slgA) plantibodies in tobacco 
plants (CaroRx™), which recognises and binds the oral pathogen Streptococcus mutans. with 
yields of antibody up to 0.5 mg/gram of fresh weight of tobacco recorded.
5.1.8.2. Transgenic Milk:
The possibility of using the mammalian milk gland as a means of producing antibodies in 
transgenic dairy animals is currently being investigated (Pollock et al., 1999). Expression 
vectors containing the gene encoding the specific protein fused to milk specific regulatory 
genes can be introduced by microinjection into one embryo cells. Following a period of in 
vitro culture the embryos can be transferred to pscudopregnant animals and development to 
full term (Little et al., 2000). Following integration into the germline, the transgene is 
transmitted in Mendelian fashion and if expressed, will become a dominant characteristic to 
offspring which can be tested for the transgene. The identified animals can then be bred or 
induced to lactate. Dairy goats have been shown to be excellent animals for the production 
of transgenic milk, capable of producing between 1 and 5 g/1 of recombinant antibody 
(Pollock et al., 1999). The efficiency of microinjection has limited the development of this 
technology as the integration into the genome of specific transgenes is typically low, 0.1% in 
cattle to 5% in mice. The antibodies can be separated from the majority of milk proteins by
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standard dairy procedures to relatively pure antibody (~60%) which can be further purified 
by traditional chromatography procedures (e.g. Ion exchange, Protein A/G chromatography). 
A variety of antibodies have been produced in the milk o f transgenic animals, and in 
particular cases been shown to be produced at levels 160,000 fold times those recorded in 
cell culture systems whilst retaining all biological activity (Newton et al., 1999).
5.1.9. New Antibody Constructs
S. 1.9.1. ‘Plastibodies’ -Molecular Imprinted Polymers (MIPs):
The technique of molecular imprinting polymers allows for the generation of specific 
recognition sites in synthetic polymers that mimic the binding sites of antibodies. A target 
molecule provides a template for the polymerisation process, whereby monomers carrying 
specific functional groups are arranged around the template molecule through covalent and 
non-covalent interactions, and secured into position by the crosslinking process. Following 
removal of the template molecule from the polymer, a cavity remains in the polymer whose 
shape, size and arrangement of functional groups closely resemble that of the target 
molecule. MIPs are rigid and insoluble, and consequently cannot compete with antibodies 
for procedures that rely on antibody solubility, such as immunodiffusion and 
immunoelectrophoresis. Areas of application where plastibodies have shown potential 
application include immunoaffinity procedures and immunoassays (Haupt and Mosbach, 
1998). The high stability of MIPs renders them suitable for sample pre-treatment and solid 
state extraction procedures particularly those employing organic solvents. MIPs have 
already been used for the extraction of hcrbicides from beef-liver extracts and various drugs 
from dilute serum and urine (Muldoon & Stanker, 1997). Molecular Imprint Sorbent 
Assays (MISA) have also been developed for the detection of various drugs, herbicides and 
corticosteroids (Ramstrom et ah, 1996). Results for the MISA correlated very well with 
those for conventional ELISA for theophylline, the cross reactivity profile of the plastibodies 
closely resembling that of the MAb. MIPs have also been used in biosensors employing 
field-effect transistors (Hedborg et ah, 1993), electrochemical (Piletsky et al., 1995) and 
optical (Levi et al., 1997) transducers. MIPs also give rise to a heterogeneous mix of 
antibody binding sites similar to polyclonal antibodies, with the frequency of high affinity 
sites (Kd ~ nanomolar range) between 0.1-1.0% (Andersson et ah, 1996). The majority of 
molecular imprinting to date has been developed using non-polar solvents, and work is 
currently under going to develop imprinting in polar solvents such as water, which can 
disrupt the prepolymerisation complex during imprinting, and polymers with more 
homogenous binding sites similar to MAbs through stabilisation of the polymer complex.
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5.1.9.2. Diabodies:
Diabodies are constructed by two functional scFv joined by a short polypeptide linker. 
Careful selection of the linker length dictates the size (kDa), and thus the valency of the scFv 
multimer formed (Hudson & Kortt, 1999). The production of monomeric scFv requires that 
the linker employed be at least 12 residues in length. By selecting a  residue o f 3-10 residues 
in length, the scFv cannot fold into a functional scFv and associates with a second scFv to 
form a diabody (60 kDa). Reducing the linker length below 3 residues forces the scFv to 
form triabodies (90 kDa) or tetramers (120 kDa). As a result of the increase in valency, scFv 
multimers exhibit very high avidity and reduced off rates as a result of multiple binding and 
re-binding when one Fv dissociates (Pluckthhun & Pack, 1997). In BIAcore studies 
conducted, Iliades et al. (1997) found that the trimers produced from a scFv exhibited an 
approximate 4-fold apparent slower off-rate compared to the monomeric unit.
The association of two different scFv molecules from different parent IgG will result in the 
formation of bispecific diabodies (Hollinger et al., 1993), which have been successfully used 
for ELISA, immunohistochemistry and immunoblotting procedures (Kontermann et al., 
1997).
VL l Vh V l  L v h
scFv Diabody
Figure 5.4: Schematic diagram o f  scFv and diabodies showing antigen binding sites.
When joined by a peptide linker (L) at least 12 residues long scFv’s are predominantly 
monomeric, diabodies (~60Kda) are formed by selecting linkers between 3 and 12 residues. 
Reducing the linker length below 3 residues can force scFv into triabodies (-90 kDa) and 
tetramers (-120 kDa).
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The use of diabodies has gained increasing interest particularly in the areas of 
immunotherapy and tumour imaging. The reduced size of diabodies compared to whole Ig 
for tumour targeting has the advantage of increased tumour penetration and faster clearancc 
rates in vivo. Bispecific diabodies have also been shown to induce cytotoxic and ‘vaccine 
effects’ in vivo (van Spriel et al., 2000), and a number are currently under trial for the 
treatment of various cancer cell types.
5.1.9.3. ‘Affibodies9:
The combination of genetic engineering and advanced selection techniques has led to the 
development of a novel range of protein ligands, ‘affibodies’ (affinity ligands) with specific 
binding capacities similar to natural antibodies. Knottins, are a small group of small 
disulphide-bonded proteins capable of binding to target molecules. Smith et al. (1998) have 
created knottin scaffolds with binding capacities in the micromolar range for target antigens 
such as alkaline phosphatase. Nord et al. (1997) have also created ‘affibodies’ from the a- 
helical bacterial receptor domain Z derived from staphylococcal protein A, which does not 
depend on disulphide bridges for stability, that has been shown to be exceptionally stable to 
pH extremes and harsh regeneration conditions and thus potentially useful in areas such as 
affinity purification (Nord et al., 2000). The potential for improving binding affinity has 
also been exploited through the use of in vitro affinity maturation strategies, such as a-helix 
shuffling strategy employed by Gunneriusson et al. (1999) which resulted in a 20-30-fold 
increase in functional affinity.
5.1.10. Applications o f  M onoclonal Antibodies:
Monoclonal antibodies have become the cornerstone of most diagnostic kits, immunoaffinity 
procedures and found extensive use for the detection of a wide variety of target antigens 
ranging from pesticides, illicit drugs and toxins to blood markers (Fitzpatrick et al., 2000). 
Coupled with the development of biosensing platforms they have led to the development, 
standardisation and automation of the majority of previously laborious laboratory 
procedures. Their use in the monitoring of enviromental (e.g. pesticides, pollutants) and 
food (e.g. growth promoters) residues have been recently reviewed (Fitzpatrick el al., 2000). 
The diagnostic market, is today almost completely reliant on the use o f monoclonal 
antibodies which allowed for the standardisation of laboratory reagents with regard to 
affinity and specificities. Indeed, one has only to browse the antibody catalogues available 
to witness the greater than 100,000 monoclonal antibodies currently commercially available. 
Some of the potential clinical uses and developing areas of monoclonal antibody technology 
are described below:
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5.1,10.1. Clinical Applications o f  Monoclonal Antibodies:
The application of monoclonal antibodies for the treatment of a variety of clinical disorders 
has not fully developed following the initial potential shown in 1982; with the complete 
response of an individual with lymphoma following a brief treatment with a murine antibody 
(Miller et al., 1982). However, the expected progress that Mabs brought to diagnostics and 
basic research, did not occur as quickly as expected in the area of therapeutics. The 
advances of genetic engineering which has allowed for the development of fully functional 
human antibodies has overcome many of the initial difficulties associated with murine 
MAbs: namely their inability to elicit the requisite effector functions and notably short half- 
life. Currently there are 8 FDA licensed MAbs and numerous others at various stages of 
clinical trials for use against cancer, transplant rejection and a variety o f other diseases 
including Rheumatoid Arthritis and Crohn’s disease (Glennie & Johnson, 2000).
The most successful murine antibody to date, OKT3 (anti-CD3), approved by the FDA in 
1986, for acute allograft rejection prevents tissue rejection by binding to CD3, thereby 
blocking the action of T-cclls. Two other recently licensed anti-CD25 Mabs (Zenapax® 
Chimeric IgGl, Simulect® Humanized IgGl) are also currently available for allograft 
rejection therapy which prevent binding of inteleukin-2 to CD25, blocking the transduction 
of IL-2 and suppressing the action of T-cells.
Currently successful anti-cancer Mabs include the use o f rituximab (anti-CD20) and 
trastuzumab (antiHER2/neu). The binding of trastuzumab to it’s receptor (antiHER2/neu) 
has been shown to induce a number of signalling events believed to play a role in tumour 
growth (Goldenberg, 1999). Rituximab also induces a number of signalling events, and has 
been shown to induce apoptosis in a number of B-cell lines. However, the median recurrence 
interval in patients with low grade B-cell malignancies is approximately 1 year (McLaughlin 
et al., 1998), suggesting that this particular Mab therapy may be useful as an adjunct therapy 
to surgery. Clynes et al. (2000) has recently shown that the direct interaction between 
antibodies and Fc receptor is responsible for the cytotoxic anti-tumour effects of both 
rituximab and trastuzumab in therapy, suggesting that greater efforts should be made to 
maximise particular Fc receptor interactions to increase the efficacy of various 
immunotherapies.
Current therapies are focusing on the use of conjugated MAbs to deliver toxins selectively to 
tumour bearing antigen cells, with the potential for increased efficacy o f treatment while 
minimising systemic toxicity (Trail & Bianchi, 1999). Calicheamin conjugates are among 
the most potent antitumour compounds used to date and produce double-stranded breaks in
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DNA. Clinical trials of CMA-676, an immunoconjugate of calicheamin and anti-CD33 Mab 
have shown a 20% response rate in patients with AML (Acute Myeloid Leukemia). BR96- 
DOX, an immunoconjugate coupled to the antibiotic doxorubicin which binds to a Le7- 
related tumour antigen expressed on most carcinomas has shown partial remissions in phase 
1 clinical trials. The immunotherapy conjugate was also shown to induce cures o f multiple 
carcinoma types, in athymic rats and mice (Trail & Bianchi, 1999).
Radioimmunotherapy (RIT) offers the possibility of delivering 3-50 times the normal 
radiation dose to tumour cells (DeNardo et al., 1999), and has been shown to be particularly 
useful in the treatment of Non-Hodgkins’ Lymphoma. One of the more interesting 
developments in RIT, is the Pretarget® system that exploits the streptavidin-biotin 
interaction and makes use of a three-step system for targeting radionuclides to the tumour 
cell, with promising results to date. Streptavidin-conjugated Mabs are initially administered 
and localise at the tumour antigen site. A second ‘chase’ reagent is then added to complex 
any unbound tumour Mab. Radiolabelled biotin is then administered and binds to the 
streptavidin complex. The small size of the biotin conjugate enables its quick elimination 
from the kidneys (DeNardo et al., 1999).
The use of bispecific antibodies and newer recombinant antibody constructs are also under 
investigation, to exploit the potential signalling potential of these particular antibodies as 
therapeutic agents with the ability of recruiting specific effector molecules to tumour cells 
(Segal et al., 1999; Hudson, 1999). The potential for development in the field of 
immunotherapy is enormous, which combined with developments in antibody engineering, 
an increase in our understanding of cellular signalling pathways, the development of newer 
more potent anti-tumour agents, augurs well for the concept of Ehrlich’s ‘magic bullets’ 
being finally realised in the new millennium.
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5.1.11.1. Basic Antibody:Antigen Reaction Kinetics:
The equilibrium between an antibody, antigen and immune complex can be described by the 
following expression:
[Ag] + [Ab]
ka
[Ag:Ab] (1)
Where
kd
[Ag] Antigen
[Ab] Antibody
[Ag:Ab] = Immune Complex
ka Equilibrium association rate constant
kd Equilibrium dissociation rate constant
The overall association rate constant can thus be described by the following expressions:
k  = = (2)
kd K d
Where [K a]
[Kd]
Equilibrium Association rate constant 
Equilibrium Dissociation rate constant
Various techniques are available for the determination of the antibody affinity constants 
including equilibrium dialysis (Lehtonen & Eerola, 1982), polyethylene glycol precipitation 
(Stanley et al., 1983), affinity chromatography (Chaiken et al., 1992) and those involving the 
use of enzyme-linked immunosorbent assay (Friguet et al., 1985; Chu et al., 1995). These 
techniques rely on the concentration measurement o f either analyte or antibody:antigen 
complex at equilibrium for determination of overall affinity constants.
Liquid phase affinity constants for monovalent antigens are based on the use of enzyme- 
linked immunosorbent assays, and partitioning of antibody between solid and liquid phase 
antigen offer a relatively simple procedure for the determination of overall affinity constants 
(Nieto et al., 1984; Friguet et al., 1985). The procedure described by Friguet et al. (1985) 
has the advantage that affinity determinations may be made with crude antibody 
preparations, whose exact antibody concentration does not need to be known.
Two antibodies with similar affinity constants (KA) may possess completely different kinetic 
rate constants, and consequently vary considerably in their time taken to reach equilibrium 
which can be of considerable significance depending on the intended use of the antibody. 
The use of ‘real-time’ biomolecular interaction analysis (i.e. BIACORE) is a useful means of 
affinity ranking antibodies, and can also be used early in the selection process as a screening 
device for the selection of particular antibodies (monoclonal/scFv) based on their individual
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kinetic rate constants (Deunas et al., 1996). For a detailed description of the theory and 
practice of this instrument, the reader is referred to sections 2.12. and 4.1.2.
For a one-to-one interaction in solution the rate of complex formation at the sensor chip 
surface at time t  between reactants [A], and [B] to form the complex [ABJ can be described 
by the following equation (Fagerstam & O’ Shannessy, 1993):
= ka[A]{B]t -  kd[AB~\t (3)dt
Where
[AB]t = Molar concentration of complex at interaction surface at time t
[AB] = Molar concentration of complex at interaction surface
[A ]t = Molar concentration of analyte at interaction surface at time t
[B ]t = Molar concentration of immobilised ligand at interaction surface at
time t.
However, the concentration of ligand at time t, [BJt, equals the initial concentration [B]o 
minus the formed complex [AB]t at time t:
[B]t = [B ]o-[A B]t (4)
therefore equation (3) becomes:
d[A B ]
dt ka[A\t([B]0 -  [Æ8],) -  kü[AB}< (5)
In BIAcore, the ligand, B, is immobilised and the analyte is continually replenished over the 
sensor chip surface. The response signal measured, R, is related to the formation o f the 
complex, AB, at the chip surface. The maximal response attainable, Rmax, will therefore 
depend on the immobilised surface concentration of ligand and equation (5) can therefore be 
rewritten as:
—  = ka[A]t(Rmax- R i) - k 4 R t ]  (6)dt
Where Rt = Response measured at time t
Rmax = Maximal response if  all ligand binding sites are occupied
2 0 0
The concentration of analyte passing over the ligand surface is continually replenished by 
fresh analyte, and the concentration at interaction surface [A] t , can thus be approximated to 
be equal to the injected analyte concentration [A] ¡:
[A }* [A ]t (7)
Equation (6) can therefore be rewritten as:
d R—  = ka[A\i(Rmax -  Rt) -  kd[R,] (8)dt
Rearranging equation (8):
dR—  = ka[A\i(Rmax) -  (>L [A } + kd)(Rt) (9)dt
The integrated form of the rate equation can be described by the following relationship:
ka[AJiRmax (1 ~  exp[-ka [A Ji + kd]t) .Kt —------------------------------------------------ (10)ka[AJi + kd  
and used to calculate the values of R max, ka and kj.
A plot of dR/dt versus Rt from equation (9) yields a line of slope, ks, which is equal to
(ka[A]i +kd).
k  = {ka[A]i + kd) (11)
By calculating the slope, ks, at different analyte concentrations [AJi, the quadratic equation 
(11) can be used to construct of ks versus [A]i whose slope is equal to ka and intercept is kd. 
Following withdrawal of the analyte {[AJi = 0) from the interaction surface allows for 
visualisation of the dissociation phase and equation (11) can be simplified to (i.e : as [A]i = 
0).
—  = -kdRt (12)dt
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5.1.11.2. Conditions o f  Mass Transport Limitation (MTL):
Mass transport limitations (MTL) conditions have been exploited in BIACORE for the 
development of novel quantitative assays, capable of determining the ‘active’ antibody 
concentration in solution. The Universal curve technique utilises low flow rates and high 
immobilised ligand concentrations to establish conditions of MTL (Karlsson et al., 1993). 
Under such conditions the antibody-binding rate (dR/dt) becomes proportional to the active 
analyte concentration |CA] (equation 16). A similar MTL technique for the quantitative 
determination of antibody concentrations has been described by Christensen (1997), 
exploiting the flow rate dependence of the binding rate under MTL conditions. 
Consequently, an understanding of the basic fundamentals of MTL is important before such 
useful quantitative techniques may be implemented.
In BIACORE, the binding response measured can be described by two distinct processes 
occurring at the sensor chip surface following introduction of an analyte into the flow cell:
and
\_A~\bulk <----—>[A]surface (13)
[A\surfaoe + B  — AB] ( 14)
Where [A]bulk
[A]surface
AB
B
Lm
Bulk Analyte concentration (M) 
Surface Analyte concentration (M) 
Complex 
Ligand
Mass-transport Coefficient
The mass transport coefficient, Lm, is dependent on flow cell geometry and flow rates into 
the flow cell and is described by the following relationship:
Lm = 1.212 \P 2Fh 2bl (15)
Where F = 
h,b, I = 
D
Flow rate (m3/s)
height, breadth and length of flow cell (m)
Diffusion coefficient for the analyte in solution (m2/s)
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If  mass transfer of analyte from the bulk flow to the immobilised surface ligand is greater 
than the binding of ligand to the analyte, then the concentration of analyte in the bulk flow 
will be essentially the same as that at the immobilised ligand (i.e. [ A]b u ik~  [ A]surfa ce )• The 
measured response will, therefore, reflect the reaction kinetics (i.e. ka /ka). I f  the reaction is 
mass transport controlled the rate of binding reflects the mass transport, which is influenced 
by flow rates, diffusion coefficients, the flow cell dimensions and active analyte 
concentrations (Christensen, 1997). For a particular molecule at a given flow rate in a 
particular flow cell these conditions of mass transport will be constant. Provided sufficient 
ligand is immobilised at the chip surface for the reaction to be mass transport limited, the 
binding rate will reflect the active analyte concentration and can be used for concentration 
determinations (Karlsson et al., 1993).
Under conditions o f mass transport limitation (MTL), if the kinetic association rate is high, 
the mass transfer rate becomes limiting and the maximal slope attained (dR/dt) can be 
described by the following expression (Piehler et al., 1997):
dR ^  D[Ca] 
dt d
Where D = Diffusion coefficient for the analyte in solution (m2/s)
[CA]  = Concentration of analyte within the boundary layer (M)
d  = Thickness of the boundary layer (m)
In other words, the rate of antibody binding dR/dt is dependent on the diffusion of analyte to 
the sensor chip surface and independent of kinetic rate constants and identity of the 
immobilised ligand and therefore reflects the active analyte concentration in solution.
Mass transport Limitation (MTL) can be quantitatively described by the following
expresssion:
MTL  =  — ——  (17)L r + Lm
Where
Lr = Onsager coefficient of reaction flux (m/s)
The Onsager coefficient reaction Flux is described by the following relationship:
Z> = Jb[5] (18)
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From equation (17) it is evident that % MTL can be reduced by decreasing the ligand 
concentration [B] (i.e. decrease Lr), and increased by increasing the mass transfer coefficient 
(Lm) by simply increasing the flow rate of analyte into the flow cell. Inspection o f equations 
(17) reveals that for kinetic experiments (i.e. low % MTL) the value for mass transport 
coefficient, Lm, should be high to ensure that equation (7) is maintained (i.e. ([A|buik»[A]3Urfac(., 
use high flow rates), and also that the Onsager reaction coefficient is low (i.e. reduce surface 
ligand concentration [B]). To ensure mass transport limiting conditions (i.e. 100% MTL) the 
converse logic should be applied, that is maximal concentrations of immobilised ligand 
employed and the analyte introduced to the flow cell under low flow rates.
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5.2 Results & Discussion:
5.2.1. Production o f  a panel o f  m onoclonal antibodies to warfarin 
Mice were initially immunised with a panel of conjugates including 4'-azowarfarin (4'-AW) 
thyroglobulin, 4-AW-DST-BSA (DiSuccinimidyl Tartrate) and 4f-AW-KLH (Keyhole 
Limpet Haemocyanin) prepared in Freund’s Complete Adjuvant. Conventional ELISA as 
described in section 2.11.1. was used to measure the specific antibody titre o f each animal 
for the production of antibodies to warfarin. Dilutions o f mouse serum were prepared as 
described in section 2.11.1. from 1/200 to 1/50,000, using the serum from pre-immunised 
animals as a control. The titre was described as that dilution of immunised serum giving a 
response greater than the control at the same dilution + 3 standard deviations. The specific 
antibody response to warfarin for the mice receiving the combined conjugate injection of 4'- 
azowarfarin-thyroglobu 1 i n/KLH, illustrated a marked increase in titre as illustrated in Figure
5.5. compared to immunisation with the individual conjugates alone. The mice were boosted 
and immunised approximately 4 weeks later with the same drug-protein conjugate as used 
for the initial immunisation. The serum antibody responses elicited in the animals receiving 
the combined drug-protein conjugate (i.e. 4'-AW-Thyroglobulin/KLH) were again 
significantly higher than immunisation with the individual conjugates alone and the 
conjugate mix was thus used for all subsequent immunisation procedures. The warfarin- 
DST crosslinked proteins were used primarily for subsequent screening steps, as the use of 
conjugates with different coupling chemistries is highly recommended when screening for 
antibodies to small haptens (Danilova, 1994).
The mice were immunised at 3-monthly intervals, and the antibody titres of four mice that 
had been immunised for greater than a 12-month period is illustrated in Figure 5.6. The 
specific antibody titres of all mice was greater than 1/250,000, a 10-fold increase in titre as 
compared to the initial antibody titres, and the titres measured after the first boost which 
were 1/25,000 and 1/35,000, respectively.
Spleen cells were then harvested from immunised mice and fused with Sp2/0 myeloma cells 
as described in section 2.10.7. Following the fusion procedure, hybridoma supernatants were 
screened approximately 10 days post fusion for specific antibody by ELISA as described in 
section 2.11.1. ‘Positive’ wells were scored on the basis of a positive result being > normal 
background reading + 3 standard deviations, and scaled up to 48-well plates. At this stage, 
supernatants were screened using 4'-aminowarfarin-DST (Disuccinimidyl tartrate) protein 
conjugates in a competitive immunoassay format to ensure selection of hybrids secreting
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antibody specific for the hapten molecule only. Sulfo-Disuccinimidyl tartrate is a 
homobifunctional 7V-hydroxysuccinimide ester, which reacts with protein and target 
molecules via primary amine groups, resulting in a covalent bond with the release of N- 
hydroxysuccinimide. The use of a spacer arm employing a different coupling chemistry and 
via different amino acid residues is essential when screening supernatants for antibodies to 
low molecular weight compounds to ensure recognition of free antigen in solution and not a 
combined drug-protein epitope (Danilova, 1994; Fasciglione el al., 1996).
Positive wells were then grown up in 24-well and 6-well plates and finally in culture flasks 
and frozen down in liquid nitrogen as described in section 2.10.5. An aliquot of cells was 
cloned using the method of limiting dilution (Harlow & Lane, 1988) until all of the wells 
demonstrating growth were shown to be secreting antibody of the desired specificity, at 
which stage they were considered to be statistically ‘monoclonal’ in nature (Lietske & 
Unsicker, 1985). During the screening protocol for fusion procedures, two ‘positive’ clones 
were also identified that bound to immobilised conjugate, but not free hapten in solution, 
although the supernatants were screened using a different carrier protein and via a different 
coupling chemistry. These supernatants were further screened using a variety of conjugates 
in an attempt to determine the particular specificity of these antibodies. The supernatant 
binding profiles interestingly showed increased binding to the hapten-protein conjugates 
over the native protein at similar coating densities, probably occurring as a result of 
electrostatic interactions between the antibodies and hapten-protein conjugates (Figure 5.7). 
The binding of these particular ‘sticky’immunoglobulins to protein on ELISA plates also 
identified by Breen (1987) and Keating (1998), highlights the importance of screening for 
hapten-specific antibodies in a competitive assay format.
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Figure 5.5: Specific antibody titres following the initial immunisation o f  mice with the
various warfarin-protein conjugates, namely: 4'-azowarfarin-KLH, 4'- 
azowarfarin-thyroglobulin, 4'-aminowarfarin-DST-thyroglobulin and a 
combined emulsion o f  4'-azowarfarin-thyroglobulin/KLH. As the results 
demonstrate, mice immunised initially with the combined conjugate 
emulsion 4'-azowarfarin-thyroglobulin/KLH elicited a significantly greater 
titre than those immunised with the individual conjugates alone, showing a 
titre o f  greater than 1/30,000. These results were also evident following the 
second immunisation, and the combined conjugate mix was thus used fo r  all 
subsequent immunisations. The results illustrated are the average o f  
duplicate measurements.
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Figure 5.6: Specific antibody titres to warfarin from mice (n=4) which had been
previously immunised fo r  greater than >12month period. The mice were 
boosted intraperitoneally 5 days prior to the somatic cell fusion procedure. 
Specific antibody titres greater than 1/250,000 were recorded for each 
mouse. The results shown are the average o f  triplicate measurements (±  
S.D.). Legends M l, M2, M3 and M4 correspond to the antibody titres from  
mice 1,2, 3, and 4, respectively.
Warferin-BSA 
Ovalbumin 
■■■ Warfarin-1 )ST-BSA
fs s s a  BSA
Wf-BSA OVA Wf-DST-BSA BSA  Parathion-BSA
Figure 5.7: Binding profile o f  clone 48-12 to various immobilised conjugates, highlighting
the importance o f  screening in competitive assay formats to ensure selection 
o f  hapten-specific clones only. Results shown are the average o f (n=6) results 
±  standard deviation. A similar binding profile fo r  clone 48-13 was observed.
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5.2.2. M onoclonal Antibody Purification:
200mls o f ‘spent’ hybridoma supernatant from each clone were concentrated using an 
Amicon™ filtration device as described in section 2.9.2.1. The concentrate was then passed 
through a  Protein G/A column as described in section 2.9.2.2. The fractions were then 
assayed using a spectrophotometer at 280 nm, and the fractions containing protein were 
pooled and dialysed against several changes of PBS-2. The elution profile illustrated in 
Figure 5.7 for the purification o f monoclonal 3-2-19 murine IgG2a on a Protein-G column is 
typical o f that recorded for other purified clones.
The purity of the IgG fractions was assessed by HPLC-SEC (Size Exclusion 
Chromatography). The affinity-purified antibody fraction was analysed by size exclusion 
chromatography as described in section 2.6.1. The molecular weight of the antibody was 
estimated to be approximately 150,000 Da, by reference to a calibration curve containing 
standards of known molecular weight. A plot overlay of the chromatograms for affinity- 
purified hybridoma supernatant and standard IgG is shown in Figure 5.9 demonstrating the 
purity and character of the dialysed fraction.
Figure 5.8: Elution profile o f  monoclonal 3-2-19 following purification on a Protein G
column. 20 ml o f concentrated ‘spent’ hybridoma supernatant were applied 
to the Protein G column which was then washed with two column volumes o f  
wash buffer. 0.1 M  Glycine-HCl (pH 2.5) was then applied to the column 
and 850 p i extracts were collected in eppendorf tubes containing 150 id  o f  I 
MTris-HCl (pH 8.0). The samples were then measured fo r  protein content 
by recording absorbance 280 nm, and those fractions (i.e. fractions 2-7) 
containing immunoglobulin were pooled and dialysed against several 
changes o f  PBS-2 at 4°C.
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Figure 5.9: Size exclusion chromatography o f  purified hybridoma mouse IgG and
standard mouse IgG run on a Phenomenex SEC 3000 column (Size 
Exclusion Column) according to section 2.6.1. The column effluent was 
measured at 280 nm, using PBS-1 as mobile phase at a flow rate o f  0.5 
ml/min. The molecular weight o f  the purified immunoglobulin was estimated 
to be approximately 150,000 Da by reference to a calibration curve o f  
standards o f  known molecular weight, the p lo t overlay o f  the purified 
fraction and standard mouse IgG  preparation confirms the purity and 
identity o f  the purifiedfraction.
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5.2.3. Screening o f  Hybridoma supernatants:
The purified antibody fractions were then assayed for antibody activity as described in 
section 2.11.1. Titres of the hybridoma supernatant prior to, following concentration, and 
after affinity purification are shown in Figures 5.10-5.13, for each o f the 4 clones 
characterised. The levels of antibody secreted from clones W1 and 48-5 as measured by 
antibody titre (Figure 5.10-5.11) were significantly lower than that of the other clones 
assayed, namely 2-5-16 and 3-2-19 (Figure 5.12-5.13). Clones W1 and 48-5, were 
‘recloned’ by limiting dilution several times in an attempt to isolate ‘stable’ clones from the 
hybridoma colonies. The results showed that the number o f wells producing antibody as 
measured by ELISA, decreased significantly following cloning at one cell per well, however, 
they appeared to produce ‘adequately’ following cloning at 10 cells per well. It was thought 
that the low levels of antibody production may have been a result of mycoplasma infection 
and the hybridoma cells were cultured in antibiotic-free media and screened for mycoplasma. 
The results following staining with Hoechst 33258 showed no evidence of infection.
Attempts were also made to enhance the levels o f monoclonal antibody production by 
growth as an ascitic fluid in mice. The antibody titre following ascitic fluid development 
shown in Figure 5.10 demonstrates a 10-fold increase in the antibody titre obtained, giving a 
final titre of greater than 1/50,000. Hybridoma growth as ascitic fluid has also been shown 
to be usefiil as a means of ridding cells of mycoplasma infection (Carroll & O’Kennedy, 
1988). Following growth as ascitic fluid, the hybridoma cells were aseptically collected and 
cultured in vitro and recloned by limiting dilution. There was a slight increase (~15%) in the 
levels of antibody production achieved following cell culture of the hybridoma cells grown 
as an ascitic fluid as seen in Figure 5.14, compared to cells cultured in vitro continually. 
Cloning of the hybridoma cells following growth as ascitic fluid and in vitro culture did not 
prove successful, however, in increasing the number o f positive antibody-secreting clones in 
the masterwells, and it was thus concluded that these two particular hybridomas were ‘low 
secrctors’ in terms of antibody production.
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Figure 5.11:
48-5 Affi nity-Purified Supernatant
1/Diluti on Factor
Typical antibody titres from  ‘spent’ hybridoma medium from clone 
48-5 were approximately 1/600, which increased to 1/6000 
following concentration and affinity purification. Following growth 
o f  the hybridomas as an ascitic flu id  the antibody titre increased to 
over 1/50,000. However, this was still considerably lower than that 
obtained with other hybridoma lines (Figure 5.12-5.13). The results 
shown are the average o f  triplicate results ±S.D.
1/Dilution Factor Hybridoma supemant
Typical hybridoma supernatant titre fo r  clone Wl, which was 
greater than 1/1200. This titre was considerably less than that 
obtained with other clones assayed (namely 3-2-19 and 2-5-16) and 
various attempts to increase the levels o f  secretion through repeated 
cloning to try and isolate stable clones proved unsuccessful. Wl 
and 48-5 were thus considered to be 'low secretors' in terms o f  
antibody production. The results shown are the average o f  
triplicate results ±S.D.
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Figure 5.12: Typical antibody titre fo r  clone 2-5-16 from 'spent' hybridoma supernatant
and affinity-purified antibody sample were greater than 1/10,000 and 
1/200,000, respectively. Results shown are the average o f triplicate 
measurements ±S.D..
1/Dilution Factor Antibody Fraction
Figure 5.13: Typical antibody titre fo r clone 3-2-19 from  'spent' hybridoma supernatant
and affinity-purified antibody sample were greater than 1/10,000 and 
1/200,000, respectively. Results shown are the average o f  triplicate 
measurements ±  S.D. Clone 3-2-19 was a particularly high secretor, with 
typical antibody 'spent' hybridoma antibody concentrations «  35 fjg/ml 
(section 5.2.4).
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Figure 5.14:
In vitro Cond. cells
In Vitro cultured cells 
Ksssafr Conditioned Cells cultured in vitro following passage as Ascitic fluid
Titres from  cells from clone 48-5 cultured in vitro, and conditioned cells 
following growth as ascitic flu id  and cultured in vitro. Dilutions (1/10) o f  
supernatants from both sets o f  cells were titrated fo r antibody as described 
in section 2.11.1. Results show an increase (~15%) in antibody titre and 
although statistically significant (a  = 0.05), the levels o f antibody recorded 
were still significantly less than those recorded for other clones, and no 
significant increase in the number o f 'positive' antibody-secreting clones 
following cloning by limiting dilution was achieved. This clone, 48-5, and 
clone Wl, were thus concluded to be ‘low secretors ’ o f  antibody.
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5.2.4. Antibody Concentration Determinations:
The exact concentration of antibody must be initially known for accurate determinations of 
equilibrium affinity constants on BIACORE. Affinity-based techniques such as ELISA and 
other biosensor-based techniques provide a unique means of determining the biologically 
active concentration of antibody, unlike spectroscopic techniques that provide total protein 
concentrations, and consequently inaccurate thermodynamic constants. Antibody 
concentrations in purified and neat hybridoma supernatants were determined using the 
Universal Standard Curve method of Karlsson et al. (1993) on BIAcore described in section
2.12.5, and also using a well-based ELISA capture system employing purified polyclonal 
anti-mouse immunoglobulin (M6149) as the capture antibody described in section 2.11.7.
5.2.4.1. Mouse IgG Determination by Antibody Capture ELISA:
Goat anti-mouse immunoglobulin (M6149) was initially purified on a Protein-G sepharose 
column as described in section 2.9.2.2. The concentration of protein in the purified fraction 
was estimated by means of UV absorbance at 280 nm (1 mg/ml IgG O.D.28o nm ~ 1.35) 
(Hudson & Hay, 1988). The wells of an ELISA microtitre plate were coated with a solution 
containing approximately 10 pg/ml anti-mouse immunoglobulin (M6149) in PBS-1, and 
blocked as described in section 2.11.1. Serial dilutions of murine IgG of known 
concentration ranging from 3.90-1000 ng/ml were prepared in blocking buffer. Dilutions of 
affinity-purified antibody and ‘spent’ hybridoma supernatant ranging from 1/2000 to 
1/16000, and 1/1000 to 1/4000, respectively, were also prepared. The known concentrations 
of murine IgG and the dilutions of hybridoma supernatant and affinity purified antibody 
were then added to the wells of the microtitre plate and the ELISA was then developed as 
described in section 2.11.1. The concentration of antibody in both the purified antibody 
fraction and the hybridoma supernatant were calculated by constructing a standard curve of 
known mouse immunoglobulin concentration (ng/ml) versus absorbance at 405 nm. A cubic 
spline calibration plot was constructed using BIAevaluation 3.1 software™, and a linear 
standard curve was also constructed. From the results from the cubic spline calibration plot 
concentration of antibody in the affinity-purified fraction for clone 3-2-19 was calculated to 
be approximately 0.56 ± 0.04 mg/ml, and the concentration in the hybridoma supernatant to 
be approximately 35.70 + 0.7 pg/ml. Linear regression analysis determined the 
concentrations of immunoglobulin for purified antibody and the hybridoma supernatant to be 
0.62 + 0.04 mg/ml and 30.25 + 6.4 mg/ml, respectively, as shown in Table 5.2:
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Figure 5.15: Calibration plot fo r  the determination o f  mouse IgG concentrations in
Protein G-purified antibody fractions and ‘spent’ hybridoma supernatant. 
Goat anti-mouse IgG was used as capture antibody. Dilutions o f  mouse IgG 
o f  known concentration from  1,000 to 3.90 ng/ml were prepared, as were 
serial dilutions o f  purified antibody (1/1,000-16,000), and ‘spent’ 
hybridoma supernatant (1/1,000-4,000), and applied to the wells o f  an 
ELISA plate as described as in section 2.11.7. Using regression analysis the 
concentration o f  mouse IgG in the purified antibody fractions and that o f  
‘spent’ hybridoma supernatant were calculated and shown in Table 5.2. 
Each point on the calibration curve is the average o f  three replicates ±S.D.
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Figure 5.16: Mouse IgG calibration plot constructed using BIAevaluation™
software. A spline is fitted  to the data set fo r  non-linear plots, 
allowing fo r  the calculation o f  the mouse IgG in the affinity-purified 
and neat hybridoma fractions. Each point on the curve is the average 
o f  three replicates ±  S.D.
5.2.4.2. Universal standard Curve:
Under conditions o f mass transfer limitation (MTL) the rate of antibody binding (dR/dt) is 
independent of the identity and concentration of the immobilised antigen and can be used for 
the evaluation of active antibody concentrations in solution (Karlsson et al., 1993). 
Conditions of MTL may be confirmed by comparing the antibody binding rates on surfaces 
with different immobilised ligand densities, which should be identical under conditions of 
mass transport limitation. The technique can also be used as a means of monitoring specific 
antibody titres, and able to discriminate between the specific antibody class (Karlsson et al., 
1993).
The concentrations of the Protein G affinity-purified antibody and neat hybridoma 
supernatants were evaluated using the Universal standard curve method as described in 
section 2.12.5. 4'-aminowarfarin was directly immobilised as described in section 2.12.2.2., 
in order to attain as high as possible a ligand density on the sensor chip surface to fulfil
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conditions o f MTL. Immobilisation o f a sufficiently high ligand density to fulfil conditions 
of MTL can be difficult to achieve with hapten-protein conjugates with low isoelectric points 
(e.g. 4'-azowarfarin-BSA). The purified antibody fraction and the neat hybridoma 
supernatant were serially diluted in HBS buffer (running buffer) and passed sequentially 
over the derivatised sensor chip surface and regenerated between antibody pulses by 25mM 
HC1. To assess the degree of non-specific binding of media to the sensor chip surface, 
dilutions were also made o f fresh tissue culture media. These values were then subtracted 
from the values obtained for ‘spent’ hybridoma supernatant.
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Figure 5.17: Plot o f  antibody-binding rate (dR/dt) versus dilution factor o f  media
used. Dilutions o f  ‘spent’ hybridoma supernatant and fresh media 
were passed over the sutface at 10 fM/min under conditions o f  mass 
transport limitation, and the binding rate dR/dt calculated. The 
non-specific binding rate was subtracted from the measured 
hybridoma binding rate for the purpose o f  active antibody 
concentration determinations.
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The slope of each binding curve (dR/dT) was calculated, and a plot of binding rate (dR/dt)
versus the log of antibody dilution (Log(DF)) constructed, from which the slope, m, could be
calculated. According to Karlsson et al. (1993) the following mathematical model can be 
applied to concentration measurements.
rJRL°g  —  = mLogiÇÀ)(nM) (19)a l
Where
m = slope of regression line 
dRL o g —  = mLog(DF) (20)at
where DF = Antibody Dilution factor
From the constructed plots of log of antibody-binding rate (dR/dt) versus log dilution factor, 
the concentration of antibody in the purified fractions and neat hybridoma supernatant were 
determined by substituting the slope of regression line into equation (19). The antibody 
concentration of hybridoma supernatant and affinity-purified samples are tabulated in Table
5.2. Under similar conditions of MTL, a single antibody curve can thus be used for various 
antibody concentration determinations. The slope of the line is dependent on mass transfer 
coefficients (Lm), and will thus have to be recalculated under different flow rates and flow 
cell dimensions as described in equation (15).
The calculated concentration measurements for the purified antibody fraction and hybridoma 
supernatant for hybridoma 3-2-19 correlate closely with the values measured using the 
mouse IgG capture ELISA. The Universal standard Curve method of Karlsson et al. (1993), 
has several advantages over the ELISA capture assay in that active antibody concentrations 
can be determined over a much shorter time interval, as measurements can be taken in early 
part of binding curve (i.e. under conditions of MTL during first 30 seconds) versus hours for 
the ELISA, and also that the procedure is fully automated. One drawback of the Universal 
standard curve method is that conditions o f MTL may be difficult to establish for antibodies 
with low association rates (<10"5M' s'1).
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Table 5.2. Antibody Concentration Determinations:
Sample Affinity Capture Universal Standard
Antibody Assay Curve Method
(fig/ml ±S.D.) (fig/ml ± S.D.)
3-2-19: Hybridoma supernatant 35.70 ± 0.70 (S) 36.98 ±1.09
30.25 ± 6.40 (L)
3-2-19: Purified Antibody fraction 560.0 ± 40.0 (S) 570.0 ±35.0
620.0 +40.0 (L)
The concentration o f  antibody was determined using an affinity capture ELISA and 
the Universal Standard curve method. The concentration o f  antibody in the two 
fractions was determined by ELISA using two different calibration curves, namely a 
cubic spline (S) and a linear regression line (L). The mean antibody concentration 
in the affinity-purified and hybridoma supernatant fractions were 583.33± 32.14 
/ug/mland 34.31 ±3.57fig/ml, respectively.
Log (Dilution Factor x 1000)
Figure 5.18: Antibody concentration were determined using the Universal standard curve
method o f  Karlsson et al. (1993). The slope o f  the regression line was 
substituted into equation (19) and used to determine the concentration o f  
active antibody in ‘spent ’ hybridoma supernatant fo r clone 3-2-19. Results 
shown are the average o f  5 replicate measurements.
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5.2.5. Use o fpanel o f m onoclonal antibodies in competitive E LISA :
Protein G affinity-purified monoclonal antibody from each of the individual hybridoma 
clones was used in a competitive ELISA format for the detection of warfarin in solution as 
described in section 2.11.5. The optimal working dilution of antibody to be employed for 
competitive immunoassay procedures was determined from the antibody dilution curves 
obtained for each clone from Figures 5.10-5.13.
Immunoassay response curves are inherently non-linear and adopt a sigmoidal bell shape on 
log-linear plots (Findlay et al., 2000). Immunoassays are generally best modelled using a 
four-parameter fit equation, of the form:
R  =  Rh i  - R ii i  -  R lo
1 + r Cone
(21)
Ai
Where Rhi ~ Response at infinite concentration
Rlo Response at zero concentration
Cone = Analyte Concentration (M)
-Aj = Fitting constant
A-2 Fitting constant
Four-parameter equations of the form above were fitted to the data sets obtained for 
immunoassays curves using BIAevaluation 3.1 software. Such calibration curves also 
allowed for the determination of unknown values from the constructed plot. In this way it 
was possible to calculate the degree of precision of analytical measurements at different 
concentrations points relative to the fitted four-parameter equation.
Fitting a four-parameter curve to the data set as opposed to utilising the straight line portion 
of the sigmoidal plot conventionally obtained with ELISAs, greatly extends the working 
range of the plot at the asymptotes of the curve for both ends of the concentration range 
employed. 4-parameter curves were fitted to the data obtained using BIAevaluation 
software™. A comparison of the extended working range obtained can be observed in Table 
5.3 and 5.4 and Figures 5.19 and 5.20, which illustrates that the working range of the ELISA 
has been extended by a factor of 4 at each end of the calibration plot with no significant 
effect on the degree of assay precision.
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To determine the intra-assay variation of the ELISA, 4 replicate measurements per 
concentration point were used. These absorbance values (A) were then divided by the 
absorbance measurement in the presence of zero antigen concentration (A0) to give 
normalised absorbance values (A/A0)(Appendix 1A). A calibration plot of the mean 
normalised absorbance value versus warfarin concentration in ng/ml was then constructed 
using BIAevaluation software™. From the calibration curve it was possible to calculate the 
mean, standard deviation, coefficient of variation and precision for intra-assay 
measurements. The results are shown in Table 5.3 for clone 3-2-19.
The inter-assay variation was calculated by performing the assay over three separate days. A 
separate calibration curve plotting normalised values (A/Ao) versus concentration values 
(ng/ml) was then constructed for each assay curve. The normalised values from each curve 
for each concentration determination were then back-calculated using the calibration curve 
and BIAevaluation software. The mean back-calculated concentration from each of the 
calibration curves was then used to calculate the mean, standard deviation and coefficient of 
variation for the inter-assay curve. Residual plots for the calibration curves are included for 
each calibration curve, which illustrate the 'goodness o f the fit' of the applied 4-parameter 
equations. The residual plots also illustrate the precision profile of the calibration curves 
over the assayed concentration range and illustrate that the 4-parameter equation 
demonstrates no bias over the assayed concentration range, unlike linear plots which have a 
tendency to demonstrate increased bias at the extremities of the linear plot.
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Table 5.3: Intra-Assay results fo r  Clone 3-2-19 (n=4) curve:
(From 4-parameter f i t  curve constructed using BIAevaluation software)
Actual Warfarin Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin Concentration from 
calibration curve (ng/ml)
% C.V % Difference 
Accuracy
312.50 315.84 5.99 1.07
156.25 161.22 8.02 3.18
78.13 73.43 21.95 -6.01
39.06 39.24 9.10 0.45
19.53 21.02 1.12 7.62
9.77 8.81 2.23 -9.79
4.88 5.32 1.00 8.95
2.44 2.36 1.80 -3.33
1.22 1.21 3.23 -0.87
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Figure 5.19: Intra Assay Spline Curve & Residual plot:
A 4-parameter equation was fitted to the data using BIAevaluation software™, 
from which the intra-assay mean, coefficient o f  variation and precision were 
calculated and shown in Table 5.3. Each point on the curve is the mean o f  (n=4) 
replicate measurements. The residual plot and low value obtained (2.80 x 10'4) 
demonstrates the 'goodness o f  the f i t ' o f  the 4-parameterfit applied to the data set.
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Table 5.4: Intra-Assay results fo r Clone 3-2-19 (n= 4) using linear regression:
Actual Warfarin 
Concentration (ng/ml)
Mean Back Calculated 
Warfarin Concentration 
(ng/ml)
% C.V. % Difference Accuracy
39.06 37.28 9.10 -4.78
19.53 22.27 0.30 12.3
9.76 8.76 0.51 -12.6
4.88 4.99 0.63 2.10
2.44 2.46 0.78 0.75
Warfarin Concentration (ng/ml)
Figure 5.20: Intra Assay Curve:
Linear regression analysis was applied to the data set giving the line o f  best fit, from  
which the intra-assay mean, coefficient o f  variation and precision were calculated 
and shown in Table 5.4. Each point on the curve is the mean o f  (n=4) replicate 
measurements + standard deviation.
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Table 5.5: Inter-Assay results fo r  Clone 3-2-19 (n=3):
Actual Warfarin 
Concentration (ng/ml)
Mean Back Calculated 
Warfarin Concentration 
from spline curve (ng/ml)
% C.V. % Difference Accuracy
500.00 494.80 13.39 1.04
250.00 239.10 14.37 4.36
125.00 125.92 12.44 -0.74
62.50 62.56 9.68 -0.10
31.25 31.90 9.90 -2.09
15.63 15.48 8.32 0.92
7.81 7.62 8.98 2.41
3.91 3.92 4.07 -0.32
1.95 2.23 4.82 -14.36
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Figure 5.21: Mean Inter-assay calibration curve
The mean normalised absorbance value at each drug concentration was calculated 
fo r each o f  the intra-assay curves (n=4), was then used to calculate the inter-assay 
mean (n=3), coefficient o f  variation and precision. Each point on the curve is the 
mean o f  triplicate measurements ±  standard deviation (n=3).
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Table 5.6.:lntra-Assay results fo r Clone 48-5 (n= 4):
Actual Warfarin 
Concentration (ng/ml)
Mean Back Calculated 
Warfarin Concentration 
from spline curve 
(ng/ml)
% C.V % Difference Accuracy
3125 3369.56 4.14 7.83
1562.50 1546.82 2.99 -1.00
781.25 753.64 1.79 -3.53
390.63 400.34 1.26 2.49
195.31 196.53 1.26 0.62
97.656 95.10 1.39 -2.61
48.828 45.74 1.83 -6.28
24.4 22.93 1.17 -6.02
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0TO% -5e-3 |
2 -001 4a:
-0.015
Warfarin Concentration (ng/ml)
—1— ............... I----- *— ■ -■ '"— I—
10 100 1000
Warfarin Concentration (ng/ml)
10000
Figure 5.22: Intra Assay curve fo r  warfarin with clone 48-5 
The intra-assay mean, coefficient o f  variation and precision were calculated from  
the calibration curve using the software and shown in Table 5.6. Each point on the 
curve is the mean o f  (n=4) replicate measurements ±  standard deviation
2 2 6
Table 5.7:Intra-Assay results for Clone WJ (n -  3):
Actual Warfarin 
Concentration (ng/ml)
Mean Back Calculated 
Warfarin Concentration 
from spline curve (ng/ml)
%C.V. % Difference Accuracy
3.91 3.92 1.23 0.37
7.81 7.80 0.10 -0.12
15.62 15.32 0.13 -1.95
31.25 33.06 2.70 5.78
62.5 59.08 2.99 -5.46
125.0 120.77 9.11 -3.38
250.0 273.76 8.44 9.50
500.0 502.35 12.49 0.46
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Figure 5.23:Intra assay spline curve fo r  clone WJ
Each point on the curve is the mean o f  triplicate measurements (n=3). The intra­
assay mean, coefficient o f  variation and precision were calculated from  the 
calibration curve using the software and shown in Table 5.7.
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5.2.6. Affinity Constants determinations:
Various techniques are available for the determination o f antibody affinity constants 
including equilibrium dialysis (Lehtonen & Eerola, 1982), polyethylene glycol precipitation 
(Stanley et al., 1983), affinity chromatography (Chaiken et ah, 1992), and those involving 
the use of enzyme-linked immunosorbent assay (Friguet et ah, 1985; Chu et ah, 1995). 
These techniques rely on the concentration measurement of either analyte or 
antibodyiantigen complex at equilibrium for determination of overall affinity constants.
Two antibodies with similar affinity constants (Ka) may possess completely different kinetic 
constants, which can be of considerable significance depending on the intended use of the 
antibody. The use of ‘real-time’ biomolecular interaction analysis is a useful means of 
affinity ranking antibodies, and can also be used early in the selection process as a screening 
device for the selection of particular antibodies (monoclonal/scFv) based on their individual 
kinetic rate constants (Deunas et al., 1996).
5.2.6.1. Method ofFriguet etal. (1985):
The method described by Friguet et al. (1985) was used to assess the affinity of the 
monoclonal antibodies raised to warfarin and structurally related analogues, by calculation of 
the dissociation constant (KD) of antibodyiantigen mixtures at equilibrium in solution. For 
determination of overall affinity constants, antibody at a constant concentration is mixed 
with solutions of antigen of varying concentration. The antibody: antigen mixtures are 
allowed to attain equilibrium and the ‘bound’ concentration of antibody (V) can then be 
calculated by indirect ELISA as described in section 2.11.6. by the expression:
V = - °— A] (22)Ao
Where A0= Absorbance in the absence of antigen 
A i- Absorbance in the presence of antigen
The concentration of bound antibody can be related to the antigen concentration by the 
following equation:
V
KD
Ag + 1 (23)
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A plot of 1/(V) versus l/[Ag] will thus yield a straight line graph with a y-intercept of 1, with 
the slope of the regression line (KD), describing the overall equilibrium constant for the 
antibody: antigen interaction at equilibrium.
l/ l Ag]
Figure 5.24: Typical plot attained using the method ofFriguet et al. (1985). A plot o f  the
reciprocal o f  bound antibody (1/V) versus the reciprocal o f  antigen 
concentration (l/[Ag]) should yield a straight line plot with a y-intecept o f  1 
and whose slope defined the dissociation constant fo r the particular 
antibody: antigen interaction at equilibrium.
For the method to provide reliable dissociation constants two prerequisites must firstly be 
met. The first prerequisite is to demonstrate the correlation between ‘free’ (i.e. unbound) 
antibody concentration in solution and enzymatic activity, and adding various dilutions of 
antibody to antigen-coated wells of an ELTSA plate as described in section 2.11.6 and 
constructing a calibration plot of nominal antibody concentration versus absorbance. A 
straight line plot similar to that in Figure 5.26 of ‘nominal’ antibody concentration (i.e. 
1/dilution factor) versus enzymatic activity at 405 nm is attained, demonstrating the linear 
correlation between antibody concentration and enzymatic activity. This calibration plot can 
then be used to calculate the concentration of antigen bound antibody at equilibrium in the 
antibody: antigen mixtures.
The ‘free’ antibody concentration, i, following incubation with the antigen can be related to 
absorbance by the following equation:
-  =  ~  (2 4 > 
jo  Ao
Where Ao = absorbance in the absence of antigen.
A = absorbance in the absence of antigen.
i0 = total antibody concentration.
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The second prerequisite is that no readjustment of the antibody: antigen equilibrium mixture 
should occur during the incubation in the antigen-coated wells. This can be demonstrated 
experimentally by placing serial dilutions of antibody into the wells of an antigen coated 
ELISA plate for a specified time interval, and then transferring the contents o f the well into 
the adjacent antigen coated wells on the ELISA plate for a similar incubation period. An 
overlay of the plots for the developed ELISA of wells 1 and 2, as shown in Figure 5.25 
should demonstrate no significant decrease in the antibody bound in the second set of wells, 
implying that the amount of antibody bound by the solid phase antigen is negligible 
compared to the amount of antibody in solution, and therefore unlikely to cause any 
significant displacement of the antibody:antigen mixture at equilibrium. The fraction of 
antibody retained by the first set of wells, / ,  can be calculated by the following equation:
M e)
Where
/  = fraction of antibody retained
A¡(c) /  A2(c)  = enzymatic activities in the first and second set of wells, respectively.
(i.e. absorbance measurements) 
c = initial concentration of antibody
The antigen concentration has been shown to have the greatest effect on the solid phase 
disruption of fluid phase equilibrium in affinity assays (Hetherington, 1990). Reducing the 
incubation period in the antigen-coated wells also minimises the disruption of the fluid phase 
equilibrium. The incubation period for each clone was determined individually, and the 
incubation periods on the plate were typically of the order of 15-20 minutes. The value of /  
calculated for clone W l, as shown in Figure 5.25, was approximately = 0.01, demonstrating 
that the amount of bound antibody is negligible compared to overall antibody concentration. 
By calculating the amount of unbound antibody at equilibrium by reference to the antibody 
concentration calibration plot, the amount of ligand-bound antibody (V), can thus be 
estimated and used to calculate the overall affinity constant.
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Table 5.8: Calculation o f  free antibody concentrations.
| Warfarin] 
mol/1
l/[Warferin]
1/mol
l/[Ag]
Abs at 405nm Nominal
Antibody
concentration.
NC
1/V
3.246 308000 0.029 0.022 1.02
1.623 c 6 616000 0.053 0.041 1.04
8.12 e 7 1232000 0.074 0.056 1.06
4.06 e 7 2464000 0.129 0.098 1.10
2.03 e 7 4920000 0.219 0.167 1.19
1.015 e 7 9840000 0.333 0.254 1.32
5.07 e'8 19680000 0.564 0.430 1.69
2.54 e 8 39380000 0.774 0.590 2.26
0 oo 1.387 1.057 OO
Table 5.8: Calculation o f  free antibody concentrations.
The nominal concentrations o f  antibody were calculated by reference to the constructed 
antibody standard curve and substituting the value obtained into equation (22). The value 
fo r  bound antibody was calculated to yield the values o f  J/V, from  which a plot o f  l/[Ag] 
versus 1/V was constructed, whose slope (KD) defined the dissociation constant KD o f  the 
overall interaction.
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1/Dilution Factor Nominal Antibody Concentration
Figure 5.25: Antibody was applied to the wells o f  a microtitre plate as described in section
2.11.6. fo r  a predetermined incubation period. A prerequisite o f  the Friguet 
assay is to ensure that there is the minimal disturbance o f  the antibody:antigen 
equilibrium mixtures in solution when transferring the equilibration mixtures to 
the microtitre plate. This can be determined experimentally by firstly preparing 
a set o f  antibody dilutions and applying these to a set o f  wells in a microtitre 
plate for a specified incubation period. The contents o f  these wells would then 
be transferred to a second set o f  wells on the same microtitre plate and the 
ELISA developed as described previously. The value o f  f  as described in 
equation (25), could then be calculated from the graph. By ensuring that this 
value is kept as close to zero as possible it can be stated that the amount o f  
antibody bound by the plate is negligible compared to the total antibody 
concentration and will not disturb the fluid  phase equilibrium o f  the the 
antigen:antibody complex. The results shown are the average o f  triplicate 
measurements + standard deviation.
2 3 2
1/[A] (M-1)
Figure 5.27: Determination o f  the equilibrium dissociation constant fo r  the interaction
between warfarin and clone WJ by the method o f  Friguet et al. (1985). The 
nominal unbound antibody concentrations were calculated using the standard 
curve constructed in Figure 5.26, and equation (22) from which the values o f  
1/V were subsequently determined at the respective antigen concentrations as 
shown in Table 5.8. The calculated equilibrium dissociation constant fo r  the 
interaction between warfarin and monoclonal antibody W1 was calculated to 
be 2.89x 1 0 'sM.
However, an antibody whether monovalently bound or completely unbound with respect to 
its specific antigen, will be able to bind to an ELISA plate. The concentration of antibody 
complex measured at equilibrium does not take into account the fact that monovalently 
bound antibodies may also bind to the plate. The apparent binding constant measured will 
therefore not equal that of the corresponding antibody Fab fragments. Stevens (1987) 
developed a ‘correction factor’ based on the binomial distribution theory to provide the 
‘correct’ concentration of liganded antibody binding sites to allow for the calculation o f the 
‘correct’ thermodynamic constant. Stevens (1987) postulated that if the probability that a 
Fab binding site is bound is taken as, z, then the probability that the binding site is free can 
then be interpreted as l-z. For the case of an intact IgG molecule, the following relationships
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can be used to describe the three populations of antibody fractions existing within the 
equilibrium complex:
Completely Unbound: (7-z2J
Monovalently bound: 2z (1-z)
Bivalently bound: z2 (26)
On the basis of binomial distribution, assuming that the binding of one Fab does not preclude 
the binding of a second Fab (which is the case for small haptens, not necessarily true for 
larger molecular weight haptens due to steric hindrance factors (Quinn & O’Kennedy,
2001)), of the three antibody populations present at equilibrium, only the bivalently bound 
antibody, (z2), is incapable of binding to the ELISA plate. The fraction of free antibody 
assayed by ELISA (m) is therefore equal to 1-z2.
m = 1 -  z 1 (27)
and
z  = s j l - m  (28)
represents the corrected fraction of liganded binding sites in terms of the apparent free IgG. 
The method of Friguet et al. (1985) measures the ‘bound’ fraction of unbound IgG (V), using 
the relationship:
V = A—  — (23)Ao
It can be seen therefore that as the concentration in equation (26) represents the bivalently 
bound antibody fraction, the corrected fraction of occupied antibody binding sites at any 
antigen concentration is given by:
z = y/V  (29)
Stevens (1987) found that overall association constants were overestimated by a factor of at 
least 2, with the level of error inversely proportional to the level of binding site occupancy. 
By substituting the corrected value of liganded binding sites a more ‘realistic’ value of 
association constants is determined which takes into account the bivalent nature of the 
antibody giving association constants for whole IgG that closely mirror those for Fab 
fragments.
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Table 5.9: ‘Corrected’ Free Antibody Concentrations according to Stevens (1987):
[Warfarin]
mol/1
¡/[Warfarin | 
1/mol
l/[Ag]
Nominal
Antibody
concentration.
NC
1/V Corrected Free 
Antibody 
concentration 
1/z =(1/V)1/2
3.246 e* 308000 0.022 1.02 1.01
1.623 c* 616000 0.041 1.04 1.02
8.12 e'7 1232000 0.056 1.06 1.03
4.06 o'7 2464000 0.098 1.10 1.05
2.03 e 7 4920000 0.167 1.19 1.09
1.015 e 7 9840000 0.254 1.32 1.15
5.07 e 8 19680000 0.430 1.69 1.30
2.54 e 8 39380000 0.590 2.26 1.50
0 00 1.057 OO
l/[Ag]
Figure 5.28: Friguet assay fo r  warfarin with clone Wl using ‘corrected’ IgG
concentrations described by Stevens (1987) to account fo r  bivalency o f  IgG- The 
corrected overall dissociation constant (Ko =1.26 x 10~8 M) shows a 2.3 fo ld  
increase in estimation o f  overall affinity constant compared to that observed for  
the ’uncorrected’IgG concentration shown in Figure 5.27 (KD=2.88 x  10 ~SM). 
The method of Friguet et al. (1985) it could be argued only works particularly well for high 
affinity antibodies, as the incubation step in ELISA must be sufficiently short not to perturb 
the antibody: antigen equilibrium complex, for low affinity antibodies (high off rates) such a 
condition can be difficult to achieve in practice. Friguet assays for the various other clones 
with particular antigens are shown in Figures 5.29 to 5.41 and overall affinities shown in 
Table 5.10.
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2e+7 4e+7 6e+-7 8e+7
Figure 5.29:48-5:4-Hydroxycoumarin
'/[Ag]
Figure 5.30:48-5:6-Hydroxywarfarin
1^1 Ag]
Figure 5.31:48-5:7-Hydroxywarfarin
l/[Ag]
Figure 5.32:48-5:Acenocoumarin
l/[Ag]
Figure 5 .33:48-5:Warfarin
Figure 5.29-5.33: Friguet affinity determinations o f  equilibrium dissociation constants for
the interaction between clone 48-5 and the antigens 4-hydroxycoumarin, 6-hydroxywarfarin, 7- 
hydroxywarfarin, acenocoumarin and warfarin, respectively.
2 3 7
Il/[Ag]
KA]
Figure 5.34: W l:6-Hydroxywarfarin Figure 5.35: W 1:7-Hydroxywarfarin
Figure 5.34-35: Friguet affinity determinations o f  equilibrium dissociation constants fo r
the interaction between clone W1 and 6- and 7-Hydroxywarfarin.
I/|AJ 1/LA]
Figure 5.36: 2-5-16:4-Hydroxycoumarin Figure 5.37:2-5-16: W arfarin
Figure 5.36-37: Friguet affinity determinations o f  equilibrium dissociation constants fo r
the interaction between clone 2-5-16 and 4-Hydroxycoumartn and 
warfarin
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1/[A] 1/[A]
Figure 5.38:3-2-19:4~Hydroxycoumarin Figure 5.39:3-2-19 6-Hyroxywarfarin
1/[A] 1/[A]
Figure 5.40:3-2-19:7-Hydroxywarfarin Figure 5.41:3-2-19:Warfarin
Figure 5.38-5.41: Friguet affinity determination o f  equilibrium dissociation constant for
the interaction between clone 3-2-19 and 4-hydroxycoumarin, 6- 
hydroxywatfarin, 7-hydroxywarfarin and warfarin, respectively.
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Table 5.10.: Equilibrium dissociation constants (KD) determined using the method o f  Friguet et 
al. (1985) fo r  the interaction between warfarin and four particular monoclonal 
antibodies. The affinity o f  the monoclonal antibodies to structurally related 
molecules o f  warfarin was also measured, and the equilibrium dissociation 
constants determined are tabulated below:
Antigen Clone W1 Clone 48-5 Clone 3-2-19 Clone 2-5- 
16
Warfarin
6-Hydroxywarfarin
7-HydroxywarJarin 
Acenocoumarin 
4-Hydroxycou marin
2.89 x  10’8 
1.05 x i t r 6 
1.09 x  10'8 
ND 
ND
2.39 x 10'8 
6.28 x 10^
2.40 x  10-6 
2.36 x 10'7 
6.85 x lO -6
1.64 x 10'y 
8.50 x  1 O’7 
1.10 x  10-6 
ND 
1.28 x 10'5
4.25 x 10’8 
ND 
ND 
ND 
6.37 x  10’7
ND = Not determined
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5.2.6.2. Solution Phase Steady State A ffin ity  determinations:
The use of BIAcore technology was employed to determine and compare the dissociation 
constants obtained using ‘real-time’ biomolecular interaction with those determined using a 
well-based ELISA analysis for the interaction between anti-warfarin monoclonal antibodies and 
specific target antigens. The method employed utilises the same principle as that employed in 
the ELISA method of Friguet et al. (1985), but has several advantages over the ELISA 
technique. The short contact time of the antibody.antigen equilibrium mixture in the flow cell 
(compared to incubation step in the ELISA) and continual flow of fresh equilibrium mixture 
over the warfarin-coated sensor chip limits the possibility o f a re-equilibration of the 
antibody:antigen mixture, and subsequent underestimation o f the affinity constant. The method 
also does not require additional labelling o f either reagent, or the addition o f secondary reagents, 
which may affect the intrinsic thermodynamic binding constants.
A known concentration of anti-warfarin antibodies were serially doubly diluted in HBS buffer 
and used to construct a calibration curve o f free antibody concentration versus response as 
described in section 2.12.7. and shown in Figure 5.42. A known concentration of antibody 
(nM) was then mixed with serial doubling dilutions of antigen o f known concentration and 
allowed to attain equilibrium. Each equilibrium mixture was then assayed for ‘free-unliganded’ 
anti-warfarin antibodies by passing the equilibrated mixtures over a warfarin-coated sensor chip 
surface. The concentration of free antibody at equilibrium was determined by reference to the 
standard curve.
The model described below is used to calculate the solution equilibrium dissociation constant:
The equilibrium dissociation constant can be calculated by constructing a plot of free anti­
warfarin antibodies versus warfarin concentration as shown in Figure 5.43. Equation (30) 
describing the model for solution phase affinity assumes that the antibodies are monovalently 
bound. The assay format utilised is capable of detecting free and monovalently bound antibody, 
and a correction similar to that applied to the ELISA measurements may be applied, so that the 
concentration of free antibody in the equilibrated antibody:antigen mixture is not overestimated 
giving an underestimated affinity constant. Piehler et al. (1997) amended the solution phase
A B (30)
Where Bfiee is the free concentration of anti-warfarin IgG 
A  is the total concentration of warfarin 
B is the total anti-warfarin IgG concentration 
Ki is the equilibrium dissociation constant.
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model based on the binomial distribution principle described by Stevens (1987), and expressed 
the ‘corrected’ concentration of free antibody with at least one antibody binding site free by the 
expression:
Bfree  — (31)
The symbols have the same meaning as described for equation (30).
The model described in equation (31) assumes that the sensor responses for free and 
monovalently occupied antibody are similar. The assumption that the sensor responses 
measured would be similar for free and monovalently liganded antibodies particularly with 
larger target antigens is obviously incorrect, however with small molecules such as warfarin, the 
response measured for monovalently bound antibodies and free antibodies would be similar, 
given the small molecular weight of warfarin compared to an intact IgG molecule. The bivalent 
model when fitted to the data resulted in a higher association constant, deriving an equilibrium 
dissociation constant of, KD = 8.57xl0‘9± 1.3lx  10'9 M. The data does not fit the bivalent 
model particularly well as seen in Figure 5.44, and the monovalent fit appears to describe the 
interaction better between the antibody and the conjugate-immobilised drug surface.
The likelihood of a monovalently ligand-bound (i.e. 4-azowarfarin-BSA) antibody molecule 
encountering a second free warfarin molecule bound to the conjugate within the ‘sweep of the 
arm’ of the monovalently conjugate-bound antibody molecule could be regarded as low, given 
the relatively low epitope density of warfarin molecules on the protein. This assumption 
implies with the use of conjugates that the incidence of bivalent antibody binding to the 
immobilised conjugate surface would also be low. Given the inhomogeneity o f the surface 
ligand (4'-azowarfarin-BSA) immobilised, it is impossible to predict what conformation the 
conjugate bound warfarin molecules would adopt when immobilised, and whether or not 
bivalent analyte binding is sterically possible with the use o f protein conjugates. The possibility 
of bivalent binding would therefore be a function of the drug epitope density, and given the 
manner in which such drug-protein conjugates are synthesised, conformity o f structural epitope 
density would be impossible to control.
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Figure 5.42:
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Serial doubling dilutions o f  anti-warfarin antibodies o f  known concentration 
(nM) were passed sequentially over a warfarin-coated (i.e. 4'-azowarfarin-BSA 
or 4’-aminowarfarin) sensor chip surface. A calibration plot was constructed o f  
anti-warfarin antibodies (nM) versus response measured (RU). The calibration 
plot was then used to calculate the concentration o f  free antibody at 
equilibrium. Results shown are the average o f  triplicate measurements.
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Figure 5.43: Determination o f overall solution equilibrium affinity constant between clone 3- 
2-19 and warfarin on a 4'-azowarfarin-BSA-coated chip surface. Warfarin 
concentrations were plotted against free anti-warfarin antibody concentration, 
determined by reference to a calibration plot o f  anti-warfarin antibodies. A 1:1 
interaction model was used to describe the interaction (equation (30)), and 
fitted to the data set using BlAevaluation software, deriving an equilibrium 
dissociation constant o f KD=2.44 x I f f 8M, fo r  the interaction between clone 3- 
2-19 and warfarin.
Warfarin concentration (M)
Figure 5.44: Solution phase affinity fo r  warfarin and clone 3-2-19 on 4'-azowarfarin-BSA -
coated chip surface. The model describing bivalent binding was applied to the 
data set, giving an overall, equilibrium constant o f  KD = 8.57 x  10'9 ±  1.31 x 
10'9 M. The bivalent model described in equation (31) fitted to the data using 
BlAevaluation software, does not describe the interaction particularly well as 
seen from the plot.
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To assess the effect that immobilisation of drug-protein conjugates had on the dissociation 
constants determined solution phase assays were replicated using directly coated drug surfaces 
prepared as described in section 2.12.2.2. In this context, the homogeneity and orientation of 
the surface ligand warfarin molecules was assured. The assays were replicated over a similar 
inhibitor concentration range. A 20-fold less concentration o f antibody was required for 
experiments with the use o f the directly immobilised 4'-aminowarfarin drug sensor chip surfaces 
(i.e. 20nM for conjugate surface and InM for directly immobilised drug surface). The 
concentration of free antibody for the equilibrium mixtures was determined as previously 
described, and the models for monovalent and bivalent binding applied. The models fitted to 
the data generated on directly immobilised drug surface, describe the interaction better than 
those employing the use of drug protein conjugates, upon inspection of the fitted data set. 
Interesting to observe is that the model for bivalent binding fits the data set better than the 
monovalent model, as shown from the fit and residual values obtained. Given the high surface 
ligand concentration of warfarin directly immobilised, the likelihood of a monovalently surface- 
ligand bound antibody binding a second warfarin ligand-bound molecule would be extremely 
high, and thus bivalent antibody binding to the chip surface would most probably be the net 
result, resulting in increased association constants as a result of avidity effects. The dissociation 
constant obtained for bivalent model is 2.6 fold lower than that obtained for the monovalent 
model. The value obtained for the bivalent model, KD = 1.53 x 10'9 + 8.66 x 10'n M, results in a 
dissociation constant almost identical to that recorded for the ELISA based Friguet assay (KD 
=1.64 x 109M). The monovalent fit results in a dissociation constant of, KD = 4 x 10‘8 + 3.72 x 
10"10 M. Avidity effects and rebinding occurring as a result of the high ligand density at the 
sensor chip surface could, therefore, be used to explain the deviation obtained between the 
equilibrium dissociation constants determined using drug-protein and directly immobilised drug 
sensor chip surfaces. An investigation into the affinity constants determined for the 
corresponding Fab fragments for each clone would have given the ‘true affinity’ for each 
antibody binding site. This would also have reduced the complexity of the fits as a result of 
bivalent antibody binding, and illustrated how well each of the binding models and affinity 
constants determined with the correction factors employed resemble that of the corresponding 
Fab fragment. The solution phase equilibrium constants for clones 3-2-19 and 2-5-16 with 
structurally similar analogues o f warfarin were also determined using the immobilised conjugate 
and drug surfaces. The results are tabulated in Table 5.11 and 5.12 and the corresponding 
equilibrium dissociation plots illustrated in Figures 5.47-5.53.
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Figure 5.45:
Figure 5.46:
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Determination o f solution affinity fo r  interaction between warfarin and clone 3- 
2-19 on a chip surface directly immobilised with 4'-aminowarfarin. The 
bivalent model fitted to the data set describes the interaction particularly well 
as seen from the residual plot, and derives a dissociation constant, KD = 1.53 x 
ltT9 ± 8 .6 6  x  I0  n M for the interaction.
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Determination o f  solution affinity fo r  interaction between warfarin and clone 3- 
2-19 on a chip surface directly immobilised with 4'-aminowarfarin. The 
monovalent binding model was fitted to the data set and derives a dissociation 
constant, KD = 4.08 x  10~9 ±  3.72 x  10'10 M fo r  the interaction. This value is 
slightly lower than that obtained fo r  the bivalent f it  as would have been 
expected based on the binomial model described by Piehler et cd. (1997).
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The binding interaction models described previously were fitted to the relevant data sets, and 
used to calculate the equilibrium dissociation constant, KD, for the interaction between anti- 
warfarin antibodies from clone 3-2-19 and particular antigens. The results are shown below in 
Figures 5.47-5.50, and the calculated dissociation constants based on the fitting of both 
monovalent and bivalent models to the data set are shown in Table 5.11.
4-Hydroxycoumarin conc. (M)
Figure 5.47: Determination o f equilibrium dissociation constant between clone 3-2-19 and
4-hydroxycoumarin on a 4 '-azowarfarin-BSA -coated chip surface. The solution 
phase affinity models were fitted  to the data using BlAevaluation software, 
deriving an equilibrium dissociation constant fo r the interaction o f  1.29 x  10'5 
± 6 .9 4 x  1 O'7M using equation (30).
1e-8 1e-7 1e-6
Acenocoumarin Concentration (M)
Figure 5.48: Determination o f equilibrium dissociation constant between clone 3-2-19 and
acenocoumarin on a 4'-azowarfarin-BSA-coated chip surface. The solution 
phase affinity models were fitted  to the data using BlAevaluation software, 
deriving an equilibrium dissociation constant fo r  the interaction o f  3.19 x 10 
±  6.02 x 10 "9M using equation (30).
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Determination o f  equilibrium dissociation constant between clone 3-2-19 and
6-hydroxywarfarin on a 4'-azowarfarin-BSA-coated chip surface. The solution 
phase affinity models were fitted  to the data using BIAevaluation software, 
deriving an equilibrium dissociation constant fo r  the interaction o f  1.86 x 10 ~6 
± 2 .23  x  10 ~7M using equation (30).
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Determination o f  equilibrium dissociation constant between clone 3-2-19 and 
7-hydroxywarfarin on a 4'-azowarfarin-BSA-coated chip surface. The solution 
phase affinity models were fitted  to the data using BIAevaluation software, 
deriving an equilibrium dissociation constant fo r  the interaction o f  1.27 x 10 ~6 
± 8 .9 4 x 1 0  M using equation (30).
7-Hydroxywarfahn Cone. (M)
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Table 5.11: Equilibrium solution phase dissociation constants (Ko) determinations for
clone 3-2-19 with particular antigens. The dissociation constants were 
determined using both the monovalent (equation 30) and bivalent models 
(equation 31) using BIAevaluation software.
Antigen Kd Monovalent model + S.E. Ko Bivalent Model + S.E.
(a) 4-hydroxycoumarin
(b) Acenocoumarin
(c) 6-Hydroxywarfarin
(d) 7-Hydroxywarfarin
(e) 4-hydroxycoumarin*
(*4 ’-aminowarfarin-coated
sensor chip)
1.29 x 10-s ± 6 .94  x  10 7M  
3.19 x lO -8 ± 6 .0 2  x 1 0 '9M  
1.86x10  6± 2 .2 3 x 1 0 '7M  
1.27 x  1 0 '6 ±  8.94 x  10 ^ M  
1.13 x lO '5 ± 7 .46  x l 0 ' 7M
4.88x 1 0 'S±  3.47x 10~7M  
l .U x l O '8 ± 9 .2 4  x l 0 AOM  
6.95 x lO '7 ± 1 .1 0  x l 0 ' 7M  
4.4 x  1 0 -7± 3 .9 5  x 10 ^ M  
4.35 x 10-6±5 .13  x lO '?M
The binding interaction models described previously were fitted to the relevant data seta and 
used to calculate the equilibrium dissociation constant, KD, for the interaction between anti­
warfarin antibodies from clone 2-5-16 and the corresponding antigens. The results are shown 
below in Figure 5.51-5.53 and tabulated below in Table 5.12.
Warfarin Cone. (M)
Figure 5.51: Determination o f  equilibrium dissociation constant between clone 2-5-16 and
warfarin on a 4’-aminowarfarin-coated chip surface. The solution phase 
affinity models were fitted  to the data using BIAevaluation software, deriving 
an equilibrium dissociation constant for the interaction o f  8.26 x 10 ~8 ± 3 .1 6  x  
10 9M using equation (31).
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Determination o f  equilibrium dissociation constant between clone 2-5-16 and 
4-hydroxycoumarin on a 4'-aminowarfarin-coated chip surface. The solution 
phase affinity models were fitted to the data using BlAevaluation software, 
deriving an equilibrium dissociation constant fo r  the interaction o f2.06 x 
10 ~6 + 3.16x 10 9M using equation (31).
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Determination o f  equilibrium dissociation constant between clone 2-5-16 and
7-hydroxywarfarin on a 4'-aminowarfarin-coated chip surface. The solution 
phase affinity models were fitted to the data using BlAevaluation software, 
deriving an equilibrium dissociation constant fo r  the interaction o f1.03 x 
10 ~7 ± 8 .0 7  x  10 ~gM  using equation (31).
Table 5.12: Equilibrium solution phase dissociation constants (Kq) determinations for
clone 2-5-16 with particular antigens on a 4'-aminowarfarin-coated chip 
surface and determined using both the monovalent and bivalent models using 
BlAevaluation software.
Antigen Kd Monovalent model ±S.E. Kd Bivalent Model + S.E.
(a) 4-hydroxycoumarin
(b) Warfarin
(c) 7-Hydroxywarfarin
(d) 6-Hydroxywarfarin
2 .0 6 x l0 ~ 6 ± 1 .8 7 x 1 0 - ' M  
8.26x10-* ± 1 .1 7 x W *  M  
1.03 x  1 0 -7± 8 .0 7 x 10-9M  
2.00 x 1 0 -5 ± 5 .1 9 x 1 0 '6M
2.06x 1 0 '6±  6.73x 10'*M  
3 .1 6 x1 0 *  ± 4 .52  x 10-9M  
4.03x 10-* ± 4 .22  x 10-9M  
7.35 x lO '6 ± 1 .98  x 10-6M
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5.2.6.3. Steady-State A ffinity Determinations:
4'-azowarfarin-BSA was immobilised at a sufficiently low surface concentration to give a 
maximum response of approximately 200 RU on the sensor chip surface using conventional 
coupling chemistry. Direct immobilisation of 4'-aminowarfarin at a sufficiently low ligand 
density on the chip surface was difficult to control, and consequently drug-protein conjugates 
were immobilised. BSA was immobilised on a second flow cell at a similar surface 
concentration. BIACORE 3000 is capable of on-line reference curve subtraction, thereby 
removing matrix effects, and baseline jumps due to sample injection and refractive index 
changes. Ideally, it would have been preferable to immobilise the antibody to the chip surface 
by affinity capture using Protein A/G. Direct immobilisation of the antibody would remove the 
complexity arising from a bivalent analyte binding to the drug surface, and possible avidity 
effects at the chip surface resulting in elevated affinity constant determinations. However, the 
surface concentration of antibody required to achieve a quantifiable response signal following 
binding o f warfarin to the affinity captured antibody proved to be a limiting factor and 
consequently the use of drug-protein conjugates was employed. For example, affinity capture 
of 10,000RU of anti-warfarin antibody via protein G, (which is difficult to achieve in practice) 
would only result in a maximal saturation response of 41RU even when taking antibody 
bivalency into account given the ratio of the molecular weights of the antibody (~150,000Da), 
and warfarin (308Da). Given the large concentration of antibody required to generate such a 
quantifiable signal, the time taken to reach equilibrium and saturation of the surface would have 
been extremely long.
The steady state affinity for a surface interaction can be described by the expression:
=  K a X P J L R m z x  
Ka.n.(CA)i +  \
Where n = Steric hindrance factor and represents the average number o f ligand
sites occupied per analyte molecule.
Req = Response at equilibrium
(CA)i = Injected concentration of analyte (M)
Rmax = Maximal response
Ka = Equilibrium association constant
The value for steric hindrance factor, n, can be determined experimentally by calculating the 
fraction of the response measured versus the theoretical maximal response attainable given a 
specific immobilised ligand surface concentration. The value of n, could therefore not be
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calculated using drug protein conjugates and was set to 1, for the purposes o f modelling 
experiments.
Serial dilutions of anti-warfarin antibody of known concentration were simultaneously injected 
over warfarin-BSA and BSA coated surfaces at a flow rate of 2 pl/min for 40 minutes, using 
‘on-line’ reference curve subtraction as illustrated in Figures 5.54 and 5.55. A plot of the 
equilibrium response (Req) measured versus the injected antibody concentration was 
constructed, and the steady state affinity model described in equation (32) was fitted to the plot 
deriving an association constant (KA) value of 1.78 x 10s ± 0.28 x 108 M '1 for the steady-state 
interaction between clone 3-2-19 and warfarin.
The steady-state affinity model derives an association constant higher than that obtained for the 
solution phase constant using immobilised drug conjugates, but less than that obtained with 
directly immobilised drug surface. One would expect the solution phase affinity constant to 
yield a slightly higher value for the association constant, given that both interacting molecules 
(i.e. antibody and antigen) are free in solution. The overall reaction flux (Lr) would therefore be 
greater, compared to the steady state experiments where one of the interacting molccules is 
immobilised (i.e. warfarin-BSA). The low molecular weight o f the target analytes and 
difficulties involved in immobilising a sufficiently low ligand density of 4,-aminowarfarin 
directly (i.e. Rmax < 200RU), restricted the various types of immunoassay format possible. 
Similar to the solution phase assays, the possibility of bivalent analyte binding to the chip 
surface also exists. However, given the low surface ligand concentration of warfarin-BSA 
employed, and for similar but highly more probable reasons than those discussed for the 
solution phase assays, the likelihood of a monovalently bound antibody bound to the conjugate 
surface, encountering a second free ligand site would be particularly small, given also the 
saturating concentrations of antibody employed. In this context, the restrictions enforced by the 
small molecular weight of the analyte and the use of drug conjugate surfaces allows for 
approximations of overall association constants, given that values for the steric hindrance factor, 
n, were impossible to calculate given the in-homogeneity of the surface ligand.
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Figure 5.54:
Figure 5.55:
Time (seconds)
Warfarin-BSA (— ) and BSA (— )  were immobilised onto two flow (Fc) cells 
o f  a sensor chip surface, namely Fc2 and Fcl, respectively. 80nM o f  affinity- 
purified anti-warfarin antibodies were injected over the two sensor chip 
surfaces and monitored simultaneously using ‘on-line ’ reference curve 
subtraction (i.e Fc2-Fcl).
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The interaction curve from figure 5.54 following ‘on-line’ reference curve 
subtraction is shown. The equilibrium binding response was measured at a 
variety o f  injected antibody concentrations, and used to plot a curve o f  the 
binding response at equilibrium (Req) versus injected antibody concentration 
(Figure 5.57).
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Figure 5.56. Reference curve subtracted binding curves fo r  various concentrations o f  anti­
warfarin antibodies and a warfarin-BSA-coated chip surface, following 
injection over the surface at a flow rate o f  2 ¡A/min fo r  40 minutes.
Anti-warfarin antibody Cone. (M)
Figure 5.57: The value obtained for Req was plotted against the molar concentration o f
antibody injected. The steady state model described in equation (32) was fitted  
to the data, and assuming a value o f  n=l, the value fo r  the association 
constant, Ka, fo r the interaction between warfarin and affinity-purified 
antibodies from  clone 3-2-19 was determined using BIAevaluation software to 
be 1.78 x  108 ±0.28 x  l ( f  M 1.
2 5 4
5.2.7. Conclusions:
The results presented in this chapter describe the production and characterisation of a panel of 
monoclonal antibodies to the small hapten molecule, warfarin (Mol. Wt. 308 Da). Balb/C mice 
were initially immunised with a variety of immunogens to assess which of the conjugates would 
be the best immunogen. The results show that the use of a combined ‘cocktail’ of conjugates 
proved to be the most effective. Difficulties in generating sufficiently high titres against small 
hydrophobic haptens have been reported in the literature, and attributed to protein modifications 
of the carrier protein with the hapten molecule reassociating with hydrophobic residues within 
the protein core, thereby reducing the surface epitope concentration o f hapten and subsequent 
interaction with the immune system (Fasciglione et al., 1996). No such difficulties were 
encountered in the generation of an immune response to warfarin, and results demonstrate a >10 
fold increase in the final antibody titres recorded compared to the initial antibody titres 
measured over the course o f the immunisation schedule (>15 months).
Hapten-specific clones were selected by ELISA, and cloned by the method o f limiting dilution. 
The fusion efficiency measured in terms of the number of wells containing hybridomas, was in 
all cases relatively high (> 70%). However, the ‘relative’ success of the fusion procedure 
measured in terms of hapten-specific clones following the cloning and scale-up procedure was 
low, ranging from individual to multiple clones isolated for the various fusion procedures 
carried out. The final fusion procedure generated 7 hybridomas and highlights the importance 
of extended immunisation procedures for the generation of high serum titres (> 250,000) and 
high affinity monoclonal antibodies (~KD = 10"9 M). Other authors have reported difficulties 
associated with the selection of antibodies to small molecular weight haptens during screening 
procedures, resulting in the selection of antibodies sharing a combined drug-protein epitope 
(Danilova, 1994; Keating, 1998; Killard, 1998). The use of conjugates employing different 
coupling chemistries and carrier protein homology than those used for immunisation procedures 
is thus strongly recommended. Whilst it may not be logistically possible initially given the 
large number of wells screened during an initial hybridoma screening procedure (> 600 wells), 
the use of a competitive immunoassay format is highly recommended as early as possible into 
the screening procedure. The use of such a competitive selection system can generally be 
employed after the initial screen when the number o f ‘positive’ wells is logistically more 
manageable. Competitive screening procedures thus ensure the selection of hybrids secreting 
antibody specific for the free hapten. Despite the fact that different conjugates were used in 
screening procedures, several ‘positive’ wells were identified which bound to the conjugate but 
not free hapten. Further analysis of these clones identified that the ‘sticky’ immunoglobulins 
produced demonstrated a non-specific binding profile to a variety of conjugates and native
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proteins, highlighting the importance of such competitive immunoassay screens so that reagents, 
labour and time will not be wasted cultivating such useless clones.
The cloned hybridomas were cultured in vitro and the supernatants collected and purified for 
further analysis. Two of the clones (i.e. W1 and 48-5) demonstrated significantly lower titres 
than those recorded for the other hybridomas. Attempts to increase the levels of specific 
antibody production were made by repeated cloning by limiting dilution to try and isolate more 
stable clones, which proved unsuccessful. Propagation of these hybridomas as ascites increased 
the antibody titres recorded. However, in vitro culture of the cells following growth as ascites 
and subsequent cloning by limiting dilution produced only slightly elevated levels of antibody 
production and no significant increase in the number of antibody-secreting wells. It was thus 
concluded that these clones were considered to be genetically unstable or ‘low secretors’ of 
antibody. A practical decision should thus be made at this stage with respect to such clones as 
to whether or not the levels of antibody recorded from such clones are sufficiently high for the 
desired purposes before performing new fusions.
The levels of antibody produced by the hybridoma cells were measured using a well-based 
ELISA aifinity-capture assay and on BIAcore using the Universal standard curve method of 
Karlsson et al. (1993). The results obtained using these two techniques correlated extremely 
well, and showed clone 3-2-19 to be a high secretor of antibody with levels of «35 fag/ml 
culture media recorded. The Universal standard curve method offers several advantages over 
the ELISA-based system in that once a single calibration curve has been constructed for a 
particular molecule under specific conditions of MTL, it can be used repeatedly under the same 
conditions for subsequent concentration determinations. In this context, the use of BIAcore and 
namely the Universal standard curve should be encouraged as a means of monitoring serum 
responses and screening supernatants for the presence of monoclonal antibodies/scFvs. Using 
the Universal standard curve as a screening tool can also give a wide range o f information with 
regard to particular clones. For example, a single injection will not only identify ‘positive’ 
hybrids, but also yield important protein concentration information. A second follow up 
injection based on this initial positive result, where the antibody could be mixed with a 
competing antigen, could then be used as a means of affinity ranking antibodies in a similar 
fashion to IC50 values. All this information could be generated in two simple injection 
procedures in the order of minutes, as opposed to carrying out several independent ELISAs, 
each of which is based on the previous result and can thus take many days to conduct. The 
technique could thus prove very valuable in laboratories where a large number of hybridomas 
may warrant screening and further identification.
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Each of the hybridomas was then used to develop a competitive immunoassay for warfarin. For 
all immunoassay calibration plots the use of a spline function in BlAevaluation™ software was 
adopted which fitted an advanced smoothed curved cubic polynomial to the data set. 
Immunoassay curves are inherently non-linear in origin and adopt a familiar sigmoidal bell 
shaped curve on log-linear plots. The fitting o f linear plots to such data sets ignores the inherent 
shape of the plot, with the resulting ‘linear’ plots showing a greatly reduced dynamic range with 
reduced precision at both the upper and lower ends of the calibration set. Fitting 4-parameter 
equations to immunoassay curves offers a much more realistic fitting of the data set, and as 
shown can increase the detection range by 4-fold at both ends of the linear range increasing the 
dynamic range considerably with no significant effect on the degree of assay precision or 
performance.
The method of Friguet et al. (1985) was used to assess the overall dissociation constants for 
each of the hybridomas to warfarin and structurally related analogues. All o f the conjugates 
used for immunisation and screening utilised the same point of attachment (i.e. the amine group 
on position 4 of the benzyl ring). This particular point of attachment was chosen for a number 
of reasons: primarily because it offered a convenient means of protein conjugation. Secondly, 
as the majority of warfarin metabolites involve various hydroxylations of the coumarin part of 
the molecule, it was suggested that a point of conjugation away from this area might confer 
extra specificity to the monoclonals produced, as antibody specificity is directed primarily at the 
area of the hapten most sterically accessible (Landsteiner’s principle)(i.e. the 4- 
hydroxycoumarin moiety of warfarin). The affinity profile of the monoclonals produced 
measured by the equilibrium dissociation constants, was generally of the order: 
warfarin > acenocoumarin > 7-/6-Hydroxywarfarin »  4-hydroxycoumarin with the exception 
of clone 2-5-16 which showed increased affinity for 4-hydroxycoumarin. These results suggest 
that the majority o f the antibodies were directed against an epitope on the coumarin portion of 
the molecule. However, when tested for reactivity against a series of coumarin-based molecules 
including: coumarin, 7- and 6-hydroxycoumarin, esculetin and 7-hydroxy-4-acetic acid none of 
the clones exhibited any affinity towards these coumarin-based molecules with the exception of 
clone 2-5-16. This implies that the monoclonal antibodies produced from clones W l, 3-2-19 
and 48-5 were directed against a combined epitope near the 4-hydroxycoumarin residue and the 
branched keto substituent at position 3 part of the coumarin molecule. This also explains why 
there was a reasonably high degree of affinity of the antibodies for the hydroxylated 
metabolites. Clone 2-5-16 exhibited increased affinity relative to the other clones to 4- 
hydroxycoumarin, suggesting that the majority of the specificity of this particular antibody is 
directed against the 4-hydroxycoumarin residue. The dissociation constants measured by the 
method of Friguet et al. (1985)(despite it’s many limitations) correlate well with those
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Idetermined using steady state and solution phase affinity analysis on BIAcore over a wide range 
of antibody affinities studied (i.e. KD 10'5 -  10'9 M). Using BIAcore analysis affinity 
determinations were made using both directly immobilised drug and conjugate surfaces. All of 
the assay formats employed an immobilised monovalent ligand (warfarin-BSA, 4'- 
aminowarfarin) with a bivalent analyte (antibody) in solution, with the potential, therefore, of 
bivalent analyte binding. Dissociation plots fitted to the data generated on drug-protein 
conjugate surfaces appeared to conform to the fit of monovalent binding better than bivalent 
model, whilst the plots generated on directly immobilised drug surfaces fitted the bivalent 
model better. The reality is that the dissociation fit lies somewhere between the modelled 
mono- and bivalent fit. The increased affinity constants measured on the directly immobilised 
drug surfaces compared to the conjugate bound surfaces are in all probability the net result of 
bivalent antibody binding at the chip surface as a result of the high ligand concentration 
immobilised. The high ligand concentrations employed would thus encourage rebinding events 
within the flow cell and avidity effects at the chip surface resulting in the observed elevated 
association constants. The likelihood of an antibody being bound to two immobilised conjugate 
bound warfarin molecules simultaneously would be small as a result of the lower epitope 
concentration and possible steric hindrance factors at the chip surface, giving slightly lower 
association constants. The lower dissociation constant values generally obtained using solution 
phase assays compared to steady state analysis, agrees with what one might have predicted. 
Given that for solution phase assays both interacting molecules (i.e. antibody and antigen) are 
free in solution and hence have an increased collision frequency, thus affecting the kinetic rate 
constants and the measured affinity constants, unlike steady state analysis where one of the 
intcractants is immobilised.
In conclusion, for the generation of high affinity monoclonal antibodies to small haptens the use 
of extended immunisation schedules and a variety of conjugates for immunisation procedures is 
encouraged to enhance the serum response generated. Selection should as soon as logistically 
possible be carried out using a competitive assay format to ensure selection of hapten specific 
clones only. The use of BIAcore at this stage of screening could therefore be used to rank 
antibodies with respect to specific active antibody concentration and also affinity, allowing the 
selection and cultivation of the more precious higher affinity clones. Such clones could then be 
further characterised based on kinetic rate constants for the selection of specific antibodies for 
particular purposes (i.e. ELISA, biosensor purposes). The dissociation constants determined by 
the method of Friguet et al. (1985) demonstrate the method to be an accurate means of 
determining equilibrium affinity constants for crude samples when more techniques such as the 
BIAcore are not available, provided the initial assay prerequisites are fulfilled. Ultimately, the 
method (solution phase/steady state analysis) of measuring antibody affinity should resemble
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the environment for their intended use (i.e. steady state analysis should be used for measuring 
antibody affinity to surface bound molecules and solution phase assays for situations where the 
antibody might encounter the antigen in solution).
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Chapter 6 
Overall Conclusions
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6.1. Overall Conclusions:
The purpose of the research work carried out was to develop antibodies to warfarin (i.e. 
polyclonal and monoclonal) which following characterisation could be used for the 
development of antibody-based assay systems for the detection of warfarin in biological fluids.
Initial work focused on the production of drug-protein conjugates which were then used for 
subsequent immunisation, purification and assay purposes. Given that the specificity of the 
antibodies produced will ultimately be a function of the particular epitopes available the point of 
attachment is of hapten to carrier protein is therefore of considerable importance. The use of 
molecular modelling was employed for the generation of 3-dimensional configurations of 
warfarin and it’s major primary metabolites. Molecular modelling techniques, as the 
experimental observations demonstrate, provide a useful insight as to the 3-dimensional 
configurations of small atoms that are not always evident from 2-dimensional representations. 
On the basis of these representations, coupled with the various functional groups available for 
coupling the nitro group of acenocoumarin was chosen as the point of attachment of hapten to 
the carrier molecule. A variety of drug-protein conjugates were initially produced, and as the 
results demonstrate, high specific antibody responses were recorded, with rabbit serum titres 
exceeding 1/500,000. The high drug-protein coupling ratios recorded underlines the 
immunogenicity of the conjugates produced. Similar antigen-specific mouse serum titres of 
antibody were obtained, which demonstrated a > 10 fold increase in specific antibody titre over 
the course of the immunisation schedule. Somatic cell fusion procedures were carried out at 
various time intervals throughout the immunisation schedule, and the monoclonal antibodies 
produced demonstrate a 20-fold increase in antibody affinity during the course o f the 
immunisation schedule, underlining the importance of extended immunisation protocols (i.e. 6 
months post initial immunisation clone 48-5 KD = 2.8 x 10'8, 15 months post initial 
immunisation clone 3-2-19 KD = 1.6 x 10 ~9) for the generation of high affinity clones 
(Danilova, 1994).
The levels of antibody produced by selected monoclonal antibody preparations were compared 
using a well-based ELISA affinity-capture assay and also using a biosensor-based assay 
technique, which showed excellent correlation. The use of the biosensor-based assay procedure 
described (Karlsson et al., 1993) or a similar variant (Christensen, 1997) is encouraged 
particularly when screening hybridoma supernatants, because of the wide range of both 
qualitative (i.e. positive/negative) and quantitative (concentration determinations/affinity 
analysis/epitope mapping) information which can be recorded automatically in relatively short 
time periods (i.e. 5 minutes).
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The monoclonal antibodies were then characterised in terms of their affinity and specificity to 
warfarin and structurally-related analogues. A well-based ELISA assay and the use of BIAcore 
were then compared to measure the affinity of the monoclonal antibodies produced. The results 
generated using the well-based system generated thermodynamic results of comparable 
dissociation constants to those determined using BIAcore, highlighting the usefulness of the 
method of Friguet et al. (1985), particularly for crude antibody preparations of unknown 
antibody concentration. Each of the monoclonal antibodies produced exhibited excellent 
specificity towards the parent molecule over structurally related analogues. For example, 
monoclonal antibodies from clone 3-2-19, the highest affinity monoclonal isolated, showed a 
greater than 500-fold affinity to warfarin (KD = 1.6 x l0 ‘9) than to any of the hydroxy 
metabolites assayed (KD = 1.2xl0"5-8.5 xlO'7)(Table 5.10).
All of the antibodies produced were then used in the development of BIAcore-based inhibition 
immunoassays for the detection of warfarin in biological fluids. The assay system developed 
for the detection of warfarin in plasma ultrafiltrate had a working range between 0.5 and 250 
ng/ml. These detection limits are only paralleled by those involving the use of GC-MS (Gas 
Chromatography-Mass Spectrometry) and HPLC with post-column fluorescent techniques that 
require extensive sample pre-treatment prior to sample analysis and are not particularly well 
suited to the routine analysis of drug molecules in complex biological matrices. The biosensor- 
based assay system developed for the detection of warfarin in plasma ultrafiltrate utilised a chip 
surface with the drug 4'-aminowarfarin covalently coupled. Such surfaces demonstrated 
exceptional stability and reproducibility (% C.V. <1% ) and were capable of being used for 
greater than 1,000 assays. In the clinical setting, economics is becoming increasingly more 
important and the use of such regenerable assay formats offers a very attractive alternative to 
current high consumable-based alternatives (i.e. ELISA (immunoplates) and HPLC (solvent 
waste)). The technique developed for the analysis of warfarin could quite easily be 
reconfigured for the analysis of quite literally any analyte provided that antibodies o f the desired 
specificity are available. Indeed as the majority of current analytical techniques rely on the 
inherent physicochemical properties of small molecules for their detection, which are too often 
limiting factors with regard to assay sensitivity, the use of antibody-based techniques offers 
very attractive more sensitive, low-cost alternatives which could soon become the mainstay of 
modem analytical technology. The low degree of sample preparation required and high degree 
of automation offered by BIACORE-based detection techniques are additional advantages to 
those outlined compared to traditional techniques such as HPLC and GC-MS which rely on 
extensive sample pre-treatment. Similarly, as a consequence of the low degree of sample pre­
treatment and high degree of automation, the sample throughput of BIACORE assays (run-time
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~ 7 mins, «500 samples/day) is significantly better than those for most HPLC assays (run time ~ 
20 mins, 50-100 samples/day depending on the degree o f sample pre-treatment required)
Recent developments in antibody engineering has allowed for the development of antibody 
fragments with monovalent femtomolar antigen-binding affinity (Boder et al., 2000). These 
advances allied to the on-going development in the field of transduction technologies, are 
continually re-defining the boundaries of the clinical, therapeutic and analytical potential of 
antibodies (and fragments thereof), which ensures that the application of antibody-based 
techniques will continue to grow at an ever increasing rate as their potential in the 
clinical/therapeutic and diagnostic/analytical arena are finally fully realised.
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Appendix 1A
Glossary o f  terms and definitions commonly em ployed in B ioanalytical Validation 
procedures:
The terms listed below are commonly referred to in bioanalytical validation procedures and the 
criteria which they can be defined under have been extensively reviewed (Karnes et al., 1991; 
Shah et al., 1991; Braggio et al., 1996; Hubert et al., 1999; Currie, 1999; Findlay et al.-, 2000).
Mean
Describes the average o f replicate (x) measurements, (i.e. n1+n2+  nx/x)
Accuracy
Is defined as the closeness of agreement of the measured test result with the expected true 
reference value.
Precision
Is defined as the closeness of agreement, or variance between independent test results o f 
multiple measurements of the same sample obtained under a set o f specified analytical test 
conditions. It is normally expressed in terms of the relative standard deviation (% R.S.D.), or 
the coefficient of variation (% C.V.) of the determined concentration of a replicate number of 
assays. The degree of precision assessed between replicates (i.e. % C.V.) performed during a 
single assay batch, is commonly referred to as the intra-assay variation (also referred to as 
repeatability). The term inter-assay variation (also referred to as reproducibility) is used to 
describe the precision between assays when related to multiple batches.
Limit o f Detection (L.O.D.)
Defines the lowest analyte concentration that the analytical technique can differentiate from 
background signals and is usually determined as background noise ± 3 standard deviations.
Upper/ Lower Limit o f Quantitation (L.O.Q.):
The lowest/highest analyte concentration that can be measured from the calibration curve with 
acceptable levels of precision and accuracy, usually the L.O.D. ± 3 standard deviations.
308
Robustness:
Is a term used to describe the ability of an analytical technique to withstand fluctuations in the 
described analytical test conditions. For immunoassay procedures the term could be used to 
describe changes in the ionic strength of the matrix, as well as pH and temperature changes.
Standard Curve:
This describes the relationship between the measured analyte response (i.e. absorbance, 
response units) and the analyte concentration.
Non-specific binding:
This describes matrix effects which affect the degree o f binding of the antibody:antigen 
interaction, and can occur as a result of increased protein concentration and sample viscosity in 
the sample matrix (e.g. plasma ), and also as result o f altered ionic composition (e.g. urine) of 
the sample matrix. The assay design should therefore be robust enough to be able to withstand 
such variations in sample composition, and the degree o f non-specific binding minimised prior 
to sample analysis (e.g. use of detergents and/or surface treatment with non-specific protein 
prior to sample analysis).
Coefficient o f Variation (%C.V.)
A quantitative measure o f the precision o f an analytical measurement expressed as a percent 
function of the mean value, also referred to as the Relative Standard Deviation (% R.S.D.).
% C.V. = [S.D./Mean value] x 100
Bias:
Describes the systematic difference between measured test results and the theoretical true value, 
and is usually expressed as the relative error (% R.E.).
Batch/Run:
Refers to a single set of samples (standards) analysed together as a single sample set using the 
same analytical technique.
Residual:
Describes the difference between the value described by the equation model and the true value. 
Precision profile:
A quantitative measure o f the variation between measurements, usually the coefficient of 
variation versus the nominal concentration of analyte in the sample.
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Normalised Response Values:
The response recorded in response units (RU) at each particular antigen concentration divided 
by the response recorded in the presence of zero antigen.
Normalised Response = Response measured at particular antigen concentration
Response measured at zero antigen concentration
Normalised Absorbance Values:
The absorbance recorded (AU) at each particular antigen concentration divided by the 
absorbance recorded in the presence o f zero antigen.
Normalised Absorbance = Absorbance measured at particular antipen concentration
Absorbance measured at zero antigen concentration
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